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ABSTRACT 
 
The aim of the research project described here was to develop a novel colourimetric nu-
cleic acids biosensor based on polydiacetylene liposomes containing lipophilic peptide 
nucleic acids. Preliminary investigations in this area have shown that PNA-containing 
PDA liposomes can be constructed and that they are blue in colour as expected. How-
ever, their poor water solubility and the resulting precipitation made it necessary to syn-
thesise and evaluate a second generation. In these, the PNA head-group is separated 
from the lipid tail by an amino diethylene glycol-type spacer molecule.  
 
The first hydrophilic spacer synthesised was 8-(tert-butoxycarbonyl)amino-3,6-
dioxaoctanoic acid. Three methods based on the O-alkylation of mono-Boc, di-Boc and 
dibenzyl 5-amino-3-oxapentanol were devised. The Boc strategy afforded the corre-
sponding ether in low yield of 20% while in the case of the dibenzyl approach a suitable 
methodology to effectively cleave the protecting groups from the amino function could 
not be found. Moreover, the model reaction between dibenzyl 8-amino-3,6-
dioxaoctanoic acid and thyminyl PNA monomer afforded the corresponding conjugates 
in only 6%.  
 
An alternative type of connection to link the spacer to the PNA headgroup was thus 
sought. A 1,4-disubstituted [1,2,3]-triazole moiety was obtained in 60% yield by react-
ing spacer, 8-(tert-butoxycarbonyl)amino-3,6-dioxaoctan-1-azide and N-alkynyl PNA 
monomers bearing thymine, Cbz protected adenine and Cbz protected cytosine accord-
ing to the conditions of the ‘Click’ reaction. These ‘spacer-PNA monomer’ intermedi-
ates were then functionalised at their N-terminus using 10,12-pentacosadiynoyl fluoride, 
to afford ‘lipid-spacer-PNA monomer’ models. The saturated conjugates were obtained 
by first preparing the ‘lipid-spacer’ intermediate, N-(8-azido-3,6-
dioxaoctanyl)stearamide which was then connected to the N-alkynyl PNA monomers 
using the ‘Click’ reaction. Following this last strategy, a homothymine PNA dimer, pre-
pared in solution phase, was also functionalised with the saturated lipid chain. 
 
This second generation of lipid functionalised-PNA monomer models were incorporated 
into PDA-liposomes. Upon photo-polymerisation, the liposome solutions became blue. 
They were found to be stable in solution, at 4 oC over long period of time. Their colour 
changed to red upon environmental changes (i.e. pH and temperature). 
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Note on abbreviation of PNA oligomers: 
 
The nomenclature introduced by Nielsen et al.1 to denote PNAs has been used in this 
thesis to report the novel PNAs synthesised by Murray et al..2 For the oligomer H-
TCAG-Lys-NH2, H denotes the free N-terminus amino group; T, C, A and G the T-, C-, 
A- and G-acetyl N-(2-aminoethyl)glycine units, respectively; and Lys-NH2 indicates a 
C-terminus lysine amide. Additionally, CH3(CH2)16CO, CH3(CH2)11C4(CH2)8CO and 
Ac has been employed to denote the acyl group attached to either the N-terminus of the 
PNA oligomer or lysine side chain. 
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1 INTRODUCTION 
 
The development of nucleic acid biosensors capable to quickly provide precise informa-
tion on particular sequence of genes is an area of bio-technological research that has re-
ceived particular attention in recent years. Such an interest has been followed by the re-
search group at Heriot-Watt University since it has embarked into a research pro-
gramme to develop a novel type of colourimetric nucleic acid biosensor. This thesis de-
scribes the progress made towards the development of lipid-functionalised peptide nu-
cleic acids (PNAs). It is hoped that such materials can be used as nucleic acid biosen-
sors. 
 
The following introduction is a brief summary of recent research into the areas covered 
by the work. It includes a short introduction to nucleic acid structure and function, as 
well as a short summary on the type of nucleic acid biosensors that have been recently 
developed and that are currently available for research. PNA structures and uses are also 
described along with polydiacetylenes. In the latter case, the focus is made on their 
chromic properties and how these have been extrapolated for the development of a vari-
ety of colourimetric biosensors. 
 
Subsequently, the attention of the thesis will turn to how the research group have 
brought together these fields in an attempt to construct nucleic acid biosensors. 
 
1.1 NUCLEIC ACIDS: STRUCTURES AND FUNCTION 
 
1.1.1 Nucleic acid structures 
 
There are two classes of nucleic acids, deoxyribonucleic acid (DNA) and ribonucleic 
acid (RNA). These were first discovered in 1869 by Friedrich Miescher.3 In most living 
organisms, the genetic information is carried by genes, segments of DNA, contained 
within macromolecular structures called chromosomes. The exceptions are for some 
viruses which transport their hereditary information as RNA rather than DNA. Aside 
from long-term storage of the genetic information, DNA plays two roles: it directs its 
own replication during cell division and it directs the production of complementary 
molecules of RNA during the process of transcription. RNA may be associated with 
proteins through formation of complexes called ribonucleoproteins. All these RNA 
Introduction 
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molecules are required for the biosynthesis of proteins through the process of transla-
tion. 
 
Nucleic acids are linear polymers of monomeric units called nucleotides. Each nucleo-
tide consists of three components: a nitrogenous heterocyclic base, a pentose sugar and 
a phosphate group. The phosphate unit bridges the 3′- and 5′- positions of successive 
sugar residues. The monosaccharide unit of RNA is β-D-ribofuranose (usually referred 
to as ribose) whereas in DNA, it is β-2-deoxy-D-ribofuranose (or deoxyribose), where 
the 2’-hydroxyl group of ribose has been replaced by an hydrogen. The nitrogenous het-
erocyclic bases of nucleic acids, or nucleobases, are separated into two families: (i) the 
pyrimidines of thymine (T), cytosine (C) and uracil (U); and (ii) the purines of adenine 
(A) and guanine (G). These nucleobases are attached to the sugar moiety through a link-
age formed either between C-1′ of the sugar and N-9 of the purines or through C-1′ of 
the sugar and N-1 of the pyrimidines. Adenine, guanine and cytosine are shared by 
DNA and RNA, whereas thymine is only found in DNA; it is exchanged for uracil in 
RNA (Figure 1). The linear polymer of nucleotide subunits is called oligonucleotide 
chain. These chains have directionality; the terminus bearing the free 5′-hydroxyl on the 
sugar is referred as the 5′-end whereas the one terminating with a 3′-phosphate moiety is 
called the 3′-end. 
 
 
 
Figure 1 – Structures of DNA and RNA. 
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The structure of DNA and its key role in holding all the information required for cell 
reproduction and function were first described by James Watson and Francis Crick in 
1953.4, 5 This discovery is often associated with the birth of modern molecular biology. 
Watson and Crick found that DNA is composed of two oligonucleotide chains coiled 
around each other to form a right handed double helix (Figure 2). These strands are held 
together through the formation of specific hydrogen bonds between the nucleobases 
which reside in the centre of the helix. The sugar phosphate backbones coil about the 
periphery of the helix, in such a way as to minimise the repulsion between the negative 
charges on the phosphate units. The two strands line up in an anti-parallel orientation 
(i.e. in opposite direction) and about a common central axis to form a double helix of 
diameter ca. 2 nm. 
 
 
Figure 2 – The structure of a part of DNA double-helix  
 
Each base is hydrogen bonded, in a phenomenon known as complementary base pairing, 
to a specific base on the opposite strand. This fact contributes to the fidelity of DNA 
replication. Double-helical nucleic acid molecules contain two grooves, called the major 
groove and the minor groove (Figure 2). These grooves arise because the glycosidic 
bonds of a base pair are not diametrically opposite to each other (Figure 3). 
 
Introduction 
5 
 
 
 
Figure 3 – Base pairing in DNA. Hydrogen-bonding shown in dotted lines. 
 
There are only two types of base pairs found in DNA, A-T and G-C, namely the Wat-
son-Crick base pairs (Figure 3). The distance between the two C-1’ atoms of the sugar 
phosphate backbone is the same in the two base pairs so that they can be interchanged 
within the double helix without distortion of the structure (Figure 3). This structure al-
lows for only sequence of bases on one strand if the opposite strand has the complemen-
tary base sequence, any other combination of bases would result into a considerable re-
orientation of the polymer chain. This complementarity let Waston and Crick4, 5 to sug-
gest that hereditary information is encoded in the base sequence on either strand. 
 
The structure of DNA described by Watson and Crick is now known as B-DNA but 
double-stranded (ds) DNA can also assume two others conformations, namely A-DNA 
and Z-DNA.  
 A-DNA B-DNA Z-DNA 
Shape Broadest Intermediate Narrowest 
Rise per base pair 2.3 Å 3.4 Å 3.8 Å 
Helix diameter 25.5 Å 23.7 Å 18.4 Å 
Screw sense Right-handed Right-handed Left-handed 
Base pairs per turn of helix 11 10.4 12 
Major groove Narrow and very 
deep 
Wide and quite 
deep 
Flat 
Minor groove 
Very broad and 
shallow 
Narrow and quite 
deep 
Very narrow and 
deep 
 
Table 1 – Comparison of the different forms of DNA 
 
In B-DNA, the major groove is deeper (8.5 Å instead of 7.5 Å) and wider (12 Å instead 
of 6 Å) than the minor groove. The larger size of the major grove in B-DNA makes it 
more accessible for interactions with proteins that recognize specific DNA sequences. 
Under physiological conditions, most DNA is in the B form. When the relative humidity 
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is reduced to less than ca. 75%, then A-DNA is found. A-DNA is a right-handed double 
helix like B-DNA, but it is wider and shorter and its bases pairs are titled (by 19o) rather 
than perpendicular to the helix. On the other hand, Z-DNA is a left-handed helix in 
which the backbone phosphate zigzag. This form is adopted by short oligonucleotides 
that have a sequence of alternating purines and pyrimidines. High salt concentrations 
are required to minimize electrostatic repulsion between the backbone phosphates, 
which are closer to each other than in A- and B-DNA. The properties of A-, B- and Z-
DNA are summarised in Table 1.6 
 
The second type of nucleic acids present in nature is RNA and is as important as DNA. 
Unlike DNA, an RNA molecule usually exists as a single strand, although significant 
segments may contain self-complementary sequences that allow parts of the RNA to 
fold and pair with itself to form double helices. Cells contain several types of RNA, the 
three majors are listed below: 
- Messenger RNA (mRNA) is the template that carries information from DNA and is 
used in the synthesis of proteins (see later Sections 1.1.3 and 1.1.4). The coding se-
quence of the mRNA determines the sequence of amino acid in the protein.6 
- Transfer RNA (tRNA) carries amino acids in an activated form to the ribosome for 
peptide-bond formation, the sequence is dictated by the mRNA template. It consists of 
ca. 75 nucleotides and there is at least one type of tRNA for each of the twenty amino 
acids.6 
- Ribosomal RNA (rRNA) is the major component of ribosomes and plays both a cata-
lytic and a structural role in the synthesis of proteins. The ribosome binds mRNA and 
carries out protein synthesis. It is the most abundant type of RNA in eukaryotic cyto-
plasm, ca. 80%.6 
 
1.1.2 DNA Replication 
 
The process of DNA replication is semi-conservative, as each strand of the polynucleo-
tide acts as a template for the reproduction of the Watson-Crick complementary strand 
through base-pairing interactions. The DNA molecule unwinds to form a replication 
fork and the two daughter strands are then synthesized by enzymes called DNA poly-
merases (Figure 4). The strand running from 5′ to 3′ is called leading strand and is syn-
thesized continuously by the addition of nucleotides donated by a nucleoside triphos-
phate to the 3′-OH group of a base-paired polynucleotide. The other strand is called the 
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lagging strand and is synthesized in small segments known as Okasaki fragments. These 
are subsequently joined together by the enzyme DNA ligase to give a complete strand. 
The process of replication gives two identical dsDNA molecules, each having one 
strand from the parent molecule and a new one. 
 
 
 
Figure 4 – Schematic representation of the process of DNA replication 
 
1.1.3 Transcription 
 
Since DNA is confined in the nucleus in the eukaryotic cell and protein synthesis occurs 
in the cytoplasm, processes that allow the transfer of information contained on DNA are 
required. Transcription is the process of making RNA from a DNA template. This starts 
with the unwinding of the DNA double helix by the enzyme helicase, in order to expose 
the template strand running from 5′ to 3′. Then several transcription factors bind to the 
DNA, upstream to the portion of the DNA used to produce RNA (i.e. transcription unit) 
and help the successful binding of RNA polymerase. The RNA polymerase then adds 
ribonucleoside triphosphate monomers (GTP, CTP, ATP and UTP) that are coupled to 
their complementary Watson-Crick base on the template strand. The transcription re-
sulting in a growing sequence of RNA continues until the RNA polymerase passes 
through a terminator sequence. This triggers RNA polymerase to release the DNA and 
ends transcription.  
 
1.1.4 Translation 
 
Translation is the process of synthesising a protein from an mRNA template. The proc-
ess begins with the small unit of ribosome binding onto the 5′ end of mRNA and mov-
ing to the initiation site. One of the key molecules involved in the process is tRNA. This 
is a short sequence of RNA made of 60-95 nucleotides, carrying an anti-codon comple-
mentary to mRNA codons and the corresponding amino acid. Complementary tRNA 
binds to the mRNA start codon and this event triggers the association of the large sub-
Introduction 
8 
 
unit of ribosome to the small one, both bound to mRNA. This association creates the P-
site (peptidyle) and the A-site (amino acyle); the first tRNA occupies the P-site, while 
the second tRNA coming next, occupies the A-site (and is complementary to the second 
mRNA codon). The first amino acid is then transferred to the A-site amino acid, the first 
tRNA exits the P-site and the ribosome moves along the mRNA sequence, this is the 
process of elongation. When a stop codon is encountered in the A-site, a release factor 
enters and binds, the translation is terminated. This triggers the ribosome to dissociate 
and the release of the newly formed peptide chain. This finally undergoes post-
translational modifications in order to become a mature protein. 
 
1.1.5 Mutations of DNA 
 
The process of DNA replication (Section 1.1.2) sometimes leads to nucleotides copying 
errors called mutations. These mutations can also be caused by viruses, exposure to 
chemicals, UV- and ionizing irradiations. Gene mutations have varying effects depend-
ing on where they occur; they may alter the function of the produced protein from trans-
lation of this gene and lead to serious health conditions. Mutations are classified in two 
families depending on the effect on structure: the small-scale mutations are those affect-
ing a small gene in one or few nucleotides, while the large-scale mutations affect the 
chromosomal structures and are therefore more drastic.  
 
Here, we are interested in small-scale mutations; these are again subdivided into three 
classes: insertions, deletions and point mutations. Insertions add one or more nucleo-
sides into the DNA while deletions remove one or more nucleosides from the DNA. 
Both cause significant alterations to the gene product as the insertion or the deletion of a 
number of nucleotides that is not divisible by three can cause disruption in the grouping 
of codons, resulting in completely different translation product from the original (see 
Section 1.1.4). If such insertion or deletion occurs early in the sequence, the product ob-
tained will be more altered. On the other hand, point mutations (also called single nu-
cleotide polymorphisms or SNPs) are the exchange of one nucleotide for another one. 
Two exchanges are possible: the exchange between two nucleobases of the same nature 
(pyrimidine for pyrimidine or purine for purine), which is the most common point muta-
tion and is called transitions; the other possibility, less common, is called transvertions 
and is the exchange of a purine for a pyrimidine or vice-versa. Point mutations can arise 
anywhere on DNA and those occurring within the protein coding region of a gene can 
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have dramatic effects. Mutation can be neutral when it results in the coding of a differ-
ent but chemically similar amino acid. The effects are usually negligible and this is 
therefore very similar to silent mutation. Silent mutation leads to the coding of the same 
amino acids from a different codon (e.g. codon AUU exchanges for codon AUC still 
encode leucine) and has no discernible effects on the protein produced. Nonsense muta-
tion results in a premature stop codon, leading to a truncated and often non functional 
protein product. Finally, missense mutation results in the coding of a different amino 
acid, leading to a non-functional protein. Such point mutations are responsible for hu-
man diseases such as sickle-cell disease and are found in p53. Protein 53 is a transcrip-
tion factor (i.e. a protein that binds to specific DNA sequences controlling the transcrip-
tion process of this portion) which is encoded by the p53 gene. It is part of the regula-
tory cell cycle and acts as a tumour suppressor. On this gene, the replacement of gua-
nine by adenine at base 524 leads to an altered p53 protein with an arginine being re-
placed by a histidine amino acid. This mutation is found in ca. 50% of human tumours 
and has been associated to aggressive growth of several types of cancer.7 Sequence-
specific analysis of the p53 gene can therefore become very useful to assist monitoring 
of cancer progress. 
 
Therefore, due to the impact that such small changes can have on human proteome, it is 
evident that the ability to detect these mutations both efficiently and rapidly is of impor-
tance for health care.  
 
1.2 NUCLEIC ACID-DETECTION TOOLS 
 
1.2.1 Background 
 
From Section 1.1.5, the development of sensitive, rapid and simple diagnostic tools, 
such as biosensors, therefore offer great promise for DNA diagnostics. 
 
Biosensors are small devices employing biological recognition properties for a selective 
bioassay. They rely on the intimate coupling of a biological recognition element with a 
physical transducer. The recognition element (also referred to as recognition layer) en-
ables selective detection of the analyte, while the transducer converts the recognition 
event into a useful electronic signal proportional to the concentration of the target ana-
lyte (Figure 5). The signal obtained can take a variety of forms such as a current, poten-
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tial, temperature change, absorption of light, or mass increase obtained through electro-
chemical, optical, or piezoelectric means. The signal may be further amplified, proc-
essed, or stored for later analysis.8 
 
 
Figure 5 – Principle for the detection of an analyte using a biosensor. 
 
DNA diagnostic tools have been developed for the detection and analysis of genes. The 
basis of these tools is the base pairing feature of DNA. They rely on the immobilisation 
of a small ssDNA probe (i.e. 25 to 40 mer) of known sequence onto the surface of the 
transducer. When the biosensor is exposed to a sample solution containing the target 
sequence, the target ssDNA molecules bearing the complementary sequence hybridise 
to the ssDNA probe at the surface of the transducer. This causes the transducer to send 
out the signal informing of the successful hybridisation event (Figure 6). A perfect 
match in the target sequence produces a very stable dsDNA complex, while the pres-
ence of one or more base mismatches decreases the stability, causing modifications in 
the signal. 
G
A
T
C
G
T
C
Transducer
PROBE
G
A
T
C
G
T
C
Transducer
C
T
A
G
A
G
C
TARGET
Hybridization Signal
 
 
Figure 6 – General DNA biosensor design.  
 
Two aspects are essentials when developing hybridisation biosensors: the sensitivity and 
the selectivity. It is mandatory that the tool is able to detect DNA at low concentration 
and to detect point mutations. Therefore, one requirement to obtain such a biosensor is 
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to ensure that the probe sequences are properly orientated (i.e. vertical) to allow maxi-
mum accessibility from the target molecule. The immobilisation step for the DNA probe 
must, therefore, be controlled. Different methods have been reported in the literature 
and the most common includes electrostatic adsorption,9 covalent immobilisation,10 and 
avidin (or strepavidin)-biotin interactions.11, 12 
 
Electrostatic adsorption has the advantage that it is fairly simple as it does not require 
any nucleic acid modification but has its own drawbacks. The principle of the method is 
based on ionic interactions occurring between negatively charged phosphate backbone 
of the DNA probe and positive charges covering the surface. The problem with this 
method is that the interactions are not specific; therefore, the strong affinity of DNA for 
the surface of the transducer results in the probe being fixed on the surface in multiple 
points and not just at one end as schematically represented Figure 6. This leads to low 
hybridisation efficiencies as the configurational freedom of the probe is restricted. An-
other drawback is that the target DNA will also have affinity for the transducer’s sur-
face, leading to non-specific adsorption of DNA. 
 
As an alternative to adsorption, one end of the probe strand can be modified with a reac-
tive group that can interact with the transducer surface leading to the formation of a co-
valent bond. An example of this is to the modification of the DNA probe at one of its 
end with a mercaptoalkyl linker (i.e. thiolated-DNA). This one point attachment method 
uses the strong affinity of thiol groups for gold surfaces, ensuring a strong bond be-
tween the DNA probe and the transducer surface (Equation 1).13  
 
 
 
Equation 1 
 
Thiolated-DNA self-assembles on the gold surface but the use of mercaptoalkyl linkers 
alone was not sufficient to ensure DNA proper orientation. In fact, a low hybridisation 
efficiency with target (between 0 and 5 %) is obtained, probably because of the affinity 
of the DNA bases for gold surfaces.14 This efficiency was greatly improved when the 
DNA-modified surface was incubated in a solution of mercaptohexanol used as a dilu-
ent layer (if the alkyl linker used was mercaptohexane). The affinity of the thiol moiety 
of the mercaptohexanol diluents for the gold surface allowed the DNA probe to be 
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raised off the surface. In addition, the negative dipole of the alcohol on the distal end 
repelled the negatively-charged backbone of DNA that resulted in a vertical position 
(Figure 7).15  
 
 
 
Figure 7 
 
Finally, the last immobilisation method commonly used involved the formation of non-
covalent avidin (or streptavidin)-biotin complex. Biotin (Figure 8) is a small molecule 
that binds with high affinity to the proteins avidin and strepavidin.11  
 
 
 
Figure 8 
 
This procedure is frequently used in the preparation of DNA biosensors as the biotin-
streptavidin complex is one of the strongest non-covalent interactions known in nature. 
In a general procedure, the avidin is first deposited onto the surface of a graphite elec-
trode, then the modified electrode is dipped in a solution containing the DNA probe 
which had been first biotinylated at its 5′-end, resulting therefore in the immobilisation 
of the probes. Finally, the electrode-modified with DNA probe is subsequently incu-
bated with solutions containing the targets for analysis.12 
 
The surface coverage is another important feature that needs to be controlled in order to 
prepare a sensitive biosensor. One could think that the larger the number of probes pre-
sents at the surface of the transducer, the greater the signal response and therefore, the 
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more sensitive the device. But if the space between probes on the surface is not suffi-
cient repulsion between the incoming DNA targets may hamper hybridisation which 
will therefore lead to low detection efficiency. An ideal surface coverage of ca. 5 × 1012
 
 
molecules/cm2 had been proposed by Peterlinz and Georgiadis.16 
 
In the following three subsections, three types of transducers (i.e. electrochemical, opti-
cal, and piezoelectric) currently available on the market will be briefly introduced and 
compared. 
 
1.2.2 Optical transducers 
 
Several different optical transducers are currently available for use in the development 
of biosensors, including fluorescence, colourimetry, surface plasmon resonance (SPR), 
chemiluminescence, interferometry and surface-enhanced Raman scattering (SERS) 
spectroscopy. All of these transducers are very sensitive and offer great platforms for 
the detection of nucleic acids. 
 
The most common DNA optical biosensors rely on a fibre optic to transduce the emis-
sion signal of a fluorescence tag. Krull et al.17 developed the first biosensor of this type 
which used ethidium bromide (EB) as the fluorescent label for recognising dsDNA 
(Figure 9). 
 
 
 
Figure 9 – Chemical structure of ethidium bromide 
 
The fluorescent ethidium cation (3,8-diamino-6-phenyl-5-ethyl-phenanthridium) is well 
known to strongly associate with dsDNA by intercalating between base pair (pi-stacking 
interactions).17, 18 It was this strong interaction of EB for dsDNA which was explored in 
Krull’s biosensor. In their approach, the target sample of dsDNA was first exposed to an 
EB solution. Subsequently, any remaining unbound EB was removed by washing. The 
fluorescence intensity of EB was recorded by UV-visible spectroscopy. Since the fluo-
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rescence intensity is directly proportional to the amount of EB bound to DNA, the 
amount of dsDNA in the original sample could be determined. Today, the original 
mutagenic EB employed by Krull et al.17 has been largely replaced by Synergy Brands, 
Inc. (SYBR®) stains; these have become very popular due to their sensitivity and ease-
of-use. SYBR green I (Figure 10), SYBR green II and SYBR gold are by far the best 
high-sensitivity reagents commercially available.19  
 
 
 
Figure 10 – Chemical structure of SYBR green I 
 
The quantum yields for these new stains are many folds superior to EB. Table 2 summa-
rises the excitation and fluorescent emission characteristics of these stains. 
 
Stain Excitation max Fluorescent emission max 
SYBR Gold ~ 495 and 300 nm ~ 537 nm 
SYBR Green I ~ 497, 380 and 290 nm ~ 520 nm 
SYBR Green II ~ 497 and 254 nm ~ 520 nm 
 
Table 2 – Comparison of excitation and emission maxima. 
 
SYBR gold has a high quantum yield (~0.6) upon binding to ds and ssDNA or to RNA. 
SYBR Green II is highly sensitive for detecting RNA or ssDNA with a quantum yield 
of (~0.54) when bound to RNA. Its quantum yield to dsDNA is lower (~0.36) making it 
the stain of choice for RNA detection. Finally, the quantum yield of dsDNA/SYBR 
Green I complex is ca. 0.8 and it is much lower for ssDNA and RNA, so this stain can 
be used for the detection of dsDNA in complex mixture. These three staining reagents 
offer a great fluorescence enhancement upon binding to nucleic acids. Although, 
SYBRs dyes are less toxic than EB, they are still prepared as dimethyl sulfoxide 
(DMSO) solutions; thus, there is a risk of their skin penetration for the operator. With 
the introduction of biosensor technology, the use of staining reagent has been replaced 
by fluorescent labels that are incorporated into the DNA probe using either enzymatic 
incorporation (RNA or DNA polymerase) or the direct labelling strategy. For example, 
KREACHER Biotechnology BV have developed and patented a direct labelling method 
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using a platinum compound that connects the label in the N-7 position of guanine bases. 
Alternatively, labels can be added to the 3′-terminus of the probe by using the enzyme 
terminal deoxynucleotidyl transferase (TdT) in combination with labeled uridine 
triphosphates (UTP), deoxyuridine trisphosphates (dUTP) or deoxycytidine triphosphate 
(dCTP) nucleotides. Molecular Probes, a subsidiary of Invitrogen Ltd., has developed a 
series of fluorescent dyes that span the whole visible spectrum (Figure 11) with a supe-
rior brightness than common dyes, these are called Alexa® Fluor. Alexa® Fluor dyes 
are synthesised via sulfonation of coumarin, rhodamine, xanthenes and cyanine dyes. 
These novel fluorophore are more photostable allowing longer recording time of the im-
age obtained. Sulfonation leads to negatively charged molecules that are therefore more 
soluble in water. These dyes are also less sensitive to pH than common dyes. But they 
are also more expensive and patented by Invitrogen Ltd. 
 
 
 
Figure 11 – Diagram representing the fluorescence emission of Alexa® fluor dyes. 
 
Table 3 summarises the excitation and emission maxima as well as colour obtained. 
 
Fluorophore Ex* Em* Colour Similar dyes 
Alexa Fluor 350 346 442 Blue AMCA 
Alexa Fluor 488 490 520 Green Fluorescein 
Alexa Fluor 532 534 550 Yellow Rhodamine 6G 
Alexa Fluor 546 561 570 Orange Cy3 dye 
Alexa Fluor 568 575 600 Red Lissamine rhodamine B dye 
Alexa Fluor 594 590 615 Red Texas Red dye 
Alexa Fluor 647 650 670 Far-red Cy5 dye 
* Excitation (Ex) and Emission (Em) maxima, in nm 
 
Table 3 
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The structures of some Alexa® Fluor labels and others dyes commercially available are 
represented in Figure 12. 
 
 
 
Figure 12 – Structures of commonly used fluorescents dyes. 
 
The spectral diversity offered by these fluorescent labels (Table 3) gives researchers the 
possibility to carry out multicolour fluorescence hybridisation strategies, commonly car-
ried out on microarrays. It is possible to distinguish four to five different fluorescent 
signals in a single sample using their excitation and emission properties alone along 
with the appropriate optical filters. The use of microarray minimises the artefactual 
variation in signals. These fluorescence-based optical biosensors offer increased sensi-
tivity with nanomolar concentration detection limits. But this method has disadvantage 
of the requirement for the use of highly precise and expensive instrumentation [such as 
microscopy-coupled charge-coupled device (CCD) cameras, fluorescent scanner]. So-
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phisticated numerical algorithms to interpret the data are also mandatory, which there-
fore limit the method to research laboratories principally. Another problem commonly 
reported is the inconsistencies in yields of target DNA synthesis and labelling, as well 
as non-uniform rates of fluorophore photobleaching that can make the accuracy of the 
assay lower than what is required for gene analysis.20 
 
An alternative strategy which has been employed to detect DNA by fluorescence, in-
volves the use of molecular beacons (MBs). MBs are ssDNA probes that possess a 
stem-and-loop structure.21, 22 The loop portion is complementary to the DNA target. A 
fluorophore (e.g. 6-carboxytetramethylrhodamine, TAMRA) and a quencher (e.g. (4-(4-
(dimethylamino)-phenyl)azo)benzoic acid DABCYL) are linked to the two ends of the 
stem (Figure 13).  
  
 
 
 
Figure 13 – Immobilised molecular beacon’s strategy and structures of a fluorophore 
and a quencher. 
 
In its native state, the probe is a hairpin; in this form, the fluorophore lies close to the 
quencher and thus its fluorescence is quenched by energy transfer (Figure 13). How-
ever, in the presence of the DNA target, the MB undergoes conformational reorganiza-
tion to allow the loop to hybridise to the target. As a result the probe adopts a single 
strand structure which separates the fluorophore and the quencher. Thus, this reorgani-
sation leads to emission of an intense fluorescent signal. Biosensors based on MB tech-
Introduction 
18 
 
nology have been found to be more sequence selective than devices using linear probe. 
The detection limit is ca. 10-9 M.23, 24 
 
Surface Plasmon Resonance (SPR) is another commonly used optical technique that has 
been extensively developed in recent years in nucleic acid biosensors.25 SPR can be util-
ised to monitor refractive index changes at a surface. When light is incident on a prism 
side at a particular angle, called the resonance angle, the intensity of the reflected light 
is at its minimum. When biomolecules are present on the surface, this variation angle is 
very sensitive and the changes in reflectivity give a signal proportional to the amount of 
the target bound to the surface.13 Nucleic acid biosensors based on SPR are typically 
prepared by immobilising ssDNA probes onto the metal surface (e.g. gold); when the 
target DNA subsequently binds to the probes, the mass increases leading to an increase 
of the refractive index.26 SPR has the advantage of being able to detect nucleic acids 
without labels and allows the measurement of the kinetics of biomolecular interactions 
in real time with high degree of sensitivity (detection limit ca. 10-9 M).13 Furthermore, 
this method is suitable in array-based formats. However, the employment of SPR is hin-
dered by a few disadvantages which include the cost and complexity of the technology 
required, making this technique more suitable for research applications.27, 28 In addition, 
it has been reported that the sensitivity of the SPR technique is altered in the case of 
short-chain DNA molecules (15 mer) or highly diluted target solutions: in such cases, 
the resonance shifts are too small to facilitate detection. However, Liebermann et al.29, 30 
have reported a method that combined SPR and fluorescence detection. In their ap-
proach, the resonant excitation of an evanescent surface plasmon is used to excite a 
fluorophore that is chemically attached to the nucleic acid target. Upon binding to the 
probe immobilised at the surface of a metal, this chromophore reaches the strong optical 
fields that are obtained at the surface plasmon resonance giving rise to significant ena-
hancement.30 
 
1.2.3 Electrochemical transducers 
 
In electrochemical DNA biosensors, the transducer is an electrode onto which the DNA 
probe has been immobilised. This method involves monitoring the current response 
produced upon exposure of the electrode to the target ssDNA as a result of the hybridi-
sation event, under controlled potential conditions.31 The probe-coated electrode is im-
mersed into a solution containing the target DNA sequence to be tested. The target 
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DNA, which contains a sequence that matches that of the immobilised probe, binds to 
the probe and a DNA duplex forms at the surface of the electrode.32 The formation of 
this duplex is then detected via the increased current signal of a redox indicator. Two 
approaches are then possible: these are referred to as ‘label’ method and the ‘label-free’ 
method. 
 
‘Labelled’ methods use redox active molecules, that are present in the solution (e.g. en-
zyme,33 intercalative redox substance,34, 35 an interactive electroactive substance36), 
which preferentially interact with dsDNA, for example Co(phen)33+ (Figure 14). 
 
 
 
Figure 14 – Diagram of an electrochemical DNA biosensor based on redox indicators. 
 
This area of research was pioneered by Mikkelsen’s group36 which first demonstrated 
the possibility of using the minor groove binding redox indicator, Co(Phen)33+, for the 
detection of the cystic fibrosis ∆F508 deletion sequence.36 In their work, the ssDNA 
probe was immobilised at the surface of the electrode and hybridisation to the target 
caused an increased in the surface concentration of electrostatically bound Co(Phen)33+ 
resulting in a higher negative charge density at the surface. The readout was then pro-
vided through characteristic redox reaction of the cobalt. 
 
Brossier and Limoges33 have reported the development of an electrochemical biosensor 
which uses an enzyme as the label and used it for the detection of a gene sequence re-
lated to the human cytomegalovirus (HCMV). The probe of this biosensor was prepared 
from amplified HCMV ssDNA that has been adsorbed onto the surface of a screen-
printed carbon electrode. The target sample was a biotinylated-modified ssDNA strand 
complementary to a portion of the probe. The hybridisation event was detected via 
streptavidin which was conjugated to horseradish peroxidase (HRP). The peroxidase 
label was, subsequently, indirectly quantified by measuring the amount of the chromo-
phore and electroactive product 2,2’-diaminoazobenzene (A – Figure 15) generated 
from o-phenylenediamine. The intensity of the differential pulse voltammetric peak cur-
rents is related to the number of HCMV-amplified DNA molecules present in the sam-
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ple. The detection limit obtained with this method was 0.6 × 10-15 mol / L (i.e. 230,000-
fold more sensitive than gel electrophoresis).33 
 
 
 
Figure 15 – DNA hybridisation detection using an enzyme. 
 
New electroactive indicators, offering better distinction between ss and dsDNA have 
been reported for attaining higher sensitivity.13, 32 For example, Takenaka et al.35 have 
reported a detection limit of 10-21 mol when using the threading intercalator ferrocenyl 
naphthalene diimide (FND) that binds to the DNA duplex more tightly than usual inter-
calators and displays only negligible affinity for ssDNA probe (Figure 16). 
 
 
 
Figure 16 – Chemical structure of the FND. 
 
As mentioned earlier ‘label-free’ electrochemical approaches are also possible, they rely 
on either the change to the electrical characteristics of the DNA-modified interface upon 
hybridisation or on the natural electroactivity of DNA.32, 37 Such protocols greatly sim-
plify the sensing operation and produce an instantaneous readout.13 These assemblies 
operate by monitoring the changes in the intrinsic redox activity of the probe DNA in-
duced during the hybridisation event. Of the four nucleic acids bases present, guanine is 
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the most easily oxidized and therefore the oxidation of this nucleobase can be monitored 
in indicator-free hybridisation detectors.32 This method cannot be used for the detection 
of targets containing guanine bases. Wang et al.37 have described a way to overcome 
this limitation, by using inosine-substituted (guanine-free) probes. Inosine preferentially 
forms base pair with the target cytosine residue and its oxidation signal is well separated 
from the guanine response. This allows direct detection of the DNA hybridisation 
through the appearance of the target guanine oxidation signal. 
 
In summary, electrochemically based DNA hybridisation biosensors offer many advan-
tages, such as high sensitivity, selectivity, low cost and the possibility for miniaturiza-
tion, without the use of expensive instruments. 
 
1.2.4 Mass-sensitive devices 
 
The last transducer commonly used for the detection of DNA hybridisation uses a 
quartz-crystal microbalance (QCM). These sensors are made of a thin quartz disc sand-
wiched between a pair of electrodes. Quartz is a piezoelectric material meaning that it 
deforms when an electric field is applied across the electrode. The quartz crystal has a 
resonance frequency which is dependent on the total oscillating mass. This frequency 
increases with an increase in material mass on the QCM surface.38 Therefore, QCM bio-
sensors monitor the mass change of the immobilised recognition layer which occurs 
upon target hybridisation. These are label free biosensors.  
 
Another mass-sensitive method has recently emerged which relies on the use of micro-
cantilever sensors. Hansen et al.39 have employed this method for the detection of a sin-
gle-nucleotide polymorphism, by means of a gold-coated silicon AFM cantilevers onto 
which a thiolated 20-mer probe ssDNA was immobilised. Subsequently, hybridisation 
of the probe to the target was detected by the deflection of a laser beam reflected from 
the cantilever. These systems offer many advantages compared to conventional biosen-
sors including reduction in the size of the device and high precision. However, the costs 
associated with such specialised instrumentation currently limit these methods to re-
search laboratories. 
 
In summary, numerous methods for the detection of nucleic acids have emerged and the 
limits of detection reached are today very low. The commercially available technologies 
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in use at the moment permit both the rapid detection of DNA and reproducibility of re-
sults. However, each of the mentioned techniques has its specific advantages and disad-
vantages and the ideal method is yet to be described. For a more comprehensive cover-
age of the state-of-play of DNA biosensors, the reader is referred to the review article 
by Sassolas et al..13 
 
1.3 PNA – PEPTIDE NUCLEIC ACID 
 
1.3.1 Background 
 
Nielsen et al. originally designed and developed peptide nucleic acid (PNA) as a reagent 
to sequence specifically target dsDNA as a mimic of triplex forming oligonucleotides. 
They believed that such synthetic oligonucleotides would bind as a third strand in the 
major groove of a DNA double helix via T⋅A−T and C+⋅G−C Hoogsteen base pairing 
(Figure 17).40-44 
 
          
 
Figure 17 - T⋅A-T and C+⋅G-C triplets involving Hoogsteen / Watson-Crick base pairs. 
 
However, PNAs turned out to be a good structural mimic of DNA, attracting therefore 
wide attention in medicinal chemistry for development of gene therapeutic (i.e. an-
tisense and antigene) and in genetic diagnostics. Here the entire negatively-charged, 
sugar-phosphate backbone of DNA was replaced with a neutral, “peptide-like”, back-
bone consisting of repeating N-(2-aminoethyl)glycine monomeric units (Figure 18).42, 43 
 
 
 
Figure 18 – The structure of PNA compared to DNA (B = nucleobase) 
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The four natural nucleobases were retained and attached to the central amine via an ace-
tyl linker. This arrangement of atoms matches the ‘6 + 3’ number of bonds arrangement 
found for DNA (i.e. in DNA six bonds separate each nucleobase unit and the distance 
between the backbone and the nucleobase is three bonds).42, 43 
 
1.3.2 PNA hybridisation 
 
PNA oligomers bind strongly and with higher sequence discrimination to complemen-
tary oligomers of DNA, RNA or another PNA, than their natural counterpart.45 The re-
sulting hybrid stabilities [quantified through the measurement of its melting temperature 
(Tm)] fall into the following order: PNA-PNA > PNA-RNA > PNA-ssDNA (> RNA-
ssDNA > ssDNA-ssDNA). PNA-ssDNA hybrids are more stable than the corresponding 
DNA-DNA complexes, resulting in an increase in the melting temperature of approxi-
mately 1 oC/base.45 PNA-RNA complexes are even more stable, showing an increase of 
about 1.5 oC/base45 compared to their natural counterparts. PNA hybrids can be formed 
both in the antiparallel and the parallel configuration. The antiparallel complexes have 
the higher thermal stability, ca. 1-2 oC more stable, than the parallel ones.45 The stabili-
ties of PNA hybrids are, in contrast to hybrids between two anionic oligomers like 
DNA-DNA and DNA-RNA, relatively independent of ionic strength, due to the neutral 
character of the backbone. PNA also show greater sequence discrimination in recognis-
ing DNA. A decrease in Tm of between 8 and 20 oC for single base mismatches has been 
observed for a 15-mer PNA.45  
 
Homopyrimidine and oligomers with high pyrimidine:purine ratio have been found to 
bind to complementary DNA sequence with a 2:1 stoichiometry via the formation of 
(PNA)2/DNA triplexes using both Watson-Crick and Hoogsteen base pairing (Figure 17 
and Figure 20). These triple helices are more stable than their corresponding DNA du-
plexes: the Tm value of the hybrid of the PNA H-(T)10 with its Watson-Crick comple-
mentary deoxyribose (dA)10 has been found to be 73 oC whereas the Tm value of the 
corresponding (dT)10:(dA)10 duplex has been measured to be less than 23 oC.40  
 
Homopyrimidine PNAs can (but not always) bind to dsDNA with displacement of the 
Watson-Crick non-complementary strand to form a (PNA)2-DNA triplex and a dis-
placed strand analogous to a P-loop (Figure 20).40, 46, 47 Homopurine PNA oligomers are 
capable of invading dsDNA but fail to form triplexes and result in less stable com-
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plexes.46 With a few exceptions,47 strand displacement using mixed sequence PNAs has 
not been observed. It appears that they do not provide enough free energy upon hybridi-
sation for this mode of binding. One possible solution to this problem is the simultane-
ous targeting of both dsDNA strands. This would require two complementary sequences 
of PNA which would “quench” one each other by forming very stable PNA-PNA du-
plexes. 
 
 
 
Figure 19 – Structures and interactions between pcPNAs with adenine and thymine. 
 
However, Lohse et al.48 have reported a solution of this limitation using pseudo-
complementary PNAs (pcPNAs - here adenine and thymine have been substituted for 
diaminopurine and thiouracil, respectively - Figure 19). These recognise their DNA tar-
gets but not each other and therefore target dsDNA. This method proved successful and 
afforded double duplex strand invasion complexes whereby each of the strands in the 
DNA is bound to pcPNA. 
 
                                              
 
Figure 20 - Modes by which PNA can bind to dsDNA. 
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1.3.3 PNA in therapeutic strategies 
 
Owing to their unique properties briefly listed in the previous section, PNAs represent 
attractive candidates for the next-generation of genetic therapeutic drugs designed to 
interfere selectively with gene expression. The use of PNA oligomers in antisense and 
antigene biotechnologies holds considerable promise.  
 
 
 
Figure 21 
 
In principle, two strategies can be adopted (Figure 21): (1) PNA can be designed to rec-
ognize and hybridise to complementary sequences in a specific gene and therefore inter-
fere with the transcription of this gene (i.e. antigene therapy); and (2) a PNA oligomer 
can be designed to target mRNA and thereby inhibit its translation into proteins (i.e. an-
tisense therapy).49, 50 
 
The potential of PNAs as both transcription and translation inhibitory agents has been 
shown through a number of in vitro experiments. Translation arrest requires a (PNA)2-
RNA triplex, thus a homopurine target of 10-15 bases. Mixed sequence duplex-forming 
PNAs have been shown to exhibit antisense activity only when targeted to the AUG 
(initiation) region, whereas similar PNAs had no effect when targeting the coding re-
gion.51 Since PNA-RNA duplexes are not substrates for ribonuclease H (RNase H), the 
resulting antisense effect is based on the steric blocking of RNA processing or transla-
tion.51 Mologni et al. have reported the effects of three different types of antisense on 
the in vitro expression of the PML/RARα gene.52 The first one was complementary to 
the first AUG site. The second could bind to a sequence in the coding region that in-
cludes the second AUG, the starting site for the synthesis of an active protein. The third 
PNA was targeted against the 5′-untranslated region (UTR) of the mRNA, the point of 
assembly of the translation machinery. Limited effects were obtained when these PNAs 
were used separately, but they provided an efficient inhibition of translation when used 
together. Almost total inhibition was obtained at concentration between 0.6 and 
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0.8 µM.52 These data show that an effective translation inhibition can be achieved by 
combining PNA targeting at 5′-UTR and AUG regions. 
 
PNAs have also been shown to arrest transcriptional processes thanks to their ability to 
form a staple triplex structure and a strand-invaded or strand displacement complex with 
DNA.53 An example has been reported by Lee et al.,54 who have demonstrated that PNA 
complementary to the primary site of the HIV-I genome can completely block priming 
by tRNA3Lys. Consequently, in vitro initiation of reverse transcription by HIV-1 RT 
was blocked. These results show that PNAs targeted to various critical regions of the 
viral genome can have strong therapeutic potential for interrupting the replication of 
HIV-I.54 
 
Unfortunately due to the poor uptake of PNA by living cells, further investigations in 
vivo have been held back.55 However, a variety of potential cellular delivery systems are 
currently being investigated in order to overcome this difficulty. These involved the 
modification of PNA through conjugation to lipophilic moieties and the conjugation to 
cell-membrane crossing peptides.55 Regrettably, to date these have not shown the break-
through expected. 
 
1.3.4 PNA as a diagnostic tool 
 
Thanks to their unique hybridisation properties, PNAs have found applications in the 
field of detection of point mutation responsible for genetic diseases (see Section 1.1.5).  
PNAs have been used in pre-diagnostic tools such as PCR clamping. This application 
relies on the fact that PNAs cannot act as primers in the polymerase chain reaction 
(PCR).56, 57 PCR is widely used as amplification tools prior to performing nucleic acid 
detection, when the quantity of DNA in the sample is too small for analysis. PCR re-
quires two oligonucleotide primers, one to hybridise each DNA strand. Their binding 
sites flank the sequence to be amplified. A PCR cycle consists of the DNA first being 
denatured at high temperature (90 oC) and then allowing the primers to anneal at a lower 
temperature (50 oC). Subsequently, the polymerase chain reaction, carried out by the 
enzyme DNA polymerase, takes place at an intermediate temperature (70 oC). This cy-
cle is repeated up to 30 times in order to greatly increase quantities of the desired DNA 
sequence. Unfortunately, the general applicability of this approach is limited by the fact 
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that the majority of primer-template mismatches have no significant effect on the ampli-
fication process.58  
 
In order to improve this situation, Ørum et al.56, 57 have developed a method that en-
hances the specificity of the PCR reaction by targeting the initial step involved in non-
specific amplification, known as PCR clamping (Figure 22). 
 
 
 
 
Figure 22 – Schematic illustration of PCR clamping method. 
 
A PNA oligomer complementary to the wild-type genetic nucleic acid sequence under 
investigation is added (A – Figure 22). This hybridises to the target and sterically hin-
ders annealing of the primer. This excludes the wild-type sequence from successful 
PCR amplification. However, for mutated sequences (B) the primer is able to out-
compete the PNA and binds to the DNA. Therefore, allowing for preferential amplifica-
tion of mutated sequences only. This method has been shown to be successful at both 
the level of single56 and multiple59 base mutations. 
  
The overall performance of the DNA biosensors using ssDNA probes described in Sec-
tion 1.2 has been found to be dependent upon experimental variables that influence the 
hybridisation efficiency between the target and the analyte (e.g. temperature, probe 
length, ionic strength).60 Even under strictly controlled conditions, in the presence of 
single-mismatch ssDNA probes are still capable to hybridise to the analyte, therefore 
leading to a false result. They are therefore not very efficient for the detection of disease 
related point mutation. These limitations have been overcome by the introduction of 
PNA as a recognition element in nucleic acid biosensors and have enhanced the power 
of DNA biosensors. As mentioned earlier in this section, PNA have a higher affinity 
towards DNA than DNA does and the presence of a single mismatch is more destabiliz-
ing in PNA/DNA duplexes than it is in DNA/DNA duplexes. These properties have al-
lowed the development of more sensitive methods for the detection of mutations and 
single nucleotide polymorphisms (Section 1.1.5). 
Introduction 
28 
 
Like it is the case with ssDNA probes, the immobilisation step of PNA probes is very 
important and must result in readily accessible PNA probes surface layer. The same 
kind of immobilisation methods are used for PNA probes as it was the case for ssDNA 
probes (Section 1.2). Similar transducers (i.e. electrochemical, optical and mass-
sensitive) have also been used for monitoring the hybridisation between PNA probes 
and nucleic acids targets. The introduction of PNAs as probe has also opened the way to 
simpler indicator-free detection schemes. For example, electrochemical strategy could 
be used for detecting the sugar moiety of the hybridised DNA target (since PNA do not 
have a sugar backbone). Also PNAs do not have phosphorus, so the phosphorus signal 
can be used for detecting the hybridised DNA. Laser-based fluorescence detection, in-
volving two different PNA probes labelled with a different dye has been used to screen 
mixtures of oligonucleotide sequences.61 
 
Wang et al. have extensively studied the detection of the frequent point mutation found 
on p53 gene.7 These researchers have used two 17-mer probes with the same sequence, 
one ssDNA and one PNA. They also used three DNA targets, Target I is a 17-mer and is 
complementary to the probes while Target II (also a 17-mer) has a one-base mismatch, 
finally Target III (a 30 mer) is an extension of the 17-mer DNA at both ends (Figure 
23). 
 
PNA probe: H-GGG GCA GTG CCT CAC AA-LysNH2 
DNA probe: 5′-GGG GCA GTG CCT CAC AA-3′ 
Target I: 5′-TT GTC AGG CAC TGC CCC-3′ 
Target II: 5′-TT GTG AGG CGC TGC CCC-3′ 
Target III: 5′-CGG AGG TTG TGA GGC ACT GCC CCC ACC ATG-3′ 
 
Figure 23 
 
The hybridisation of probes to targets was monitored using the sensitive constant-
current chronopotentiometry (i.e. electrochemical) with a Co(phen)33+ redox indicator 
on a carbon paste electrode. The results obtained showed that the PNA probe was, as 
expected, more discriminating towards the single mismatch present on Target II than the 
corresponding DNA probe. 
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This remarkable mismatch discriminating capability of PNA based biosensors has also 
been illustrated in connection with the use of quartz crystal microbalance transducer.62 
Finally, PNA is easily synthesised on automated instruments and this offers the possibil-
ity to prepare high density micro-arrays for high throughput experiments.63 In the over-
all, PNA has more applicability as probes than their natural counterpart. 
 
1.4 POLYDIACETYLENE (PDA) MATERIALS 
 
1.4.1 General background and polymerisation 
 
It has been known for over a century that on application of heat, γ or UV-irradiation, 
diacetylenes undergo a colour change in the solid state.64-67 However, the chemical 
change was not understood until 1969 when Wegner et al.64 suggested a 1,4-addition of 
successive diacetylene molecules affording a polymer with a fully conjugated back-
bone.66 
 
 
Scheme 1 
 
The polymerisation can be initiated by photochemical, thermal or high-energy irradia-
tion of the monomer crystals. Polymerisation proceeds within monomer crystals and is 
completely controlled by the packing of the monomer and is therefore termed 
topochemical.  
 
 
Figure 24 
 
For polymerisation to occur, the diacetylene monomers must be stacked so that one tri-
ple bond approaches the adjacent triple bond system at a distance lower than 4 Å.67 Po-
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lymerisation proceeds by successive titling of each molecule along the ladder with a 
minimum of movement of all atoms from their lattice site, this is known as the “least 
motion principle”. The angle between the diacetylene rod and the translational axis has 
to be of ca. 45o so that the specific volume and lattice symmetry can be retained.68 It has 
been observed that the distance obtained between the two side chains (d1 and d2) is very 
similar before and after polymerisation and this for a variety of studied polydiacetylenes 
(Figure 24). The polymer obtained from this reaction is usually highly coloured, with 
shades from blue to red to yellow. 
 
When PDA monomers have amphiphilic character, the monomers align and self-
assemble in aqueous solution. Amphiphilic diacetylenes are made of two parts: a polar 
headgroup and a hydrophobic lipid tail containing the diacetylene moiety. The tail it-
self is separated in three domains: the diacetylene group, the spacer between the 
headgroup and the diacetylene, and the terminal alkyl chain or lipid-chain (Figure 25).69  
 
 
Figure 25 – Diagram of a typical amphiphilic diacetylene and examples. 
 
Each element sited above plays a role in determining the shape that the self-assembled 
material takes. For example, the headgroup chirality strongly influences colloidal struc-
ture; amphiphilic monomers with achiral headgroups usually form spherical liposomes, 
whereas chiral amphiphiles form structures such as helices and tubules. The number and 
length of the tails largely controls the range of conditions under which an amphiphile 
will undergo self-assembly.69 Tieke et al.70 showed that the relative position of the di-
acetylene plays a significant role in the polymerisation and on the colour of the PDA 
obtained. When the diacetylene was moved closer to the head-group the polymerisation 
was reduced and the generated polymer was red or yellow rather than blue. For exam-
ple, 8,10- (m = 13; n = 6 – Figure 25) and 10,12-PCDA (5) give a blue polymer under 
UV irradiation while 6,8-PCDA (m = 15; n = 4) gives a red polymer and 4,6-PCDA 
(m = 17; n = 2) gives a weakly yellow one.69 It was also reported that a shorter spacer 
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leads to better packing of the amphiphiles but poorer polymerisation, and that an even 
spacer was found to give PDA with more blue character.71 
 
A large variety of forms and shapes have been prepared, depending on the application 
they were required for. These structures have been divided into five categories:69 Lang-
muir, Langmuir-Blodgett (LB), Langmuir-Schaefer (LS) films; self-assemble monolay-
ers (SAMs); multilayer coatings; colloids; and immobilised colloids (Figure 26). 
 
 
 
Figure 26 – Variety of forms obtained for diacetylene amphiphiles. 
Reproduced from ref. 69 with permission of The Royal Society of Chemistry 
 
Langmuir films are formed by spreading amphiphilic molecules at an air/water interface 
and compressing them into close-packed arrays. This form of PDA assemblies have 
been used for a variety of detection platforms.72 These films can then be studied directly 
at the air/water interface or transferred on solid support to make LB or LS films. Lang-
muir films are useful forms for spectroscopic and microscopic studies but their prepara-
tion requires skilled workers and sophisticated instruments. Jelinek et al.73 prepared 
Langmuir films by mixing diacetylene 10,12-TCDA (2 – Figure 25) and a phosphol-
ipid. These researchers noticed that the two components phase separated and that this 
segregation could be used for the incorporation of cell membrane components (i.e. pro-
teins). This type of assembly has been used to study the biomimetic character of PDA-
based materials.74 
 
PDA liposomes (which can be called vesicles) have also proved to be a popular plat-
form for bioassays development owing to their biomimetic nature.68 The words lipo-
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somes and vesicles have been interchangeably used and broadly referred to any struc-
ture composed of amphiphilic molecular bilayers that enclose a volume. Liposomes are 
formed by hydration of the appropriate amphiphile material in water or buffer employ-
ing a variety of methods such as sonication, solvent injection, or simple shaking.75 The 
diacetylene-containing lipids must hydrate and organize themselves into the correct 
packing and orientation in order to undergo the subsequent 1,4-addition to the conju-
gated polymer. Thanks to their shape, liposomes have been extensively used as 
biomimic of cells for membrane interactions studies. It is possible to incorporate up to 
70% of non-polymerisable lipids in diacetylene liposomes to give them the biomimetic 
character, with a membrane fluidity comparable to cell membranes, without interfering 
with the polymerisation of the diacetylene components of the PDA.76-78 Liposome for-
mation can be directly verified by transmission electron microscopy (TEM) or indirectly 
by the optical detection of a resulting blue colour; the polymerisation reaction itself is 
the evidence that an ordered lipid assembly has formed (but the converse is not always 
true). The formation of a coloured polymer can, therefore, be seen as a quick (and 
cheap) “benchtop” test of vesicle formation.68 
 
Thus, it is not surprising that this class of PDA-assemblies, coupled to their chromic 
properties, has led to their investigations for use in a wide range of biosensing applica-
tions.79 The most promising of these applications will be discussed later in more details 
in Section 1.5. 
 
1.4.2 Optical properties of PDAs 
 
As mentioned earlier the polydiacetylene polymer is formed by 1,4-addition of diacety-
lenic monomers, initiated by UV irradiation and the resulting polymer is intensely col-
oured, and typically deep blue. This deep colouration arises from pi-to-pi* absorption 
within the linear pi-conjugated backbone (due to alternating triple-bond/double-bond 
backbone structure). Absorption spectra of PDA materials typically show several peaks 
with maxima at ca. 650, 550 and 500 nm. These peaks are associated with the blue (650 
nm) and the red forms (or phases) of PDA (550 and 500 nm).80 The appearance and the 
ratio of absorbance peaks for given PDA material depend on the structure of the poly-
mer side chains, the extent of the polymerisation and the environment of the polymer. 
These polymers have been found to undergo colour transitions (usually from blue to 
red) in response to environmental stimuli: organic solvents (solvatochromism)81, 82, 
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heating (thermochromism),83-87 mechanical stress (mechanochromism)72, 88 and ligand-
receptor interactions (affinochromism or biochromism).76, 89-94 This colour transition is 
believed to be caused by structural perturbations that give rise to a gauche-trans con-
formational transition of the PDA backbone, resulting in shortening of the conjugation 
network and absorption at a shorter wavelength.95 The mechanism of chromic change 
has been studied by many research groups and it is now recognized that, upon polymeri-
sation, the alkyne carbons of the diacetylenic monomer change hybridisation from sp to 
sp2. The preferred bond angle also changes from 180o to 120o. This constriction results 
in an accumulation of strain in the material as polymerisation proceeds. The packing of 
the side chains creates a barrier that prevents the backbone from adopting a more re-
laxed form. Chromic change is, therefore, seen as a way to overcome the energy barrier 
to reorganization of the polymer backbone created by the side chains packing. An in-
crease of the temperature augments the motion of the side chains and allows changes in 
their packing. pH changes alter the hydrogen-bonding in head-groups allowing the me-
thylenes between these head-groups and the backbone to reorganise. In the case of tar-
get binding, a disruptive effect may induce changes in the head-group’s hydrogen-
bonding and alkyl chain packing. These conformational changes, thus, allow the back-
bone to adopt a more relaxed conformation that leads to the colour change.69 
 
The extent of the ‘blue-to-red’ transition exhibited by PDA materials upon exposure to 
external stimuli can be quantified via the colourimetric response (% CR). This term was 
first described by Charych et al.90 and is defined in Equation 2: 
 
 =  


 × 100 %           Equation 2 
 
B is the percentage of blue component in the material calculated from Ablue, the absorb-
ance of the “blue” component (ca. 650 nm) and Ared, the absorbance of the “red” com-
ponent (ca. 550 nm) (Equation 3): 
 
 =  
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                   Equation 3 
 
B0 is the percentage of “blue” of the PDA material in the absence of the external stimuli 
while Bv is the percentage of “blue” after exposure to the external stimuli. [Note: “blue” 
and “red” refer to the visual appearance of the material, not its relative absorbance.] 
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Most examples of biosensors based on PDA structures that have been reported in the 
literature show an irreversible blue-to-red colour change. That is, on removal of the ex-
ternal stimulus, the original colour of the PDA material does not return. However, re-
versibility is a mandatory feature for a reusable biosensor. Jonas and Charych96 have 
prepared hydrazide-modified diacetylene lipids 6 and 7 (Figure 27) and constructed 
PDA liposomes. These assemblies were reported to exhibit a reversible colour change 
when the pH of the solution was cycled between acidic and basic conditions. 
 
 
 
Figure 27 
 
More recently Ahn and Kim84 have prepared the PDA assemblies from diacetylene 8 
(Figure 28) that showed reversible colour changes as the temperature of the solution 
was cycled. They demonstrated that the double hydrogen-bonding system amongst the 
head-groups provides the film with the ability to recover its initial molecular organiza-
tion once the stimuli are removed.  
 
 
Figure 28 
 
Thus, it was reasoned that the irreversibility commonly noticed in PDA assemblies, was 
due to the hydrogen-bonding involved within the head-groups that are not strong 
enough to maintain and recover the original molecular organisation that the structure 
had before the application of the stimulus. However, no reversibility in the colour 
change has been demonstrated on the removal of a biological analyte. 
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In addition to the remarkable and readily detectable chromic properties, PDA materials 
in their “red” phase have been found to be fluorescent whilst “blue” PDA assemblies are 
not. “Red” PDA liposomes or films can be excited with wavelengths above 450 nm and 
this leads to the emission of two broad fluorescent peaks at ca. 560 nm and 640 nm.69 
This feature is highly attractive as such a system would generate a fluorescence (i.e. 
turn-on type) signal which is easier to detect rather than experiencing a loss or decrease 
of fluorescence (i.e. turn-off type).80 The mechanism giving rise to this fluorescence 
property is believed to be due to energy shifts in the lowest-lying excited states; the 
lowest excited state in the “blue” PDA has the same symmetry as the ground state (Ag) 
which is a dipole-forbidden transition. In “red” PDA, the lowest excited state has Bu 
symmetry, allowing radiative decay.80 It was shown that the fluorescence signals ob-
tained from “red” PDA materials are detectable using a commercially available fluores-
cence microscope. To date very few research groups have reported the use of this prop-
erty for the development of PDA-based biosensors.97 
 
The optical properties of PDA materials and their environmental susceptibility have 
been the basis for the majority of PDA-based detection systems. PDA films, liposomes 
and immobilised liposomes have proven to be effective biosensors for the detection of 
various biological entities as schematically represented in Figure 29. 
 
 
 
Figure 29 – Schematic representation of surface ligands interactions developed in col-
ourimetric PDA sensors.Reproduced with permission from ref. 84. Copyright 2009 
American Chemical Society 
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1.5 BIO-DETECTION APPLICATIONS OF PDAS SENSORS 
 
PDA-based biosensors have been intensively investigated for the detection of various 
biological molecules including viruses,90, 91, 98 proteins,76, 99 peptides,100 oligosaccha-
rides,101 bacteria,102, 103 lipophilic enzymes,89, 104 ions,94 and drugs.105, 106 A selection of 
the most promising PDA biosensors studied to date is covered in more detail in this sec-
tion.  
 
1.5.1 The use of PDA-based biosensor for the detection of viruses 
 
The detection of viruses, such as the influenza virus, requires a bioassay both sensible 
and rapid in order to give the correct treatment to the patient. Influenza is an enveloped 
RNA virus, with two glycoproteins at its surface, hemagglutinin (HA) and neuramini-
dase (NA). These two proteins play important roles in infecting host cells. Influenza vi-
ruses are classified in three categories (A, B, C) following the type of nucleoprotein pre-
sent in the virus. Influenza A is further divided into subtypes based on serological cross-
reactivity of HA and NA antibodies and they are expressed as a combination of 15 types 
of HA (H1-H15) and nine types of NA (N1-N9), for example H3N2 or H1N1.107 This 
disease is responsible for hundreds of thousands of worldwide deaths each year and is 
circulated very rapidly through the population. Although, the methods currently avail-
able for the detection are very precise, they are also lengthy and require labour-intensive 
laboratory procedures as well as trained personal to carry them out. The period of incu-
bation for the influenza viruses is 24 hours. If the patient misses the 48 hour window, he 
will not be able to take advantage of the potent antiviral drugs (i.e. Zanamivir and Osel-
tamivir) currently available on the market. Therefore, a clinical diagnosis tool providing 
on-site result is highly demanded, for fast diagnosis of the patient.108  
 
In 1993, Charych et al.90 described the first biosensor based on a polymerized bilayer 
assembly capable of detecting influenza A virus. In this work, their research established 
the whole field of PDA-based colourimetric biosensors. The bilayer developed was 
composed of a self-assembled monolayer of octadecyltrichlorosilane (OTS) and a LB 
monolayer of functionalised PDA. This film was designed to undergo a similar col-
ourimetric response to that which occurs through solvatochromism and thermochrom-
ism. The bilayer incorporated both a molecular recognition binding site and a detection 
element, to enable rapid and quantitative detection by visible absorption spectroscopy. 
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The recognition site introduced in the assembly was in the form of a sialoside lipid 
monomer (9 – Figure 30). This monomer contains a carbon-linked sialic acid head-
group which provides the molecular recognition site for the virus. In nature, the virus 
binds to terminal α-glycosides of sialic acid of cell surface glycoproteins and glycolip-
ids via hemagglutinin, thus initiating cell infection by the virus. In this work, Charych et 
al. replaced the naturally occurring oxygen glycoside with a carbon-linked in order to 
avoid hydrolysis by neuraminidase, an enzyme present on the surface of the virus. Ear-
lier work showed that this replacement did not affect the binding affinity of hemaggluti-
nin.109 
 
 
 
 
Figure 30 – Schematic diagram of the polymerised bilayer assembly. 
 
Therefore, a solution made from mixtures of 2 to 5% of sialoside lipid 9 and matrix 
lipid 10,12-PCDA (5) was spread on the water surface of a standard LB trough. The sia-
loside lipid was uniformly dispersed within the matrix lipid which allows optimum 
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binding of the virus.90 The resulting mixed monolayer was then compressed and polym-
erized by UV irradiation. The floating polymer assembly was lifted by the horizontal 
touch method onto a glass slide previously coated with self-assembled monolayer of 
OTS.110 The resulting bilayer assembly presented an array of carbohydrate ligands at the 
surface, linked to the polydiacetylene reporter unit. The tetraethylene glycol spacer 
served to extend the carbohydrate molecular recognition site beyond the carboxylic acid 
headgroups of the matrix lipid (Figure 30).  
 
The bilayer appeared as a blue film with an absorption maximum of 620 nm and a 
weaker absorption at 550 nm (solid line Figure 31). When the film was incubated with 
X31 influenza A virus, the binding of the viral hemagglutinin to the sialic acid residues 
on the surface resulted in a blue-to-red colour transition. The maximum at 550 nm in-
creased with a decrease in the maximum at 620 nm (dotted line Figure 31). No colour 
change was observed when the blue film was incubated with a blank solution of PBS 
buffer. This result demonstrated that polydiacetylene colour change arose from affinity 
binding (affinychromism).90 From the absorption spectra (Figure 31), Charych et al. 
were able to quantify the degree of colour change using the principle of colourimetric 
response (CR), explained earlier in Section 1.4.2. 
 
 
Figure 31 – Visible absorption spectrum of bilayer assembly before (solid line) and af-
ter (dashed line) viral incubation - From Ref. 90 
 
They found that the CR was directly proportional to the quantity of influenza virus em-
ployed90 and that the colour change was specific to interactions with the sialic acid resi-
due. In order to prove the latter, a number of competitive inhibition assays were carried 
out. For example, the bilayer assembly and the virus were incubated together in the 
presence of a known binding inhibitor, α-methyl-N-acetyl neuraminic acid (10 – Figure 
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32). In this case, no CR was observed. In order to confirm that this inhibition had been 
specific, the film and the virus were incubated together in the presence of two known 
non-inhibitor compounds, β-methyl-N-acetyl neuraminic acid (11) and α-glucose (12). 
This time, for both cases, a similar colour change was observed as when the PDA as-
sembly was incubated with the virus alone. 
 
 
 
Figure 32 – Compounds used for competitive inhibition experiments. 
 
The last experiment which was performed to show that specific adhesion of the virus to 
the PDA film had provided the colour change involved the use of a bilayer assembly in 
which the sialoside lipid (9) had been replaced by a lactose lipid (13 – Figure 32). Lac-
tose does not bind to hemagglutinin lectin. In this case, only a small CR (2 to 4%)90 was 
obtained after incubation of the film with the influenza virus. Finally, incubation of the 
original sialic acid derived assembly to a concentrated solution of bovine serum albumin 
failed to show any significant CR. These last two studies, when taken together, clearly 
indicated that non-specific adsorption of virus or protein to the film was not responsible 
for the dramatic CR observed in specific upon exposure of the sialic acid-containing 
PDA film to influenza A. From these investigations, Charych and co-workers concluded 
that the observed “blue-to-red” transition had to have been triggered by the specific 
binding of the virus to the sialic acid “head-group” leading to changes in the PDA back-
bone conformation. 
 
Following this finding, the same research group investigated the possibility of con-
structing a similar influenza virus biosensor where this time the assembly would take 
the form of liposomes (Figure 33).91 As mentioned earlier (Section 1.4.1), liposomes 
form when phospholipid or amphiphilic compounds are suspended in water and are 
sonicated (i.e. agitated by ultrasonic vibration). Thus, Charych et al.91 prepared lipo-
somes using the same mixture of sialic acid-functionalised diacetylene lipid 9 (5-10%) 
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and matrix lipid 5 as in their previous work on PDA thin films. To do that, the two lip-
ids were first mixed in chloroform in a test tube followed by evaporation of the solvent 
with a gentle stream of nitrogen; this left a thin film of lipid on the glass surface. To this 
was then added an appropriate amount of de-ionised water, so that the total lipid con-
centration was 1 mM. The mixture obtained was then heated for 15 minutes at 80 oC 
whilst being subjected to sonication. The warm solution was subsequently filtered 
through a 0.8 µm nylon filter to remove undispersed lipid and finally cooled overnight 
at 4 oC. Subsequently, this liposome solution was purged with nitrogen gas for 5 min-
utes and allowed to warm to room temperature. Finally, polymerisation was achieved by 
irradiation using a UV lamp (254 nm) positioned at a distance of 3 cm, for varying peri-
ods of time. Irradiation for 5 to 10 minutes was found to result in blue coloured lipo-
somes whereas irradiation for longer (up to 30 minutes) resulted in purple solutions.91 
 
 
 
Figure 33 – Schematic diagram of the polymerised liposome assembly. 
 
These aqueous solutions of sialic acid functionalised PDA liposomes were then exam-
ined for their abilities to detect the influenza A virus. It was found that when the influ-
enza A virus was added to the liposomes in PBS buffer, the solution immediately 
changed to a pink or orange colour, depending on whether the initial liposome prepara-
tion was blue or purple, respectively. The CR was determined for the different prepara-
tions and it was shown to be dependent on the amount of UV irradiation used for the 
polymerisation. The CR was 47% for the blue liposomes whereas the purple liposomes 
gave rise to a CR of 87%. It was, therefore, postulated that the enhanced sensitivity of 
the purple PDA liposomes was due to increased polymer content, as suggested by their 
higher optical density. Identical inhibition control experiments were carried out as has 
been described previously for the analogous PDA films and again the results indicated 
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that the observed CR was triggered by specific binding of the virus to the sialic acid 
head-groups. 
 
In addition to the work reported above on the use of PDA assemblies for the detection 
of influenza A, Jiang and co-workers111 have recently shown that PDA-based liposomes 
can be effectively used for the identification of avian influenza (H5N1) hemagglutinin 
HA1. In this case, the recognition element prepared consisted of active sialic acid-β-
glucoside (G1) and inactive lactose-β-glucoside (G2) receptors (either used separately 
or in conjugation). Both were attached via a tetraethylene glycol spacer to a C12 hydro-
carbon chain. These lipids were then physically embedded at different ratio (G1 only, 
G1+G2 and G2) within a matrix lipid made from 10,12-PDCA (5) and DMPC (dimyris-
toylphosphatidylcholine), through non-covalent interactions. They found that larger 
concentration of DMPC yielded more sensitive liposomes, up to a certain threshold 
value. Jiang et al. observed that G1-liposome solutions underwent a blue to purple tran-
sition as the HA1 concentration reached 20 ng/mL, whereas the colour of the G2 ana-
logue remained blue, meaning that no conjugation occurred. Finally, liposome-
(G1+G2), especially at 5:5 ratios, caused a remarkable colour change from blue to red 
even at low concentration of HA1 (ca. 10 ng/mL), showing a strong synergistic effect 
for the recognition of virus HA1. Although these tests have yet not been carried out in 
vivo, these findings demonstrated the possibilities of using PDA liposomes for future 
detection of pandemic viruses. 
 
1.5.2 The use of PDA-based biosensor for the detection of toxins 
 
A couple of years after the development of the influenza A virus biosensor, the group of 
Charych published results on the preparation and use of PDA assemblies (films98 and 
liposomes103) incorporating receptor molecules for the detection of toxins. Gangliosides 
are part of a family of molecules that reside within the cell membranes of neurons. They 
are lipid molecules which bear a carbohydrate group covalently attached to the extracel-
lular end of the lipid unit. The lipid chain anchors the carbohydrate head-group into the 
cell membrane. Two representative members of this family are the GM1 (14) and GT1b 
(15) gangliosides (Figure 34). The GM1 gangliosides, present on the surface of intestinal 
cells, are the primary target of cholera toxin, the neurotoxin responsible for the disease 
cholera. The GT1b gangliosides are located at the neuromuscular junction and are the 
primary target of botulinum neurotoxin, the neurotoxin responsible for botulism.  
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Since here natural gangliosides already contained a lipid functionality, Charych et al.98, 
103
 demonstrated that they could be directly incorporated into artificial PDA assemblies 
through non-covalent interactions in a manner analogous to the heterogeneous mixing 
of molecules in cell membranes. 
 
 
 
 
Figure 34 – Structures of GM1 and GT1b ganglioside used by Charych et al. 
 
The chromatic unit of the neurotoxin sensor was in his core composed of PDA and of 
either sialic acid PDA (9) or lactose-derivatized PDA (13) which acted as promoters 
(Figure 35).98 The presence of the “promoter” was found to be essential for the produc-
tion of a colourimetric response. It was postulated that the “promoter” PDA lowers the 
activation barrier for the chromatic transition, by changing the lipid packing and altering 
the effective conjugated length of the PDA backbone. It may also provide a connection 
between the non-conjugated receptor and the conjugated backbone, thereby enabling 
binding of the neurotoxin to the ganglioside headgroup and induce the associated col-
ourimetric transition. The LB films contained 5% of the ganglioside lipid GM1 (14) or 
GT1b (15) and either 5% of sialic acid-functionalised lipid (9) or 2% of lactose-
functionalised lipid (13). If higher concentration of gangliosides were used, then the po-
lymerisation was hindered by steric effects and films of poor quality were formed.98  
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Figure 35 – Schematic representation of LB film assembly containing GM1 and sialic 
acid-functionalised diacetylene lipid. 
 
By analogy with the influenza virus biosensors discussed previously (Section 1.5.1), a 
blue to red colourimetric transition was observed for these PDA films upon exposure to 
the appropriate neurotoxin (for GM1-containing biosensor CR = 7% for lactose-PDA; 
CR = 5% for sialic acid-PDA).98 Similar results were obtained using the GT1b gan-
glioside biosensor.  The CR was also found to be directly proportional to the quantity of 
toxin added.98 
Following on from this work, Charych et al.103 reported the incorporation of GM1 gan-
gliosides into PDA liposomes. This was accomplished in an analogous manner to the 
PDA liposomes which had been developed as influenza sensors (Section 1.5.1) and a 
similar colourimetric response on exposure to cholera toxin was observed, as for the 
analogous thin films. In order to prepare the liposomes, GM1 (5%) was mixed with the 
diacetylene lipid 5,7-DCDA as the matrix, rather than the usual 10,12-PCDA. The rea-
son for this difference was because it was found that if 10,12-PCDA (5) was employed, 
the CR of the resulting liposome was significantly reduced.103 The enhanced sensitivity 
of the 5,7-DCDA (4) system was suggested to be due to the positioning of the diacety-
lene moiety being nearer to the interface (4 has three methylene groups instead of eight 
in 5). As before, control experiments were carried out to prove that the colour change 
observed was caused by the specific recognition event and not due to non-specific ad-
sorption. 
Introduction 
44 
 
1.5.3 The use of PDA-based biosensor for the detection of nucleic acids 
 
The development of novel types of DNA-biosensors (such as PDA-based) is largely 
driven by the needs to effectively diagnose infectious and genetic diseases, detect ge-
netically modified organisms (GMO) and gather forensic evidence. As stated earlier, in 
order to accomplish this, simple, fast, reproducible and reliable techniques are required. 
Many groups have reported successful combinations of receptors for the detections of 
various biological molecules using PDA assemblies. But, from the reports found in the 
literature it appears that only a few of them have been interested in using PDA-based 
sensors for the detection of oligonucleotides.  
 
Wang et al.93, 112 have recently reported the use of PDA liposomes functionalised with 
oligonucleotide headgroups as nucleic acid biosensors. The oligonucleotide probes 
played the role of sensor and of amplification tag. In their work, Wang and co-workers 
have prepared two sets of PDA liposomes using a mixture of 10,12-TCDA (2 - 70%), 
DMPC (29 mol %) and an oligonucleotides probe modified with cholesteryl (probe 1 or 
probe 2, 1% - Figure 36). The probe was inserted within the liposome surface through 
hydrophobic interactions. The two probes were prepared with two different sequences 
of oligonucleotides and were designed to hybridise with only half of the DNA target, 
each probe targeting a different end of the DNA from the other probe (Figure 36). 
Therefore, 20 µM of target DNA was incubated with a mixture of probes 1 and 2 and 
the colour of the system turned from deep blue to red within minutes. The correspond-
ing CR was ca. 34%. With the decrease of the concentration of target DNA, the colour 
weakened as well as the corresponding CR decreased. In contrast to this case, the colour 
transition from blue to red was not observed when target DNA was added to the solu-
tions containing probe 1 or probe 2 only. This showed that the hybridisation of one half 
of the target did not impose enough mechanical stress to the PDA framework to yield 
the colour change. When 20 µM of a mismatched DNA target was added to the mixture 
of probe 1 and 2, no colour changes were observed. 
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Figure 36 – Schematic diagram of the colourimetric detection of DNA using PDA lipo-
somes functionalised with probe DNA 
 
To address the effect of non-specific interaction between liposomes and target DNA, 
liposomes composed of DMPC and TCDA only were incubated with 20 µM of target 
DNA and no colour changes were observed. Although this method demonstrates high 
specificity for the detection of the DNA target, it has some drawbacks. In fact, the ap-
plication of this method requires that for each target to be detected, two sets of PDA li-
posomes, modified with a probe sequence corresponding to half of the target, have to be 
prepared. Also, it implies the detection of single stranded nucleic acids, otherwise an 
extra denaturation step of dsDNA would be required and the temperature used for this 
step might influence the colours of the PDA liposomes (i.e. thermochromism of PDA). 
 
Another approach that uses PDA liposomes for the detection of nucleic acids has been 
described by Kim and Park.113 The researchers based the detection on ionic interactions 
occurring between the positively charged head-groups of PDA liposomes and the nega-
tively charged phosphate backbone of dsDNA. Two different amine-functionalised di-
acetylene monomers (a primary amine and a quartenary amine) have been designed, 
prepared and subsequently used to generate PDA liposomes. Therefore, they started 
with the preparation of the quaternary amine-functionalised PDA liposomes because 
unlike primary, secondary and tertiary amines, the presence of the positive charge on a 
quaternary amine is not dependent on the pH of the solution. Thus, the cationic amine-
modified diacetylene monomer DADMDPA-bis-PDA (DADMDPA stands for 3,3’-
diamino-N-methyldipropyl-amine) was incorporated in PDA liposomes using 10,12-
PCDA (5), 10,12-TCDA (1) or 2,4-HCDA (3) (Figure 25, page 31). Due to the differ-
ence in the chain length, the resulting liposomes would exhibit their ammonium 
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headgroups with more or less exposure. The researchers anticipated that the ionic inter-
actions would be maximised if the ammonium groups are fully exposed to the aqueous 
environment. The difference in exposure is schematically represented in Figure 37.  
 
 
 
 
 
Figure 37 
 
It is clear that, when PCDA is used as matrix lipid, the quaternary amine is not well ex-
posed to the aqueous exterior containing the nucleic acid analyte. Upon the addition of 
amplified nucleic acids with a size of 605 base pairs (bp) and a concentration of 100 nM 
no colour changes were observed when the system PCDA/DADMDPA-bis-PCDA was 
tested (CR was 2%).113 TCDA contains a two carbons shorter tail than PCDA but this 
small difference did not significantly improve the result as no colour change was ob-
served. A CR of 6.6% was obtained for this system. Finally, HCDA is two carbons 
shorter in both tail and head part of the molecule. Using the HCDA/DADMDPA-bis-
PCDA system, the colour of the solution changed from blue to purple and the corre-
sponding CR was 16%. In this system, the quaternary amine was sufficiently exposed to 
interact with the dsDNA target.  
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From these results, Kim and Park113 understood that the full exposure of the amine 
group is mandatory to induce the colour change. Thus, they prepared a primary amine-
modified diacetylene monomers bearing a spacer unit, EDEA [2,2’-(ethylene-
dioxy)bis(ethylamine)], between the lipid chain and the amine (Figure 38). This amine 
is positively charged in acidic solutions and the liposomes were obtained using the same 
matrix lipids as earlier (i.e. PCDA, TCDA and HCDA).  
 
 
 
Figure 38 
 
Liposomes composed of PCDA/PCDA-EDEA (Figure 38) in a molar ratio of 5:5 
showed the most dramatic blue-to-red colour change upon the addition of the amplified 
nucleic acids with a size of 605 bp and a concentration of 100 nM (CR was 46%).113 
Although, the CR obtained was high, this sensing strategy revealed some drawbacks. 
They relate to the non-specificity of the ionic interactions responsible for the colour 
change. These positively-charged liposomes have been found to be sensitive towards the 
PCR reaction buffer solution which contains many salt components. Thus, although, 
this ionic interaction approach appears limited, it may find use as a rapid test to verify 
the presence of PCR-amplified dsDNA. 
 
1.5.4 Other applications of PDA-based biosensors 
 
PDA-based liposomes have also been constructed in order to examine enzyme activity. 
Membrane peptides and membrane bound enzymes (such as phospholipases) have at-
tracted much interest as pharmaceutical drug targets as they are involved in membrane 
interactions and play major roles in numerous physiological processes (e.g. signalling, 
cytolysis, ion-channel formation, and cellular recognition). Phospholipases catalyze the 
hydrolysis of phospholipid molecules at the water-lipid interface of cellular membranes. 
Phospholipases are involved in diverse biochemical processes, such as fat digestion, 
Introduction 
48 
 
lipid metabolism and the regulation of signal transduction. PLA2 is an acyl hydrolase 
which hydrolyses the 2-acyl ester bonds of glycerophospholipids to yield the corre-
sponding fatty acid and lysophospholipid. Phospholipid C (PLC) and phospholipid D 
(PLD) are phosphodiesterases which attack the phosphate ester moiety within the lipid 
hydrophilic head-group. 
Jelinek and Charych104 incorporated DMPC into 10,12-TCDA (1) liposome. DMPC is a 
natural substrate of phospholipases so that the activities of three phospholipases were 
investigated: PLA2, PLC and PLD. 
 
 
Figure 39 – Structure of DMPC and the points of enzymatic cleavage. 
 
The assemblies in this study was composed of 40% DMPC and 60% of TCDA (Figure 
36) and following polymerisation, the resulting liposome solution showed a deep blue 
colour. The solution was treated with each of the phospholipases individually and, in 
each case, the expected blue-to-red colour transitions were observed (in the case PLA2, 
a CR of 15% was obtained). As for the virus and toxin PDA-based biosensors, control 
experiments were carried out to confirm that it was the specific interaction of the en-
zymes with the DMPC head-group which was responsible for the observed colour 
change. In addition, NMR studies were used to confirm the DMPC cleavage sites and to 
identify for each of the phospholipases the cleavage products.104 DMPC/PDA liposomes 
were found responsive to the presence of toxins that exhibit enzyme-like activity, such 
as β-bungarotoxin (BuTx) isolated from snake venom. This toxin acts at the presynaptic 
motor nerve termini to alter neurotransmitter release and the distribution of amino-
phospholipids in the inner- and outer-membrane leaflets.114 The detection of this toxin is 
also of significance as it is suspected to be used as potential biological warfare agent. 
The colour changes of the DMPC/PDA liposomes solutions was observed after only 10 
minutes (CR was 25%), although the maximum response was obtained after 50 min-
utes.104 
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Jelinek et al. have also demonstrated that DMPC/PDA liposomes can be used to inves-
tigate peptide-membrane interactions.77 This colourimetric assay has also been coupled 
with gel chromatography so that the fractions eluted from the separating column are 
then added to a separate well within a 96-well plate containing DMPC/PDA liposome 
solution.78 These PDA liposomes have also shown to afford a colourimetric response in 
the presence of specific cations, e.g. the capability to distinguish between Na+ and K+ 
has been demonstrated.94 By adding a hydrophobic peptide displaying an epitope, which 
recognizes a specific antibody, into the same kind of assembly, Jelinek and Kolusheva 
showed that it was possible to investigate specific antibody-epitope interactions.76 
 
Jiang et al. reported the colourimetric detection of the bacteria E. coli using glucoside 
decorated PDA liposomes.92 These liposomes were prepared, separately, from 2,4-
TCDA and 10,12-PCDA with 2% dioctadecyl glycerylether-β-glucoside (DGG) incor-
porated (Figure 40).  
 
 
 
Figure 40 
 
E.Coli was dispersed in an aqueous solution of sodium chloride and this was then added 
to the PDA liposome solutions. In the case of liposomes made from PCDA, no colour 
changes were observed, whereas with the liposomes made from TCDA, the system 
turned from deep blue to red within seconds. No colour changes were observed when 
the solution of sodium chloride only was added as well as when liposomes containing 
no DGG were stirred with the solution of E. coli. These tests showed that DGG/E.Coli 
interactions are responsible for the colour transition of the PDA liposomes. 
 
Li et al. have also described colourimetric detection of E. coli. In this case, 10,12-
PCDA liposomes were constructed with 5% mannoside conjugated to a hexadecane tail 
embedded.115 The colourimetric response of the system was 62%. In order to show 
specificity of the detection system, E. coli was first mixed with TiO2 colloids which 
acted as a photocatalyst. UV irradiation of this solution for 30 minutes leads to the de-
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struction E. coli, which was evidence by the lower value of the colourimetric response 
of the liposomes upon addition of this latter solution (CR 10%). 
 
Cheng and Stevens116 synthesised a series of amino acid-modified 10,12-PCDA lipids 
and incorporated them into PDA liposomes (Figure 41). ILE-PDA and PHE-PDA lip-
ids, both containing hydrophobic segments in the head-group region, did not produce 
liposomes, showing that the head-group requires hydrophilic character in order to align 
and self-assemble. 
 
 
 
Figure 41 
 
The liposome solutions using lipids GLU-PDA, GLN-PDA and HIS-PDA respond im-
mediately to an increase of pH by undergoing rapid blue to red colour transitions.116 
HIS-PDA also showed some unique properties in response to acidic pH change, while 
GLU-PDA and GLN-PDA did not. This can be attributed to the protonation of the imi-
dazole ring in the HIS-PDA lipid. The same kind of response was obtained with amine-
terminated DMAP-PDA lipid. It was suggested that the colour change was due to the 
charge-induced head-group rearrangement causing a conformational change in the 
backbone and hence inducing a colour change.116 
 
In conclusion, the variety of shapes obtained for self assembling PDA-based system as 
well as the wide variety of binding interactions described in this section indicates the 
potential of PDA-based systems as effective colourimetric biosensors. In particular, the 
ability that the PDA-liposomes have to mimic cellular membrane environment and 
shape leads to a variety of novel biochemical applications.  
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The use of PDA does not require sophisticated instrumentation for analysis and could be 
incorporated into portable devices. The colourimetric system described is robust and 
versatile; the liposome solutions can be stored at 4 oC and retain their colour sensitivity 
for long periods of time (i.e. months). The colour response is rapid and with the incor-
poration of the correct head-group, the response can be highly specific. Although the 
majority of the examples described previously showed that the colour response is irre-
versible, new developments into this field have shown the possibility for the colour 
change to be reversible, leading to reusable bioassays. 
 
Finally, it is worth noting that the recognition element can be either covalently linked to 
the PDA framework through copolymerisation or embedded within the lipid bilayer by 
hydrophobic interactions. The latter, therefore, allows the incorporation of natural 
molecules into synthetic liposomes and avoids difficult synthetic routes. 
 
1.6 PREVIOUS WORK IN THE GROUP INVOLVING PDA  
 
Prior to embarking on the research described in this thesis, two other projects have been 
undertaken at Heriot-Watt University which involved the preparation and investigation 
of suitably functionalised PDA liposomes for use as a nucleic acid biosensor. 
 
1.6.1 Acridine-functionalised PDA liposomes 
 
Murray117 reported the design of a novel nucleic acid binding assay based on the chro-
mic effects of acridine-functionalised PDA liposomes. In order to prepare these lipo-
somes, the two acridine derivatives (20) and (21) containing a diacetylenic lipid tail, an 
ethylene glycol spacer and the acridine intercalator as the head-group were first synthe-
sised. This was successfully achieved following the route outlined in Scheme 2.  
 
Commercially available 10,12-PCDA (5) was converted into N-succinimidyl-10,12-
pentacosadiynate (16) in 93%. The desired amine 17 was then obtained by dropwise ad-
dition of a solution of 16 through a syringe pump to a solution of the co-reactant dia-
mine over 16 hours (38%). Subsequently, the target acridines 20 (74%) and 21 (69%) 
were prepared by heating 18 and, separately, 19 with the amine 17 in a solution of phe-
nol.118 
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Scheme 2 
 
PDA liposomes were subsequently constructed containing 5% of models 20 or 21 and 
95% of the matrix lipid, N-(8-amino-3,6-dioxaoctyl)-10,12-pentacosadiynamide (17). 
Murray117 discovered that the protocol reported by Charych et al.90 for the preparation 
of PDA liposomes involving sonication of the lipid mixture at 70-80 oC could not be 
utilised in this case. The reason for this was because matrix lipid 17 spontaneously po-
lymerised over this range of temperatures. The liposome solutions were thus prepared at 
room temperature. Subsequently, polymerisation of the acridine-containing liposomes 
solutions 20 and 21 was achieved using an insertion apparatus and a 400 W medium 
pressure Hg lamp. This gave deep blue polymerised liposomes with electronic absorp-
tion spectra showing λmax at 648 nm and 651 nm, respectively. The resulting blue solu-
tions containing either 20 or 21 were tested for their abilities to exhibit a colourimetric 
response in the presence of salmon testes DNA (ST-DNA). Thus, a solution of ST-DNA 
was added to the cooled liposome solutions and the mixtures were left to stir for 
48 hours. However, after this time, complete precipitation of the liposomes made from 
20 and 21 had occurred and there was no evidence of a colour change (no visible 
changes or modifications in their electronic absorption spectra). This research on the 
acridine-functionalised PDA liposomes was not taken any further because it was rea-
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soned that such liposomes would have only a limited application as nucleic acid biosen-
sors since acridine is a sequence non-specific DNA intercalator. 
 
1.6.2 Peptide nucleic acid functionalised PDA liposomes 
 
Staying with the aim to prepare a novel colourimetric nucleic acid biosensor based on 
suitably functionalised PDA liposomes, the group at Heriot-Watt University revised 
their initial idea to use acridine type compound as the recognition element based on the 
limitations reported above. Indeed, they decided to explore the use of peptide nucleic 
acids as the head-group. As stated previously (Section 1.3) PNAs offer a number of ad-
vantages over natural oligonucleotides regarding their use in biosensors; namely they 
show higher selectivity and stability. 
 
Thus, Murray2 developed synthetic routes for the preparation of model compounds 
composed of a PNA monomer head-group connected via either its C- or N-terminus to a 
saturated stearoyl or an unsaturated diacetylenic tail, (models 22, 23 and 24 – Figure 
42). It was necessary to first prepare and investigate these monomer model compounds 
in order to determine whether they could be successfully incorporated into PDA lipo-
somes and that the PNA head-group did not hinder the required topochemical polymeri-
sation from taking place. In fact Charych et al.68 have reported that the prediction of 
successful polymerisation is not possible. 
 
 
 
Figure 42 
 
Figure 42 shows only the models developed bearing thyminyl PNA monomer but the 
analogous N-terminus models bearing the adeninyl and the cytosinyl PNA monomer 
were also synthesised. The preparation of the corresponding PNA monomers has been 
extensively reported in the literature1 and will be briefly described in Chapter 2.  
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Murray2 started his investigations with the preparation of the C-terminus monomer 
model compounds such as 24 (Figure 42). Subsequently, 24 was successfully incorpo-
rated into liposomes using the matrix lipid previously employed for the acridine-
functionalised PDAs (17 – Scheme 2). The solution obtained was deep blue. Unfortu-
nately, as reported earlier by Murray117, the liposomes prepared precipitated very 
quickly at room temperature. Therefore, due to these preliminary results the C-terminus 
strategy was abandoned. 
 
Consequently, Murray2 investigated the preparation of N-terminus model compounds 
such as 22 and 23 (Figure 42). The design of the best synthetic route was inspired by 
literature precedent119 and involved the preparation of the PNA backbone unit-
functionalised with the desired lipid tail (26 or 27 - Scheme 3). 26 (65%) and 27 (60%) 
were obtained from the coupling between the PNA backbone 25 and the acid fluoride 
derivative of the chosen lipid tail. The free amino group of both 26 and 27 were subse-
quently coupled with the appropriate nucleobase acetic acid derivative (thyminyl, cy-
tosinyl or adeninyl) using HBTU as coupling agent. Models 28, 29, 30 and 31 were ob-
tained in 97%, 95%, 69% and 97% yields, respectively. 
 
 
 
Scheme 3 
 
Due to time constraints, Murray2 incorporated only the thyminyl models 28 and 31 into 
PDA liposomes. Blue solutions were observed upon polymerisation of mixtures con-
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taining 5% of the acid models 4d or 4g with 95% of 10,12-PCDA (5 – Scheme 2) matrix 
lipid. No differences between the saturated and diacetylenic model were detected visu-
ally and in the electronic absorption spectra. These results suggested that the presence of 
a PNA monomer did not hinder the formation of PDA liposomes or the polymerisation 
reaction. Murray2 discovered that the presence of a free terminal carboxylic acid was 
mandatory in order to avoid precipitation of the liposomes from the aqueous solution 
that had been observed with the corresponding ester models. 
 
Murray2 then tested the ability of these models to undergo colourimetric changes. Thus, 
a solution of adenosine in PBS buffer pH 7.4 was added to the liposome solutions con-
taining separately the saturated model 31 and the diacetylenic model 28. Unfortunately, 
no colour changes were recorded. This implied that the formation of the expected T-A 
complex did not result in enough mechanical stress to induce the ‘blue-to-red’ colour 
transition, probably because the Watson-Crick hydrogen bonding within a single base 
pair are not strong enough. It is also possible that the T-A duplexes have not been 
formed.  
 
Based on this finding Murray2 decided to investigate the preparation of PDA liposomes 
bearing PNA oligomers. It was envisaged that the PNA:DNA heteroduplex formation 
would induce more mechanical stress to the PDA framework and thus afford the desired 
colour changes. Therefore, Murray2 synthesised PNA (T)10 oligomers manually in a 
stepwise fashion on a suitably derivatized solid support employing the solid-phase pro-
tocol described by Christensen et al..120  
 
32 : CH3(CH2)16CO-(T)10-LysNH2 
33 : CH3(CH2)16CO-(T)10-AspNH2 
34 : Ac-(T)10-Lys{CO(CH2)16CH3}NH2 
35 : Ac-(T)10-Lys{CO(CH2)8C4(CH2)11}NH2 
36 : AcAsp-(T)10-Lys{CO(CH2)16CH3}NH2 
37 : AcAsp-(T)10-Lys{ CO(CH2)8C4(CH2)11}NH2 
38 : CH3(CH2)11C4(CH2)8CO-(T)10-AspNH2 
 
Figure 43 
 
The stearoyl group was incorporated at the N-terminus of oligomers 32 and 33 (Figure 
43) in the final coupling step once the PNA (T)10 had been assembled on the solid sup-
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port using the stearoyl fluoride derivative. The same approach using 10,12-
pentacosadiynoyl fluoride was unsuccessful. Therefore, in order to prepare models 33, 
34, 37 and 38 Murray2, successfully, used a post-synthetic solution-phase approach in 
which he reacted the cleaved the PNA-(T)10 oligomers with 10,12-pentacosadiynoyl 
fluoride in the presence of diisopropylethylamine (DIPEA). 
 
The formation of liposomes from two component mixtures of acid terminated models 
33, 36, 37 and 38 (5%) and 10,12-pentacosadiynoic acid (5 – Scheme 2) were subse-
quently investigated using a procedure similar to that described by Charych et al..98, 103 
Deep blue solutions of liposomes were obtained from samples containing diacetylenic-
PNA lipids 36, 37 and 38 or the stearoyl-PNA lipid 33. The solutions showed some pre-
cipitation after a couple of days at room temperature. The mixture of 36 (5%) and 5 
(95%) gave only a dilute, light blue solution of liposome and much precipitation oc-
curred during the preparation.  
 
Due to time constraints, Murray2 only managed preliminary studies of the abilities of 
these models to exhibit a colourimetric response upon hybridisation to the complemen-
tary PNAs. H-A10Lys-NH2 PNA oligomer in PBS buffer at pH 7.4 was therefore added 
to the liposome solutions, under similar conditions that have been used by Charych et 
al..91, 121, 122 Unfortunately, no colour transitions were recorded. It was rationalised that 
the precipitation of the liposomes during these studies was at the origin of this failure. 
Nevertheless, Murray’s results2 showed that it was possible to incorporate PNA oli-
gomers into PDA liposomes and that the solutions obtained turned blue upon photo-
polymerisation, therefore, the presence of the PNA oligomer as the head-group did not 
hinder the formation of liposomes. He also showed that the PNAs could be functional-
ised with either saturated or unsaturated (diacetylene-containing) lipids and that the 
electronic absorption spectra of both solutions were comparable. The colourimetric 
studies were only preliminary and further work into the field should demonstrate that 
PNA-functionalised PDA liposomes can be used as colourimetric nucleic acid biosen-
sors. 
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2 SYNTHESIS OF MODELS 
 
2.1 AIMS AND OBJECTIVES 
 
As stated in Section 1.6.2 (page 53), the ultimate aim of this research was to develop a 
novel, rapid and label-free DNA detection assay employing a colourimetric biosensor 
derived from PNA-functionalised PDA liposomes. The overall objectives of the work 
reported in this thesis was to synthesize and evaluate lipid-functionalised PNA mono-
mers bearing a more favourable hydrophilic/lipophilic contrast than the models reported 
by Murray et al.2 so that the PNA headgroups were sufficiently hydrated under the con-
ditions required for construction of the liposomes. 
 
Schneider et al.123, 124 have extensively studied peptide nucleic acid amphiphiles 
(PNAA). These conjugates are comprised of PNA molecules covalently linked to one or 
more n-alkane chains (Figure 44).  
 
 
 
Figure 44 – PNAA: (C14)2-(AEEA)2-AGTGATCTAC-(Glu)4 
 
Since PNA is uncharged, it is sparingly soluble in water and it has a tendency to self-
aggregate in solution. Nielsen et al.45 have reported that the inclusion of a terminal ly-
sine group greatly improves their solubility. In PNAA, Schneider et al.123, 124 have rea-
soned that the covalent attachment of one (or more) alkane chains would exacerbate the 
poor water solubility of PNA. By attaching charged amino acids (e.g. glutamic acid and 
lysine) to the PNA head-group, these researchers have imparted sufficient hydropho-
bic/hydrophilic contrast for micellization and water solubility of the corresponding 
PNAA.123 As a rule, they reported that four charged amino acids per 10-mers (or two 
per 6-mers) are required for adequate water solubility. They also demonstrated that 
PNA peptide can absorb on the surface of the liposome resulting in poor hybridisation 
with complementary DNA and this limitation was overcome by introducing ethylene 
glycol spacers, such as 8-amino-3,6-dioxaoctanoic acid (AEEA) (Figure 44).124, 125 
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Charych et al.90 have also included a similar spacer (i.e. AEEA) between the sialic acid 
head-group and the diacetylene reporter element in their influenza virus biosensors 
(Section 1.5.1, page 37). They reasoned that this spacer extended the bioactive head-
group beyond the matrix lipid and allowed a better contact with the virus. 
 
In the light of Schneider’s and Charych’s findings, we decided to investigate whether 
the inclusion of a similar AEEA spacer could be successfully incorporated into the 
PNA-functionalised PDA liposomes developed by Murray et al.2 and improve their wa-
ter solubility. It was envisaged that an ethylene glycol spacer could be covalently linked 
to the N-terminus of PNA at one end and the lipid tail at the other through amide bonds, 
using established peptide chemistry methods (Figure 45). 
 
 
 
Figure 45 
 
Due to the cost of N-protected derivatives of AEEA (40 and 41 - Figure 45), we first 
required a viable synthetic route to this compound in order to use it for our purpose. We 
reasoned that developing our own pathway to AEEA would also allow us to explore the 
utility of a range of “PEG-like” spacer analogues (e.g. the effect of increasing the 
CH2CH2O repeating unit) for constructing PNA-functionalised PDA liposomes. 
 
Subsequently, following the development of a suitable route to AEEA spacer 39 (Figure 
45), we planned to study the inclusion of this moiety into model ‘lipid-spacer-PNA’ 
conjugates (Figure 46) bearing either thyminyl, cytosinyl and adeninyl PNA monomers. 
We envisaged that once routes to these model conjugates had been optimised, they 
could be simply extended to the synthesis of conjugates containing PNA oligomers. 
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Figure 46 
 
Providing that these ‘lipid-PEG-like spacer-PNA’ conjugates could be prepared, we 
proposed to subsequently explore the ability of these compounds to be incorporated into 
PDA liposomes, using 10,12-PCDA (5) as the matrix lipid. If coloured solutions are ob-
tained from these model conjugates, we planned to study the electronic absorption spec-
tra of their ‘blue’ and ‘red’ forms. Following these studies, we hoped to undertake pre-
liminary investigations into their stability, and finally, to study whether any colourimet-
ric response could be obtained upon their exposure to complementary nucleic acids. 
 
Our progress towards achieving these aims and objectives will now be discussed in the 
remainder of Chapter 2 and in Chapter 3. 
 
2.2 SYNTHESIS OF ‘LIPID-PEG-LIKE SPACER-PNA’ MODELS 
 
2.2.1 Preparation of the ‘PEG-like’ spacer  
 
The preparation of PNA-functionalised PDA models bearing a “PEG-like” spacer re-
quired first development of a viable synthetic route to the Boc-AEEA spacer 40 (Figure 
45). We chose to have the amino terminus Boc-protected as this protecting group would 
be compatible with our established in-house solid phase strategy for preparation of PNA 
oligomers. We envisaged that, at a later stage in this research, it should be possible to 
attach spacer 40 to the N-terminus of the PNA oligomer as part of this solid phase ap-
proach. 
 
Koskinen et al.126 have recently reported the preparation of N-Fmoc-8-amino-3,6-
dioxaoctanoic acid 41 starting from commercially available 2-(2-aminoethoxy)ethanol 
42 as outlined Scheme 4. 
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Scheme 4 
 
In their route, the amino function of 42 was first protected with two benzyl groups by 
reaction with benzyl bromide in the presence of sodium carbonate at room temperature. 
The dibenzyl analogue 43 was obtained in 68% yield. Subsequently, alkylation of the 
hydroxyl group of 43 was achieved with methyl bromoacetate in the presence of sodium 
hydride to afford ester 44 in 96% yield. Ester 44 was then hydrolysed using aqueous 
sodium hydroxide to afford the carboxylic acid 45 in 80% yield. Consequently, 8-
amino-3,6-dioxaoctanoic acid (39, 91%) was obtained by hydrogenolysis of 45. Finally, 
the amino function of amino acid 39 was protected with an Fmoc group to give the de-
sired compound 41 in 69% yield. 
 
As mentioned earlier, we were interested in preparing the Boc analogue 40 (Scheme 5) 
because this protecting group was compatible with our established Boc solid phase pro-
tocol used by Murray et al.2 for the preparation of PNA oligomers. However, we rea-
soned that we could adapt the route developed by Koskinen et al. to yield the required 
Boc-protected compound. Our revised route is outlined in Scheme 5. In addition to re-
quiring the use of a Boc protecting group, we also needed to avoid the hydrogenation 
step used by Koskinen et al. to remove the benzyl groups. This was because the De-
partment of Chemistry at Heriot-Watt University did not have a functioning Parr hydro-
genation apparatus, needed for the reaction, at the time of this research. 
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Scheme 5 
 
Thus, the first step in our synthetic pathway involved the protection of the amino moiety 
of 42 with a Boc group (Scheme 5). This was sucessfully achieved by treatment of a so-
lution of 42 in a mixture of water and dioxane (10:1 v/v) with di-tert-butyl dicarbonate. 
Following work-up and purification by column chromatography, compound 46 was ob-
tained in 90% yield. The appearance of a singlet (integrating to 9H) at 1.34 ppm in the 
1H NMR spectrum recorded for 46 and the two extra peaks at 28.3 ppm and 79.2 ppm in 
13C NMR confirmed the introduction of the N-Boc protecting group. 
 
The next step in our route involved the alkylation of the hydroxyl function of 46 to yield 
the ethyl ester 47. We chose to follow the protocol described by Koskinen et al..126 This 
involved the slow addition of one equivalent of sodium hydride to a solution of 46 in 
anhydrous THF followed by heating the resulting solution to reflux for 75 minutes. Af-
ter this time, the solution was cooled to 0 oC and ethyl bromoacetate was added drop-
wise. After work-up, a very complex mixture of products was afforded. And after care-
ful purification by column chromatography, ester 47 was isolated in 10 % yield. Anoth-
er product was also recovered from this mixture, which was shown to be unreacted 
starting material 46 from 1H and 13C NMR spectroscopy. The reason for the low yield of 
ester 47 was not apparent. However, we had concerns about leaving the reaction mix-
ture for such a long period at high temperature after the addition of sodium hydride and 
before the addition of the alkyl halide. Alkoxide anions are highly moisture sensitive 
and particular care must be taken to ensure complete dryness of the reaction medium. 
Temperature is also known to increase the probability of side reactions from occurring. 
Therefore, we reasoned that the alkoxide of 46, once formed, would be highly reactive 
and would have a short half-life. Thus, in order to reduce the risk of side reactions oc-
curring, we decided to repeat the reaction at room temperature. Unfortunately, no im-
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provement in the yield of 47 was observed (10%). We then decided to explore the effect 
of the solvent on the reaction. Polar aprotic solvents such as DMSO, DMF, acetonitrile 
and THF have the ability to stabilize the alkoxide anion formed and therefore are favor-
able for SN2 reactions. Since DMF and acetonitrile are more polar than THF, they 
should therefore improve the reaction. Thus, we decided to repeat the reaction using 
DMF instead of THF. In this case a slight improvement in the yield of 47 was obtained 
(19%) but this yield was clearly still inadequate for our purpose. 
 
At this point it was unclear whether the alkoxide anion of 46 had formed and that, due 
to its poor stability, it accepted a proton to reform the starting material or if, under these 
reaction conditions, the hydroxyl proton of 46 had not been properly abstracted. It has 
been reported that the presence of electron-withdrawing groups attached to the alcohol 
group will increase the acidity of the -OH proton while the presence of electron-
donating groups will decrease it. In the case of the later, the alkoxide anion formed will 
be less stable and so will tend to readily accept a proton to reform the original alcohol. 
Thus, in our case, we hypothesize that the presence of the alkyl group next to the alco-
hol did not help to stabilize the corresponding alkoxide anion. In addition to the stability 
of the resulting alkoxide of 46, we should recognize that this compound has two poten-
tially acidic protons: the proton of the carbamate group (in red) and the proton of the 
alcohol (in blue - Figure 47). This was not a concern for Koskinen et al. as they had 
worked with the dibenzyl protected analogue 43 (Scheme 4) rather than the Boc-
protected compound 46. The exact pKa values of these protons in 46 are not known but 
from the data reported by Bordwell et al.127 we were able to estimate their values (Fig-
ure 47). 
 
 
 
Figure 47 – pKa values measured in DMSO127 
 
The pKa value of the proton of carbamate 48 is 24.8, while the pKa values of methanol 
(49) and iso-propanol (50) are 27.9 and 29.3, respectively. This means that the proton of 
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a carbamate 48 is ca. 1000 times more acidic and therefore more easily deprotonated 
than the hydroxyl proton of either methanol (49) or isopropanol (50). This finding might 
explain why, in our case, the yield of the ester 46 was so low. Unfortunately, we did not 
isolate any of the possible N-alkylated side product (51 – Figure 48) from the complex 
mixture of products. Therefore, we were unable to confirm whether this is an issue. 
 
 
 
Figure 48 
 
In an attempt to see whether this alkylation could be achieved under alternative condi-
tions, we decided to investigate other bases in this reaction. Jung et al.128 have reported 
the use of cesium hydroxide monohydrate for the preparation of a series of ethers from 
primary alcohols. Cesium bases have shown a number of advantages in alkylation reac-
tions with one being that the in situ generated cesium alkoxides are considered to be 
more nucleophilic than their corresponding alkaline earth metal alkoxides due to their 
weak solvation.129 For example, Jung et al.128 treated a solution of alcohol 52 (Scheme 
6) with bromobutane in the presence of cesium hydroxide monohydrate, TBAI and mo-
lecular sieves.  
 
 
 
Scheme 6 
 
The corresponding ether 53 was subsequently obtained in yields of more than 90% 
when either anhydrous acetonitrile or anhydrous DMF was the reaction solvent. The 
presence of powdered 4 Å molecular sieves was used to remove traces of water and 
therefore prevent the alkoxide, once generated, from being protonated. The contribution 
from TBAI stemmed presumably from a Finkelstein type reaction and phase transfer 
catalysis.128 
 
Therefore, the conditions described by Jung et al.128 seemed very promising for our 
purpose. We decided to first investigate the use of one equivalent of cesium hydroxide 
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monohydrate without the contribution of TBAI in our initial study. Thus, a solution of 
alcohol 46 (Scheme 5) in anhydrous DMF was treated with cesium hydroxide monohy-
drate in the presence of 4 Å powdered molecular sieves for 30 minutes at room tempera-
ture before one equivalent of ethyl bromoacetate was added. After work-up and purifi-
cation by column chromatography, none of the products isolated from the complex reac-
tion mixture corresponded to the expected alkylated product 47. Subsequently, we de-
cided to repeat the reaction in the presence of one equivalent of TBAI and this time 
product 47 was obtained in an 18% yield. Since Jung et al. reported similar a yield when 
anhydrous acetonitrile was used instead of anhydrous DMF, we decided to repeat the 
reaction using anhydrous acetonitrile. However, in our case the yield for 47 was lower 
than in anhydrous DMF (10%). We also repeated the reaction using potassium carbon-
ate and cesium carbonate in anhydrous DMF but in both cases, ester 47 was isolated in a 
low yield of 17%. Due to our concerns regarding selective deprotonation of the alcohol 
function relative to the carbamate proton, we decided to see if this problem could be 
overcome by the use of the di-Boc protected analogue 56 (Scheme 7). After all, Koski-
nen et al.126 had selected to protect the amino function of 42 with two benzyl groups. 
 
 
 
Scheme 7 
 
A route to the di-Boc derivative 56 was therefore required starting from mono-Boc pro-
tected alcohol 46. We chose to start from 46 rather than the free amino alcohol 42 be-
cause 46 was readily available in the lab in large amounts. We decided to employ the 
procedure described by Appella et al.130 for the preparation of the di-Boc compound 56. 
The conditions used by this group to prepare their di-Boc analogues implied the treat-
ment of a solution of a mono-Boc protected amino acid in anhydrous acetonitrile with 
an excess of di-tert-butyl dicarbonate in the presence of 4-dimethylaminopyridine 
(DMAP). DMAP is also known to react preferably with alcohols than with amino func-
tion, therefore, this function in 46 required to be protected before the second Boc group 
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could be inserted. Thus, we selected to use the tert-butyldimethylsilyl protecting group 
for this purpose. A solution of alcohol 46 in anhydrous DMF was therefore treated with 
tert-butylchlorodimethylsilane and imidazole. After work-up and purification by flash 
column chromatography, silyl ether 54 was obtained as a white solid in 84% yield. In 
the 1H NMR spectrum recorded for 50, a singlet appeared at 0.05 ppm which was at-
tributed to the two methyl groups attached to the silicon atom. The singlet at 0.87 ppm 
corresponded to the nine tert-butyl silyl protons. 
 
Subsequently, the di-Boc protected analogue 55 was obtained by treating a solution of 
54 in anhydrous acetonitrile under the same conditions as described earlier by Appella 
et al..130 The progress of the reaction was monitored by TLC. Following completion of 
the reaction, work-up and purification by column chromatography, the expected product 
55 was obtained in 80% yield. In the 1H NMR spectrum recorded for 55, the singlet at 
1.48 ppm integrated now for 18 protons rather than nine as in the analogous spectrum 
recorded for 54. This confirmed the presence of two Boc groups attached to the same 
atom in 51. HRMS analysis further confirmed the molecular formula of the product ob-
tained. 
 
The final step in the synthetic pathway involved the cleavage of the silyl ether protect-
ing group from 55. This was accomplished under standard conditions using TBAF. Af-
ter leaving a solution of 55 and TBAF in THF to stir at room temperature for five hours, 
TLC analysis showed that no starting material remained. Work-up and flash column 
chromatography gave the expected product 56 in a quantitative yield. The disappearance 
of the proton signals corresponding to the silyl ether moiety in the 1H NMR spectrum 
together with the appearance of a broad singlet at 2.47 ppm confirmed that the removal 
of the silyl ether had been successful and that the corresponding alcohol 56 has been 
formed. 
 
Having successfully prepared the required di-Boc protected alcohol 56, we then em-
barked upon investigation of its ability to be O-alkylated (Scheme 8).  
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Scheme 8 
Our initial attempt involved treatment of a solution of alcohol 56 in THF with sodium 
hydride followed ethyl bromoacetate under the same conditions as those described by 
Koskinen et al..126 After work-up and flash column chromatography, spectral analysis of 
the fractions isolated failed to show the presence of the desired ether 57 (Scheme 8). 
However, a side reaction product was isolated from the complex crude reaction mixture 
which was identified as carbonate 58 (40% - Figure 49).  
 
 
 
Figure 49 
 
Despite this result, we decided to continue our examination of this reaction. Our next 
attempt involved a treatment of a solution of 52 and ethyl bromoacetate (3 eq.) in anhy-
drous THF, cooled to 0 oC, with sodium hydride (1.5 eq.). By performing the reaction in 
this manner, it was hoped that the ethyl bromoacetate would react instantly with the 
alkoxide anion of 56 as soon as it was formed. This reaction met with some success 
with 57 being isolated in a 19% yield, following work-up and purification by column 
chromatography. However, the yield of 57 was similar to those obtained earlier for the 
alkylation of the mono Boc derivative 46. Surprisingly, carbonate 58 had been produced 
again, this time in a 68% yield. Unfortunately, the reason for this is unknown. 
 
At this time in the project, we realised that the preparation of the N-Boc protection ver-
sion of the desired AEEA spacer was going to be more challenging than first expected. 
Since time was moving on, we decided to revise our initial strategy for preparation of 
the Boc-AEEA spacer 40. We reasoned that, although the Boc protected compound was 
required, it did not have to be introduced at the beginning of the scheme. Instead, the 
Boc protecting group could be introduced after 8-amino-3,6-dioxaoctanoic acid (39 – 
Scheme 4) had been prepared in the same way that Koskinen et al.126 had prepared the 
Fmoc N-protected analogue 41. Therefore, we decided to follow Koskinen’s approach 
exactly, initially protecting the amino function of the starting material 42 with a diben-
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zyl protecting group. This would subsequently be cleaved and replaced in the last step 
of the synthetic pathway for our desired Boc protecting group. 
 
The first step in this strategy concerned the protection of the amino moiety of 42 with 
two benzyl groups. The reaction was carried out in the same manner as described by 
Koskinen et al.126 (page 61) and dibenzylated product 43 was obtained in 80% yield. 
This yield was comparable to that reported by Koskinen (Scheme 9). The next step in 
this pathway involved O-alkylation. Thus, a solution of alcohol 43 in anhydrous THF 
was heated to reflux in the presence of sodium hydride for 75 min. After this time, the 
solution was cooled to room temperature and ethyl bromoacetate was slowly added. Af-
ter work-up and purification by column chromatography, ethyl ester 59 was afforded in 
a 40% yield. This yield was lower than the one reported by Koskinen et al.126 (i.e. 96%) 
but deemed to be sufficient for our purpose. The structure of the product was confirmed 
by 1H and 13C NMR spectral analysis. The appearance of a singlet at 3.71 ppm in the 1H 
NMR spectrum was attributed to the new CH2 attached to the oxygen atom of the alco-
hol. The presence of this new CH2 group was further confirmed by 13C NMR, with the 
appearance of a signal at 68.5 ppm. 
 
 
 
Scheme 9 
 
Finally, ester 59 was hydrolysed to the corresponding carboxylic acid 45 by treatment 
with 2 M aqueous sodium hydroxide in methanol at room temperature. After work-up 
and column chromatography purification, product 45 was obtained in 55% yield. The 
formation of carboxylic acid 45 was verified by 1H NMR spectroscopy as the signals at 
1.16 ppm and 4.10 ppm, corresponding to the ethyl ester group, were no longer visible. 
In addition, the broad singlet that appeared at 8.60 ppm was attributed to the proton sig-
nal of the carboxylic acid group. 
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At this point in the synthesis, the dibenzyl protecting group of 45 needed to be cleaved. 
Koskinen et al.126 had carried out this reaction using H2(g) at 3 atm. in the presence of a 
palladium on charcoal catalyst. As mentioned earlier, at this time the Chemistry depart-
ment at Heriot-Watt University did not have a functioning Parr apparatus to enable us to 
perform similar reaction. Therefore, we attempted to remove this group at atmospheric 
pressure. Thus, carboxylic acid 45 was dissolved in absolute ethanol and to this was 
carefully added a small portion of 5% Pd/C catalyst. The black heterogeneous mixture 
was evacuated and purged with H2(g) several times before being left to react at room 
temperature for two days (Scheme 10). After this time, the reaction was worked up and 
the crude product obtained was analysed by both 1H and 13C NMR. However, both spec-
tra still showed the presence of two benzyl groups in the exact ratio as found for the 
starting material 45. This implied that no reaction had occurred; we therefore sought 
alternative strategies for removal of benzyl groups. 
 
 
 
Scheme 10 
 
Catalytic transfer-hydrogenation (CTH) offers the possibility for an efficient cleavage of 
benzyl groups. CTH has successfully been applied to the removal of benzyl groups from 
amino functions131 as well as hydroxyl moieties.132 It has also found applications in the 
reduction of multiple bonds (alkenes, alkynes), carbonyl compounds, nitriles, imines, 
azo compounds, nitro compounds etc.133 The reaction is accomplished with the aid of an 
organic molecule which acts as the hydrogen donor in the presence of a catalyst. Al-
though this approach has been principally reported for use of palladium-based catalysts, 
other catalysts based on rhodium , nickel and platinum can also be used.133 Using this 
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approach, there are many different hydrogen donors that have been employed for the 
removal of benzyl groups from amino functions. The most common are formic acid,134 
1,4-cyclohexadiene,135 hydrazine hydrate136 and ammonium formate.131, 137, 138 
Based on these reports, we reasoned that the methods described by Ram et al.131, 138 
could be utilised to remove the dibenzyl protecting group of 45. Therefore, carboxylic 
acid 45 was dissolved in methanol and to this solution were carefully added one equiva-
lent of 10% Pd/C and two equivalents of ammonium formate. The resulting heterogene-
ous mixture was heated at a gentle reflux and the progress of the reaction was carefully 
followed by TLC. Unfortunately, after five hours, TLC analysis still showed the pres-
ence of a UV active compound. Subsequent 1H NMR spectral analysis of the crude 
product after work-up revealed a mixture of both the di-benzyl protected starting mate-
rial 45 and the mono-benzylated intermediate 60 (Scheme 10). In an attempt to drive the 
reaction further, the CTH reaction was repeated on this crude mixture. However, after 
another five hours, the reaction failed to reach completion. Furthermore, none of the de-
sired, completely de-benzylated, product 39 could be observed. Therefore, it appeared 
that CTH could not be utilised for this reaction. 
 
The preparation of the Boc-protected hydrophilic spacer 40 was brought with difficul-
ties in our hands. Although we were able to repeat the work described by Koski-
nen et al.,126 the yields for the intermediates were not as high as reported. Due to in-
strumental limitations, we were not able to complete this reaction scheme and further 
investigations would be necessary to finish the reaction pathway. However, with time 
pressing on, we decided to take the limited amounts of the Boc-protected intermediate 
47 (Scheme 5) and the dibenzylated intermediate 45 (Scheme 9) obtained from this work 
and use them in the next stage of this project, i.e. the preparation of lipid-spacer-PNA 
monomer models. We reasoned that if these studies proved fruitful, we could revisit the 
preparation of the Boc-protected AEEA spacer in a later stage.  
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2.2.2 Preparation of PNA monomers 
 
The preparation of PNA monomers has been extensively reported in the literature since 
their development by Nielsen et al.40 in 1991. The commonest synthetic pathway used 
to prepare the classical PNA monomers, such as 61, is highlighted in Scheme 11. The 
key step involves linking the protected N-(2-amino)glycine ester backbone (59) to the 
acetic acid derivative of the appropriate nucleobase (60).  
 
 
 
Scheme 11 
 
During the course of the earlier studies conducted by Murray,2 a number of the strate-
gies reported in the literature for the preparation of the PNA backbone 62 were evalu-
ated. From this work, the approach developed by Finn et al.,139 leading to the Boc-
protected PNA backbone, gave the best results. This strategy starts with the Boc protec-
tion of commercially available 3-amino-1,2-propanediol 64 using di-tert-butyl dicar-
bonate, affording diol 65 in quantitative yield. Periodate cleavage of the vicinal diol 65 
leads to the Boc protected amino aldehyde 66 in high yield, reductive amination of 
which with cyanoborohydride and ethyl glycinate affords N-(2-Boc-amino-
ethyl)glycinate 67 (Scheme 12).139 
 
 
 
Scheme 12 
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This strategy was therefore repeated in our case and comparable yield to Finn et al. 
were obtained for backbone 67 (i.e. 55%).  
 
Now that the PNA monomer backbone had been successfully prepared, we needed to 
prepare the nucleobase acetic acid derivatives next. At this stage in the project, we de-
cided to concentrate our efforts on the preparation of the thyminyl PNA monomer be-
cause this nucleobase does not have any exocyclic nucleophilic functionality that could 
interfere in the later steps of the synthetic pathways. 
 
The preparation of thyminyl acetic acid 69 is outlined in Scheme 13. This involved 
treatment of an aqueous solution of commercially available thymine (68) with bro-
moacetic acid in the presence of potassium hydroxide, as reported by Kosynkina et 
al..140 This methodology had also been used by Murray.2 This reaction was successfully 
reproduced here to yield thyminyl acetic acid 69 in 97% yield, following filtration of the 
acidic aqueous reaction mixture. 
 
 
 
Scheme 13 
 
At this point, we were ready to connect the thyminyl acetic acid derivative 69 to the 
Boc-protected PNA backbone 67. In order to carry out this reaction, the carboxylic acid 
function of derivative 69 required first to be activated. A range of different strategies 
have been reported in the literature to achieve this activation. In situ activation using 3-
hydroxy-1,2,3-benzotriazin-4(3H)-one (DhbtOH) and N,N’-dicyclohexylcarbodiimide 
(DCC) was one of the first methods published (Figure 50). This was found to be very 
efficient1, 141 for the introduction of thyminyl, cytosinyl and adeninyl derivatives. In an-
other work, the guaninyl derivative was reported to be efficiently attached to the PNA 
backbone via condensation using bromotris(pyrrolidino)phosphonium hexafluorophos-
phate (PyBroP®) as the activating agent.141 More recently, the use of uronium and amin-
ium salts such as HATU, HBTU and TBTU, have been reported to give higher yields 
that the originally DhbtOH/DCC strategy.141-144 TBTU145 and HBTU146 are two most 
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popular in situ activation reagents used in solid phase and solution phase peptide syn-
thesis.147  
 
 
 
Figure 50 
 
For our purpose, we decided to follow the work of Murray2 and chose to couple 
thyminyl acetic acid 69 to the PNA backbone 67 using HBTU as the activating agent. 
After work-up and purification by column chromatography, the desired thyminyl PNA 
monomer 70 was obtained in 70% yield (Scheme 14). 
 
 
 
Scheme 14 
 
Finn and co-workers139 have reported high barriers of rotation (10-25 kcal⋅M-1)148 and 
low exchange rate (0.5-2 s-1, 37 oC)148 around the tertiary amide bond of 70, resulting in 
a two rotational isomers, cis:trans, in a 1:2 ratio (Scheme 14). 1H NMR studies carried 
out by Chen149 and Brown150 (separately) have shown that the major form is the trans 
rotational isomer (70a), where the methylene protons (a) next to the nucleobase are to-
ward the 2-aminoethyl unit. In the minor cis isomer (70b), they are on the side of the 
glycyl unit. This result had been obtained using 2D NOESY149 spectra, showing the in-
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teractions between the protons of the methylene protons (a) (Scheme 15) with the me-
thylene protons present on the PNA backbone. 
 
 
 
Scheme 15 
 
We, likewise, observed the presence of two rotamers in the 1H and 13C NMR spectra 
recorded for 70. Their presence was clearly indicated by the “splitting” of certain NMR 
signals, as exemplified in the 1H NMR spectrum shown in Figure 51. For example, the 
CH2 a (Scheme 15) was split into two singlets; a smaller one at 4.45 ppm and a larger 
one at 4.60 ppm. The ratio of the major rotamer to the minor rotamer was found to be 
2:1, which was consistent with the report of Finn et al..139 
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Figure 51 – 1H NMR of 70 (400 MHz, CDCl3) 
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The preparation of thyminyl PNA monomer 70 was further confirmed using X-ray crys-
tallography. A suitable crystal of 70 was grown for these studies from diethyl ether and 
methanol using the vapour diffusion method at room temperature. Compound 70 crys-
tallised in the monoclinic space group, P2(1)/n, with one molecule in the asymmetric 
unit as shown in Figure 52. The full crystallographic data are shown in Appendix A. Al-
though in solution the tertiary amide bond in 70 exists as a rotameric mixture, in the 
crystal structure only the trans rotamers was observed (i.e. where the carbonyl was di-
rected towards the glycyl component of the PNA backbone). 
 
 
 
Figure 52 – ORTEP view of 70 
 
The packing analysis, shown in Figure 53, revealed that 70 exhibited the anticipated 
centrosymmetric hydrogen-bonded dimeric structure with an H⋅⋅⋅O distance of 1.86 Å.  
 
 
Figure 53 
 
Such arrangement leads to pi-stacking of the nucleobase pairs in a stepwise manner, as 
depicted in Figure 54. The vertical distance between the two carbonyl groups of two 
adjacent thymine rings in the stack was found to be 6.89 Å. 
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Figure 54 
 
Finally, the adjacent molecules were held together by the formation of two N-H⋅⋅⋅O hy-
drogen bonds. One was formed between the NH of the PNA backbone and the oxygen 
atom of the neighbouring ester carbonyl group; the H⋅⋅⋅O distance was 2.83 Å. The sec-
ond was formed between the same NH group and the C11 carbonyl oxygen of the 
neighbouring thyminyl ring (H⋅⋅⋅O12 distance = 2.36 Å - Figure 55). 
 
 
Figure 55 
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2.2.3 Preparation of lipid-‘PEG-like’ spacer-PNA monomer models 
 
The retrosynthetic analysis outlined in Scheme 16 identified two potential strategies for 
the preparation of lipid-‘PEG-like’ spacer-PNA monomer models 71 and 72 from the 
three components, i.e. the thyminyl PNA monomer 70, the AEEA spacer intermediates 
45 and 47, and the lipids 5 and 75. We proposed to covalently attach the PNA monomer 
to the carboxylic acid terminus of the AEEA spacer and the lipid to the amino terminus 
through the formation of amide bonds. 
 
 
 
Scheme 16 
 
As highlighted in Section 2.2.1, the synthesis of Boc AEEA spacer 40 (Scheme 5) had 
proved more difficult than expected and the synthetic route had not yet been completely 
devised. However, during the course of our research to develop a viable pathway to 40, 
we had managed to prepare a small amount of 47. This was sufficient to enable us to 
start exploring the use of this spacer in the construction of the desired lipid-spacer-PNA 
conjugates. 
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Our initial investigations centred on Strategy A and the first step involved removal of 
the Boc protecting group from 47 (Scheme 17). 
 
 
Scheme 17 
 
The removal of the Boc group from 47 was successfully achieved using a mixture of 
TFA and dichloromethane (1:1 v/v) to afford the corresponding trifluoroacetic acid salt 
77 in a quantitative yield. The next step in Strategy A involved the attachment of the 
lipid chain to the AEEA spacer. Before being able to accomplish this, the carboxylic 
acid of the lipid needed to be activated. Murray2 had prepared the acid fluoride deriva-
tive of commercially available stearic acid (75) and 10,12-pentacosa-diynoic acid (5) to 
attach the lipids to his PNA monomers. Therefore, we decided to adopt the same meth-
odology here. A solution of 75 in DCM was treated with cyanuric fluoride in the pres-
ence of pyridine and the resulting mixture was heated to gentle reflux for three hours. 
The desired acid fluoride 78 was obtained as a waxy solid in 92% yield after an aqueous 
work-up. The 1H NMR spectrum showed the expected peaks for 78 with the signal as-
signed to the CH2 group adjacent to the carbonyl function, moving downfield from 2.35 
ppm in the spectrum recorded for 75 to 2.49 ppm. The multiplicity of this signal also 
increased to a doublet of triplets due to the methylene protons coupling to the fluorine 
atom as well as the neighbouring CH2 protons. The 13C NMR spectrum also showed the 
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expected peaks; the carbonyl carbon of 78 appeared as a doublet at 163.8 ppm due to 
coupling to the neighbouring fluorine atom. Additionally, in the IR spectrum of 75, we 
observed that the absorbance for the carbonyl group had moved from 1681 cm-1 for the 
acid to 1846 cm-1 which is characteristic of an acid fluoride function. These results were 
comparable with the report by Murray.2 
 
Having successfully prepared steraoyl fluoride 78, this was now ready to be coupled to 
to 77 (Scheme 17). Thus, a solution 77 in DMF was treated with DIPEA and then added 
to a solution of 78 in dichloromethane. The resulting mixture was allowed to stir over-
night at room temperature. After work-up and purification by column chromatography, 
the lipid-spacer adduct 79 was obtained in 79% yield. 1H and 13C NMR spectra recorded 
for 79 showed all the expected signals apart for the ethyl ester CH3 that was hidden by 
the large signal corresponding to the aliphatic CH2 of the lipid chain. The appearance of 
the broad triplet at 5.95 ppm on the 1H NMR spectrum was assigned to the NH proton 
of the new peptide bond. 
 
Strategy A was also followed for the attachment of the spacer to 10,12-PCDA (5). 
Again the commercially available lipid 5 was first converted into its acid fluoride de-
rivative 80 following the same procedure described for the preparation of 78. After 
work-up, 80 was obtained in 82% yield. 80 was then successfully coupled to 77 using a 
similar protocol to that employed for the preparation of saturated analogue 79. After 
work-up and purification by column chromatography, 81 was obtained in 69% yield. 
Again, the formation of 81 was confirmed by 1H and 13C NMR spectroscopy. As it was 
the case for 79, the appearance of the broad triplet at 6.29 ppm on the 1H NMR spec-
trum corresponding to the NH proton of the new peptide bond. Unfortunately, diacety-
lene 81 was found to be unstable in its solid state; it quickly turned from colourless to 
blue, as a result of topochemical polymerisation, even in the dark at -20 oC. This pre-
cluded any further chemical manipulations of 81. It therefore appeared that Strategy A 
was not applicable for the preparation of diacetylenic lipid-PEG-like spacer-PNA 
monomer model 72 (Scheme 16). 
 
The next planned steps in Strategy A involved hydrolysis of the ethyl ester of 79 to 
yield the corresponding carboxylic acid 73. This would then be coupled to the free N-
terminus PNA monomer 82 using HBTU as the activating reagent to afford model 71. 
Unfortunately, due to the small amounts of 47 collected and used for the preparation of 
Chapter 2 : Synthesis of models 
81 
 
77 only small amounts of 79 and 81 were obtained. This was deemed insufficient for the 
final two steps required for the preparation of models 68 and 69 and these were there-
fore not attempted. 
 
We have also carried out some preliminary investigations into the utility of Strategy B 
for the preparation of the lipid-spacer-PNA monomer models 71 and 72. For these stud-
ies we chose to use the dibenzyl protected AEEA spacer 45 (Scheme 16) because we 
had a small quantity of this compound in the lab. This model reaction was only used to 
identify which strategy would be more applicable for the preparation of models 71 and 
72. We reasoned that, once we had developed a more viable route to Boc-protected 
spacer 40, it could be easily substituted for 45.  
 
The first step in this model strategy involved the removal of the Boc protecting group 
from the N-terminus of PNA monomer 70, under acidic conditions, to afford the 
trifluoroacetic acid salt derivative 82 in a quantitative yield (Scheme 18). In order to 
couple 82 to carboxylic acid 45, we decided to use HBTU as the activating agent in the 
presence of DIPEA. However, after work-up, a complex crude mixture was obtained. 
Careful purification of this crude product by flash column chromatography, finally af-
forded 76 in the very low yield of 6%. The reason for this low yield is unknown and due 
to the lack of any further amount of 45, we were unable to repeat the reaction. 
 
 
 
Scheme 18 
 
Thus it appeared from our Strategy A model studies, that the PEG-like spacer could be 
coupled to the lipid tail through amide bond formation in reasonable yield. However, 
Chapter 2 : Synthesis of models 
82 
 
from our Strategy B model studies, it was concluded that peptide coupling was not 
adapted to connect the PEG-like spacer to the PNA monomer due to the low yield ob-
tained. 
 
At this stage of the project, it became apparent that we needed to re-evaluate our initial 
strategies. The problems of developing a viable synthetic route to the required Boc-
AEEA spacer 40, coupled with the low yield obtained when trying to attach the PNA 
monomer to the spacer through amide bond formation meant that our original plans 
were unworkable. We therefore started to look for other approaches to couple the spacer 
to the PNA monomer which would not involve peptide bond formation. We reasoned 
that the new approach sought should avoid the requirement for the synthesis of the Boc-
PEG-CO2H spacer 40 (Scheme 5). We became aware of literature reports based on the 
‘Click’ reaction. This novel reaction is a copper(I)-catalysed version of the Huisgen 1,3-
dipolar [3,2] cycloaddition involving terminal alkynes and organic azides. The corre-
sponding 1,4-disubstituted [1,2,3]-triazoles-containing products are formed both chemo- 
and regioselectively in high yields. These triazoles have generated large biological in-
terest as they have been found to mimic amide bonds. The preparation of these triazole 
linkages will be discussed in the next section (Section 2.3). Bearing this in mind, we 
therefore decided to embark upon the investigation into the utility of this reaction for 
coupling of the PEG-like spacer to the N-terminus of PNA monomers (Scheme 19). 
 
 
 
Scheme 19 
 
As shown in Scheme 19, it was decided that the spacer would contain the azido moiety 
while the PNA monomer would be functionalised at its N-terminus with an alkynyl 
function. Therefore, synthetic pathways to both the azido component 83 and the N-
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alkynyl PNA monomer 84 have to be developed. This time, we decided to concentrate 
on preparing model conjugates containing thyminyl, adeninyl and cytosinyl PNA 
monomers to validate our proposal. If successful, PNA oligomers would be incorpo-
rated at a later stage. The development towards these goals will be discussed in detail in 
Section 2.4 of this chapter. 
 
2.3 DI-SUBSTITUTED 1,2,3-TRIAZOLE 
 
2.3.1 Background 
 
The [1,2,3]-triazole moiety can be found in biologically active molecules including anti-
HIV activity,151 anti-microbial activity against Gram positive bacteria,152 potent anti-
histaminic,153 anti-platelet agents154 and tuberculosis inhibition activity155 (Figure 56). 
This chemical function is also widely found in industrial materials such as dyes and ag-
rochemicals. 
 
 
 Figure 56 – examples of some biologically active molecules containing [1,2,3]-
triazoles 
 
[1,2,3]-Triazole occurrence may be explained by the fact that these appear to mimic 
peptide bonds, i.e. they are a cis peptide bioisostere. This rigid heterocyclic function has 
been shown to imitate the atom placement and electronic properties of a peptide bond 
without holding the same susceptibility to cleavage. [1,2,3]-triazoles are also nearly im-
possible to oxidise or reduce.156 
 
It is rather surprising that [1,2,3]-triazoles should act as peptide mimics as, as shown in 
Scheme 20, the triazole backbone contains an additional atom which increases the dis-
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tance between R1 and R2 by 1.1 Å. However, van Maarseveen et al.156 have stated that 
the peptide bond mimicry of [1,2,3]-triazoles is facilitated by the fact that they possess a 
much stronger dipole moment than an amide bond. These researchers reported that both 
the N(2) and N(3) triazolyl atoms could act as hydrogen-bond acceptors while the 
strong dipole could polarize the C(5) proton so that it functions as a hydrogen-bond do-
nor, similar to the N-H proton of amides.156 
 
 
 
Scheme 20 
 
The commonest route for the synthesis of [1,2,3]-triazoles involves the well known 1,3-
dipolar cycloaddition between azides and terminal alkynes as established by Huisgen in 
1963 (Scheme 21).157 
 
 
 
Scheme 21 
 
Azides and alkynes are relatively stable under a variety of conditions and they are inert 
towards most biological and organic conditions, particularly water and oxygen. Thanks 
to their stability, azides remain invisible unless a good dipolarophile (such as an alkyne) 
is presented. However, elevated temperatures and long reaction times are often required 
and the result of this 1,3-dipolar cycloaddition is usually a mixture of the 1,4 and 1,5 
regioisomers of [1,2,3]-triazole in approximately 1:1 ratio (Scheme 21). 
 
In addition to the regioselectivity issue, another problem with this reaction is that azides 
can decompose exothermically, with loss of N2, and therefore must be treated with care. 
Although aliphatic azides have a particularly high kinetic stability relative to other 
azides, the presence of other energetic functional groups in the molecule, such as al-
kynes, increases this hazard. Probably due to this safety hazard, the Huisgen 1,3-dipolar 
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cycloaddition between azides and alkynes had, until recently, never been exploited in 
depth.  
 
2.3.2 The copper(I) catalyzed “click” reaction 
 
Renewed interest in the 1,3-dipolar cycloaddition, described above involving azides and 
organic alkynes, has occurred in the last seven years due to the findings reported sepa-
rately by Sharpless158 and Meldal.159 In 2002, these researchers independently reported 
the use of a copper(I) catalyst in this reaction to improve product yield, decrease the 
time of reaction and eliminate the need for elevated temperatures. Furthermore, they 
discovered that this catalysed variant of 1,3-dipolar addition improved the 1,4- versus 
1,5-regioselectivity. Due to the key features exhibited by the reaction, this copper(I)-
catalysed [2+3] cycloaddition has been classified within the family of “click” reactions 
and it has become one of the most popular reactions for preparing [1,2,3]-triazole func-
tions. Today, “click chemistry” as become synonymous with this specific copper(I)-
catalysed [2+3] cycloaddition.  
 
Click chemistry processes are a family of chemical reactions that were first described by 
Sharpless et al.160 in 2001. These reactions were defined as being “modular, wide in 
scope, giving high yields, generating only inoffensive by-products, stereospecific and 
simple to perform”.160 In order to be considered as a “click” reaction, the process has to 
be insensitive to oxygen and water, use readily available starting materials and reagents, 
employ easily removed or non-hazardous solvents, i.e water and finally the product iso-
lation must be simple, i.e. non chromatographic. Many types of reactions that adhere to 
these principles of “click” chemistry have since been described, including cycloaddi-
tions involving unsaturated species (e.g. hetero-Diels-Alder and 1,3-dipolar cycloaddi-
tions), nucleophilic substitutions (e.g. ring opening of epoxides, aziridines, aziridinium 
ions and episulfonium ions), “non-aldol” type carbonyl reactions (e.g. formation of 
ureas, thioureas, aromatic heterocycles, oxime ethers, hydrazones and amide) and addi-
tions to carbon-carbon multiple bonds (e.g. epoxidation, dehydroxylation, aziridination 
and sulfenyl halide addition, as well as Michael additions of Nu-H reactants).160 
 
In the case of the Huisgen-1,3-dipolar “click” variant, numerous sources of copper(I) 
catalysts have been investigated. Two different experimental strategies have been de-
scribed by Sharpless et al..161 In the first one, the active copper(I) catalyst was produced 
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in situ from a copper(II) salt (i.e. CuSO4 ⋅ 5 H2O) via reduction with ascorbic acid or 
sodium ascorbate in excess, as outlined in Scheme 22.158 The presence of excess sodium 
ascorbate was found to prevent the formation of oxidative coupling side products that 
have often been observed when a copper(I) source (i.e. CuI) was directly used.161 
 
 
 
Scheme 22 
 
In the second procedure, the catalyst was introduced in the form of the copper wire or 
shavings. The active Cu(I) catalyst was formed via comproportionation of the 
Cu(II)/Cu(0) couple.161  This method has proved to be convenient in biosynthesis where 
substrates do not tolerate sodium ascorbate or its oxidation products. 162 
 
As mentioned above, in the presence of a copper(I) catalyst the 1,3-dipolar cycloaddi-
tion of a variety of terminal alkynes and organic azides has resulted in the regioselective 
formation of 1,4-disubstituted-[1,2,3]-triazoles. The reaction has been shown to be tol-
erant to a wide range of pH (ca. 4 to 12), resistant to a broad range of temperatures 
(from 0 to 160 oC), and finally, to proceed in a variety of solvent systems (with a prefer-
ence for aqueous systems, including serum and whole blood161). Moreover, the other 
functional groups present on the reactant do not require protection as they do not inter-
fere with the reaction. The corresponding triazole cycloadducts can usually be isolated 
in a pure form in high yields by simple filtration or extraction. Since the foundation of 
this type of “click” reaction have been laid, there has been an exponential growth in 
publications in the literature describing its applications.163 Two examples that have been 
recently reported are described below due to their close relation to the work being un-
dertaken in this research project. 
 
Park and Lee164 have applied the “click” reaction to verify the successful immobilisation 
of PNA oligomers onto microarrays. This involved first derivatising an amine-activated 
glass slide by incubation with [(4-ethynylphenylcarbamoyl)-methoxy]-acetic acid 
(4EPA) in DMA containing HBTU and DIPEA (Figure 57).164 The immobilisation of 
the PNA was then achieved by treating the phenylacetylene-derivatised glass slide with 
(3-azido-2-oxo-2H-chromen-7-yloxy)-acetic acid (AZCO)-linked PNA oligomers, un-
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der standard “click” reaction conditions. The spots, thus, obtained were highly fluores-
cent due to the presence of conjugated aromatic groups. Therefore, the successful im-
mobilization was verified through the non-destructive and direct fluorescence 
method.164 They therefore showed the possibility to couple PNA oligomers to solid sub-
strates using the highly efficient “click” reaction. 
 
 
 
Figure 57 
 
‘Click’ chemistry has also been used by Schuber et al.165 for the preparation of man-
nose-functionalised liposome 87 (Scheme 23).  
 
 
 
Scheme 23 
 
In their work, an unprotected α-D-mannosyl derivative 85 carrying a spacer functional-
ised with an azide group was reacted at the surface of preformed liposomes 86 which 
incorporated a synthetic lipid bearing a terminal triple bond.165 The integrity of the 
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newly functionalised liposomes 87 was then verified using a dynamic light scattering 
technique. The research group also showed that the reaction did not affect the mannose 
now present at the surface of the vesicles and that these residues could be engaged into 
further interactions.165 
 
These two examples were relevant for our work, as we aimed to construct liposomes 
from [1,2,3]-triazoles-containing lipids and we required the head-groups present on the 
outer surface to be readily accessible for later investigations. 
 
2.3.3 Mechanism of copper(I)-catalysed Huisgen cycloaddition 
 
Computational studies have been carried out in order to try to identify the roles of the 
copper(I) catalyst. It has been known for a long time that the uncatalysed Huisgen 
cycloaddition is a concerted process. The energy barriers for the formation of both 1,4- 
and 1,5-regioisomers have been found to be very close, 25.7 and 26.0 kcal / mol respec-
tively. As mentioned earlier, the experimental data collected support these calculation, 
as ca. 1:1 mixture of the two regioisomers are typically obtained.161 However, these 
studies have also shown that the copper(I) catalysed variant cannot occur in a concerted 
fashion.  
 
In light of this, Sharpless et al.161 have proposed the mechanism outlined in Scheme 25. 
This suggestion has been supported by DFT calculations and experimental evidence. 
Thus, the sequence of this metal catalysed process begins with the coordination of the 
alkyne 88 to the copper(I) species (step A – Scheme 24). It has been reasoned that spe-
cies 90 (Scheme 24) is formed via the initial pi-complex formation 89, in which one of 
the ligands L has been displaced by the incoming terminal alkyne. 
 
 
 
Scheme 24 
 
Conversion of the alkyne 88 to the acetylide 90 is known to be involved in many C-C 
bond forming reactions where Cu acetylide species 89 are intermediates. This initial co-
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ordination to form 89 lowers the pKa value of alkyne C-H  by up to 9.8 units, making 
the attack onto the C-H bond possible.161 Although the coordination of the acetylene to 
the copper(I) (without its deprotection) should activates a mechanism toward a 1,3-
dipolar cycloaddition, Sharpless et al.161 found that the calculated the barrier for this 
process to be at 27.8 kcal / mol. And the value for this new barrier is actually higher 
than the barrier for the uncatalysed process (ca. 26 kcal / mol). Among direct cycloaddi-
tion alternatives, the one with the neutral acetylide 90 resulted in an energy barrier cal-
culated at 23.7 kcal / mol. Therefore, from these results, it was evident that the direct 
cycloaddition had to be ruled out.161 
 
 
 
Scheme 25 – Mechanism proposed by Noodleman, Sharpless and Fokin 161 
 
Thus, Sharpless et al. proposed that in the next step (B – Scheme 25) the azide replaces 
one of the ligands and binds to the copper atom via the nitrogen proximal to carbon, 
forming intermediate 91. The exact nature of this reactive intermediate is still unknown 
but recently, Leigh et al.166 have proposed various structures, based on recent DFT stud-
ies. These are summarized in Figure 58. This research group have proposed that it may 
be that the nature of the exact intermediate involved in the reaction pathways may de-
pend upon the conditions employed, e.g. solvents, bulk and coordination number of the 
ligand added. 
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Type A: i) one copper atom or ii) one copper atom 
and pi-activation of Cu-acetylide by a second cop-
per atom. 
 
Type B: i) Bis-alkyne bridged intermediate, or  
ii) two µ-coordinated copper atoms featuring a pi-
activated Cu-acetylide. These studies differ from 
A(ii) only by two copper atoms being double 
bridged. Doubly-bridged intermediates are not 
possible with bidentate ligands for copper (assum-
ing RN3 coordinates to Cu). 
 
 
Type C: The azide and the alkyne are on different 
copper atoms. i) non-pi-activated alkyne or ii) pi-
activated alkyne. These differ from B only in the 
location of the alkyne which reacts with the azide. 
 
Figure 58 166 
 
After the formation of 91, the next step in the mechanistic pathway involves the distal 
nitrogen of the azide in 91 attacking the C-2 carbon of the acetylide, to yield the unusual 
copper(III) metallacycle 92 (step C). The calculated energy barrier for this step was 
found to be 14.9 kcal / mol, which is lower than the barrier reported for the uncatalysed 
reaction. This discovery can be used to explain the enormous rate acceleration found for 
the copper(I)-catalyzed process (7 to 8 orders of magnitude) as compared to the uncata-
lysed thermal cycloaddition. 
 
The final two steps in the reaction mechanism postulated by Sharpless et al. involve 
first ring contraction of 92 to afford the triazolyl-copper derivative 93 (D – Scheme 25). 
Subsequently, proteolysis of 93 releases the triazole product 94, thereby completing the 
catalytic cycle. Sharpless et al. have also shown that this triazolyl-copper intermediate 
can be captured by electrophiles other than a proton. For example, the incorporation of 
deuterium at the C-5 of the triazole product has been accomplished in near quantitative 
yield when the reaction was performed in D2O.161 
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2.3.4 Proposed synthesis for the new monomer models 
 
From the examples described previously (Section 2.3.2), we reasoned that the copper(I) 
catalysed “click” reaction could be applied to the preparation of the lipid-spacer-PNA 
monomer models. It was believed that this method would help to overcome our syn-
thetic difficulties, encountered with the peptide linkage. Therefore, the spacer and the 
PNA monomer were redesigned in order to incorporate the required terminal alkyne and 
azido moieties respectively. As mentioned earlier, for synthetic reasons we propose that, 
the spacer should bear the azido function while the PNA monomer should be functional-
ised at its N-terminus with an alkynyl group. The retrosynthetic analysis of the lipid-
spacer-PNA monomer models based on this principle is outlined in Scheme 26. 
 
 
 
Scheme 26 – B = T or CCbz or ACbz 
 
Therefore, we needed to develop suitable synthetic pathways to both the azido spacer 83 
and the N-alkynyl PNA monomers 84. As it has been the case for the earlier amide-
based models (71 and 72 – Section 2.2.3), we proposed that the desired lipid-spacer-
PNA monomer conjugates 95 and 96 could be assembled via two strategies, as outlined 
in Scheme 26. Strategy A involved first the use of the ‘Click’ reaction to connect azide 
83 to alkyne 84 to form the 1,4-disubstituted [1,2,3]-triazole heterocyclic compound 97. 
This intermediate would then be functionalised with the chosen lipid tail (i.e. stearic or 
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diacetylenic) using the acid fluoride procedure reported earlier in Section 2.2.3, to yield 
conjugates 95 and 96. In the alternative approach of strategy B, the azide spacer 83 
would first be functionalised with the desired lipid chain to form compounds 98 and 99. 
The free azide of 98 (or 99) would subsequently be reacted with the N-alkynyl PNA 
monomer 84 using a ‘Click’ reaction, to afford again the lipid-spacer-PNA monomer 
models 95 and 96. 
 
For both strategy A and B, we needed a viable synthetic pathway to AEE azide 83 and 
the N-alkynyl PNA monomer 84. 
 
2.4 SYNTHESIS OF MODELS USING 1,2,3-TRIAZOLE LINKAGE 
 
2.4.1 Synthesis of the AEEA azide spacer 
 
We decided to start our investigation into the employment of the ‘Click’ reaction for the 
preparation of lipid-spacer-PNA monomer conjugates with the synthesis of the Boc-
protected AEE azide 83, since the preparation of the Boc-AEEA analogous 40 (Section 
2.2.1, page 60) has limited our studies into the amide-linked compounds. 
 
Many reports have been found in the literature for the introduction of azide functions 
into organic molecules. One of these strategies involves the displacement of a mesylate 
group with sodium azide. Mesylates are very good leaving groups that can be easily 
prepared from the corresponding alcohol. In Section 2.2.1 (page 68), we had reported 
that ethyl ester 59 could be successfully prepared in a reasonable yield in two steps from 
commercially available 2-(2-aminoethoxy)ethanol 39. We reasoned that the ester func-
tion of 59 could then be reduced to alcohol 100. This alcohol could subsequently be 
converted to the mesylate intermediate 101 which could be displaced in the final step to 
yield azide derivative 102 (Scheme 27). Our initial exploration of this synthetic pathway 
was focussed on model reactions using N-protected dibenzyl analogues. However, it 
was anticipated that this protecting group could be exchanged for the more appropriated 
Boc analogue once a suitable pathway as been developed, to yield the desired Boc-
protected spacer 83. 
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Scheme 27 
 
Therefore, the first step involved the reduction of ethyl ester 59 to the corresponding 
alcohol 100. Ester reduction is a common reaction in organic synthesis and is usually 
carried out using hydride reagents such as LiAlH4 or NaBH4. LiAlH4 has been reported 
to be more powerful than NaBH4 as it can reduce esters under ambient conditions. 
Therefore, we decided to first explore the use of LiAlH4 in this reaction. Thus, a solu-
tion of ester 59 in anhydrous THF at -78 oC was carefully treated with a slurry of      
LiAlH4 in THF. After aqueous work-up and column chromatography, the alcohol 100 
was obtained in 72% yield. Our original method for quenching the reaction, involving 
addition of a water saturated solution of diethyl ether, limited the scale of the reaction. 
However, this restriction was eventually overcome by employing another approach for 
destroying excess LiAlH4. This involved slow addition aqueous 2 M sodium hydroxide 
to the reaction mixture followed by stirring at room temperature for one hour.167 The 
reaction was then filtered through a Celite bed to remove the salts. When adopting this 
work-up method, the yield of 100 remained unchanged.  
 
Due to this limitation, we decided to investigate the use of NaBH4 in this reduction reac-
tion. Although NaBH4 is not a viable reducing agent under ambient conditions, its reac-
tivity has been found to be greatly improved by the addition of methanol. De Souza et 
al.168 have reported a simple and efficient route using the NaBH4-MeOH system for the 
reduction of aliphatic and aromatic methyl and ethyl esters. This approach was therefore 
attempted for the reduction of ester 59. A solution of 59 in THF was heated to gentle 
reflux and then small portions of solid NaBH4 were carefully added. Once the addition 
was completed, methanol was then very cautiously added. The resulting mixture was 
kept at reflux until TLC analysis showed that no starting material remained. After work-
up and purification by column chromatography, the alcohol 100 was obtained in an 82% 
yield. In both cases, the signals corresponding to the ester group in 59 had disappeared 
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from the 1H and 13C NMR spectra recorded for 100. With the NaBH4 method, in addi-
tion to 100, another product was isolated in 20% yield and this was identified as being 
the starting alcohol 42 (Scheme 12, page 68). This implied that although ester 59 had 
been deemed to be pure according to the analytical data collected, a small amount of 
starting material 42 must have been present. 
 
The next step towards azide 102 involved the preparation of the intermediate mesylate 
101 (Scheme 27). This was undertaken according to the protocol reported by Smith et 
al..169 Thus, triethylamine was added to a solution of alcohol 100 in anhydrous DCM at 
ca. 5 oC. Subsequently, methanesulfonyl chloride was slowly added and the solution 
was left to warm up to room temperature. After work-up and purification by column 
chromatography, mesylate 101 was obtained in an 82% yield. The formation of mesy-
late 101 was verified by 1H NMR spectroscopy, with the new singlet appearing at 
2.92 ppm being assigned to the CH3 group of the sulfonyl function. The IR spectrum 
obtained for 98 showed two new strong vibrational bands at 1176 cm-1 and 1354 cm-1, 
corresponding respectively to the symmetric and anti-symmetric S=O stretch of the me-
sylate group. 
 
The final step in this synthetic pathway involved treatment of a solution of mesylate 
101, in anhydrous DMF, with sodium azide at 60 oC. The progress of the reaction was 
followed by TLC analysis until the starting material had been consumed. After work-up 
and evaporation of the solvent, azide 102 was obtained as a yellow liquid in 87% yield. 
1H and 13C NMR spectra recorded for 102 showed the complete disappearance of the 
signals corresponding to the CH3 function of the mesylate group. The IR spectrum re-
corded for 102 showed the disappearance of the vibrational bands for the SO2 group and 
the appearance of a new strong band at 2109 cm-1 corresponding to the azide group. 
 
Thus, a viable synthetic pathway to dibenzyl-protected azide spacer 102 has been de-
veloped starting from the dibenzyl-protected ethyl ester 59. However, the azide 102 ob-
tained was not suitable for our overall synthetic strategy to lipid-spacer-PNA monomer 
conjugates. Ideally we required the Boc-protected azide 83. At this point in this syn-
thetic pathway, we therefore needed to substitute the dibenzyl amino protecting group 
for Boc. We reasoned that the best place for the removal of the dibenzyl protecting 
groups was following preparation of the alcohol 100 because, if performed at a later 
stage, the hydrogenolysis required for their cleavage could affect other functionalities 
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present in the molecule. Therefore, our adapted strategy for the preparation of the Boc-
protected azide 83 is shown in Scheme 28. 
 
 
 
Scheme 28 
 
As it has been the case for analogue 45 (Scheme 10, page 69), we screened a number of 
different methods that were available for the removal of the dibenzyl protecting groups. 
The first method involved hydrogenation of 100 in methanol in the presence of Pd/C 
catalyst at atmospheric pressure. The amino alcohol 103 had been formed in a nearly 
quantitative yield. This result was surprising as this reaction had proved unsuccessful 
for the analogous compound 45. 1H and 13C NMR spectra recorded for 103 confirmed 
the successful cleavage of the benzyl groups but on the spectra small impurities were 
present. However, due to the polar character of amino alcohol 103, it could not be puri-
fied by column chromatography and compound 103 was used in the next steps. 
 
We also investigated the catalytic transfer hydrogenation (CTH) approach. Thus, Pd/C 
catalyst (1 eq. w/w) and ammonium formate (2 eq.) were added to a solution of 100 in 
methanol. The heterogeneous solution obtained was heated to gentle reflux until TLC 
analysis showed complete disappearance of starting material 100. After filtration and 
evaporation of the solvent, the amino alcohol 103 was obtained as an oily residue in 
nearly quantitative yield. The CTH method exhibited some advantages compare to the 
atmospheric pressure hydrogenation strategy mentioned above. CTH was easy to set-up 
and gave the possibility for scaling up the reaction to ca. 2 g of starting material 100. 
However, it does suffer one major disadvantage in that it requires large quantity of Pd/C 
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catalyst (at least one equivalent compare to the dibenzyl substrate). Taddei et al.170 have 
reported a way for overcoming this limitation; they have carried out the reaction in an 
unmodified domestic microwave oven (600 W), using only 5% of Pd/C (weight with 
respect to the substrate), ammonium formate and isopropanol. Under these conditions, 
these researchers observed complete removal of both N-Cbz and N-benzyl protecting 
groups from a variety of different substrates within minutes.170 Unfortunately, we were 
not able to examine this modification due to time constraints. 
 
A final approach was undertaken for the removal of dibenzyl protecting groups using an 
H-Cube® instrument that Prof. Adams (at Heriot-Watt University) had on loan for a 
short period of time. H-Cube® is an analytical instrument developed by ThalesNano 
Nanotechnology Inc., allowing continuous-flow hydrogenation at high temperature and 
high pressure. In this instrument, the hydrogen gas is safely generated on demand at 
high pressure from de-ionized water. The advantage of the technique resides in the fact 
that hydrogen gas is not stored allowing the use of the instrument on an open bench 
without any risks. Thus, alcohol 100 was dissolved in absolute ethanol (concentration 
ca. 0.05 M) and passed through the H-Cube® instrument wich was set at 75 oC with the 
hydrogen pressure at 70 bar. Again product 103 was obtained in quantitative yield after 
evaporation of the solvent and it was spectroscopically identical to the material afforded 
by atmospheric hydrogenation and CTH. 
 
Having successfully removed the dibenzyl protecting group, the free amino group of 
103 was re-protected with a Boc group. This was achieved by heating a solution of 103, 
di-tert-butyl dicarbonate and triethylamine to gentle reflux. After work-up and purifica-
tion by column chromatography, the N-Boc derivative 104 was obtained in an 84% 
yield. 
 
The last two steps for the preparation of Boc-protected azide 83 involved formation of 
the mesylate intermediate followed by diplacement of the latter using sodium azide. 
Both reactions were successfully carried out using the same reagents and conditions as 
had been used for the synthesis of the analogous dibenzyl azide 102 (Scheme 27). The 
Boc-protected azide 83 was obtained as a yellow liquid in a 71% yield over the two 
steps. 
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Thus, we had successfully developed a high yielding synthetic pathway to the desired 
Boc-protected azide 83 from the dibenzyl-protected ethyl ester 59. This was ready for 
use in the ‘Click’ reaction once the N-alkynyl PNA monomers had been prepared. 
 
2.4.2 Preparation of N-alkyne PNA monomers 
 
With the synthesis of the Boc-protected azide spacer 83 now complete, we focussed our 
attention to the synthesis of the novel PNA monomer bearing an alkynyl moiety at its N-
terminus. It was reasoned that the N-alkynyl PNA monomers 84a, 84b and 84c could all 
be obtained in a similar fashion involving coupling of the appropriate nucleobase acetic 
acid (69, 107, 108) to ethyl 2-(prop-2-ynylamino)acetate 106 (Scheme 29). 
 
 
 
Scheme 29 
 
The novel PNA monomer backbone unit 106 was prepared from commercially available 
glycine ethyl ester hydrochloride 109 (Scheme 30). The amino function of amino acid 
109 was firstly Boc-protected by treating a cold aqueous solution of 109 with di-tert-
butyl dicarbonate whilst keeping the pH of the solution at 10.5. After work-up and col-
umn chromatography, the N-Boc protected amino acid 110 was obtained in a 63% yield. 
This reaction could be easily scaled up to ca. 3 g of 109 without any effect on the yield 
being observed. 
 
Scheme 30 
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In the next step, the nitrogen atom of the carbamate group was alkylated using 
propargyl bromide and sodium hydride. Hoffmann et al.171 have reported the conditions 
for a similar reaction and these were employed here. Therefore, a solution of 110 in an-
hydrous THF was cooled to 0 oC before being treated with 3-bromopropyne followed by 
sodium hydride. The reaction mixture obtained was left to stir at room temperature 
overnight. After careful work-up and purification by column chromatography, com-
pound 111 was obtained in a 50% yield. Along with 111, a small amount of starting ma-
terial 110 was also recovered. We investigated whether the yield of 111 could be im-
proved by changing the solvent. Thus, the reaction was repeated in anhydrous acetoni-
trile and DMF separately. In both cases an increase in the yield of 111 was observed; 
111 was produced in 68% yield for the former and 76% for the latter. The 1H NMR 
spectrum recorded for 111 showed the appearance of a narrow triplet at 2.22 ppm corre-
sponding to the terminal alkynyl proton coupling to the new CH2 now attached to the 
carbamate. Interestingly, other signals in the same spectrum appeared doubled; for ex-
ample, the signal for the NCH2CO protons was found at 3.89 and 4.09 ppm whereas the 
signal for the HCCCH2N protons was found at 4.13 and 4.19 ppm. This splitting was 
also evident in the 13C spectra and 2D NOE experiments recorded for 111. From our 
knowledge of the NMR characteristics of PNA monomers,139 we hypothesized that this 
splitting was due to the existence of rotational isomers, arising from the restricted rota-
tion around the N-CO bond as represented Figure 59. Such rotamers have been ob-
served earlier in the NMR spectra reported for the thyminyl PNA monomer 70 (Section 
2.2.2, page 74). 
 
 
 
Figure 59 
 
The final step in the synthetic pathway to ethyl 2-(prop-2-ynylamino)acetate 106 
(Scheme 30) involved removal of the Boc group. This was carried out using TFA in di-
chloromethane to afford the trifluoroacetic acid salt of 106 in quantitative yield. In the 
1H NMR spectrum recorded for 111, the disappearance of the singlets at 1.39 ppm and 
1.49 ppm both corresponding to the protons of the Boc group of 111 (both rotamers) 
confirmed the effective cleavage. 
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The novel PNA backbone 106 was now ready to be coupled to the appropriate acetic 
acid derivatives of the nucleobases as previously shown in Scheme 29. The preparation 
of thyminyl acetic acid 69 has already been described earlier in Section 2.2.2. For these 
studies we also required the preparation of the cytosinyl 107 and adeninyl 108 ana-
logues. 
 
In order to prepare the cytosinyl acetic acid 107, the exocyclic amino group of cytosine 
had to be first protected so as to prevent its interference in the later coupling step. A Cbz 
protecting group was selected as this has been used by Nielsen et al.1 for the preparation 
of cytosinyl PNA monomer. Therefore, a solution of cytosine 112 in anhydrous pyridine 
was treated with benzyl chloroformate under the conditions reported by Nielsen et al.1 
to yield 113 in a 54% yield (Scheme 31). The addition of this lipophilic group was 
found to improve considerably the solubility of cytosine in organic solvents. Having 
formed 113, this compound was alkylated at its N(1) position using methyl bromoace-
tate in the presence of potassium carbonate. The intermediate methyl ester was not iso-
lated but directly cleaved under basic conditions to afford the desired carboxylic acid 
107 in a 30% yield. The yield obtained was consistent with that reported by Nielsen et 
al..1 
 
 
 
Scheme 31 
 
Adenine has an exocyclic amino group that requires protection too. However, in order 
to ensure that alkylation occurs at the N(9) position the exocyclic amino group of ade-
nine has to be protected after alkylation according to Nielsen et al..1 Thus, adenine 116 
was treated with ethyl bromoacetate in the presence of sodium hydride following the 
procedure reported by Nielsen et al..1 This gave 115 in 41% yield after work-up and pu-
rification. This procedure yielded only the alkylation at the N(9) position (verified by X-
Ray crystallography by Egholm et al.172). Nielsen et al.1 also reported that 115 gave rise 
to a complex mixture when reacted with benzyloxycarbonyl chloride (116) under a vari-
ety of conditions.1 However, they found that when 115 was reacted with an excess of N-
Cbz-N’-ethylimidazolium tetrafluoroborate 118 (Rapoport’s reagent173, 174) for 24 hours, 
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compound 119 could be isolated in good yield. Thus, this procedure was repeated here 
and ethyl (N6-Cbz-adenin-9-yl)acetate 119 was obtained in a 90% yield. The final step 
involved hydrolysis of the ethyl ester of 119 which was successfully achieved by treat-
ing a suspension of 119 in methanol with a 2 M aqueous solution of sodium hydroxide, 
at 0 °C. After work-up and filtration, carboxylic acid 108 was obtained in near quantita-
tive yield (Scheme 32). 
 
 
Scheme 32 
 
With supplies of the thyminyl acetic acid 69, Cbz-protected cytosinyl acetic acid 107 
and Cbz-protected adeninyl acetic acid 108 to hand, we could now examine their cou-
pling to the ethyl 2-(prop-2-ynylamino)acetate 106. Thus, a solution of 69, 107 or 108 
in DMF was treated with HBTU in the presence of DIPEA. After 15 minutes, this solu-
tion was added to a solution of 106 in DMF and DIPEA. After work up and purification 
by column chromatography, N-alkynyl PNA monomers 84a, 84b and 84c were obtained 
in 60%, 51% and 36% yield, respectively (Scheme 33).  
 
 
 
Scheme 33 
 
The 1H and 13C NMR spectra recorded for 84a, 84b and 84c showed ‘splitting’ of some 
of the signals as it had been observed for the Boc-protected intermediate 111. Again this 
splitting was reasoned to be due to the presence of rotational isomers. By comparing the 
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integrations of the split peaks in the 1H NMR spectra we deduced that the two rotamers 
were present in a ca. 1:1 ratio. Thus, for these compounds, there did not appear to be 
any rotameric preference as it had been the case for the Nielsen’s PNA monomers. In 
order to confirm this observation, we decided to carry out NOE experiments on one of 
these novels PNA monomers. For these studies, we chose to use the cytosinyl PNA 
monomer 84b. Based on our knowledge from literature reports we reasoned that the two 
possible isomers of 84b are as shown in Figure 60; the carbonyl group can either point 
towards the ester group (84ba – trans isomer) or towards the propargyl unit (84bb – cis 
isomer). The NOE contacts which we were interested in are represented with red ar-
rows. 
 
 
Figure 60 – NOE contacts shown in red 
 
These contacts arose from interactions between the protons of the methylene groups, b 
and c, on the backbone unit and the side chain methylene protons next to the nucleo-
base, a. The ROESY* spectrum recorded for 84b is shown in Figure 61. The intensities 
of the resulting contacts a—b (found in the trans isomer) and a—c (i.e. cis isomer) are 
similar in intensities. These observations confirmed the first deduction obtained from 
the 1D 1H NMR mentioned earlier, i.e. that there is not rotameric preference in the N-
alkynyl PNA monomers. This can be understood from the structure of the backbone, as 
the bulky Boc group of 70 has been replaced with a smaller and linear alkyne group. 
The rotation around the tertiary amide bond in 84a is eased due to the absence of the 
hinderance of the Boc group. However, further complex calculations would have been 
required to confirm this hypothesis.  
 
                                                 
*
 ROESY spectrum obtained by Dr Alan Boyd. 
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Figure 61 – ROESY of 84b (CDCl3, 25 oC) 
 
Subsequently, an X-Ray crystal structure for 84a was obtained from crystals grown in 
diethyl ether and methanol using the same slow vapour diffusion method as used for 70. 
The ORTEP diagram of 84a is shown in Figure 62. The full crystallographic data of 
84a is available in Appendix B. Compound 84a was found to crystallise in the mono-
clinic space group, P2/(1)n. This was the same as it had been observed for thyminyl 
PNA monomer 70 (Section 2.2.2, page 76).  
 
Although in solution, the tertiary amide bond exists as a rotameric mixture, in crystal 
structure the amide bond is trans (i.e. with the carbonyl pointing toward the glycyl 
component). 
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Figure 62 
 
The packing analysis of 84a (Figure 63) showed that it exhibited the same anticipated 
centrosymmetric hydrogen-bonded dimeric structure with an H---O distance of 1.90 Å 
as it had been the case for 70. The hydrogen bond lengths are similar for both cases (c.f. 
1.86 Å for 70). 
 
 
Figure 63 
 
Intermolecular interactions analysis showed that the adjacent molecules of 84a are held 
together by a series of donor-H⋅⋅⋅acceptor type of bonds represented in Figure 64. One 
was between the alkynyl hydrogen H13 (see ORTEP Figure 62) and the oxygen atom of 
the amide bond (O19) with a H⋅⋅⋅O distance of 2.30 Å. The oxygen atom of the carbonyl 
group of the ester was in close contact with the two methylene groups C11 and C14. C11-
H11⋅⋅⋅O9 had a distance of 2.60 Å while for C14-H14⋅⋅⋅O9 the H⋅⋅⋅O distance is 2.46 Å. 
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Figure 64 
 
Finally the same kind of pi-stacking arrangement of the nucleobases pairs in a stepwise 
manner is found in 84a as observed in the case for 70 (Figure 65). This time, however, 
the “steps” were not as long as those found for 70. This is probably because in 84a the 
bulky Boc group has been replaced by the alkynyl group which allows the molecules to 
lie closer to one another. The vertical distance between two carbonyls of two stacked 
thymine rings was 4.90 Å. 
 
 
 
Figure 65 
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Although the crystal structure of the unmodified PNA monomer 70 has never been re-
ported in the literature, crystal structures of PNA:PNA, PNA:DNA and PNA:RNA du-
plexes have been described. The X-ray structures of other modified PNA monomers 
have also been described, e.g. the cyanuryl-PNA monomer175 and the aminocyclohexyl 
glycyl PNA monomers176 (Figure 66). 
 
 
 
Figure 66 
 
We have calculated the characteristic torsion angles of 70 and 84a and compared them 
to those reported in the literature for other PNA structures. These torsion angles are re-
ported in Table 4 and they are defined as in the report by Nielsen et al.177 as highlighted 
in Figure 67. 
 
 
 
Figure 67 
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Compound α β γ δ χ1 χ2 
84a - 43 103 89 -7 173 
70 -176 62 68 97 10 178 
Cyanuryl-PNA -77 -60 -86 118 1 142 
PNA-PNA177       
Strand 1 -112 56 73 114 5 -176 
Strand 2 -118 69 65 106 6 -179 
 
Table 4 – Torsion angles (o)† in known PNA crystal structures 
 
Torsion angles χ2 in 84a and 70 are very close in magnitude to those found in 
PNA:PNA duplexes. Their values indicate the planarity of the linkage between the nu-
cleobase and the backbone. Ganesh et al.175 proposed that the magnitude of χ1 can be 
used to state whether the cyanuryl PNA monomer was locked in the trans or in cis form. 
A similar argument can be applied in our case. Although the signs of torsion angle χ1 
are opposite in 70 and 84a, their relative magnitudes are close and consistent with Ga-
nesh et al. This, therefore, confirms that both crystal structures are locked in the trans 
form. In general the values obtained for the torsion angles in 84a are similar to those 
found in 70, apart for torsion angle γ. This departure can be understood by the fact that 
the bulky Boc substituent in 70 as been replaced by a smaller alkynyl group in 84a. 
Therefore, the minimized steric hindrance led to a less restricted torsion angle. 
 
The last investigation carried out on the crystal structures of 70 and 84a was to check 
their structural matching and departure.‡ We decided to set the fitting from the thymine 
ring to the tertiary amide bond. Unfortunately, the resulting match failed. It was rea-
soned that this was due to the fact that both compounds have a centrosymmetric space 
group. This means that the space group has an inversion centre as one of its symmetry 
elements. Therefore, for every point (x, y, z) in the unit cell, there is an indistinguish-
able point (-x, -y, -z). Subsequently, we repeated the fitting analysis by inverting one of 
                                                 
†
 Torsion angle definition : α=C1’−N−C5’−C4’, β=N− C5’−C4’−N3’, 
γ=C5’−C4’−N3’−C2’, δ=C4’−N3’−C2’−C1’, χ1=C4’−N3’−C6’−C7’, χ2=N3’−C6’−C7’−N1  
from Figure 25 
‡
 Data collected by Dr Georgina Rosair 
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the molecules to its mirror image. Using this approach we were able to perform struc-
tural matching. The result, shown in Figure 68 and Figure 69, was unexpected.  
 
 
 
Figure 68 – 70 in dotted line, 84a in solid line 
 
From Figure 68, it can clearly been seen that both compounds matched well from the 
thymine ring down to the tertiary amide bond. However, the glycyl unit of 84a did not 
correspond to the one of unmodified PNA monomer 70. This departure is clearer in 
Figure 69 that represents a view in which the thymine rings reside perpendicular to the 
plan of the page. From this projection it is apparent that there is a difference in the ori-
entation of the CH2 group joining the ester group to the amide in 70 and in 84a. This 
difference in orientation is also found in the methylene group on the other side of the 
amide. The reasons for these are not fully understood and due to time pressing they 
were not further investigated. 
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Figure 69 – 70 in dotted line, 84a in solid line 
 
Thus, in conclusion the preparation of the novel N-alkynyl PNA monomers bearing 
thyminyl, cytosyl and adenyl moieties (respectively 84a, 84b and 84c) was successfully 
accomplished. The focus of this project now moved on the preparation of the lipid-
spacer-PNA monomer models. As mentioned in Section 2.3.4, two strategies for their 
construction were possible and our investigations into each will be discussed in the fol-
lowing two sections (2.4.3 and 2.4.4). 
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2.4.3 Synthesis of lipid-spacer-PNA monomer models using Strategy A 
 
Our investigation in preparation of the lipid-spacer-PNA monomer models 95 started 
with the application of the Strategy A, described previously in Scheme 26 (page 91) and 
represented below in Scheme 34. 
 
N
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O
O
BocHN
O
O
N3 +
BocHN
O
O
N
NN
N
B
O
OEt
O
83
97a : B =T
97b : B = CCbz
97c : B = ACbz
CuSO4.5H2O (10 % mol)
NaAsc (20 % mol)
H2O:t-BuOH (1:1)
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84b : B = CCbz
84c : B = ACbz
N
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O
O
N
NN
N
B
O
OEt
O
R
O
95a : R = CH3(CH2)11C4(CH2)8, B = T
95b : R = CH3(CH2)11C4(CH2)8, B = C
Cbz
95c : R = CH3(CH2)11C4(CH2)8, B = A
Cbz
120a : B =T
120b : B = CCbz
120c : B = ACbz
 
 
Scheme 34 
 
We were interested in first verifying that the ‘Click’ reaction could be applied to our 
own substrates. Before using our PNA monomers (84a, 84b and 84c), we decided to 
perform a model reaction using the N-alkynyl intermediate 111 (Scheme 30, page 97), 
which contained a Boc group in place of the nucleobase. Once the reaction conditions 
had been optimised, we proposed to replace intermediate 111 with the N-alkynyl PNA 
monomers (84a, 84b and 84c).  
 
This model reaction was performed following the procedure reported by Fokin et al..158 
Thus, solid CuSO4 ⋅ 5 H2O was added to a solution of azide 83 and alkynyl intermediate 
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111 in tert-BuOH and water (2:1) followed by a freshly prepared aqueous solution of 
1 M sodium ascorbate (Scheme 35). 
 
 
 
Scheme 35 
 
The colour of the solution obtained quickly changed from colourless to bright yellow as 
a result of the reduction of the copper metal from Cu(II) to Cu(I). The resulting solution 
obtained was left to stir at room temperature and the progress of the reaction was fol-
lowed by TLC analysis. This quickly revealed the formation of a new product along 
with the gradual disappearance of starting materials. After 24 hours, TLC analysis did 
not show any further changes. By this time, the solution had become green in colour. 
This observation implied that Cu(II) had been reformed. Thus the reaction was worked 
up and the crude mixture obtained was carefully purified by column chromatography. 
Product 121 was obtained in a 75% yield. 
 
The 1H NMR spectra recorded for 121 showed a combination of all the signals from 
starting materials 83 and 111, in the correct integration. The disappearance of the signal 
for the alkynyl proton of 111 at 2.22 ppm along with the appearance of a new singlet 
split at 7.56 ppm and 7.75 ppm corresponding to the C(5) triazolyl proton, indicated that 
[1,2,3] triazole ring had been formed. This was also verified in the 13C NMR spectrum 
recorded for 121. As it had been seen before for the PNA monomer, some of the signals 
from compound 121 were split in both 1H and 13C NMR spectra. Once again this im-
plied two rotamers were present. For example, as just mentioned in the 1H NMR, the 
signal the C(5) triazolyl proton was found at 7.56 ppm and 7.75 ppm, whereas in the 13C 
NMR spectra, the signal for the triazolyl C(5) was found at 123.1 ppm and 123.9 ppm. 
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In order to confirm that the expected 1,4-disubstituted [1,2,3] triazole regioisomer had 
been formed rather than the 1,5-regioisomer a NOESY 1H NMR of 121 was recorded. It 
was reasoned that if the 1,4-regioisomer had been formed, the contact between the tria-
zolyl C(5) proton with CH2 groups on either side (a and b – Figure 70) would be ob-
served. However, if the 1,5-regioisomer was present, the triazolyl C(5) proton should 
only show contact with the CH2 b. CH2 b would also show a contact with CH2 a in the 
latter regioisomer. 
 
 
 
 
 
Figure 70 –NOESY of 121 (400 MHz, CDCl3, 25 oC) 
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The NOESY 1H NMR spectrum recorded for 121 is shown in Figure 70. This clearly 
shows the predicted characteristic NOE contacts for the 1,4-regioisomer. No contacts 
corresponding to the 1,5-regioisomer were evident. This experiment confirmed that this 
‘Click’ reaction had given rise to the 1,4-disubstituted [1,2,3]-triazole only as expected. 
 
Following the successful coupling of azide 83 to intermediate 111 using the ‘Click’ re-
action (Scheme 35), we decided to repeat this reaction exchanging the model alkynyl 
111 for N-alkynyl PNA monomers (84a, 84b and 84c – Scheme 34). Initially, we 
worked with the thyminyl PNA monomer 84a. When we performed the ‘Click’ reaction 
with 84a, we modified the procedure slightly from the conditions used for the model 
alkyne 111. This was because we noticed that the PNA monomer 84a did not readily 
dissolve in the original solvent mixture used (i.e. tert-butanol and water). This limitation 
was overcome by first dissolving the N-alkynyl PNA monomer in dichloromethane. 
This solution was then added to the aqueous solution containing the azide 83, closely 
followed by the copper catalyst and the solution of sodium ascorbate. This modification 
also simplified work-up of the reaction, as a simple separation of the aqueous phase 
from the organic phase enabled the organic reaction products to be easily separated 
from the copper salts. The crude product afforded was subsequently purified by column 
chromatography to afford 97a in 72% yield. The spectral analysis of 1H and 13C NMR 
showed all the signals expected for 97a. Again some signals were split due to the pres-
ence of rotamers. This reaction was repeated using N4-Cbz cytosinyl PNA monomer 
84b and N9-Cbz adeninyl PNA monomer 84c in the place of 84a to yield the corre-
sponding intermediates 97b (76%) and 97c (64%) respectively (Scheme 34). 
 
The next step in Strategy A, for the preparation of ‘lipid-spacer-PNA monomer’ model 
compounds, involved connection of the lipid chain to the N-terminal of the intermedi-
ates 97a, 97b and 97c. This connection involved the formation of a peptide bond, a 
similar methodology to the one described for the preparation of lipid-spacer intermedi-
ates 73 and 74 (Section 2.2.3, Scheme 17, page 79) was applied here. In order to carry 
out this connection, the Boc protecting group of compounds 97a, 97b and 97c has to be 
first removed. Therefore, starting with the thyminyl intermediate 97a, its N-Boc protect-
ing group was cleaved by stirring a solution of 97a in dichloromethane in the presence 
of TFA at room temperature (Scheme 34). After one hour, TLC analysis showed that the 
starting material had been consumed. After work up, analogue 120a was obtained as its 
trifluoroacetic acid salt in quantitative yield. The disappearance of the signal at 
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1.42 ppm corresponding to the Boc group in the 1H NMR spectrum recorded for 120a 
indicated that successful N-deprotection had been accomplished. Intermediates 97b and 
97c were similarly deprotected and comparable yields had been accomplished. The 1H 
NMR spectral analysis showed similar features as for 120a. 
 
The trifluoroacetic acid salts obtained were used without further purification in the cou-
pling step, which involved reaction with the appropriate lipid fluorides. The preparation 
of diacetylenic and stearoyl acid fluorides 78 and 79 has been reported in Section 2.2.3 
(page 79). The reaction between the deprotected N-terminus of 97a, 97b and 97c and 
the acid fluoride should afford the ‘lipid-spacer-PNA monomer’ models. Thus, the 
thyminyl derivative 120a was treated with diacetylene acid fluoride 78 under the same 
conditions as described earlier in Section 2.2.3 (page 80). After work-up and purifica-
tion by column chromatography, conjugate 95a was obtained in a 71% yield. The 1H 
NMR spectrum showed all the signals corresponding to the three building blocks in 
their ratios. For example, the CH3 group of the diacetylene chain and the thyminyl 
C(5)CH3 were found at 0.88 ppm and 1.90 ppm, respectively. Again, some signals were 
split, indicating the presence of two rotational isomers. These were estimated to be in a 
1:1 ratio. HRMS supported the preparation of 95a where the [M+H]+ molecular ion was 
found at 838.5443. Theoretically, C45H72N7O8 requires a m/z of 838.5437. This reaction 
was then repeated using the cytosinyl and adeninyl analogues, 120b and 120c respec-
tively (Scheme 34) to give the corresponding models 95b and 95c. These too were ob-
tained in good yields (70% and 74% respectively). The 1H and 13C NMR spectra re-
corded were consistent with the preparation of 95b and 95c. 
 
A characteristic feature of diacetylenic models 95a-c is their gradual change on expo-
sure to light from colourless to deep blue in the solid state as a result of a topochemical 
polymerisation. The same compounds, however, did not seem to polymerise in solution 
(e.g. they remained stable in the NMR sample in CDCl3). 
 
Even though strategy A worked well for the construction of the ‘lipid-spacer-PNA 
monomer’ models we devised to explore strategy B to see if any improvement in yields 
could be achieved. 
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2.4.4 Preparation of monomer models based on Strategy B 
 
Strategy A allowed the preparation of the second generation of diacetylenic models 
bearing thyminyl, cytosinyl or adeninyl functions in good yields (ca. 70%). However, 
the retrosynthetic analysis of preparation of these models showed that another strategy 
(i.e. strategy B, Scheme 26, page 91) could be also used. As mentioned above we were 
interested in verifying the applicability of strategy B to prepare models 95a-c.  
 
Strategy B first involved the coupling of the lipid chain (i.e. diacetylenic or saturated) to 
the N-terminal of the azide spacer 83. Subsequently, the free azide of this intermediate 
was reacted with the N-alkynyl function of the PNA monomers 84a-c, to afford the 
‘lipid-spacer-PNA monomer’ models desired. A variety of model compounds could be 
easily prepared by applying strategy B to parallel synthesis. In fact, it was reasoned that 
the lipid-spacer intermediates could be reacted with different N-alkynyl analogues e.g. 
PNA monomer, dimers and even oligomers (Figure 71). Therefore, specificity is intro-
duced to the model compounds in the last step of the synthetic pathway rather than in 
the first step as it was the case using strategy A. 
 
 
 
Figure 71 
 
Therefore, the first step in this new synthetic pathway leading to the coupling between 
the chosen lipid and the N-terminus of azide spacer 83 required first the cleavage of the 
Boc protecting group from 83 (Scheme 36). This was achieved by treating a solution of 
83 in ethyl acetate with concentrated hydrochloric acid at room temperature. After one 
hour, TLC analysis showed that the starting material had been consumed. After work 
up, analogue 122 was obtained as its hydrochloride salt, in a quantitative yield. The dis-
appearance of the signal at 1.42 ppm corresponding to the tert-butyl protons in the 1H 
NMR spectrum recorded for 122 indicated that successful N-deprotection had been ac-
complished. 
 
Subsequently, the N-terminus of 122 was coupled to the acid fluoride derivative of 
10,12-PCDA 78 under the same conditions as described previously in Section 2.2.3 
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(page 80). After work-up and purification by column chromatography, the correspond-
ing lipid-spacer intermediate 98 was obtained in 80% yield (Scheme 36). The 1H NMR 
spectra recorded for 98 showed all the signals corresponding to both starting materials 
in their correct ratio. The appearance of a new broad triplet at 5.55 ppm was assigned to 
NH proton coupling to the neighbouring CH2, indicating the formation of the peptide 
bond. This reaction was repeated using the acid fluoride derivative of stearic acid 79. 
After work-up and purification by column chromatography, intermediate 99 was ob-
tained in 80% yield. Again, the 1H NMR spectra recorded for 99 showed all the ex-
pected signals in their correct ratio. The formation of the peptide bond in 99 was evident 
from the appearance of a similar broad triplet at 5.55 ppm (i.e. assigned to NH proton 
coupling to the neighbouring CH2) as it had been the case in 98.  
 
 
 
Scheme 36 
 
The saturated compound 99 was found to be stable at ambient conditions and could be 
stored at -20 oC for long periods of time without degradation occurring. On the other 
hand, the unsaturated compound 98 was found to be unstable in the solid state. 98 was 
obtained as a white solid that very quickly turned blue on exposure to light. This charac-
teristic had already been observed in our earlier work with the diacetylenic models 95a, 
95b and 95c (page 113). The change of colour is an indication of the reaction of polym-
erisation taking place. This change of colour was also obtained when 98 was stored in 
Chapter 2 : Synthesis of models 
116 
 
the dark at -20 oC but it did not seem to polymerise in solution (i.e. in the NMR sample 
in CDCl3). Due to this problem, we reasoned that strategy B was not suitable for the 
preparation of ‘lipid-spacer-PNA monomer’ models bearing the diacetylenic lipid tail. 
 
Despite the problems reported above, having prepared 98, its coupling with the N-
alkynyl PNA monomers 95a-c was still investigated (Scheme 32). We first selected for 
this purpose the thyminyl PNA monomer 84a which was reacted with 98 under the 
same conditions of ‘Click’ reaction as described in strategy A (page 112). The N-
alkynyl PNA monomer 84a and the lipid intermediate 98 were first dissolved in di-
chloromethane, followed by the aqueous mixture of water and tertbutanol (1:1) contain-
ing the copper catalyst and the solution of sodium ascorbate. The progress of the reac-
tion was carefully followed by TLC and after 30 hours at room temperature, it showed 
that the two starting materials 84a and 98 were still present and that along with them a 
novel compound had formed. The reaction mixture was further stirred (total time 
48 hours) but unfortunately TLC analysis kept revealing the presence of both starting 
materials. Nevertheless, after this time, the reaction was worked up and, after careful 
purification by column chromatography, the model 95a was obtained in 59% yield. This 
reaction product was spectroscopically identical to the one obtained with strategy A. 
The synthetic pathway was then repeated for the cytosinyl PNA monomer 84b and the 
analogous model 95b was obtained in a 30% yield. The reaction product was spectro-
scopically identical to the 95b obtained in strategy A. 
 
Both yields of 95a and 95b obtained using strategy B were lower than when following 
strategy A. One reason for this is possibly because of the polymerisation problems of 
starting material 98. Due to these low yields, we decided not to prepare the analogous 
adeninyl model 95c according to this strategy. 
 
With the preparation of the diacetylenic models now completed we decided to move to 
the synthesis of the models functionalised with a saturated lipid chain. As already dis-
cussed in Section 1.5.2 (page 41), Charych et al.98, 103 have demonstrated that when con-
structing liposomes for use as biosensors it is not always necessary for the bioactive 
head-group to be covalently linked to the polydiacetylene matrix. Given the stability of 
intermediate 99 we decided to explore the ‘Click’ reaction using this starting material. 
Therefore, ‘lipid-spacer’ intermediate 99 was reacted with N-alkynyl PNA monomers 
84a, 84b and 84c separately, under the same reaction conditions described for the con-
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nection of the diacetylenic lipid 98. Once again, after 48 hours of stirring at room tem-
perature, TLC analysis indicated that the reaction did not reach completion. However, 
after this time, we decided to work up the reaction. After purification by column chro-
matography, the corresponding models 96a, 96b and 96c were obtained, in 74%, 62% 
and 55% yields, respectively. The 1H NMR spectra recorded for these models showed 
the expected combination of all the signals from the starting material 99 and the N-
alkynyl PNA monomer (84a-c), in the correct ratio. For example, in the spectrum of 
model 96a, the disappearance of the signal at 2.22 ppm corresponding to the alkynyl 
proton of 84a along with the appearance of the new singlet split at 7.71 ppm and 
7.94 ppm corresponding to the C(5) triazolyl proton, indicated that [1,2,3] triazole ring 
had formed. 13C NMR spectra also verified the formation of this ring with the appear-
ance of two new signals, the triazolyl quaternary carbon C(4) was found at 142.4 ppm 
and 142.8 ppm, and the triazolyl CH group found at 123.8 ppm and 124.2 ppm. As it 
had been the case for diacetylenic models 95a-c, some of the signals of the stearoyl 
models 96a-c were split in both 1H and 13C NMR spectra, implying the presence of ro-
tameric isomers. 
 
At this stage of the research project we were in the possession of a library of six models 
made from two different types of lipid chains and three different nucleobases (Scheme 
36). Two strategies had been carried out to produce these conjugates and from our stud-
ies it appeared that in the case of the diacetylenic models, the lipid chain should be con-
nected in the last step of the synthetic pathway. Although we did not attempt strategy A 
for the preparation of saturated models, the yields obtained with strategy B were really 
good (above 50%), indicating that this strategy is suitable. We believe that similar 
yields would have been obtained with strategy A but due to time constraints we did not 
investigate further. 
 
It is worth noting that the conditions used for the ‘Click’ reaction were not optimised 
and that further investigations into their improvement would be necessary in the future. 
Improvements in yields of ‘Click’ reaction are regularly being published in the litera-
ture. For example, it has been reported by Fokin et al.178 that the use of ligands such as 
TBTA (Figure 72) can improve both the purity and yields of the final product by stabi-
lizing the copper(I) and protecting it from oxidation and disproportionation.  
 
Chapter 2 : Synthesis of models 
118 
 
 
 
Figure 72 – Structure of TBTA 
 
2.4.5 Preparation of cytosinyl model using strategy C 
 
Finally, during the course of our investigations into strategy B a third strategy was de-
signed. Strategy C was based on the same principle as strategy B but here, the N-alkynyl 
PNA monomer was replaced with the Boc intermediate 111. This strategy involved the 
preparation of the lipid-spacer-PNA monomer backbone model 120 that would then be 
functionalised with appropriate nucleobase acetic acid derivative. Thus, on the same 
principle as strategy B had been designed (Figure 71, page 114), we reasoned that 
specificity into the models would be inserted in a later step, after the preparation of the 
backbone of the models. 
 
Strategy C was investigated for the preparation of model 96b and started with the 
‘Click’ reaction between lipid-spacer intermediate 99 and N-alkynyl PNA intermediate 
111 (Scheme 37).  
 
 
 
Scheme 37 
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The same conditions described in Section 2.4.4 (page 113) were used here. After work-
up and purification by column chromatography, the lipid-spacer-Boc monomer 123 was 
obtained in an 89% yield. The 1H NMR spectrum recorded for 123 showed all signals 
expected such as the split singlet at 7.61 ppm and 7.78 ppm corresponding to the tria-
zolyl C(5)H newly formed. 13C NMR analysis also confirmed the formation of the 
[1,2,3]-triazole ring. Subsequently, the Boc protecting group of 123 was cleaved to lib-
erate the secondary amino group under acidic conditions. The disappearance of the split 
signal at 1.35 ppm and 1.40 ppm corresponding to the tert-butyl protons in the 1H NMR 
spectrum, confirmed the successful deprotection. The trifluoroacetic acid salt 123 was 
then directly reacted with cytosinyl acetic acid 107 using HBTU as the activating agent 
in the presence on DIPEA. After work-up and purification by column chromatography, 
the ‘lipid-spacer-PNA monomer’ 96b was obtained in a 53% yield. The product was 
spectroscopically identical to the one obtained from strategy B. Although the yield ob-
tained with this strategy is slightly lower than with strategy B (c.f. 62%, page 116), the 
overall synthetic pathway was simplified since it did not require the preparation of the 
N-alkynyl PNA monomer 84b. Overall, fewer purification steps by column chromatog-
raphy were required. However, due to time constraint only the cytosinyl model 91b has 
been prepared using this pathway but future investigations involving the other nucleo-
bases acetic acid derivatives should be carried out.  
 
We mentioned earlier that strategy B was not suitable for the preparation of diacetylenic 
models 95a-c due to the instability of intermediate 98. Therefore, it would be interesting 
to verify the stability of the diacetylenic analogues of 123 and its applicability in this 
strategy. 
 
2.4.6 Preparation of the corresponding acid models 
 
In the preliminary studies carried out within our research group, Murray2 discovered 
that for successful incorporation of the N-lipid functionalised PNA models into PDA-
liposomes a C-terminus carboxylic acid was required. This was evidences with the in-
corporation of 100% of their ‘lipid-PNA monomer’ models into PDA-liposomes; the C-
terminus ester model precipitated during the step of polymerisation leading to pale blue 
solutions, while the carboxylic acid terminated model yielded dark purple solution after 
photopolymerisation. 
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With these results in mind, we decided to also prepare the carboxylic acid analogues of 
the ‘lipid-spacer-PNA monomer’ models obtained in sections 2.4.3 and 2.4.4 (95a-c and 
96a-c) as shown in Scheme 38. 
 
 
 
 
 
Scheme 38 
 
Therefore, our investigations into the hydrolysis of ‘lipid-spacer-PNA monomer’ mod-
els started with the thyminyl models 95a and 96a. A solution of 95a was dissolved in 
THF and treated with 1 M aqueous solution of lithium hydroxide (Scheme 38). After 
work-up and purification by column chromatography, the corresponding acid 125a was 
obtained in an 82% yield. 1H NMR spectrum recorded for 125a evidenced the cleavage 
of the ester with the disappearance of the signal at 4.21 ppm corresponding to the CH2 
group of the ethyl function of 95a. In the 1H NMR of 95a, the signal corresponding to 
the CH3 group was hidden under the peak corresponding to the methylene of the lipid 
chain. 13C spectrum also confirmed the hydrolysis of the ester and the formation of 
125a. Finally, a HRMS further confirmed the formation of 125 with the molecular ion 
giving rise to a peak at m/z of 810.5113; a compound with molecular formula 
C43H68N7O8 is theoretically expected to produce an m/z of 810.5124. Similar results 
were obtained when the saturated conjugate 96a was treated under the same conditions, 
to yield 126a in an identical yield. 
 
After these successful conversions, the cytosinyl model compounds 95b and 96b were 
reacted using the same conditions. Unfortunately, despite numerous attempts to prepare 
and isolate the corresponding acids (125b and 126b) from the complicated crude reac-
tion mixtures, 125b and 126b were not obtained. The reasons for this are still not under-
stood as the reactions conditions employed here were the same as those used earlier by 
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Murray.2 Due to the lack of time and material, further investigations were not attempted 
and our intention to prepare 125b and 126b was abandoned.  
 
Lastly, we focused on the hydrolysis of adeninyl models 95c and 96c. This time, the 
conditions were changed and we decided to use a diluted aqueous solution of sodium 
hydroxide (0.77 M) as reported by Howarth et al.179 for similar purpose. After work up 
and purification by column chromatography, the corresponding acids 125c and 126c 
were obtained in 92% and 53% yields, respectively. Again the disappearance of the sig-
nals for the ethyl group in both 1H and 13C NMR spectra confirmed the cleavage of the 
ester. 
 
In summary, we now have successfully prepared ten ‘lipid-spacer-PNA monomer’ 
models out of the twelve expected. These were prepared from a combination of three 
different PNA monomers and two types of lipid chain. Six of them had an ester function 
at their C-terminus while the thyminyl and adeninyl have also been prepared in their N-
terminus carboxylic acid derivatives. We, therefore, decided to move onto the investiga-
tion of their abilities to incorporate into PDA-liposomes. This area of the project will be 
the focus of Chapter 3. 
 
2.4.7 Synthesis of dimer models 
 
It was evidenced that monomer models could be successfully synthesised and the ulti-
mate aim of the synthetic part of this project concerned the preparation of compounds 
bearing a PNA oligomer as the headgroup. As mentioned earlier (Chapter 1, Section 
1.6.2, page 55), Murray2 reported the preparation of homothymine (T10) oligomers using 
the Merrifield solid phase approach and following the procedure reported by Christen-
sen et al..120 Their functionalisation with both diacetylenic and stearoyl lipids was also 
described by Murray. In our case, the preparation of similar compounds containing the 
spacer was necessary to fully assess the benefits of this spacer. However, the time spent 
on model reactions prevented us to perform solid phase synthesis, even though the pro-
tocol had been developed in our laboratories. It was still reasoned that we should try to 
produce models bearing a larger PNA headgroup than a simple monomer. This would 
give us some insight into the applicability of our synthetic strategies to prepare conju-
gates bearing a PNA oligomer as headgroup. Therefore, we decided to prepare a 
thyminyl PNA dimer functionalised with an alkynyl moiety at its N-terminus using so-
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lution phase synthesis. Then, according to the principle developed in Strategy B (Sec-
tion 2.4.4, page 114) this PNA dimer would be functionalised with the stearoyl lipid 
chain. In fact, the polymerisation of lipid-spacer intermediate 98 (page 115) restrained 
us from using it. We also reasoned that for preliminary explorations we should start 
with the simplest lipid chain, i.e. stearic acid derivative. Once the synthetic pathway to 
the thyminyl PNA dimer was optimised, it would be easy to explore its functionalisation 
with either lipid chains. 
 
Therefore, according to Strategy B, the synthesis of ‘lipid-spacer-PNA thyminyl dimer’ 
model 128 involved performing the ‘Click’ reaction between the azide moiety of the 
lipid-spacer intermediate 99 and the N-alkynyl function of the dimer 128. We proposed 
that dimer 128 could be prepared by conducting a peptide coupling between the N-
alkynyl thyminyl PNA monomer 84a and the thyminyl PNA monomer 70 (Scheme 39). 
 
 
 
Scheme 39 
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In order to carry out this coupling step, the two PNA monomers needed to be first de-
protected at their N- and C-terminus respectively. In order to remove the ethyl ester of 
84a, a solution of 84a in dioxane was treated with a highly diluted aqueous solution of 
sodium hydroxide (i.e. 0.7 M).179 After work-up and purification by column chromatog-
raphy, carboxylic acid 127 was obtained in an 89% yield. In 1H NMR spectrum re-
corded for 127 the disappearance of the split signals at 1.26 ppm and 1.31 ppm, and 
4.18 ppm and 4.26 ppm corresponding to the ethyl ester in 84a confirmed the cleavage 
of the ester group. This observation was also evidenced on the 13C NMR spectrum with 
the disappearance of the split signals at 14.0 ppm and 14.1 ppm, and at 61.7 ppm and 
62.3 ppm. The Boc group of the thyminyl PNA monomer 70 was cleaved under acidic 
conditions, to yield the trifluoroacetic acid salt derivative 82 in a quantitative yield. 
 
Subsequently, 127 and 82 were coupled using HATU as a coupling agent in the pres-
ence of DIPEA. After work-up and purification by column chromatography, dimer 128 
was obtained in 37 % yield. All the signals corresponding to both starting materials 
could be observed on both 1H and 13C NMR spectra recorded for 128. For example, in 
the 1H NMR the signal at 0.88 ppm corresponding to the CH3 group of ethyl ester func-
tion and the signal at 1.85 ppm, integrating to 6 protons corresponded to the two C(5)-
CH3 groups of the thyminyl rings. However, we did not observe the signal correspond-
ing to the NH proton of the new peptide bond but in the 13C NMR spectrum we rea-
soned that the signal at 168.6 ppm corresponded to the amide carbonyl group therefore 
confirming the formation of the peptide bond. Finally, a HRMS further confirmed the 
formation of 128 through the formation of an [M+NH4]+ ion peak at m/z of 591.2514; a 
compound with molecular formula C25H35N8O9 is theoretically expected to produce an 
m/z of 591.2522. 
 
The low yield obtained for 128 was not a surprise since Condom et al.119 have reported 
low yields for the coupling of PNA monomer using solution phase protocols. In their 
work they have overcome this problem by developing a slightly different strategy to 
prepare PNA hexamer in high yields, using solution-phase synthesis.119, 180 Instead of 
coupling directly two PNA monomers, these researchers coupled a PNA monomer unit 
130 bearing a free C-terminus to the ethyl N-(2-aminoethyl)glycinate backbone unit 131 
yielding intermediate 132 (Scheme 40). The nucleobase acetic acid 133 was then cou-
pled in a separate step, affording dimer 134. Dimer 132 was then hydrolysed to carbox-
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ylic acid 135 and the sequence of step was repeated until the hexamer was formed. 
Therefore, a similar strategy could be investigated in the future for our purpose. 
 
 
 
Scheme 40 
 
Despite the low yield of 128 afforded, we still had it in sufficient quantity to carry out 
the next step. Thus, 128 was treated with the ‘lipid-spacer’ intermediate 99 under the 
same ‘Click’ reaction conditions that we had used previously for the preparation of the 
monomer models (Scheme 39). After work-up and purification using column chroma-
tography, dimer model 129 was obtained in 46% yield. Due the extremely small amount 
of material isolated (0.012 g) we were not able to record any NMR spectra for 129. 
However, HRMS measurement recorded for 129 showed the molecular ion peak at m/z 
1014.5977 and theoretically a compound of molecular formula C49H80N11O12 is ex-
pected to produce an m/z of 1014.5982. 
 
Due to the poor yields of the coupling steps and the time restrictions, we did not attempt 
to prepare the diacetylenic dimer analogues. However, with the incorporation of com-
pound 129 into PDA liposomes, we wanted to show that the inclusion of a larger PNA 
headgroup in addition to the spacer did not hinder formation and the polymerisation of 
these liposomes. In addition, we hoped that the inclusion of the PEG-like hydrophilic 
spacer would help to overcome the precipitation problems encountered by Murray.2 
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3 LIPOSOME INVESTIGATIONS 
 
As defined earlier, liposomes are aggregates of an amphiphilic molecular bilayer. Am-
phiphilic diacetylenes with polar headgroups and extended hydrocarbon chains form 
liposomes in aqueous solutions with one set of head-groups exposed at the surface and 
the other enclosing an interior hydration sphere. The incorporation of suitable receptor 
elements at the surface of such PDA-liposomes, either by covalent linking to the PDA 
or by physical embedding within the matrix, can produce sensors in which interactions 
with specific substrates induce changes in polymer conformation with concomitant col-
our transitions.181 In this Chapter, the abilities for all the model compounds (prepared in 
Chapter 2) to be incorporated into PDA-liposomes will be summarised. 
 
3.1 BACKGROUND 
 
Murray2 has incorporated thyminyl-PNA monomer and oligomers functionalised with 
stearic and diacetylenic lipid tail, into PDA-liposomes. His investigations started with 
the incorporation of 100% of model compounds 22 and 136 (Figure 73) and compared 
these results with the control solution made from 10,12-PCDA (5 also referred to as ma-
trix lipid) only.  
 
 
 
Figure 73 
 
He observed that the acid model 22 incorporated well producing a deep purple solution, 
while the ester model 136 also resulted in a purple solution, but additionally showed 
significant precipitation. The electronic spectrum of the polymerised 100% matrix lipid 
showed visible absorption bands at 639 and 591 nm and a UV absorption band at 
241 nm. These absorptions compared well with the absorptions reported by Charych et 
al.,122 however in their case, absorption below 400 nm was not reported. The electronic 
spectrum of polymerised acid model 22 showed intense absorption bands at 626, 578, 
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515 and 273 nm. The band at 273 nm was assigned to the absorption of the thymine 
residues.2, 181 The ester model 136 showed the same range of absorption but at lower 
intensities due to the reduction in concentration due to precipitation. From these results 
Murray2 showed that the addition of a PNA monomer head-group did not inhibit or hin-
der the polymerisation, and that the presence a free carboxylic acid was required in or-
der to prevent precipitation. 
 
Murray2 reported similar investigations using 1:1 mixtures of the matrix lipid (5) and 
either the acid model 22 or the ester model 136. Liposomes containing the ester model 
136 precipitated upon polymerisation while those containing the acid model 22 gave 
blue solutions. The electronic spectrum of this blue solution showed absorption bands at 
646, 599 and 264 nm. These results demonstrated that model compound 22 was suc-
cessfully incorporated into PDA-liposomes using 5 as the matrix lipid. Following these 
results, Murray et al.2, 181 successfully prepared liposomes according to the ratios used 
by Charych et al.,98 i.e. 95% of matrix lipid and 5 % of sialic-model. 
 
3.2 LIPOSOME PREPARATION 
 
Before presenting the results obtained for the incorporation of the lipid-spacer-PNA 
monomer models, the protocol for the preparation of liposome is described. It follows 
the one that has been described by Charych et al..98 Separate solutions of 10,12-PCDA 
(5) and models were prepared in chloroform. Then, the appropriate amounts of 5 and of 
the chosen model were measured using micro syringes and were mixed in a glass test 
tube. The chloroform was subsequently evaporated using a gentle stream of nitrogen 
gas, to obtain a thin film of lipid at the bottom of the test tube. Consequently, the appro-
priate amount of deionised water was added so that the total lipid concentration was 
1 mM. The sample was then heated to ca. 80 oC using a hot water bath. The titanium tip 
of the sonicating probe (Sonozap®) was then inserted in the aqueous solution and main-
tained at ca. 1 cm from the bottom of the test tube. Finally, the solution was sonicated 
for ca. 15 to 20 minutes. Charych et al.91 reported that, after sonication, the warm solu-
tion should be filtered through a 0.8 µm nylon filter to remove undispersed lipid and 
traces of titanium particles. Initially this step was also repeated in our case, but after UV 
irradiation of the filtrate, the solution had only a pale blue shade. It appeared that the 
filtration had removed all lipids, i.e. undispersed and preformed vesicles. Therefore, the 
filtration step was avoided in consecutive attempts. Thus, after sonication the test tube 
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was corked and stored overnight at 4 oC to cool down. The solution obtained was 
opaque but uncoloured. After this time, the solution was warmed up to room tempera-
ture and purged with nitrogen gas for five minutes. Small aliquots of solutions were 
then placed in a sample holder and placed at ca. 3 cm distance under a UV lamp (254 
nm) for up to 30 minutes. After this time, the solutions colour ranged from deep blue to 
purple (depending on the time of UV exposure). Solutions were subsequently stored in 
glass vials at 4 oC for several months. 
 
3.3 INCORPORATION OF LIPID-SPACER-PNA MONOMER MODELS 
 
Therefore, we based our preliminary investigations on the results reported by Murray et 
al..181 Although the structures of the models described in Chapter 2 are slightly different 
from those presented by Murray2 we believed that the inclusion of the hydrophilic 
spacer would not hamper the polymerisation process. In fact, Charych et al.98 have in-
cluded a similar spacer in the receptor molecules used for the detection of the influenza 
virus. Therefore, the preliminary investigations involving the preparation of liposomes 
composed entirely of each model compounds was not attempted. 
 
Our studies started with the preparation of liposomes composed of 10,12-PCDA (5) 
only. The results obtained will serve as a control for future incorporation. It was also 
necessary to familiarise ourselves with the protocols before using our lipid-spacer-PNA 
monomer models. 
 
Therefore, after 20 minutes of UV irradiation, the opaque liposomes solution obtained 
from lipid 5 became deep blue in colour (Figure 74). 
 
 
 
Figure 74 – Liposome solution of 100% 5, before UV irradiation (left),  
after (right) and after addition of 2 M (aq.) NaOH. 
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As highlighted in Section 1.4.2, the colour change observed for PDA-liposomes arise 
due to a conformational change in the PDA backbone which is caused by environmental 
stimuli, i.e. temperature, pH, mechanical stress. Therefore, on addition of a few drops of 
a 2 M aqueous solution of sodium hydroxide, the blue liposome solutions made of 5 
only immediately changed colour to pink (right vessel Figure 74). This colour transition 
was also observed on the electronic absorption spectra recorded for liposome solutions 
of 5, before and after, addition of 2 M aqueous sodium hydroxide solution (Figure 75). 
 
 
 
Figure 75 – Electronic absorption spectra of 1 mM liposome solutions of 5  
before (blue line) and after (red line) lowering the pH. 
 
The electronic spectrum of the blue solution showed absorption maxima at 627, 580 and 
270 nm, while the red solution absorption maxima were at 529, 487 and 258 nm. These 
compare well with the electronic absorption spectra reported by Charych et al..91 
 
Following this, mixtures composed of 95% matrix lipid 5 and 5% of the thyminyl PNA 
monomers 95a and 125a (Figure 76) were prepared separately, and the liposomes were 
constructed following the protocols described earlier.  
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R1 B 
R2 
-OCH2CH3 -OH 
CH3(CH2)11C4(CH2)8 
T 95a 125a 
CCbz 95b N / A 
ACbz 95c 125c 
CH3(CH2)16 
T 96a 126a 
CCbz 96b N / A 
ACbz 96c 126c 
 
Figure 76 
 
After polymerisation, these solutions were blue to purple (depending on the irradiation 
time) and indistinguishable by eye, from the control liposome made of 100% matrix 
lipid 5 (Figure 77). 
 
Unlike Murray2 our ester model 95a incorporated properly into the PDA-liposome, 
showing similar absorbance to the acid model 125a, and no precipitation was observed. 
This indicates that the inclusion of the hydrophilic spacer has improved the hydro-
philic/hydrophobic balance of the ester model 95a. The electronic absorption spectra of 
these solutions were also very similar to that of the control liposome. The thymine moi-
ety gave rise to a small shoulder on the absorption band in the UV region at ca. 270 nm. 
The resulting absorption bands maxima (λmax) are reported in Figure 77. 
 
As mentioned earlier, the incorporation of a sensing element into PDA-liposomes does 
not necessarily require the element to be covalently linked to the PDA framework. It 
could simply be physically embedded through hydrophobic interactions. Murray2 have 
already studied and reported that PNA monomer model compounds bearing a saturated 
lipid tail could be incorporated into PDA-liposomes, without inhibiting the polymerisa-
tion. Therefore, this work was repeated with our own models 96a and 126a. These lipo-
some solutions were visually indistinguishable from the control liposome solution and 
the electronic absorption spectra showed no difference with the corresponding diacety-
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lene analogues (Figure 77). Furthermore, no precipitation was observed with the ester 
model 96a. 
 
Liposome λmax (nm) 
poly-5 627 580 270 
poly-5 (95%) + poly-95a (5%) 623 577 268 
poly-5 (95%) + poly-125a (5%) 623 579 275 
poly-5 (95%) + poly-96a (5%) 630 586 288 
poly-5 (95%) + poly-126a (5%) 615 572 273 
 
 
 
Figure 77 – Liposome solutions of matrix lipid 5 and 5% monomer models:  
(left to right) 96a, 126a, 95a and 125a. 
 
At this stage, it was necessary to verify if the addition of the novel recognition element 
would interfere with the colour change. Thus, a few drops of 2 M aqueous sodium hy-
droxide were added to each sample vial and the colour of the solutions immediately 
changed to pink or orange (depending on the colour of the starting solution – Figure 
78). The electronic absorption spectra further evidenced these changes (Figure 79). 
 
 
 
Figure 78 - Liposome solutions of matrix lipid 5 and 5% monomer models:  
(left to right) 96a, 126a, 95a, 125a, (top to bottom) before and after addition of 2 M 
NaOH. 
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Figure 79 - Electronic absorption spectra of 1 mM liposome solutions of 95a and 125a 
before (blue and purple) and after (pink and orange) lowering the pH. 
 
From the electronic spectra in Figure 79, it was clear that the purple solution gave rise 
to higher absorbance than the blue solution. However, the corresponding wavelength 
values (λmax) were very similar for both the ester and the acid model. Comparable re-
sults were obtained for the monomer models bearing the saturated lipid chain (96a and 
126a). 
 
The next step in our study involved the incorporation of models bearing cytosinyl or 
adeninyl PNA monomers. However, since Murray2 had not undertaken the incorpora-
tion of their analogous models, we could not make any comparisons. Therefore, lipo-
somes made of mixtures composed of 95% matrix lipid 5 and 5% of cytosinyl PNA 
monomers 95b and 96b or adeninyl PNA monomers 95c, 96c, 125c or 126c (Figure 76) 
were prepared separately, following the same protocol as for the thyminyl models. After 
polymerisation, the solutions colour varied from blue to purple, depending on the irra-
diation time, but they were indistinguishable by eye from the control liposome made of 
100% matrix lipid 5 (Figure 80). 
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Liposome λmax (nm) 
poly-5 (95%) + poly-95b (5%) 628 584 269 
poly-5 (95%) + poly-96b (5%) 634 587 289 
poly-5 (95%) + poly-95c (5%) 624 581 257 
poly-5 (95%) + poly-125c (5%) 634 582 270 
poly-5 (95%) + poly-96c (5%) 627 583 270 
poly-5 (95%) + poly-126c (5%) 628 581 270 
 
Figure 80 - Liposome solutions of matrix lipid 5 and 5% monomer models:  
(left to right) control 5, 96b, 95b, 96c, 95c, 126c and 125c. 
 
On addition of a few drops of 2 M aqueous sodium hydroxide the same colour change 
was observed. The colour change of PDA-liposomes can also be induced by an increase 
of the temperature (i.e. thermochromism). Therefore, a blue sample made from 95% of 
matrix lipid 5 and 5% of model 125c was equilibrated for ten minutes after each tem-
perature increase (i.e. 30 oC, 40 oC, 50 oC, 60 oC and 70 oC) and the UV-vis absorption 
spectrum of the resulting solutions was recorded. It appeared that although the visible 
colour change was not readily observed by naked eye (between room temperature and 
40 oC), the variations were more obvious on the electronic absorption spectrum. The 
results obtained were collected in Figure 81. 
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Figure 81 – Electronic absorption spectra of liposome solutions of matrix lipid 5 and  
5% 125c at different temperatures  
 
The shift of the wavelength maxima is evident in Figure 81. As the temperature in-
creased, the absorbance maxima of the ‘blue-form’ decreased and the absorbance 
maxima of the ‘red-form’ consequently increased. At intermediate temperatures, the 
PDA-liposomes framework contained a mixture of both the ‘blue-’ and the ‘red-form’ 
with the maxima of each forms still present. 
 
Due to time constraints, we were unable to study the ability of dimer model compound 
129 to incorporate into PDA-liposomes. Further benefits of the inclusion of the hydro-
philic spacer to overcome the precipitation problems experienced by Murray.2 would 
have been demonstrated with this last experiment. If time had not been a problem we 
would have also been able to study their ability to exhibit the colour transition upon hy-
bridisation to complementary nucleobase using poly(d)A, for example. However, the 
preliminary studies carried out by Murray were inconclusive and lengthy investigations 
of the correct conditions were necessary. Even though, the studies using PNA monomer 
models bearing the hydrophilic spacer proved important in gaining experience in con-
struction of PDA-liposomes. The inclusion of either thymine, cytosine of adenine did 
not hinder polymerisation or prevent the pH and temperature dependent colour transi-
tion of the PDA-liposomes from occurring. 
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4 CONCLUSIONS AND SUGGESTIONS FOR FUTURE WORK 
 
The combination of preliminary results obtained by Murray2 and the work described in 
this research project, has laid foundations for the preparation of polydiacetylene-based 
nucleic acid biosensors. The principal aim of the project was to improve the hydro-
philic/hydrophobic balance of the first generation of PNA-functionalised PDA-
liposomes that Murray had synthesized. In fact, they were reported to precipitate from 
the aqueous solution. From literature precedent by Charych et al.98 and Schneider et 
al.125 it was reasoned that the inclusion of a PEG-like spacer between the lipid tail and 
the PNA head-group would overcome precipitation problems endured by Murray.2 Our 
first investigations focused on the synthesis of a suitable spacer, and the ethylene glycol 
derivative, 8-amino-3,6-dioxaoctanoic acid (AEEA - 39) was our first target. 
 
Compound 39 was chosen because its structure would have allowed peptide connections 
between its carboxylic acid and the N-terminus of the PNA head-group using a peptide 
bond, as well as between its amino group and the carboxylic acid function of the chosen 
lipid (i.e. 10,12-PCDA or stearic acid). Thus, our initial efforts were concentrated on the 
development of an efficient synthetic pathway for the preparation of the Boc-protected 
AEEA spacer 40. A number of routes towards 40 were attempted but all afforded lim-
ited results. The O-alkylation of Boc-protected 46 with ethyl bromoacetate in the pres-
ence of sodium hydride or cesium hydroxide only afforded ester 47 in low yields (ca. 
15%). The same type of reaction of the di-Boc protected 56 again gave only limited 
amount of the corresponding ether (57). Finally, the O-alkylation of the di-benzyl ana-
logue 43 afforded 59 in a good yield but this pathway had one limitation, which was the 
efficient cleavage of the benzyl protecting groups from carboxylic acid analogue 45. 
The equipment available at the department at that stage of the project did not allow safe 
high pressure hydrogenation and therefore, many alternatives were attempted. Due the 
use of compound 47 in the next steps of the research project, it was mandatory to obtain 
it in high yields. 
 
With the limited amounts of 47 collected we managed to couple the deprotected amino 
group of 47 to the lipid tails through amide bonds in reasonable yields (Strategy A). 
However, a inadequate yield was obtained when di-benzyl carboxylic acid 45 was cou-
pled to N-terminus of PNA monomer 70 (Strategy B). 
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Due to the poor yields for the production of Boc-protected ester 47 and for the peptide 
coupling according to Strategy B, the group started screening for a different type of 
connection to be used. Quickly, we became aware of an emerging type of connection, in 
increasing use in screening chemistry. This reaction is the Huisgen 1,3-dipolar cycload-
dition of azides and alkynes which had been revisited and separately reported by Shar-
pless et al.158 and Meldal et al.159 in 2002. These two research groups have established 
that the copper(I) catalysed alternative (also called ‘click’ reaction) allowed the prepara-
tion of [1,2,3]-triazole heterocycles both regioselectively (1,4- versus 1,5-regioisomer) 
and in high yields.  
 
With this in mind, our focus moved towards the application of the ‘Click’ reaction for 
our purpose. The subsequent design of the novel hydrophilic spacer and the novel PNA 
monomer were required. It was decided that the azide function would be installed on a 
Boc-protected PEG-like spacer, analogous to 40. The alkyne moiety required for the 
reaction would be at the N-terminus of the PNA monomer analogue. Efficient synthetic 
routes were consequently developed to 8-(tert-butoxycarbonyl)amino-3,6-dioxaoctan-1-
azide (83) and N-alkynyl PNA monomers bearing thymine, Cbz protected cytosine and 
Cbz protected adenine (84a-c). The analogous synthesis exploring the guanine PNA 
monomer was not attempted as this purine possesses too many synthetic problems. It 
was deemed that this analogue was not really required at this stage of the initial investi-
gations. With the novel spacer and PNA monomer synthesis nearly optimised, the ma-
jority of the following work involved the exploration of the three strategies that have 
been identified for the preparation of ‘lipid-spacer-PNA monomer’ models (95 and 96). 
 
Our first strategy involved the application of the ‘click’ reaction to first connect the 
azide 83 to the alkyne of the PNA monomer (84a-c). This intermediate (97) was then 
functionalised with pentacosa-10,12-diynoyl fluoride (78), prepared accordingly with 
Murray.2 This method was efficient for the preparation of the monomer models bearing 
thymine, Cbz protected cytosine and Cbz protected adenine (95a-c). 
 
Our second strategy implicated the reaction between compound 78 and 8-amino-3,6-
dioxaoctan-1-azide hydrochloride (122). The azide that was still present in the reaction 
product 98 was subsequently reacted with the alkyne of the PNA monomers (84a-c) us-
ing the ‘click’ reaction conditions, affording models 95a-c. Compound 98, however, 
underwent solid state polymerisation which restricted its use in the next ‘Click’ reaction 
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step. This strategy was repeated using stearoyl fluoride (79), yielding intermediate 99. 
Using this strategy, the saturated lipid-spacer-PNA monomer models 96a-c were pre-
pared in good yields (above 60%). 
 
Finally, the last strategy led to the preparation of the intermediate ethyl 2-{[1-(8-
stearamido-3,6-dioxaoctanyl)-1H-1,2,3-triazol-4-yl]methyl}aminoacetate trifluoroacetic 
acid 124, which contained the backbone unit of a PNA monomer coupled to the spacer 
through the 1,4-disubstiuted [1,2,3]-triazole. The spacer was also connected to the 
stearoyl lipid chain through an amide bond. The secondary amine (obtained as a salt) on 
the backbone section of 122 was available for subsequent attachment of the appropriate 
nucleobase acetic acid derivatives. This strategy was only partially investigated to af-
ford model 96b in a reasonable yield (ca. 50%). This strategy would have to be further 
investigated for the preparation of the other lipid-spacer-PNA monomer models. It 
would be interesting to also verify the photochemical stability of the diacetylenic ana-
logue of 122. 
 
Having developed models bearing PNA monomers as headgroup, a thyminyl PNA 
dimer (128) was then prepared. Its preparation was carried out by coupling the carbox-
ylic acid of N-alkynyl PNA monomer (127), to the N-terminus of the PNA monomer 82, 
using HATU as the activating reagent. The reaction only gave a poor yield (less than 
40%). The reason for this low yield has been reported by Condom et al..180 A different 
strategy for the preparation of 128 was suggested but not attempted due to time con-
straints. Nevertheless, the small amount of dimer 128 was sucessfully functionalised 
using the stearoyl spacer 99 using the ‘Click’ reaction conditions. This step yielded to 
the dimer model compounds 129. 
 
Finally, the last stage of the project focused on the investigation of the preparation of 
PDA-liposomes using the new monomer model compounds prepared. Both ester (90a-c 
and 91a-c) and acid models (obtained after basic hydrolysis, 125a/c and 126a/c) were 
successfully incorporated into PDA-liposomes (5% of the model in 95% of matrix lipid 
5). The solutions obtained after photopolymerisation were blue in colour and indistin-
guishable from the control solution made from 100% 10,12-pentacosadyinoic acid (5). 
No significant differences between the diacetylenic and saturated models in terms of 
liposome formation could be observed.  
 
Conclusions 
139 
 
These preliminary results demonstrated that the inclusion of the novel spacer 83 did not 
hinder the formation of liposomes and the polymerisation process. Murray2 have ob-
served precipitation for their ester monomer analogues. In our case, the absence of pre-
cipitation suggested that the hydrophilic spacer had helped to improve the solvation of 
the ‘lipid-spacer-PNA monomer’ models. However, in order to fully assess the advan-
tages of including a hydrophilic spacer, it would have been necessary to also incorporate 
the dimer model 129 into such PDA-liposomes. Unfortunately, due to time and instru-
mental restrictions the full assessment of the hydrophilic spacer was not completed.  
 
Unfortunately we have not made on time to also incorporate PNA oligomer models, it is 
still worth noting that hydrophilic spacer 83 alone might not impart enough hydrophilic 
character. Schneider et al.125 have, indeed, reported the use of two units of 8-amino-3,6-
dioxaoctanoic acid and four glutamic acid residues to obtain an amphiphile with enough 
hydrophilic/hydrophobic balance to prepare liposome. Additionally, the incorporation of 
such models into liposomes necessitates further investigations. We used the electronic 
absorption spectra obtained from the liposome solutions, and reproduced in this thesis, 
to provide conclusions regarding the incorporation of PNA monomer models into the 
PDA liposome. However, it would be important to find and develop a more conclusive 
method for examining the composition of the liposome. Differential scanning calo-
rimetry (DSC) and transmission electron microscopy (TEM) are two analytical tech-
niques that have been used by Charych et al. to investigate PDA-based liposomes.68, 69 
Finally, in future experiments, it may be interesting to prepare a wide range of lipid-
spacer-PNA oligomers models for evaluation as nucleic acid biosensors. For example, it 
would be interesting to investigate the functionalisation and incorporation into PDA-
liposomes of the PNA oligomer H-GGG GCA GTG CCT CAC AA-NH2, used by Wang 
et al.7 for the detection of a common point mutation in the p53 gene. 
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5 GENERAL EXPERIMENTAL 
 
Commercially available reagents from Sigma-Aldrich, Alfa Aesar and NovaBiochem 
companies were generally used as supplied without further purification. Unless other-
wise stated, all solvents were used without further purification. Solvents were dried fol-
lowing standard procedures.182 Light petroleum refers to the fraction boiling between 
40 ºC and 60 ºC. Reactions were routinely carried out under an inert atmosphere of ar-
gon or nitrogen. Analytical thin layer chromatography (TLC) was performed on Merck 
aluminium backed plates coated with Merck Kieselgel 60 GF254 (Art. 05554). Devel-
oped plates were visualised under ultra-violet light (254 nm) and/or with an alkaline po-
tassium permanganate dip. Flash column chromatography was performed using DAV-
ISIL® silica (60 Å; 35-70 µm) purchased from Fisher (cat. S/0693/60). Fully character-
ised compounds were chromatographically homogeneous. 
 
Melting points were determined using a Stuart Melting Point SMP10 apparatus and are 
uncorrected. IR spectra were recorded on a Perkin-Elmer 1600 FT IR spectrometer. 
Spectra were recorded as potassium bromide discs or as films between sodium chloride 
plates. Bands are defined as br (broad), s (strong), m (medium) and w (weak). UV-vis 
spectra were recorded on a Shimadzu UV-160 spectrophotometer. NMR spectra were 
recorded on a Bruker AC200 at 200 MHz (1H) and 50 MHz (13C), or a Bruker DPX400 
at 400 MHz (1H) and 101 MHz (13C). Chemical shifts are reported in parts per million 
(δ in ppm) relative to tetramethylsilane (0 ppm) and are referenced against solvent re-
sidual resonances (δH 7.26 for chloroform, δH 2.50 for dimethyl sulfoxide, δH 4.79 deu-
terium oxide and δH 3.31 for methanol) for 1H NMR spectra and solvent signals (δC 
77.16 for chloroform, δC 39.52 for methyl sulfoxide and δC 49.00 for methanol) for 13C 
NMR spectra.183 Chemical shift values are accurate to ±0.01 ppm and ±0.1 ppm respec-
tively. Coupling constants (J) are reported in Hertz (Hz). Multiplicities are described as 
s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dt (doublet of triplet) and br 
(broad signal). In 13C NMR spectra, signals corresponding to CH, CH2 or CH3 groups 
are assigned from DEPT. Products containing amide bonds were isolated as mixtures of 
two rotamers, several NMR signals of these products were doubled. Low resolution 
(LRMS) and high resolution mass spectra (HRMS) were obtained using electron ionisa-
tion (EI) or electrospray (ESI) and were performed at the EPSRC National Mass Spec-
trometry Service Centre, University of Wales, Swansea. Elemental analyses were car-
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ried out by the analytical service within the Chemistry Department at Heriot-Watt Uni-
versity using an Exeter CE-440 Elemental Analyser. 
 
Preparation of 5-(tert-butoxycarbonyl)amino-3-oxapentan-1-ol (46) 
 
 
 
C9H19NO4 
 
A solution of 5-amino-3-oxapentan-1-ol (42; 6.29 g, 60.0 mmol) in water (200 mL) was 
cooled in an ice bath. A solution of di-tert-butyl dicarbonate (13.1 g, 60.1 mmol) in di-
oxane (3 mL) was added and the temperature was allowed to rise to room temperature 
whilst the pH was maintained at 10.5 by the addition of 2 M sodium hydroxide solution. 
After 2 h, the mixture was concentrated to a paste and triturated with dichloromethane 
(300 mL). The suspension was filtered and the organic phase was dried with anhydrous 
magnesium sulphate. After filtration, the solvent was removed under reduced pressure 
to afford the title compound (46; 13.7 g, 66.7 mmol; 90%) as a clear oil; Rf (dichloro-
methane-methanol 95:5) = 0.28; υmax(film)/cm-1 3364br s, 2977s, 2934s, 2875s, 1689s, 
1529s; δH (200 MHz, CDCl3) 1.34 (9H, s, (CH3)3), 2.98 (1H, br s, OH), 3.25 (2H, dt, 
3JH-NH 4.9 and 3JH-CH2 5.4, NHCH2CH2), 3.43-3.49 (4H, m, CH2OCH2), 3.60-3.63 (2H, 
m, CH2OH), 5.45 (1H, br t, NHCH2); δC (50 MHz, CDCl3) 28.3 ((CH3)3), 40.2 (CH2), 
61.1 (CH2), 70.2 (CH2), 70.2 (CH2), 79.2 (C(CH3)3), 155.1 (CONH); m/z (ESI) 206 
([M+H]+, 40%), 167 (100), 150 (44), 106 (28), 44 (80); HRMS (ESI) (Found: [M+H]+, 
206.1390. C9H20NO4 requires m/z, 206.1387). 
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Preparation of 8-(tert-butoxycarbonyl)amino-3,6-dioxaoctanoic acid ethyl ester 
(47) 
 
 
 
C13H25NO6 
 
Method A 
A solution of 5-(tert-butoxycarbonyl)amino-3-oxapentan-1-ol (46; 1.49 g, 7.26 mmol) 
in anhydrous tetrahydrofuran (15 mL) was slowly added to a stirred mixture of NaH 
(60% in mineral oil, 0.32 g, 8.00 mmol) in anhydrous tetrahydrofuran (30 mL). The 
mixture was heated at reflux for 75 min and then cooled to between -5 to -10 °C where-
upon ethyl bromoacetate (1.3 g, 8.0 mmol) was slowly added. The reaction mixture was 
then stirred overnight at room temperature. After this time the reaction was quenched by 
addition of water (10 mL) and tetrahydrofuran was concentrated under reduce pressure. 
The aqueous solution was extracted with ethyl acetate (5 × 20 mL) and the combined 
organic layers were washed with water (2 × 10 mL). The aqueous layers were back-
extracted with ethyl acetate (2 × 20 mL) and the combined organic extracts were 
washed with brine (10 mL) before being dried over anhydrous magnesium sulphate and 
filtrated. The solvent was removed in vacuo to give a crude, dark yellow liquid which 
was subjected to flash column chromatography (ethyl acetate-light petroleum ether 1:1 
to 9:1) to afford the title compound (47; 0.21 g, 0.72 mmol; 9.9%) as a yellow liquid. 
 
Method B 
The same procedure was used as method A except that 46 (4.31 g, 21.0 mmol) was re-
acted with NaH (60% in mineral oil, 1.02 g, 25.2 mmol) in anhydrous tetrahydrofuran 
(50 mL) at room temperature for 15 min, before the slow addition of ethyl bromoacetate 
(4.21 g, 25.2 mmol). The work-up procedure was as described in method A. The title 
compound (47; 0.58 g, 1.99 mmol; 10%) was obtained as a yellow liquid. 
 
Method C 
The same procedure was used as method A except that 46 (1.74 g, 8.48 mmol) was re-
acted with NaH (60% in mineral oil, 0.41 g, 10.3 mmol) in anhydrous dimethylforma-
mide (30 mL) at room temperature for 15 min, before the slow addition of ethyl bro-
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moacetate (1.84 g, 11.0 mmol). The work-up procedure was as described in method A. 
The title compound (47; 0.46 g, 1.58 mmol; 19%) was obtained as a yellow liquid 
 
Method D 
To a suspension containing activated powdered 4 Å molecular sieves (1.00 g) in anhy-
drous dimethylformamide (15 mL) was added cesium hydroxide monohydrate (0.40 g, 
2.38 mmol) and the mixture was stirred under argon for 30 min. A solution of 46 
(0.49 g, 2.38 mmol) solution in anhydrous dimethylformamide (10 mL) was then added 
and the following mixture was stirred for 1 h. After the slow addition of ethyl bro-
moacetate (0.47 g, 2.40 mmol), the reaction was allowed to proceed at room tempera-
ture overnight. After this time dimethylformamide was evaporated under reduced pres-
sure and the paste obtained was coevaporated with toluene (2 × 10 mL) and diethyl 
ether (2 × 10 mL). Unfortunately, none of the products collected after purification cor-
responded to 47. 
 
Method E 
To a similar suspension as method D [activated powdered 4 Å molecular sieves (2.00 g) 
in anhydrous dimethylformamide (15 mL) and cesium hydroxide monohydrate (0.51 g, 
3.06 mmol)] was added 46 (0.52 g, 2.53 mmol) and the solution was stirred for 1 h. To 
this solution was then added ethyl bromoacetate (0.51 g, 3.06 mmol) and tetrabutyl 
ammonium iodide (1.12 g, 3.03 mmol) and the reaction was allowed to proceed at room 
temperature for 24 h. After this time the work-up was as described method F and the 
title compound (47; 0.13 g, 0.44 mmol; 18%) was obtained as a yellow liquid. 
 
Method F 
To a suspension containing activated powdered 4 Å molecular sieves (1.00 g) in anhy-
drous acetonitrile (15 mL) was added cesium hydroxide monohydrate (0.52 g, 3.08 
mmol) and the mixture was stirred under argon for 30 min. 46 (0.53 g, 2.56 mmol) in 
anhydrous acetonitrile (10 mL) was then added and the following mixture was stirred 
for 1 h. After this time ethyl bromoacetate (0.51 g, 3.07 mmol) and tetrabutyl ammo-
nium iodide (1.14 g, 3.07 mmol) were then added and the reaction was allowed to pro-
ceed at room temperature for 24 h. After this time the work-up was as described for 
method F and the title compound (47; 0.089 g, 0.31 mmol; 10%) was obtained as a yel-
low liquid. 
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Method G 
The same procedure as method F was used except that anhydrous cesium carbonate 
(1.67 g, 5.12 mmol) was used [46 (0.53 g, 2.56 mmol) in anhydrous dimethylformamide 
(10 mL)]. Ethyl bromoacetate (0.51 g, 3.07 mmol) was then added and the reaction was 
allowed to proceed at room temperature for 24 h. After a similar work-up as method F, 
none of the products collected after purification corresponded to 47.  
 
Method H 
46 (2.05 g, 9.92 mmol) and anhydrous potassium carbonate (2.80 g, 20.2 mmol) were 
dissolved in anhydrous dimethylformamide (20 mL) and the heterogeneous solution was 
stirred for 3 h before the slow addition of ethyl bromoacetate (4.14 g, 24.8 mmol). The 
reaction mixture was stirred overnight and the work-up was as described in method A. 
The title compound (47; 0.49 g, 16.8 mmol; 17%) was obtained as a yellow liquid; Rf 
(ethyl acetate-light petroleum 8:2) = 0.30; υmax(film)/cm-1 2981s, 2933s, 2878s, 1749s, 
1706s, 1507s; δH (200 MHz; CDCl3) 0.85 (3H, t, J 7.1, CH3), 1.10 (9H, s, (CH3)3), 2.88 
(2H, br dt, NHCH2), 3.11 (2H, t, J 5.4, OCH2CH2O), 3.23-3.24 (4H, m, CH2OCH2), 
3.71 (2H, s, OCH2COO), 3.78 (2H, q, J 7.1,OCH2), 4.81 (1H, br t, NHCH2); δC (50 
MHz; CDCl3) 14.1 (CH3), 28.3 (C(CH3)3), 40.2 (NHCH2), 60.2 (OCH2CH3), 68.5 
(OCH2), 70.1 (OCH2), 70.5 (OCH2), 70.7 (OCH2), 78.8 (C(CH3)3), 155.9 (CONH), 
170.3 (COO); m/z (ESI) 292 ([M+H]+, 88%), 314 ([M+NH4]+, 100), 236 (44), 192 (41), 
134 (10); HRMS (ESI) (Found: [M+H]+, 292.1754. C13H26NO6 requires m/z, 292.1755). 
 
Preparation of (tert-butoxycarbonyl)amino(tert-butyldimethylsilyloxy)-3-
oxapentan (54) 
 
 
 
C15H33NO4Si 
 
To a solution of 5-(tert-butoxycarbonyl)amino-3-oxapentan-1-ol (46; 1.03 g, 
5.00 mmol) in anhydrous dimethylformamide (20 mL) was added tert-butylchloro-
dimethylsilane (0.96 g, 6.4 mmol) and imidazole (0.51 g, 7.5 mmol). The mixture was 
stirred for 18 h at room temperature. After this time the yellow solution obtained was 
poured in water and extracted with ethyl acetate (6 × 10 mL). The combined organic 
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phase was dried over anhydrous magnesium sulphate. After filtration, the solvent was 
removed to give a colourless oil that solidified to a white solid, which was subjected to 
flash column chromatography (ethyl acetate-light petroleum ether 20:80) to yield the 
title compound (54; 1.34 g, 4.2 mmol; 84%) as a white solid: m.p. 41-42 °C; Rf (ethyl 
acetate-light petroleum 2:8) = 0.28; υmax(film)/cm-1 2932m, 2861m, 1715s, 1510s; 
δH (200 MHz; CDCl3) 0.05 (6H, s, Si(CH3)2), 0.87 (9H, s, SiC(CH3)3), 1.41 (9H, s, 
OC(CH3)3), 3.24-3.28 (2H, m, NHCH2), 3.47-3.54 (4H, m, OCH2CH2O), 3.73 (2H, t, J 
3.4, NHCH2CH2O), 4.98 (1H, br t, NHCH2); δC (50 MHz; CDCl3) 18.4 (Si(CH3)2), 25.9 
(SiC(CH3)3), 28.4 (OC(CH3)3), 40.4 (NHCH2), 62.7 (OCH2), 70.1 (OCH2), 72.3 
(OCH2), 79.1 (OC(CH3)3 and SiC(CH3)3), 155.9 (CONH); m/z (ESI) 320 ([M+H]+, 
54%), 337 ([M+NH4]+, 100), 264 (41), 220 (15); HRMS (ESI) (Found: [M+H]+, 
320.2251. C15H33NO4Si requires m/z, 320.2252). 
 
Preparation N,N-bis(tert-butoxycarbonyl)amino(tert-butyldimethylsilyloxy)-3-oxa-
pentan (55) 
 
 
 
C20H41NO6Si 
 
Compound 54 (0.12 g, 0.38 mmol), 4-dimethylaminopyridine (0.046 g, 0.38 mmol) and 
di-tert-butyl dicarbonate (0.13 g, 0.58 mmol) were dissolved in anhydrous acetonitrile 
(5 mL) leading to a pale yellow solution. The reaction mixture was stirred at room tem-
perature for 24 h, after which time the solution was dark yellow and TLC analysis (ethyl 
acetate-light petroleum 1:9) showed that the reaction was not completed, therefore an-
other portion of di-tert-butyl dicarbonate (0.124 g, 0.57 mmol) was added and the reac-
tion mixture was stirred for another 24 h. After this time, the solution was deep orange, 
it was poured on water and extracted with ethyl acetate (4 × 10 mL). The combined or-
ganic phase was successively washed with 1 M hydrochloric acid solution (10 mL) and 
brine (4 × 10 mL). The combined organic phase was finally dried with anhydrous mag-
nesium sulphate, filtered and the solvent was evaporated. The crude residue was sub-
jected to flash column chromatography (light petroleum ether-ethyl acetate 80:20) to 
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yield the title compound (55; 0.128 g, 0.30 mmol; 80%) as a pale yellow oil; Rf (ethyl 
acetate-light petroleum 1:9) = 0.34; υmax(film)/cm-1 2979s, 2957s, 2930s, 2860s, 1750s, 
1699s; δH (400 MHz; CDCl3) 0.21 (6H, s, Si(CH3)2), 0.88 (9H, s, SiC(CH3)3), 1.48 
(18H, s, 2 × C(CH3)3), 3.54 (2H, t, J 5.5, CH2(3)), 3.62 (2H, t, J 6.3, CH2(2)), 3.75 (2H, 
t, J 5.5, CH2(4)), 3.80 (2H, t, J 6.3, CH2(1)); δC (100 MHz; CDCl3) -5.30 (Si(CH3)2), 
25.9 (SiC(CH3)3), 28.0 (C(CH3)3), 45.3 (NCH2), 62.6 (CH2Si), 69.3 (CH2(2)O), 72.3 
(OCH2(3)), 82.2 (C(CH3)3 and SiC(CH3)3), 152.6 (CONCH2); m/z (ESI) 420 ([M+H]+, 
25%), 364 (100), 308 (37), 220 (10), 60 (45); HRMS (ESI) (Found: [M+H]+, 420.2776. 
C20H41NO6Si requires m/z, 420.2781). The identity of the product was deduced from the 
NOESY spectrum.  
 
Preparation N,N-bis(tert-butoxycarbonyl)amino-3-oxapentan-1-ol (56) 
 
 
 
C14H27NO6 
 
55 (1.05 g, 2.50 mmol) was dissolved in anhydrous tetrahydrofuran (11 mL) and TBAF 
(5 mL; 1 M in tetrahydrofuran, dried over 4 Å molecular sieves) was added via a sy-
ringe. The reaction mixture was stirred for 5 h and after this time it was concentrated in 
vacuo. The crude residue was subjected to flash column chromatography (ethyl acetate-
light petroleum 7:3) to yield the title compound (56; 0.763 g, 2.50 mmol; 100%) as col-
ourless oil; Rf (ethyl acetate-light petroleum 6:4) = 0.34; υmax(film)/cm-1 3321br s, 
2979s, 2956s, 2928s, 2861s, 1762s, 1689m; δH (400 MHz; CDCl3) 1.49 (18H, s, 2 × 
C(CH3)3), 2.47 (1H, br s, OH), 3.50 (2H, br dt, CH2OH), 3.53-3.62 (4H, m, 
NCH2CH2OCH2), 3.72 (2H, t, J 5.8 , NCH2CH2); δC (100 MHz; CDCl3) 27.9 (C(CH3)3), 
45.4 (NCH2), 61.6 (CH2OH), 69.3 (OCH2), 72.1 (OCH2), 82.4 (C(CH3)3), 152.9 (COO); 
m/z (EI) 306 (M+, 15%). 
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Preparation 8-bis(tert-butoxycarbonyl)amino-3,6-dioxaoctanoic ethyl ester (57) 
 
 
 
C18H33NO8 
 
Method A 
To a slurry of sodium hydride (60% in mineral oil; 0.017 g, 0.43 mmol) in anhydrous 
tetrahydrofuran (3 mL) was added a solution of 56 (0.103 g, 0.340 mmol) in anhydrous 
tetrahydrofuran (3 mL). The mixture was heated to a gentle reflux for 75 min, after be-
ing cooled to 0 °C using a ice/salt bath. Ethyl bromoacetate (0.060 mL, 0.51 mmol) was 
then slowly added to the solution and the stirring was continued for 17 h at room tem-
perature. After this time, water (4 mL) was very carefully added and tetrahydrofuran 
was removed. The aqueous phase was extracted with ethyl acetate (5 × 10 mL). The 
combined organic layer was washed with water (2 × 10 mL) and brine (10 mL). The 
aqueous phase was back-extracted with ethyl acetate (10 mL). The combined organic 
phase was finally dried over anhydrous magnesium sulphate and the evaporation of the 
solvent yielded a pale yellow oil. The crude mixture was subjected to flash column 
chromatography (ethyl acetate-light petroleum 4:6) but 1H NMR spectra of fractions 
obtained failed showing signals corresponding to 57. 
 
Method B 
56 (0.402 g, 1.32 mmol) was dissolved in anhydrous tetrahydrofuran (5 mL) and ethyl 
bromoacetate (0.440 mL, 3.90 mmol) was then added. The solution was cooled in an ice 
bath and sodium hydride (60% in mineral oil; 0.0790 g, 1.98 mmol) was carefully added 
in small portions. The reaction was stirred for 17 h while it was allowed to slowly reach 
room temperature. After this time, water (5 mL) was very carefully added and tetrahy-
drofuran was removed. The aqueous phase was extracted with ethyl acetate (5 × 10 
mL). The combined organic layer was washed with water (2 × 10 mL) and brine (10 
mL). The combined organic phase was finally dried over anhydrous magnesium sul-
phate and the evaporation of the solvent yielded a deep yellow oil. The crude mixture 
was subjected to flash column chromatography (ethyl acetate-light petroleum 4:6), af-
fording the title compound (57; 0.099 g, 0.25 mmol; 19%) as a pale yellow oil; Rf (ethyl 
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acetate-light petroleum 4:6) = 0.28; δH (400 MHz; CDCl3) 1.23 (3H, t, J 7.1, CH3), 1.45 
(18H, s, 2 × C(CH3)3), 3.57 (2H, t, J 5.8, NCH2CH2), 3.59-3.68 (4H, m, OCH2CH2O), 
3.75 (2H, t, J 5.8, NCH2CH2), 4.09 (2H, s, OCH2COO), 4.16 (2H, q, J 7.1, OCH2); 
δC (100 MHz; CDCl3) 14.8 (CH3), 27.9 (C(CH3)3), 45.4 (NCH2), 61.6 (OCH2CH3), 68.7 
(OCH2), 69.2 (OCH2), 70.1 (OCH2), 70.5 (OCH2), 82.4 (C(CH3)3), 152.9 (NCOO), 
169.2 (COO). 
 
Preparation of 8-(tert-butoxycarbonyl)amino-3,6-dioxaoctanoic tert-butyl ester (58) 
 
 
 
C14H27NO6 
 
Method A 
To a slurry of sodium hydride (60% in mineral oil; 0.017 g, 0.43 mmol) in anhydrous 
tetrahydrofuran (3 mL) was added a solution of 56 (0.103 g, 0.340 mmol) in anhydrous 
tetrahydrofuran (3 mL). The mixture was heated to a gentle reflux for 75 min, after be-
ing cooled to 0 °C using an ice/salt bath. Ethyl bromoacetate (0.060 mL, 0.51 mmol) 
was then slowly added to the solution and the stirring was continued for 17 h at room 
temperature. After this time, water (4 mL) was very carefully added and tetrahydrofuran 
was removed under reduced pressure. The aqueous phase was extracted with ethyl ace-
tate (5 × 10 mL). The combined organic layer was washed with water (2 × 10 mL) and 
brine (10 mL). The aqueous phase was back-extracted with ethyl acetate (10 mL). The 
combined organic phase was finally dried over anhydrous magnesium sulphate and the 
evaporation of the solvent yielded a pale yellow oil. The crude mixture was subjected to 
flash column chromatography (ethyl acetate-light petroleum 4:6), affording the title 
compound (58; 0.043 g, 0.14 mmol; 40%) as a colourless oil. 
 
Method B 
To a suspension of powdered 4 Å molecular sieves (0.18 g) in anhydrous dimethylfor-
mamide (6 mL) was added cesium hydroxide monohydrate (0.251 g, 1.49 mmol). This 
heterogeneous mixture was stirred for 15 min, then N,N-bis(tert-butoxycarbonyl)amino-
3-oxapentan-1-ol (56; 0.145 g, 0.48 mmol) in anhydrous dimethylformamide (2 mL) 
was added and the reaction mixture was stirred at room temperature for 1 h. Ethyl bro-
moacetate (0.265 mL, 2.38 mmol) was then added and the reaction was stirred for 24 h. 
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After this time, water (6 mL) was added and dimethylformamide was removed under 
reduced pressure. The residue was dissolved in ethyl acetate (10 mL) and filtered. The 
organic phase was separated and the aqueous phase was extracted with ethyl acetate (4 
× 10 mL). The combined organic layer was washed with water (2 × 10 mL) and brine 
(10 mL) and finally dried over anhydrous magnesium sulphate. The solvent was evapo-
rated and the crude mixture obtained was subjected to flash column chromatography 
(ethyl acetate-light petroleum 4:6), affording the title compound (58; 0.13 g, 0.43 mmol; 
90%) as a pale yellow oil; Rf (ethyl acetate-light petroleum 4:6) = 0.31; δH (200 MHz; 
CDCl3) 1.38 (9H, s, C(CH3)3), 1.42 (9H, s, C(CH3)3), 3.50 (2H, br dt, NCH2CH2), 3.72 
(2H, t, J 3.4, OCH2CH2OCO), 3.58-3.63 (2H, m, NCH2CH2), 4.13-4.18 (2H, m, 
CH2OCO), 4.88 (1H, br s, NH). 
 
Preparation of N,N-dibenzyl-5-amino-3-oxapentan-1-ol (43)126 
 
 
 
C18H23NO2 
 
5-Amino-3-oxapentan-1-ol (42; 3.15 g, 29.9 mmol) and potassium carbonate (8.30 g, 
60.1 mmol) were mixed in water (8 mL). Benzyl bromide (7.2 mL, 59.9 mmol) was 
then added dropwise over 50 min and, after this time, the reaction mixture was stirred at 
room temperature for 50 h. After this time, diethyl ether (50 mL) was added and the 
layers were separated. The aqueous layer was extracted with diethyl ether (2 × 20 mL) 
and the combined organic phase was washed with brine (20 mL) and dried over anhy-
drous magnesium sulphate. The pale yellow oil obtained on evaporation of the solvent 
was subjected to flash column chromatography (ethyl acetate-light petroleum 4:6) and 
the title compound (43; 6.82 g, 23.9 mmol; 80%) was obtained as a pale yellow oil; Rf 
(ethyl acetate-light petroleum 3:7) = 0.28; υmax(film)/cm-1 3421m, 3027m, 2925m, 
2871m, 1494s, 1433s; δH (200 MHz; CDCl3) 2.76 (2H, t, J 5.9, NCH2CH2), 2.97 (1H, br 
s, OH), 3.51-3.54 (2H, m, CH2CH2OH), 3.61-3.65 (4H, m, CH2OCH2), 3.72 (4H, s, 2 × 
NCH2Ar), 7.26-7.46 (10H, m, 10 × Ar-H); δC (50 MHz; CDCl3) 52.6 (NCH2), 58.7 
(NCH2Ar), 61.5 (CH2OH), 69.3 (OCH2), 71.8 (OCH2), 126.7 (Ar-CH), 127.9 (Ar-CH), 
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128.6 (Ar-CH), 139.1 (Ar-C); m/z (ESI) 286 ([M+H]+, 100%); HRMS (ESI) (Found: 
[M+H]+, 286.1802. C18H23NO2 requires m/z, 286.1802). 
 
Preparation of N,N-dibenzyl-8-amino-3,6-dioxaoctanoic acid ethyl ester (59) 
 
 
 
C22H29NO4 
 
To a slurry of sodium hydride (60% in mineral oil; 0.48 g, 12 mmol) in anhydrous tet-
rahydrofuran (15 mL) was added a solution of N,N-dibenzyl-5-amino-3-oxapentan-1-ol 
(43; 2.86 g, 10.0 mmol) in anhydrous tetrahydrofuran (8 mL). The mixture was heated 
to reflux for 2 h after being cooled to 0 °C using an ice/salt bath. Ethyl bromoacetate 
(1.22 mL, 11.0 mmol) was then slowly added to the solution and the stirring was con-
tinued for 17 h at room temperature. After this time, water (5 mL) was carefully added 
and tetrahydrofuran was removed under reduced pressure. The aqueous phase was ex-
tracted with ethyl acetate (5 × 20 mL). The combined organic layer was washed with 
water (2 × 10 mL) and brine (10 mL). The aqueous phase was backextracted with ethyl 
acetate (20 mL). The combined organic phase was finally dried over anhydrous magne-
sium sulphate and the evaporation of the solvent yielded a brown liquid. The crude mix-
ture was subjected to flash column chromatography (ethyl acetate-light petroleum 4:6), 
affording the title compound (59; 2.16 g, 5.82 mmol; 40%) as a pale yellow oil; Rf 
(ethyl acetate-light petroleum 4:6) = 0.38; υmax(film)/cm-1 3027w, 2872m, 1754s, 
1494m; δH (200 MHz; CDCl3) 1.16 (3H, t, J 7.1, CH3), 3.61 (2H, t, J 6.2, NCH2), 3.46-
3.52 (6H, m, CH2OCH2CH2O), 3.57 (4H, s, 2 × NCH2Ar), 4.03 (2H, s, OCH2COO), 
4.10 (2H, q, J 7.1, OCH2), 7.12-7.32 (10H, m, 10 × Ar-H); δC (50 MHz; CDCl3) 14.4 
(CH3), 52.8 (NCH2), 59.1 (NCH2Ar), 60.9 (OCH2CH3), 68.9 (OCH2COO), 70.1 
(OCH2), 70.5 (OCH2), 71.1 (OCH2), 126.9 (Ar-CH), 128.3 (Ar-CH), 128.9 (Ar-CH), 
139.8 (Ar-C), 170.6 (COO); m/z (ESI) 372 ([M+H]+, 100%), 153 (50); HRMS (ESI) 
(Found: [M+H]+, 372.2170. C22H29NO4 requires m/z, 372.2169). 
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Preparation of N,N-dibenzyl-8-amino-3,6-dioxaoctanoic acid (45)126 
 
 
 
C20H25NO4 
 
Ester 59 (1.57 g, 4.23 mmol) was dissolved in methanol (15 mL) and 1 M sodium hy-
droxide solution (14 mL) was added to this clear solution. The mixture was stirred at 
room temperature for 3 h. After this time, the pH of the solution was adjusted to 7 with 
the addition of 6 M hydrochloric acid solution and methanol was evaporated under re-
duced pressure. The aqueous solution was further acidified to pH 6 by the addition of 6 
M hydrochloric acid solution and extracted with ethyl acetate (6 × 20 mL). The organic 
phases were separated and dried over anhydrous magnesium sulphate. Evaporation of 
the solvents yielded a crude residue that required flash column chromatography (ethyl 
acetate-methanol-glacial acetic acid 89:10:1). The title compound (45; 0.800 g, 2.33 
mmol; 55%) was obtained as a colourless oil; Rf (ethyl acetate-methanol-glacial acetic 
acid 89:10:1) = 0.18; υmax(film)/cm-1 3448br w, 3061w, 3028w, 2876m, 1729m, 1599m; 
δH (200 MHz; CDCl3) 2.71 (2H, t, J 6.2, NCH2), 3.38-3.57 (6H, m, CH2OCH2CH2O), 
3.77 (4H, s, 2 × NCH2Ar), 3.91 (2H, s, OCH2CO), 7.12-7.37 (10H, m, 10 × Ar-H), 8.60 
(1H, br s, COOH); δC (50 MHz; CDCl3) 51.9 (NCH2), 58.4 (NCH2Ar), 68.6 
(OCH2COO), 70.0 (OCH2), 70.1 (OCH2), 70.5 (OCH2), 127.7 (Ar-CH), 128.5 (Ar-CH), 
129.7 (Ar-CH), 136.8 (Ar-C), 174.2 (COOH). 
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Preparation of tert-butoxycarbonylamino-1,2-propanediol (65)139 
 
 
 
C8H17NO4 
 
A solution of 3-amino-1,2-propanediol (64; 4.96 g, 54.4 mmol) in water (130 mL) was 
cooled in an ice bath. A solution of di-tert-butyl dicarbonate (17.9 g, 82.0 mmol) in di-
oxane (5 mL) was added and the temperature was allowed to rise to room temperature, 
whilst the pH was maintained at 10.5 by the addition of 2 M sodium hydroxide solution. 
After 2 h, this mixture was concentrated in vacuo and the paste was triturated with di-
chloromethane (175 mL). The suspension was then filtered and the organic phase was 
dried over anhydrous magnesium sulphate. After filtration, the solvent was removed to 
afford the title compound (65; 9.31 g, 48.7 mmol; 90%) as an oil which solidified on 
cooling to a white solid; Rf (dichloromethane-ethyl acetate 1:1) = 0.60; υmax(film)/cm-1 
3358br s, 2979s, 2934s, 2520s, 1792w, 1745m, 1690s, 1526s; δH (200 MHz; CDCl3) 
1.40 (9H, s, C(CH3)3), 2.95-3.05 (2H, m, NHCH2CH), 3.22-3.45 (2H, m, CH2OH), 
3.49-3.53 (1H, m, CH), 3.82 (2H, br s, 2 × OH), 5.07 (1H, br t, NH); δC (50 MHz; 
CDCl3) 28.3 (C(CH3)3), 42.7 (NHCH2), 63.5 (CH2OH), 71.3 (CH), 80.2 (C(CH3)3), 
157.4 (CONH). 
 
Preparation of (tert-butoxycarbonyl)aminoacetaldehyde (66)139 
 
 
 
C7H13NO3 
 
Sodium periodate (9.31 g, 48.7 mmol) was added to tert-butoxycarbonylamino-1,2-
propanediol (65; 10.7 g, 50.2 mmol) in water (100 mL) and the solution was stirred at 
room temperature for 2 h. The mixture was then filtered and the filtrate was extracted 
with dichloromethane (5 × 100 mL). The combined organic phase was dried over anhy-
drous magnesium sulphate and after filtration, the solvent was removed to yield the title 
compound (66; 7.13 g, 44.8 mmol; 92%) as a colourless oil that solidified on cooling; Rf 
(dichloromethane-methanol 9:1) = 0.61; υmax(film)/cm-1 2979s, 2935s, 1706br s, 1522br 
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s, 1455s; δH (200 MHz; CDCl3) 1.43 (9H, s, C(CH3)3), 4.06 (2H, d, J 5.0, NHCH2), 5.23 
(1H, br s, NH), 9.63 (1H, apparent s, CHO); δC (50 MHz; CDCl3) 28.2 (C(CH3)3), 51.3 
(CH2), 80.1 (C(CH3)3), 155.2 (CONH), 197.2 (CHO). 
 
Preparation of ethyl N-[2-(tert-butoxycarbonyl)aminoethyl]glycinate (67)139 
 
 
 
C11H22N2O4 
 
To a solution of (tert-butoxycarbonylamino)acetaldehyde (66; 7.13 g, 44.8 mmol) in 
methanol (100 mL) was added glycine ethyl ester hydrochloride (15.6 g, 112 mmol) and 
sodium borohydride (2.81 g, 44.8 mmol). The mixture was stirred at room temperature 
for 17 h. After this time, the solvent was evaporated and the residue was dissolved in 
water (120 mL). The pH of the resulting aqueous solution was adjusted to 8 by addition 
of 2 M sodium hydroxide solution. This solution was then extracted with dichloro-
methane (5 × 170 mL). The combined organic fraction was washed with brine (50 mL), 
dried over anhydrous magnesium sulphate and, after filtration, the solvent was evapo-
rated to give a crude colourless oil. This oil was subjected to flash column chromatog-
raphy (ethyl acetate–methanol 95:5) to afford the title compound (67; 6.03 g, 
24.5 mmol; 55%) as a colourless oil; Rf (ethyl acetate-methanol 95:5) = 0.41; 
υmax(film)/cm-1 2978m, 2933m, 1739s, 1713s, 1518m, 1457w; δH (200 MHz; CDCl3) 
1.15 (3H, t, J 7.1, CH3), 1.31 (9H, s, (CH3)3), 1.77 (1H, br s, CH2NHCH2), 2.61 (2H, t, J 
5.8, NHCH2), 3.08 (2H, br dt, CH2CH2NH), 3.27 (2H, s, CH2CO), 4.05 (2H, q, J 7.1, 
OCH2), 5.32 (1H, br t, NHCH2); δC (50 MHz; CDCl3) 13.9 (CH3), 28.1 ((CH3)3), 39.9 
(NHCH2), 48.5 (CH2CH2NH), 50.1 (CH2CO), 60.5 (OCH2), 78.7 (C(CH3)3), 155.9 
(CONH), 172.2 (COO). 
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Preparation of thymin-1-yl acetic acid (69)140 
 
 
 
C7H8N2O4 
 
Thymine (68; 3.79 g, 31.6 mmol) was added to a solution of potassium hydroxide 
(6.74 g, 120 mmol) in water (20 mL). The solution was warmed in a water bath to 40 oC 
whereupon a solution of bromoacetic acid (6.59 g, 47.6 mmol) in water (10 mL) was 
slowly added over 30 min. The resulting mixture was stirred for another 30 min before 
being cooled to room temperature.  The pH was then adjusted to 5.5 using concentrated 
hydrochloric acid. The reaction mixture was then cooled at 4 °C for 2 h. The following 
solution was then filtered and the pH was further reduced to 2.0 using concentrated hy-
drochloric acid before being cooled at -20 °C for 2 h. The resulting precipitate was col-
lected by filtration and dried in vacuo over P2O5 to obtain the title compound as a white 
solid (69; 5.64 g, 30.6 mmol; 97%); Rf (ethyl acetate-methanol-acetic acid 75:20:5) = 
0.21; υmax(KBr)/cm-1 3410s, 3181s, 2962s, 2520s, 1739s, 1707s, 1665s, 1634s, 1485s; 
δH (200 MHz; DMSO-d6) 1.75 (3H, s, CH3), 4.40 (2H, s, CH2), 7.60 (1H, s, C(6)H); δC 
(50 MHz; DMSO-d6) 1.75 (CH3), 48.9 (CH2), 108.8 (C(5)), 142.3 (C(6)H), 151.4 
(C(2)O), 164.9 (C(4)O), 170.1 (COOH). 
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Preparation of N-(2-tert-butoxycarbonylaminoethyl)-N-(thymin-1-ylacetyl) glycine 
ethyl ester (70)139 
 
 
 
C18H28N4O7 
 
To thymin-1-ylacetic (69; 0.392 g, 2.13 mmol) in dimethylformamide (5 mL) was 
added HBTU (0.803 g, 2.12 mmol) followed by triethylamine (0.30 mL, 2.2 mmol) and 
the mixture was stirred for 15 min. After this time, a solution of ethyl N-[2-(tert-
butoxycarbonyl)aminoethyl]glycinate (67; 0.478 g, 1.94 mmol) in dimethylformamide 
(5 mL) was added to this mixture followed by triethylamine (0.57 mL, 4.1 mmol). The 
resulting mixture was stirred for 17 h at room temperature after which time the solvent 
was removed in vacuo. The residue was dissolved in dichloromethane (100 mL) and the 
solution was washed successively with 1 M sodium bicarbonate (3 × 50 mL), 1 M po-
tassium hydrogensulphate (2 × 50 mL), water (50 mL) and finally brine (50 mL). The 
organic layer was then dried over anhydrous magnesium sulphate and the solvent was 
evaporated under reduced pressure to yield a cream-coloured foam which was purified 
by flash column chromatography (dichloromethane-methanol 95:5) yielding the title 
compound (70; 0.615 g, 1.49 mmol; 70%) as a white foam; Rf (dichloromethane-
methanol 95:5) = 0.44; υmax(KBr)/cm-1 3347m, 3193m, 2980m, 2972m, 1678br s, 
1531m; δH (400 MHz; CDCl3) (2 rotational isomers in a 2:1 ratio observed due to re-
stricted rotation about the tertiary amide bond) 1.29 (ma.) and 1.34 (mi.) (3H, t, J 7.1, 
CH3), 1.44 (ma.) and 1.46 (mi.) (9H, s, (CH3)3), 1.93 (ma.) and 1.94 (mi.) (3H, s, C(5)-
CH3), 3.27-3.30 (mi.) and 3.34-3.36 (ma.) (2H, m, NHCH2CH2), 3.49-3.55 (2H, m, 
NHCH2CH2), 4.07 (ma.) and 4.22 (mi.) (2H, s, CH2COO), 4.22 (ma.) and 4.28 (mi.) 
(2H, q, J 7.1, OCH2), 4.45 (mi.) and 4.60 (ma.) (2H, s, CH2CON), 5.10 (mi.) and 5.74 
(ma.) (1H, br t, J 5.8, NH), 7.00 (mi.) and 7.05 (ma.) (1H, s, C(6)H), 9.30 (ma.) and 
9.37 (mi.) (1H, br s, N(3)H); δC (100 MHz; CDCl3) (2 rotational isomers in a 2:1 ratio 
observed due to restricted rotation about the tertiary amide bond) 12.3 (C(5)-CH3), 14.0 
(CH3), 28.3 (mi.) and 28.4 (ma.) ((CH3)3), 38.6 (ma.) and 38.7 (mi.) (NHCH2CH2), 47.6 
(mi.) and 47.7 (ma.) (CH2CON), 48.8 (NHCH2CH2), 49.1 (ma.) and 50.2 (mi.) 
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(CH2COO), 61.7 (ma.) and 62.2 (mi.) (OCH2), 79.9 (C(CH3)3), 110.7 (ma.) and 110.8 
(mi.) (C(5)), 140.9 (C(6)H), 151.1 (ma.) and 151.2 (mi.) (C(2)O), 156.0 (CONH), 164.2 
(C(4)O), 167.3 (ma.) and 167.7 (mi.) (CON), 169.3 (mi.) and 169.6 (ma.) (COO). The 
identity of the product was verified by COSY and 15N-1H multiple-bond correlation. An 
X-Ray crystal structure (Appendix A) was acquired from crystals obtained from diethyl 
ether and methanol, thereby confirming the structure of the product. 
 
Preparation of 8-amino-3,6-dioxaoctanoic acid ethyl ester trifluoroacetate (77) 
 
 
 
C10H18F3NO6 
 
To a solution of 8-(tert-butoxycarbonyl)amino-3,6-dioxaoctanoic acid ethyl ester (47; 
0.10 g, 0.34 mmol) in dichloromethane (2 mL) was slowly added trifluoroacetic acid 
(2 mL). The reaction mixture was stirred for 1 h at room temperature after which time 
the solvents were removed. The brown residue obtained was coevaporated with toluene 
(3 × 5 mL) and diethyl ether (3 × 5 mL) and used without further purification. 
 
Preparation of stearoyl fluoride (78)2 
 
 
 
C18H35FO 
 
To a solution of stearic acid (75; 0.711 g, 2.50 mmol) in dichloromethane (10 mL) was 
added pyridine (0.202 mL, 2.50 mmol) followed by cyanuric fluoride (0.432 mL, 5.00 
mmol). The mixture was heated to reflux for 3 h and after which time dichloromethane 
(10 mL) was added. The solution was filtered and washed with water (2 × 20 mL), the 
organic phase was then dried over anhydrous magnesium sulphate. The solvent was fi-
nally removed under reduced pressure to yield the title compound (78; 0.658 g, 
2.30 mmol; 92%) as a white oily solid; υmax(film)/cm-1 2924s, 2854s, 1846s; δH (200 
MHz; CDCl3) 0.88 (3H, t, J 6.3, CH3), 1.26 (28H, s, 14 × CH2), 1.67 (2H, m, 
CH2CH2COF), 2.49 (2H, dt, 3JHH 7.5, 3JHF 1.3, CH2COF); δC (50 MHz; CDCl3) 14.0 
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(CH3), 22.6 (CH2), 23.9 (CH2), 28.6 (CH2), 28.9 (CH2), 29.3 (CH2), 29.6 (CH2), 31.6 
(CH2), 31.9 (CH2), 32.6 (CH2COF) and 163.8 (d, COF, 1J13C-19F 361). Seven signals 
corresponding to CH2 are missing due to the overlap in the aliphatic region of 13C NMR 
spectrum. 
 
Preparation of ethyl 8-stearamido-3,6-dioxaoctanoate (79) 
 
 
 
C26H51NO5 
 
To a solution of 77 (0.10 g, 0.33 mmol) in dimethylformamide (5 mL) was added 
DIPEA (0.287 mL; 1.65 mmol) followed by a solution of stearoyl fluoride (78; 0.13 g, 
0.46 mmol) in dichloromethane (5 mL). The mixture was stirred for 20 h at room tem-
perature. After this time the solvent was removed under reduced pressure and the resi-
due was dissolved in dichloromethane (10 mL). This was then washed with 1 M sodium 
bicarbonate (2 × 10 mL), 1 M potassium hydrogen sulphate (2 × 10 mL), water (15 mL) 
and brine (15 mL). The organic layer was dried over magnesium sulphate and the sol-
vent removed under reduced pressure. The resulting yellow solid was subjected to flash 
column chromatography (ethyl acetate-methanol 95:5) to yield the title compound (79; 
0.12 g, 0.26 mmol, 79%) as a white solid: m.p. 65-66 °C; Rf (ethyl acetate-methanol 
95:5) = 0.25; (Found C, 68.14; H, 11.17; N, 3.21% C26H51NO5 requires C, 68.23; H, 
11.23; N, 3.06%); υmax(film)/cm-1 3307s, 3083m, 2980s, 2850s, 1749s, 1703s, 1641s; 
δH (200 MHz, CDCl3) 0.68 (3H, t, J 6.3, CH3), 0.95-1.26 (31H, m, OCH2CH3 and 14 × 
CH2), 1.31-1.48 (2H, m, CH2CH2CO), 1.97 (2H, br t, J 7.5, CH2CONH), 3.22 (2H, br 
dt, NHCH2), 3.30-3.53 (6H, m, CH2OCH2CH2O), 3.40 (2H, s, OCH2CO), 4.01 (2H, q, J 
7.1, OCH2CH3), 5.95 (1H, br t, NH); δC (50 MHz, CDCl3) 13.6 (CH3CH2 and 
OCH2CH3), 22.1 (CH2), 25.2 (CH2CH2CO), 28.8 (CH2), 28.9 (CH2), 29.0 (CH2), 29.1 
(CH2), 29.2 (CH2), 31.4 (CH2), 36.2 (CH2CO), 38.5 (NHCH2), 60.4 (OCH2CH3), 68.0 
(OCH2CO), 69.5 (OCH2), 69.6 (OCH2), 70.4 (OCH2), 160.3 (COO), 173.2 (CONH); 
m/z (EI) 458 ([M]+, 22%), 327 (80), 234 (74), 132 (96), 103 (90), 85 (100). Seven sig-
nals corresponding to CH2 from the lipid chain are missing due to the overlap in the ali-
phatic region of 13C NMR spectrum. 
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Preparation of pentacosa-10,12-diynoyl fluoride (80)2 
 
 
 
C25H41FO 
 
To a solution of 10,12-pentacosadiynoic acid (5; 0.716 g, 1.91 mmol) in dichloro-
methane (20 mL) was added pyridine (0.155 mL, 1.92 mmol) followed by cyanuric 
fluoride (0.230 mL, 2.67 mmol). This mixture was heated to reflux for 3 h after which 
time dichloromethane (10 mL) was added and the mixture filtered. The filtrate was then 
washed with water (2 × 20 mL) and the organic extract was dried over anhydrous mag-
nesium sulphate. The solvent was evaporated under reduced pressure to yield the title 
compound (80; 0.589 g, 1.56 mmol; 82 %) as a white oily solid; υmax(film)/cm-1 2917m, 
2845m, 2240w, 1863s; δH (200 MHz; CDCl3) 0.85 (3H, t, J 6.4, CH3), 1.20-1.40 (30H, 
m, 15 × CH2), 1.51-1.72 (2H, m, CH2CH2COF), 2.15 (4H, t, J 6.7, 2 × CH2C≡C), 2.45 
(2H, dt, 3J1H-1H 4.9, 3J1H-19F 0.9, CH2COF); δC (50 MHz; CDCl3) 14.2 (CH3), 19.2 
(CH2C≡C), 22.7 (CH2), 23.9 (CH2), 28.3 (CH2), 28.9 (CH2), 28.7 (CH2), 28.8 (CH2), 
28.9 (CH2), 28.9 (CH2), 29.2 (CH2), 29.4 (CH2), 29.5 (CH2), 29.7 (CH2), 31.6 (CH2), 
31.9 (CH2), 32.6 (CH2COF), 65.2 and 65.4 (C≡C-C≡C), 77.3 and 77.7 (C≡C-C≡C), 
160.3 (d, COF, 1J13C-19F 361). Three signals corresponding to CH2 are missing due to 
the overlap in the aliphatic region of 13C NMR spectrum. 
 
Preparation of ethyl 8-(pentacosa-10,12-diynamido)-3,6-dioxactonoate (81) 
 
 
 
C33H57NO5 
 
To a solution of 77 (0.058 g, 0.19 mmol) in dimethylformamide (5 mL) was added 
DIPEA (0.17 mL, 0.95 mmol) followed by a solution of pentacosa-10,12-diynoyl fluo-
ride (80; 0.087 g, 0.23 mmol) in dichloromethane (5 mL). The mixture was stirred for 
20 h at room temperature. After this time the solvent was removed under reduced pres-
sure and the residue was dissolved in dichloromethane (10 mL). This was then washed 
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with 1 M sodium bicarbonate (2 × 10 mL), 1 M potassium hydrogen sulphate (2 × 
10 mL), water (15 mL) and brine (15 mL). The organic layer was dried over magnesium 
sulphate and the solvent removed under reduced pressure. The resulting yellow solid 
was subjected to flash column chromatography (dichloromethane-methanol 95:5) to 
yield the title compound (81; 0.072 g, 0.13 mmol, 69 %) as a white solid: m.p. 60 °C; 
δH (200 MHz, CDCl3) 0.93 (3H, t, J 6.4, CH3CH2), 1.23-1.76 (35H, m, OCH2CH3 and 
16 × CH2), 2.15 (2H, t, J 7.6, CH2CONH), 2.28 (4H, t, J 6.7, 2 × CH2C≡C), 3.52 (2H, br 
dt, NHCH2CH2O), 3.58-3.66 (2H, m, NHCH2CH2O), 3.68-3.72 (m, 4H, OCH2CH2O), 
4.19 (2H, s, OCH2CO), 4.28 (2H, q, J 7.1, OCH2), 6.29 (1H, br t, NH); δC (50 MHz, 
CDCl3) 13.8 (CH3), 14.1 (OCH2CH3), 18.9 (CH2C≡C), 22.4 (CH2), 25.4 (CH2), 28.1 
(CH2), 28.5 (CH2), 28.6 (CH2), 28.7 (CH2), 28.8 (CH2), 28.9 (CH2), 29.0 (CH2), 29.2 
(CH2), 29.3 (CH2), 31.6 (CH2), 36.4 (CH2CO), 38.8 (NHCH2), 60.7 (OCH2CH3), 64.9 
and 65.2 (C≡C-C≡C), 68.2 (OCH2CO), 69.7 (OCH2), 69.8 (OCH2), 70.7 (OCH2),  77.2 
and 77.3 (C≡C-C≡C), 170.2 (COO), 173.0 (CONH); m/z (ESI) 570 ([M+Na]+, 45%), 
378 (13), 101 (40), 81 (33), 59 (100); HRMS (ESI) (Found: [M+Na]+, 570.4125. 
C33H57N O5Na requires m/z, 570.4129). Five signals corresponding to CH2 from the 
lipid chain are missing due to the overlap in the aliphatic region of 13C NMR spectrum. 
 
Preparation of N-(2-aminoethyl)-N-(thymin-1-ylacetyl)glycine ethyl ester trifluoro-
acetate (82) 
 
 
 
C15H21F3N4O7 
 
PNA monomer 70 (0.0536 g, 0.130 mmol) was dissolved in dichloromethane (2 mL) 
and trifluoroacetic acid (2 mL) was added dropwise. The solution was stirred for 1 h 
after which time the solvent was evaporated under reduced pressure to yield a brown 
residue. This residue was coevaporated with toluene (2 × 5 mL) and diethyl ether (4 × 
5 mL) and finally dried in vacuo over phosphorus pentoxide, to yield a brown sticky 
solid (82; 0.0554 g, 0.130 mmol; 100%) which was used without further purification; δH 
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(200 MHz; D2O) (2 rotational isomers in a 2:1 ratio observed due to restricted rotation 
about the tertiary amide bond) 1.10 (mi.) and 1.15 (ma.) (3H, t, J 7.1, CH3), 1.74 (3H, s, 
C(5)-CH3), 3.02-3.15 (ma.) and 3.18-3.29 (mi.) (2H, m, NHCH2CH2), 3.58-3.68 (ma.) 
and 3.70-3.80 (mi.) (2H, m, NHCH2CH2), 4.06 (mi.) and 4.28 (ma.) (2H, s, CH2COO), 
4.09 (mi.) and 4.17 (ma.) (2H, q, J 7.1, OCH2), 4.51 (ma.) and 4.69 (mi.) (2H, s, 
CH2CON), 7.20 (ma.) and 7.26 (mi.) (1H, s, C(6)H); δC (50 MHz; D2O) (2 rotational 
isomers in a 2:1 ratio observed due to restricted rotation about the tertiary amide bond) 
10.7 (C(5)-CH3), 12.7 (CH3), 37.1 (NHCH2CH2), 48.5 (CH2CON), 48.8 (NHCH2CH2), 
49.0 (CH2COO), 62.7 (OCH2), 110.6 (C(5)), 142.3 (C(6)H), 151.7 (C(2)O), 166.1 
(C(4)O), 169.1 (CON), 170.2 (COO). Signals corresponding to NH were exchanged on 
deuteration. 
 
Attempted preparation of ethyl 14-(dibenzylamino)-3-(2-(thymin-1-yl)acetyl)-7-
oxo-9,12-dioxa-3,6-diazatetradecan-1-oate (76) 
 
 
 
C33H43N5O8 
 
To a solution of 45 (0.33 g, 0.80 mmol) in dimethylformamide (5 mL) was added 
HBTU (0.31 g, 0.81 mmol) followed by diisopropylethylamine (0.15 mL, 0.83 mmol) 
and the mixture was stirred for 15 min. After this time, a solution of 82 (0.33 g, 
0.78 mmol) in dimethylformamide (5 mL) was added to this mixture followed by diiso-
propylethylamine (0.30 mL, 1.66 mmol). The resulting mixture was stirred for 18 h at 
room temperature after which time the solvent was removed in vacuo. The residue was 
dissolved in dichloromethane (10 mL) and the solution was washed successively with 1 
M sodium bicarbonate (3 × 10 mL), 1 M potassium hydrogensulphate (2 × 10 mL), wa-
ter (10 mL) and finally brine (15 mL). The organic layer was then dried over anhydrous 
magnesium sulphate and the solvent was evaporated under reduced pressure to yield a 
yellow residue which was purified by flash column chromatography (dichloromethane-
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methanol 95:5) yielding the title compound (76; 0.029 g, 0.045 mmol; 6%) as a yellow 
sticky powder. The yield was too low for recording a clean 1H NMR. 
 
Preparation of N,N-dibenzyl-8-amino-3,6-dioxaoctan-1-ol (100) 
 
 
 
C20H27NO3 
 
Method A 
Lithium aluminium hydride (0.0590 g, 1.58 mmol) was dissolved in anhydrous tetrahy-
drofuran (1.60 mL) and the slurry obtained was cooled to -78 °C. Compound 59 (0.590 
g, 1.58 mmol) in anhydrous tetrahydrofuran (20 mL) was added dropwise. The mixture 
was stirred for 1 h, after being allowed to slowly warm-up to room temperature. It was 
left stirring for another 17 h. After this time 2 M ammonium hydroxide solution (1 mL) 
was added carefully and the solvent was evaporated. The aqueous phase was extracted 
with ethyl acetate (5 × 20 mL) and the combined organic layer was dried over anhy-
drous magnesium sulphate. The filtrate was concentrated and the crude material was 
subjected to flash column chromatography (ethyl acetate - light petroleum 3:2) to yield 
the title compound (100; 0.406 g, 1.23 mmol; 72%) as a colourless oil. 
 
Method B 
Compound 59 (5.83 g, 15.7 mmol) in tetrahydrofuran (80 mL) was heated to reflux and 
to this was added sodium borohydride (3.86 g, 102 mmol) over a period of 15 min. 
Methanol (80 mL) was then carefully added dropwise to the refluxing reaction over an-
other 15 min. The reaction mixture finally obtained was further heated to reflux for 60 
min. After this time, the reaction was quenched by the addition of saturated ammonium 
chloride solution (80 mL) and the organic phase was separated. The aqueous phase was 
extracted with ethyl acetate (6 × 80 mL) and the combined organic phase was dried over 
anhydrous magnesium sulphate. The filtrate was concentrated to a crude oil, which was 
then subjected to flash column chromatography (ethyl acetate – light petroleum 2:1) to 
yield the title compound (100; 4.22 g, 12.8 mmol; 82%) as  a colourless oil, a minor 
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product (43; 0.896 g, 3.14 mmol; 20%) was also isolated as a colourless oil; Rf (ethyl 
acetate-light petroleum 7:3) = 0.33; υmax(film)/cm-1 3436br s, 3027s, 2871s, 2871m, 
1494s, 1453s; δH (200 MHz; CDCl3) 2.73 (2H, t, J 6.2, NCH2), 2.90 (1H, br s, OH), 
3.57-3.69 (10H, m, CH2OCH2CH2OCH2CH2), 3.72 (4H, s, 2 × NCH2Ar), 7.24-7.48 
(10H, m, 10 × Ar-H); δC (50 MHz; CDCl3) 52.8 (NCH2), 59.1 (2 × NCH2Ar), 61.8 
(OCH2), 70.1 (OCH2), 70.5 (2 × OCH2), 72.7 (OCH2), 127.0 (Ar-CH), 128.3 (Ar-CH), 
128.9 (Ar-CH), 139.8 (Ar-C); m/z (CI) 330 ([M+H]+, 100%), 268 (3), 254 (6), 240 (30), 
238 (23), 210 (30); HRMS (ESI) (Found: [M+H]+, 330.2068. C20H27NO3 requires m/z, 
330.2064).  
 
Preparation of N,N-dibenzyl-8-amino-3,6-dioxaoctanyl methanesulfonate (101) 
 
 
 
C21H29NO5S 
 
To an ice-cooled solution of 100 (0.665 g, 2.02 mmol) and triethylamine (0.430 mL, 
3.09 mmol) in anhydrous dichloromethane (10 mL) was slowly added via a syringe 
methanesulfonyl chloride (0.170 mL, 2.22 mmol). The reaction was stirred and allowed 
to slowly warm up to room temperature. The stirring was continued overnight and after 
this time the reaction mixture was washed successively with ice cooled water (15 mL), 
saturated sodium bicarbonate solution (15 mL) and brine (20 mL). The organic phase 
was dried over magnesium sulphate and evaporated. The crude residue obtained was 
subjected to flash column chromatography (ethyl acetate - light petroleum 4:6) and the 
title compound (101; 0.675 g, 1.66 mmol; 82%) was obtained as a colourless liquid; Rf 
(ethyl acetate-light petroleum 4:6) = 0.29; υmax(film)/cm-1 3027s, 2871s, 2871m, 1494s, 
1453s, 1354s (SO2OR str as), 1176s (SO2OR str sy); δH (200 MHz; CDCl3) 2.62 (2H, t, 
J 6.2, NCH2), 2.92 (3H, s, SO2CH3), 3.45-3.56 (6H, m, OCH2CH2OCH2), 3.59 (4H, s, 2 
× NCH2Ar), 3.63-3.68 (2H, m, NCH2CH2O), 4.25-4.29 (2H, m, CH2OSO2), 7.13-7.35 
(10H, m, 10 × Ar-H); δC (50 MHz; CDCl3) 37.6 (SO2CH3), 52.6 (NCH2), 58.9 (2 × 
NCH2Ar), 69.0 (CH2SO2), 69.3 (CH2CH2SO2), 70.0 (OCH2), 70.2 (OCH2), 70.6 
(OCH2), 126.9 (Ar-CH), 128.2 (Ar-CH), 128.7 (Ar-CH), 139.6 (Ar-C). 
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Preparation of N,N-dibenzyl-8-amino-3,6-dioxaoctan-1-azide (102) 
 
 
 
C20H26N4O2 
 
Compound 101 (1.05 g, 2.59 mmol) was dissolved in anhydrous dimethylformamide 
(25 mL) and sodium azide (0.42 g, 6.5 mmol) was then added in one portion. The reac-
tion mixture was gently heated to 60 °C for 4 h. After this time the mixture was poured 
on a mixture of ice/water (ca. 20 g) and extracted with dichloromethane (3 × 50 mL). 
The organic phase was separated, dried over magnesium sulphate and the solvent was 
removed to yield the title compound (102; 0.798 g, 2.25 mmol; 87%) as a yellow liquid; 
υmax(film)/cm-1 3061m, 3027s, 2977s, 2827s, 2799s, 2104s (N3), 1680m; δH (200 MHz; 
CDCl3) 2.77 (2H, t, J 6.2, NCH2), 3.41 (3H, t, J 5.1, CH2N3), 3.60-3.76 (8H, 
m, CH2OCH2CH2OCH2), 3.71 (4H, s, 2 × NCH2Ar), 7.21-7.49 (10H, m, 10 × Ar-H); 
δC (50 MHz; CDCl3) 50.5 (CH2N3), 52.5 (NCH2), 58.8 (2 × NCH2Ar), 69.8 (OCH2), 
69.9 (OCH2), 70.1 (OCH2), 70.5 (OCH2), 126.7 (Ar-CH), 127.9 (Ar-CH), 128.6 (Ar-
CH), 139.6 (Ar-C); m/z (CI) 355 ([M+H]+, 100%); HRMS (ESI) (Found: [M+H]+, 
355.2127. C20H26N4O2 requires m/z, 355.2129). 
 
Preparation of 8-amino-3,6-dioxaoctan-1-ol (103) 
 
 
 
C6H15NO3 
 
Method A 
Compound 100 (1.30 g, 3.94 mmol) was dissolved in absolute ethanol (50 mL) and 10% 
Pd/C (0.2 g) was then carefully added. The black heterogeneous mixture was evacuated 
and purged with H2(g) several times and stirred at room temperature under 1 atm of 
H2(g) for 48 h. The reaction mixture was then purged with nitrogen and filtered over 
Celite®, washing with ethanol (100 mL) and ethyl acetate (100 mL). The filtrate was 
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concentrated to afford the title compound (103; 0.58 g, 3.9 mmol; 99%) as a colourless 
oil. 
 
Method B 
Compound 100 (1.20 g, 3.64 mmol) was dissolved in methanol (20 mL). Ammonium 
formate (0.459 g, 7.28 mmol) and 10% Pd/C (1 g) were then carefully added. The black 
heterogeneous mixture was heated to gentle reflux for 3 h and then filtered over Celite®, 
washing with methanol (40 mL) and ethyl acetate (40 mL). The filtrate was concen-
trated to afford the title compound (103; 0.533 g, 3.57 mmol; 98%) as a colourless oil. 
 
Method C 
Compound 100 (1.00 g, 3.04 mmol) was dissolved in absolute ethanol (60 mL) so that 
the concentration was 0.05 M. The solution was pumped (1 mL/min) through an H-
cube® instrument (provided by Prof Adams) using 10% Pd/C cartridge at 70 bar pres-
sure and at 70 °C. The solution was run two times to ensure completion (using the same 
cartridge). The solvent was then evaporated to yield the title compound (103; 0.45 g, 
3.00 mmol; 99%) as colourless oil; υmax(film)/cm-1 3365br s, 3312s, 3302s, 2873s, 
2854s, 1599m; δH (200 MHz; D2O) 2.88 (2H, t, J 5.3, NCH2CH2), 3.54-3.72 (10H, m, 
CH2OCH2CH2OCH2CH2); δC (50 MHz; D2O) 39.1 (NH2CH2), 60.0 (CH2OH), 68.6 
(OCH2), 69.2 (OCH2), 69.3 (OCH2) 71.4 (OCH2). Signals for protons NH and OH were 
not observed due to deuteration. 
 
Preparation of 8-(tert-butoxycarbonyl)amino-3,6-dioxaoctan-1-ol (104) 
 
 
 
C11H23NO5 
 
Amino alcohol 103 (0.476 g, 3.19 mmol) was dissolved in a solution of 10% triethyl-
amine in methanol (20 mL). Di-tert-butyl dicarbonate (1.43 g, 6.57 mmol) was then 
added in one portion. The reaction mixture was heated to gentle reflux for 3 h, after 
which time the solvent was removed in vacuo. The residual oil was purified by flash 
column chromatography (ethyl acetate – methanol 95:5) to yield the title compound 
(104; 0.669 g, 2.68 mmol; 84%) as a colourless oil; Rf (ethyl acetate-methanol 95:5) = 
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0.40; υmax(film)/cm-1 3356br s, 2976s, 1694s, 1526m; δH (200 MHz; CDCl3) 1.38 (9H, 
s, C(CH3)3), 2.98 (1H, br s, OH), 3.25 (2H, br dt, NHCH2), 3.49 (2H, t, J 5.3, 
NHCH2CH2O), 3.54-3.61 (6H, m, OCH2CH2OCH2), 3.68 (2H, br dt, CH2CH2OH), 5.27 
(1H, br s, NH); δC (50 MHz; CDCl3) 28.7 (C(CH3)3), 39.9 (NHCH2), 61.3 (CH2OH), 
69.9 (OCH2), 70.5 (OCH2), 70.6 (OCH2), 72.3 (OCH2), 79.5 (C(CH3)3), 156.3 (CONH); 
m/z (CI) 250 ([M+H]+, 15%), 150 (100); HRMS (ESI) (Found: [M+H]+, 250.1649. 
C11H23NO5 requires m/z, 250.1649). 
 
Preparation of 8-(tert-butoxycarbonyl)amino-3,6-dioxaoctanyl methanesulfonate 
(105) 
 
 
 
C12H25NO7S 
 
To an ice-cooled solution of 104 (0.519 g, 2.08 mmol) and triethyethylamine (0.435 
mL, 3.12 mmol) in anhydrous dichloromethane (10 mL) was slowly added via a syringe 
methanesulfonyl chloride (0.175 mL, 2.29 mmol). The reaction was stirred and allowed 
to slowly warm up to room temperature. The stirring was continued overnight and after 
this time the reaction mixture was washed successively with ice cooled water (10 mL), 
saturated sodium bicarbonate solution (10 mL) and brine (10 mL). The organic phase 
was dried over magnesium sulphate and evaporated. The crude residue obtained was 
subjected to flash column chromatography (ethyl acetate - light petroleum 4:6) and the 
title compound (105; 0.531 g, 1.62 mmol; 78%) was obtained as a colourless liquid; Rf 
(ethyl acetate-methanol 95:5) = 0.46; υmax(film)/cm-1 2976m, 2935m, 2874m, 1708s, 
1521s, 1352s (SO2OR str as), 1175s (SO2OR str sy); δH (200 MHz; CDCl3) 1.38 (9H, s, 
C(CH3)3), 3.01 (3H, s, SO2CH3), 3.24 (2H, br dt, NHCH2), 3.47 (2H, t, J 5.3, 
NHCH2CH2O), 3.58-3.61 (4H, m, OCH2CH2O), 3.71 (2H, t, J 4.6, OCH2CH2SO2), 4.33 
(2H, t, J 4.6, OCH2CH2SO2), 4.93 (1H, br s, NH); δC (50 MHz; CDCl3) 28.6 (C(CH3)3), 
37.9 (SO2CH3), 40.5 (NHCH2), 69.2 (CH2SO2), 69.4 (OCH2), 70.4 (OCH2), 70.5 
(OCH2), 70.8 (OCH2), 79.5 (C(CH3)3), 155.8 (CONH); m/z (CI) 345 ([M+NH3]+, 17%), 
328 ([M+H]+, 20), 289 (70), 271 (100), 228 (35); HRMS (ESI) (Found: [M+H]+, 
328.1426. C12H26NO7S requires m/z, 328.1424). 
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Preparation of 8-(tert-butoxycarbonyl)amino-3,6-dioxaoctan-1-azide (83) 
 
 
 
C11H22N4O4 
 
Compound 105 (0.591 g, 1.81 mmol) was dissolved in anhydrous dimethylformamide 
(20 mL) and sodium azide (0.311 g, 4.76 mmol) was then added in one portion. The re-
action mixture was gently heated to 60 °C for 4 h. After this time the mixture was 
poured on a mixture of ice/water (ca. 20 g) and extracted with dichloromethane (3 × 20 
mL). The organic phase was separated, dried over magnesium sulphate and the solvent 
was removed to yield the title compound (83; 0.454 g, 1.66 mmol; 92%) as a yellow 
liquid that did not require any further purification; Rf (ethyl acetate-light petroleum 1:1) 
= 0.39; υmax(film)/cm-1 3360m, 2977m, 2930m, 2870m, 2109s (N3), 1713s; δH (400 
MHz; CDCl3) 1.42 (9H, s, (CH3)3), 3.27-3.30 (2H, m, NHCH2), 3.38 (2H, t, J 5.3, 
CH2N3), 3.52 (2H, t, J 5.3, NCH2CH2O), 3.59-3.64 (4H, m, OCH2CH2O), 3.65 (2H, t, J 
5.3, CH2CH2N3), 5.00 (1H, br s, NH); δC (100 MHz; CDCl3) 28.4 ((CH3)3), 40.3 
(NHCH2), 50.6 (CH2N3), 70.0 (OCH2CH2N3), 70.2 (OCH2CH2O), 70.3 (NCH2CH2O), 
70.5 (OCH2CH2O), 79.1 (C(CH3)3), 155.9 (OCONH); m/z (CI) 292 ([M+NH4]+, 7%), 
275 ([M+H]+, 12), 236 (50), 175 (95), 44 (100); HRMS (ESI) (Found: [M+H]+, 
275.1715. C11H23N4O4 requires m/z, 275.1714). 
 
Preparation of N-(tert-butoxycarbonyl)glycine ethyl ester (110) 
 
 
 
C9H17NO4 
 
Tert-butyl dicarbonate (5.14 g, 23.5 mmol) in dioxane (7 mL) was added to the stirred 
solution of glycine ethyl ester hydrochloride (109; 3.02 g, 21.6 mmol) dissolved into 
water (60 mL) and cooled in an ice bath to 0 °C. After 15 min at this temperature, the 
ice bath was removed and the temperature was allowed to rise to room temperature, 
whilst the pH was kept just above 10.5 by the addition of 2 M sodium hydroxide solu-
tion. Then, the reaction mixture was concentrated to a paste and the paste was triturated 
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with dichloromethane (50 mL) and water (20 mL). The aqueous phase was separated 
and extracted one more time with dichloromethane (30 mL). The combined organic 
phase was dried over magnesium sulphate anhydrous, filtered and the crude material 
obtained on evaporation was subjected to flash column chromatography (ethyl acetate-
light petroleum 6:4). The title compound (110; 2.77 g, 13.6 mmol, 63%) was obtained 
as a yellow liquid; Rf (ethyl acetate-light petroleum 6:4) = 0.66; υmax(film)/cm-1 3372m, 
2980m, 2935w, 1732s, 1717s, 1519s; δH (200 MHz; CDCl3) 1.22 (2H, t, J 7.2, CH3), 
1.39 (9H, s, (CH3)3), 3.83 (2H, d, J 5.6, NHCH2), 4.1 (2H, q, J 7.2, OCH2), 5.04 (1H, br 
s, NHCH2); δC (50 MHz; CDCl3) 14.0 (CH3), 28.2 ((CH3)3), 42.3 (NHCH2), 61.1 
(OCH2), 79.6 (C(CH3)3), 155.7 (CONH), 170.3 (COO); m/z (CI) 204 ([M+H]+, 20%), 
165 (90), 104 (100), 58 (10), 44 (16); HRMS (ESI) (Found: [M+H]+, 204.1230. 
C9H18NO4 requires 204.1230). 
 
Preparation of N-tert-butoxycarbonyl-N-(prop-2-ynyl)glycine ethyl ester (111) 
 
 
 
C12H19NO4 
 
Method A  
Ethyl 2-(tert-butoxycarbonylamino)acetate (110; 0.578 g, 2.84 mmol) was dissolved in 
anhydrous tetrahydrofuran (5 mL) and 3-bromopropyne (80% wt/v in toluene, 0.950 
mL, 8.53 mmol) was added. The solution was cooled to 0 °C in an ice bath and small 
portions of sodium hydride (60% in mineral oil, 0.175 g, 4.38 mmol) were added. After 
the evolution of hydrogen had ceased, the deep brown solution was stirred for 18 h at 
room temperature. After this time, water (5 mL) was added carefully and 
tetrahydrofuran was removed in vacuo. The paste obtained was dissolved in ethyl ace-
tate (10 ml) and the aqueous layer was separated and extracted with ethyl acetate (6 × 
10 mL). The combined organic layer was washed with water (2 × 10 mL) and brine 
(10 mL) and the aqueous layer backextracted with ethyl acetate (10 mL). The combined 
organic phase was dried over magnesium sulphate anhydrous, filtered and evaporated. 
The residue obtained was subjected to flash column chromatography (ethyl acetate-light 
petroleum 1:5) to give the title compound (111; 0.345 g, 1.43 mmol, 50%) as deep yel-
low oil. 
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Method B 
The same procedure was used as in method A except for the solvent. 110 (0.852 g, 
4.19 mmol) was dissolved in anhydrous acetonitrile (4 mL) and 3-bromopropyne (80% 
wt/v in toluene, 1.40 mL, 12.6 mmol) were then added. Sodium hydride (60% in min-
eral oil, 0.350 g, 8.75 mmol) was added at 0 °C. The work-up was as described in 
method A. The title compound (111; 0.688 g, 2.85 mmol; 68%) was obtained as deep 
yellow oil. 
 
Method C 
The same procedure was used as in method A except for the solvent. 110 (1.54 g, 
7.57 mmol) was dissolved in anhydrous dimethylformamide (5 mL) and 3-
bromopropyne (80% wt/v in toluene, 2.53 mL, 22.7 mmol) were then added. Sodium 
hydride (60% in mineral oil, 0.609 g, 15.2 mmol) was added at 0 °C. The work-up was 
as described in method A. The title compound (111; 1.39 g, 5.76 mmol; 76%) was ob-
tained as deep yellow oil; υmax(film)/cm-1 3270s, 2980s, 2934s, 1748s, 1706s; δH (400 
MHz; CDCl3) (2 rotational isomers observed due to restricted rotation about the tertiary 
amide bond) 1.26-1.30 (3H, m, CH3), 1.39 and 1.49 (9H, s, (CH3)3), 2.22 (1H, t, J 2.5, 
CH2C≡CH), 3.89 and 4.09 (2H, s, NCH2CO), 4.13 and 4.19 (s, 2H, CH2CCH), 4.18-
4.22 (m, 2H, OCH2); δC (100 MHz; CDCl3) (2 rotational isomers observed due to re-
stricted rotation about the tertiary amide bond) 14.1 and 14.2 (CH3), 28.1 and 28.2 
((CH3)3), 36.6 and 37.1 (CH2CCH), 46.9 and 47.5 (CH2COO), 61.0 (OCH2), 72.3 and 
72.6 (CH2C≡CH), 78.7 (CH), 80.9 and 81.0 (C(CH3)3), 154.6 and 154.7 (CON), 169.7 
(COO); m/z (CI) 242 ([M+H]+, 15%), 203 (75), 142 (100), 68 (26); HRMS (ESI) 
(Found: [M+H]+, 242.1387. C12H19NO4 requires m/z, 242.1387). Structure was verified 
by NOESY experiments. 
 
Preparation of N-(prop-2-ynyl)glycine ethyl ester trifluoroacetate (106) 
 
 
 
C9H12NO4F3 
 
Ethyl 2-tert-butoxycarbonyl-N-(prop-2-ynyl)aminoacetate (111; 1.00 g, 4.14 mmol) was 
dissolved in dichloromethane (8 mL) and trifluoroacetic acid (8 mL) was added. The 
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solution was stirred for 1 h. After this time the solvents were evaporated in vacuo and 
the residue was coevaporated with toluene (2 × 10 mL) and diethyl ether (2 × 10 mL) 
and stored over P2O5. The title compound was obtained as a brown oil which was used 
without further purification (106; 1.04 g, 4.06 mmol; 98%); υmax(film)/cm-1 3270w, 
2988m, 2930m, 1749s, 1668s; δH (200 MHz; CDCl3) 1.29 (3H, t, J 7.2, CH3), 2.58 (1H, 
t, J 2.3, CH2C≡CH), 3.99 (2H, s, CH2COO), 4.04 (2H, m, CH2NH), 4.27 (2H, q, J 7.2, 
OCH2), 9.23 (1H, br s, NH); δC (50 MHz; CDCl3) 13.1 (CH3), 35.7 (CH2NH), 45.3 
(CH2COO), 62.3 (OCH2), 71.5 (CCH), 77.9 (CCH), 165.5 (COO). 
 
Preparation of N4-(benzyloxycarbonyl)cytosine (113)1 
 
 
 
C12H11N3O3 
 
Cytosine (112; 1.60 g, 14.4 mmol) was suspended in anhydrous pyridine (60 mL) and 
the mixture was cooled to 0 °C. Benzyl chloroformate (4.11 mL, 28.8 mmol) was added 
dropwise and the suspension was stirred overnight at room temperature. After this time 
the solvent was evaporated and water (30 mL) was added. The residue was acidified to 
pH 1.0 using 4 M hydrochloric acid solution. The crude product was collected by filtra-
tion and washed with water. The wet precipitate was suspended in absolute ethanol 
(15 mL) and heated to reflux for 10 min. The following mixture was then cooled to 10 
°C and filtered. The resulting solid collected was washed with diethyl ether (20 mL) and 
dried in vacuo to yield the title compound (113; 1.91g, 7.78 mmol; 54%) as a white 
solid: m.p. > 250 °C (lit.[REF] > 250 °C); (Found C, 58.54; H, 4.22; N, 17.11% 
C12H11N3O3 requires C, 58.77; H, 4.52; N, 17.11%); υmax(KBr)/cm-1 3141s, 2959s, 
2800s, 1745s, 1689s, 1631s, 1589m, 1514m. 
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Preparation of N4-benzyloxycarbonyl cytosin-1-yl acetic acid (107)1 
 
 
 
C14H13N3O5 
 
N4-(Benzyloxycarbonyl)cytosine (113; 0.267 g, 1.09 mmol) and anhydrous potassium 
carbonate (0.151 g, 1.09 mmol) were suspended in dimethylformamide (5 mL). To this 
heterogeneous mixture was added ethyl bromoacetate (0.13 mL, 1.1 mmol) and the sus-
pension was stirred at room temperature for 18 h. After this time, the solvent was re-
moved under reduced pressure and the resulting residue was treated with 4 M hydro-
chloric acid solution (1 mL) and stirred for 15 min at 0 °C. The precipitate was collected 
by filtration and treated with water (4 mL) and 2 M sodium hydroxide solution (2 mL). 
The resulting solution was stirred for 30 min at room temperature before being cooled 
down to 0 °C. A white solid precipitated by the addition of 4 M hydrochloric acid solu-
tion. This crude product was collected and recrystallised from boiling methanol and 
washed with diethyl ether to yield the title compound (107; 0.10 g, 0.33 mmol; 30%) as 
a white solid: m.p. 266-274 °C (lit.1 266-274 °C); (Found C, 55.39; H, 4.26; N, 13.87% 
C14H13N3O5 requires C, 55.45; H, 4.32; N, 13.86%); υmax(KBr)/cm-1 3449br s, 3238m, 
3155m, 1747s, 1713s, 1637s; δH (200 MHz; DMSO-d6) 4.52 (2H, s, CH2COOH), 5.19 
(2H, s, OCH2Ar), 7.02 (1H, d, J 7.3, C(5)H), 7.31-7.44 (5H, m, Ar-H), 8.04 (1H, d, J 
7.3, C(6)H); δC (50 MHz; DMSO-d6) 50.5 (NCH2CO), 66.5 (OCH2Ar), 93.9 (C(5)), 
127.9 (Ar-CH), 128.1 (Ar-CH), 128.4 (Ar-CH), 135.9 (Ar-C), 150.3 (C(6)), 153.1 
(NHCOO), 155.0 (C(2)O), 163.2 (C(4)), 169.3 (COOH). 
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Preparation of ethyl adenin-9-ylacetate (112)1 
 
 
 
C9H11N5O2 
 
Adenine (114; 10.0 g, 74.0 mmol) was suspended in anhydrous dimethylformamide 
(200 mL) and sodium hydride (60% in mineral oil; 3.55 g, 89.0 mmol) was added in 
small portions. The reaction mixture was stirred for 2 h after which time ethyl bro-
moacetate (24.7 g, 148 mmol) was added dropwise at room temperature. The mixture 
was then stirred overnight. After this time, the solvent was evaporated and the resulting 
oil was shaken with water (100 mL). The crystalline compound formed was collected by 
filtration, washed with water and recrystallised from boiling methanol to yield the title 
compound (115; 6.64 g, 30.0 mmol; 41%) as white crystals: m.p. 227-228 °C (lit.1 227-
228 °C); δH (200 MHz; DMSO-d6) 1.14 (3H, t, J 7.1, OCH2CH3), 4.10 (2H, q, J 7.1, 
OCH2CH3), 4.99 (2H, s, NCH2CO), 7.22 (2H, s, NH2), 8.04 (2H, s, C(8)H), 8.06 (2H, s, 
C(2)H); δC (50 MHz; DMSO-d6) 14.4 (OCH2CH3), 53.3 (NCH2CO), 61.8 (OCH2CH3), 
118.5 (C(5)), 141.7 (C(8)H), 150.1 (C(2)H), 153.0 (C(4)), 156.4 (C(6)), 168.4 (COO). 
 
Preparation of N1-(benzyloxycarbonyl)imidazole (117)173, 174 
 
 
 
C11H10N2O2 
 
Benzyl chloroformate (116; 12.5 g, 73.2 mmol) was added to a solution of imidazole 
(10.0 g, 166 mmol) in dry toluene (100 mL) and the mixture was stirred overnight at 
room temperature. The mixture was then filtered and the filtrate was evaporated to yield 
an oil which solidified on refrigeration to afford the title compound (117; 14.8 g, 73.2 
mmol; 100%) as an off-white solid; δH (200 MHz; CDCl3) 5.30 (2H, s, CH2O), 6.93-
6.95 (1H, m, Ar-H), 7.18-7.40 (6H, m, Ar-H), 8.02-8.05 (1H, m, Ar-H); δC (50 MHz; 
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CDCl3) 69.8 (CH2O), 117.1 (Ar-CH), 128.4 (Ar-CH), 128.7 (Ar-CH), 129.2 (Ar-CH), 
130.6 (Ar-CH), 133.9 (Ar-C), 137.1 (Ar-CH), 148.6 (NCOO). 
 
Preparation of 1-(benzyloxycarbonyl)-3-ethylimidazolium tetrafluoroborate 
(118)173, 174 
 
 
 
C13H15BF4N2O2 
 
Triethyloxonium tetrafluoroborate (2.57 g, 13.5 mmol) was added to N1-(benzyloxy-
carbonyl)imidazole (117; 2.60 g, 12.9 mmol) in dichloromethane (35 mL) and the mix-
ture was stirred at room temperature for 2 h. The title compound (118) was kept in solu-
tion without further purification for the subsequent reaction (a small amount of the solu-
tion was evaporated to allow characterization); δH (200 MHz; CDCl3) 1.35 (3H, t, J 7.3, 
NCH2CH3), 4.16 (2H, q, J 7.3, NCH2CH3), 5.34 (2H, s, CH2O), 7.16-7.42 (7H, m, Ar-
H), 7.54-7.59 (1H, m, Ar-H), 9.10 (1H, s, Ar-H); δC (50 MHz; CDCl3) 14.6 (CH2CH3), 
46.3 (NCH2), 72.6 (CH2O), 120.1 (Ar-CH), 123.3 (Ar-CH), 128.9 (Ar-CH), 129.3 (Ar-
CH), 129.6 (Ar-CH), 132.6 (Ar-C), 136.5 (Ar-CH), 145.4 (NCOO). 
 
Preparation of ethyl N6-(benzyloxycarbonyl)adenin-9-ylacetate (119)1 
 
 
 
C17H17N5O4 
 
Ethyl adenin-9-ylacetate (115; 3.40 g, 15.4 mmol) was dissolved in dimethylformamide 
(50 mL) with gentle heating. The cooled solution was then added dropwise to a solution 
of 1-(benzyloxycarbonyl)-3-ethylimidazolium tetrafluoroborate (118; 62.0 mmol) in 
dichloromethane (35 mL) at 0 °C. The reaction mixture was left to stir at room tempera-
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ture overnight. After this time, a saturated sodium bicarbonate solution (100 mL) was 
added and the resulting mixture was further stirred for 10 min. The organic phase was 
separated and washed successively with water (100 mL), 1 M potassium hydrogen sul-
phate solution (2 × 50 mL) and finally brine (50 mL) before being dried over anhydrous 
magnesium sulphate. Filtration followed by evaporation yielded a colourless oil. This 
oil was dissolved in dichloromethane (20 mL) and cooled to 0 °C. Light petroleum 
(50 mL) was then slowly added to cause precipitation of the title compound, which was 
isolated by filtration (119; 4.90 g, 13.8 mmol; 90%) as an off-white solid: m.p. 130-133 
°C (lit.1 132-135 °C); δH (200 MHz; CDCl3) 1.29 (3H, t, J 7.1, CH3), 4.26 (2H, q, J 7.1, 
OCH2CH3), 4.95 (2H, s, NCH2), 5.29 (2H, s, OCH2Ar), 7.33-7.47 (5H, m, 5 × Ar-H), 
7.98 (1H, s, C(8)H), 8.68 (1H, s, NH), 8.76 (1H, s, C(2)H); δC (50 MHz; CDCl3) 14.3 
(CH3), 44.5 (NCH2), 62.7 (OCH2CH3), 68.1 (ArCH2O), 123.5 (C(5)), 128.1 (Ar-CH), 
128.2 (Ar-CH), 128.3 (Ar-CH), 135.6 (Ar-C), 143.3 (C(8)H), 146.8 (C(4)), 149.7 
(C(2)H), 151.7 (C(6)), 153.3 (NHCOO), 165.4 (COO). 
 
Preparation of N6-(benzyloxycarbonyl)adenin-9-yl acetic acid (108)1 
 
 
 
C15H13N5O4 
 
N6-(Benzyloxycarbonyl)adenin-9-ylacetate (119; 2.50 g, 7.03 mmol) was suspended in 
methanol (50 mL) at 0 °C and 2 M sodium hydroxide solution (50 mL) was added and 
the reaction was stirred for 30 min. After this time the mixture was washed with di-
chloromethane (2 × 50 mL) and the aqueous phase was cooled at 0 °C whereupon the 
pH was adjusted to 1 using 4 M hydrochloric acid solution. The title compound precipi-
tated as a white solid and was collected by filtration, washed with water and dried in 
vacuo over P2O5 (108; 2.22 g, 6.78 mmol; 96%); υmax(KBr)/cm-1 3489m, 3086m, 
2968m, 2885m, 1737s, 1695s, 1659s, 1592m; δH (200 MHz; DMSO-d6) 5.12 (2H, s, 
NCH2), 5.29 (2H, s, OCH2), 7.35-7.51 (m, 5H, 5 × Ar-H), 8.12 (s, 1H, C(8)H), 8.79 (s, 
1H, C(2)H); δC (50 MHz; DMSO-d6) 45.1 (NCH2), 67.3 (OCH2), 120.2 (C(5)), 128.0 
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(Ar-CH), 128.2 (Ar-CH), 128.5 (Ar-CH), 136.2 (Ar-C), 145.1 (C(8)H), 148.7 (C(4)), 
151.3 (C(2)H), 151.8 (C(6)), 152.3 (NHCOO), 168.7 (COOH). 
 
Preparation of N-(thymin-1-ylacetyl)-N-(prop-2-ynyl)glycine ethyl ester (84a) 
 
 
 
C14H17N3O5 
 
To a solution of thymine acetic acid (69; 0.680 g, 3.70 mmol) in dimethylformamide 
(10 mL) was added HBTU (1.34 g, 3.53 mmol) in one portion followed by DIPEA 
(2.0 mL, 12 mmol) and the mixture was stirred for 15 min. In the meantime N-(prop-2-
ynyl)glycine ethyl ester trifluoroacetate (106; 8.86 g, 3.36 mmol) was dissolved in di-
methylformamide (10 mL) and then slowly added to the reaction mixture. DIPEA 
(3.0 mL, 28 mmol) was then added and the homogeneous mixture was stirred overnight 
at room temperature. After this time, the solvent was removed in vacuo and the residue 
was dissolved in dichloromethane (30 mL). The solution was successively washed with 
1 M sodium bicarbonate solution (3 × 15 mL), 1 M potassium hydrogen sulphate solu-
tion (2 × 15 mL), water (15 mL) and finally brine (15 mL). The combined organic 
phases were then dried over magnesium sulphate anhydrous and the solvent was evapo-
rated to an orange foam, which was successively purified by flash column chromatogra-
phy (ethyl acetate-methanol 95:5) to give the title compound (84a; 0.620 g, 2.02 mmol; 
60%) as a cream-coloured foam: m.p. 162-163 °C; Rf (ethyl acetate-methanol 95:5) = 
0.32; (Found C, 54.77; H, 5.53; N, 13.38% C14H17N3O5 requires C, 54.72; H, 5.58; N, 
13.67%); υmax (film)/cm-1 3238m, 3165w, 2999m, 2832m, 1726s, 1724s, 1682s, 1664s; 
δH (400 MHz; CDCl3) (2 rotational isomers observed due to restricted rotation about the 
tertiary amide bond) 1.26 and 1.31 (2H, t, J 7.1, CH3), 1.34 (3H, s, C(5)-CH3), 2.30 and 
2.48 (1H, t, J 2.4, CH2C≡CH), 4.18 and 4.26 (2H, q, J 7.1, OCH2), 4.27-4.29 (4H, m, 
CH2NCH2), 4.50 and 4.70 (2H, s, NCH2CON), 7.01 (1H, s, C(6)H), 9.50 (1H, s, 
N(3)H); δC (100 MHz; CDCl3) (2 rotational isomers observed due to restricted rotation 
about the tertiary amide bond) 12.2 (C(5)-CH3), 14.0 and 14.1 (CH3), 36.3 and 38.0 
(HCCCH2), 47.7 (CH2COO), 48.0 and 48.1 (CH2CON), 61.7 and 62.3 (OCH2), 73.8 and 
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74.6 (HCCCH2), 76.6 and 77.1 (CH), 110.9 (C(5)), 141.1 (C(6)H), 151.3 (C(2)O), 164.5 
(C(4)O), 167.1 (CH2CON), 168.7 and 168.9 (COO); m/z (ESI) 308 ([M+H]+, 100%), 
325 (70), 142 (25); HRMS (ESI) (Found: [M+H]+, 308.1240. C14H18N3O5 requires m/z, 
308.1241). An X-Ray crystal structure (Appendix B) was acquired from crystals ob-
tained from diethyl ether and methanol, thereby confirming the structure of the product. 
 
Preparation of N-[N4-(benzyloxycarbonyl)cytosin-1-ylacetyl]-N-(prop-2-ynyl) gly-
cine ethyl ester (84b) 
 
 
C21H22N4O6 
 
To a solution of N4-benzyloxycarbonyl cytosin-1-yl acetic acid (107; 0.32 g, 1.1 mmol) 
in dimethylformamide (6 mL) was added HBTU (0.36 g, 1.5 mmol) followed by 
triethylamine (0.28 mL, 2.0 mmol) and the mixture was stirred for 15 min. In the mean-
time N-(prop-2-ynyl)glycine ethyl ester trifluoroacetate (106; 0.23 g, 1.02 mmol) was 
dissolved in dimethylformamide (6 mL) and then slowly added to the reaction mixture. 
Triethylamine (0.85 mL, 6.1 mmol) was then added and the homogeneous mixture was 
stirred overnight at room temperature. After this time, dimethylformamide was removed 
and the residue was dissolved in dichloromethane (10 mL). The solution obtained was 
successively washed with 1 M sodium bicarbonate solution (3 × 15 mL), 1 M potassium 
hydrogensulphate solution (2 × 15 mL), water (15 mL) and finally brine (15 mL). The 
combined organic phase was then dried over magnesium sulphate anhydrous and the 
solvent was evaporated to an orange foam, which was successively subjected to flash 
column chromatography (ethyl acetate-methanol 95:5) to give the title compound (84b; 
0.22 g, 0.52 mmol; 51%) as a white foam: m.p. 130-132 °C; Rf (ethyl acetate) = 0.24; 
(Found C, 59.02; H, 5.07; N, 13.19% C21H22N4O6 requires C, 59.15; H, 5.20; N, 
13.14%); υmax(KBr)/cm-1 3476m, 3280m, 2984m, 1744s, 1668s, 1629s, 1558s; 
δH (400 MHz; CDCl3) (2 rotational isomers observed due to restricted rotation about the 
tertiary amide bond) 1.16 and 1.22 (2H, t, J 7.1, CH3), 2.21 and 2.32 (1H, t, J 2.4, 
CHCCH2), 4.07 and 4.20 (2H, q, J 7.1, OCH2), 4.11 and 4.23 (2H, s, CH2COO), 4.17 
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and 4.18 (2H, s, CHCCH2), 4.52 and 4.78 (2H, s, CH2CON), 5.62 (2H, s, OCH2Ar),  
6.96-7.02 (1H, m, C(5)H), 7.26-7.32 (5H, m, 5 × Ar-H), 7.38-7.43 (1H, m, C(6)H), 9.24 
(1H, br s, NH-C(4)); δC (100 MHz; CDCl3) (2 rotational isomers observed due to re-
stricted rotation about the tertiary amide bond) 13.8 (CH3), 36.3 and 38.2 (HCCCH2), 
47.8 and 48.1 (CH2COO), 50.8 and 50.9 (CH2CON), 62.0 and 62.5 (OCH2), 67.9 
(OCH2Ar), 73.9 and 74.7 (HCCCH2), 76.4 and 76.8 (HCCCH2), 96.3 (C(5)H), 128.4 
(Ar-CH), 128.6 (Ar-CH), 128.7 (Ar-CH), 134.9 (Ar-C), 149.8 (C(6)H), 152.2 (NHCO), 
157.3 (C(2)O), 163.3 (C(4)), 167.5 and 167.6 (CH2CON), 169.4 and 169.5 (COO); m/z 
(ESI) 427 ([M+H]+, 61%), 319 (3), 85 (100); HRMS (ESI) (Found: [M+H]+, 427.1612. 
C21H23N4O6 requires m/z, 427.1612). 
 
Preparation of N-[N6-(benzyloxycarbonyl)adenin-9-ylacetyl]-N-(prop-2-ynyl) gly-
cine ethyl ester (84c) 
 
 
 
C22H22N6O5 
 
To a solution of N6-(benzyloxycarbonyl)adenin-9-yl acetic acid (108; 0.332 g, 1.01 
mmol) in dimethylformamide (30 mL) was added HBTU (0.402 g, 1.06 mmol) followed 
by DIPEA (0.19 mL, 1.1 mmol) and the mixture was stirred for 15 min. In the meantime 
N-(prop-2-ynyl)glycine ethyl ester trifluoroacetate (106; 0.298 g, 1.17 mmol) was dis-
solved in dimethylformamide (20 mL) and DIPEA (0.34 mL, 1.93 mmol) was slowly 
added. This mixture was then added to the solution of 108 and the resulting solution 
was stirred  overnight at room temperature. After this time, dimethylformamide was re-
moved in vacuo and the residue was dissolved in dichloromethane (10 mL). The follow-
ing solution was successively washed with a 1 M sodium bicarbonate solution (3 × 15 
mL), 1 M potassium hydrogen sulphate solution (2 × 15 mL), water (15 mL) and finally 
brine (15 mL). The combined organic phase was then dried over anhydrous magnesium 
sulphate and the solvent was evaporated to an orange foam, which was successively pu-
rified by flash column chromatography (ethyl acetate-methanol 9:1) to give the title 
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compound (84c; 0.164 g, 0.370 mmol; 36 %) as a white solid: m.p. 120-122 °C; Rf 
(ethyl acetate-methanol 95:5) = 0.39; (Found C, 58.49; H, 4.62; N, 18.86% C22H22N6O5 
requires C, 58.66; H, 4.92; N, 18.66%); υmax(KBr)/cm-1 3237s, 3190s, 3125m, 3029m, 
2957m, 1763s, 1749s, 1646s, 1610s; δH (400 MHz; CDCl3) (2 rotational isomers ob-
served due to restricted rotation about the tertiary amide bond) 1.24 and 1.32 (2H, t, 
J 7.1, CH3), 2.30 and 2.48 (1H, t, J 2.4, CHCCH2), 4.18 and 4.28 (2H, q, J 7.1, OCH2), 
4.25 and 4.38 (2H, s, CH2COO), 4.31 and 4.32 (2H, s, CHCCH2), 4.98 and 5.17 (2H, s, 
CH2CON), 5.28 (2H, s, OCH2Ar), 7.32-7.42 (5H, m, 5 × Ar-H), 8.02 and 8.05 (1H, s, 
C(8)H), 8.71 and 8.74 (1H, s, C(2)H), 8.86 (1H, br s, NH-C(4)); δC (100 MHz; CDCl3) 
(2 rotational isomers observed due to restricted rotation about the tertiary amide bond) 
14.0 and 14.1 (CH3), 36.4 and 38.1 (HCCCH2), 43.7 and 43.8 (CH2CON), 47.5 and 47.9 
(CH2COO), 61.6 and 62.3 (OCH2), 67.1 (OCH2Ar), 73.9 and 74.7 (HCCCH2), 76.7 and 
77.2 (HCCCH2), 121.4 (C(5)), 128.4 (Ar-CH), 128.6 (Ar-CH), 128.7 (Ar-CH), 135.4 
(Ar-C), 143.1 and 143.8 (C(8)H), 149.4 and 149.5 (C(4)), 150.9 and 151.0 (NHCOO), 
151.4 and 151.5 (C(6)), 152.9 and 153.1 (C(2)H), 165.8 and 165.9 (CH2CON), 167.2 
(COO); m/z (ESI) 451 ([M+H]+, 100%), 342 (36); HRMS (ESI) (Found: [M+H]+, 
451.1725. C22H22N6O5 requires m/z, 451.1724). 
 
Preparation of ethyl 2-{[1-(8-tert-butoxycarbonylamino-3,6-dioxaoctanyl)-1H-
1,2,3-triazol-4-yl]methyl}tert-butoxycarbonylamino acetate (121) 
 
 
 
C23H41N5O8 
 
To the azide 83 (0.089 g, 0.33 mmol) in H2O/t-BuOH/DCM (9 mL, 1:1:1) was added 
the monomer 111 (0.088 g, 0.36 mmol), followed by CuSO4 ⋅ 5H2O (0.0081 g, 10 mol 
%) and 1M sodium ascorbate solution (0.068 mL, 20 mol %). The deep yellow solution 
was stirred for 24 h at room temperature. After this time the aqueous phase was sepa-
rated and the organic phase was concentrated under reduced pressure. The crude residue 
was subjected to flash column chromatography (ethyl acetate-methanol 9:1) to give the 
title compound (121; 0.127 g, 0.25 mmol, 76 %) as a off-white sticky solid; Rf (ethyl 
acetate-methanol 9:1) = 0.40; υmax(film)/cm-1 3362m, 2977m, 2933w, 1748s, 1704s, 
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1514w; δH (400 MHz; CDCl3) (2 rotational isomers observed due to restricted rotation 
about the tertiary amide bond) 1.22 (3H, t, J 7.2, CH3), 1.38 (9H, s, (CH3)3), 1.40 (9H, s, 
(CH3)3), 3.28 (2H, br dt, NHCH2), 3.52 (2H, m, NHCH2CH2), 3.56 (4H, m, 
OCH2CH2O), 3.82 (2H, m, CH2CH2N(1’)), 3.95 and 3.99 (2H, s, NCH2COO), 4.13 (2H, 
q, J 7.2, OCH2), 4.44 (2H, m, CH2CH2N(1’)), 4.55 and 4.57 (2H, s, C(4’)CH2N), 4.92 
and 5.20 (1H, br t, NHCH2), 7.56 and 7.75 (1H, s, C(5’)H); δC (100 MHz; CDCl3) (2 
rotational isomers observed due to restricted rotation about the tertiary amide bond) 
14.0 and 14.1 (CH3), 28.2 ((CH3)3), 28.3 ((CH3)3), 40.3 (NHCH2), 42.8 and 43.4 
(C(4’)CH2), 48.1 and 48.8 (CH2COO), 50.1 and 50.2 (CH2N(1’)), 60.8 and 60.9 
(OCH2), 69.4 and 69.5 (CH2CH2N(1’)), 70.0 (OCH2), 70.2 (OCH2), 70.5 (OCH2), 80.5 
(C(CH3)3), 80.6 (C(CH3)3), 123.1 and 123.9 (C(5’)H), 144.2 and 144.6 (C(4’)), 155.2 
(CON), 155.9 (CONH), 169.8 (COO); m/z (EI) 515 ([M]+, 20%). Structure was verified 
by NOE and COSY NMR experiments. 
 
Preparation of ethyl 2-(thymin-1-ylacetyl){[1-(8-tert-butoxycarbonylamino-3,6-
dioxaoctanyl)-1H-1,2,3-triazol-4-yl]methyl}amino acetate (97a) 
 
 
 
C25H39N7O9 
 
To the azide 83 (0.090 g, 0.33 mmol) in H2O/t-BuOH/DCM (9 mL, 1:1:1) was added 
the monomer 84a (0.105 g, 0.340 mmol), followed by CuSO4 ⋅ 5H2O (0.0082 g, 10 mol 
%) and 1 M sodium ascorbate solution (0.068 mL, 21 mol %). The yellow solution was 
stirred for 48 h at room temperature. After this time the aqueous phase was separated 
and the organic phase was concentrate under reduced pressure. The crude residue was 
subjected to flash column chromatography (ethyl acetate-methanol 95:5) to give the title 
compound (97a; 0.143 g, 0.250 mmol, 76 %) as a yellow sticky foam. Rf (ethyl acetate-
methanol 95:5) = 0.12; υmax(film)/cm-1 3357m, 2978m, 1743s, 1679s, 1678s, 1514w; δH 
(400 MHz; CDCl3) (2 rotational isomers observed due to restricted rotation about the 
tertiary amide bond) 1.19 and 1.22 (3H, t, J 7.1, OCH2CH3), 1.42 (9H, s, (CH3)3), 1.89 
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and 1.91 (3H, s, C(5)-CH3), 3.28-3.30 (2H, m, NHCH2), 3.50-3.54 (2H, m, 
NHCH2CH2), 3.56-3.61 (4H, m, OCH2CH2O), 3.78-3.85 (2H, m, CH2CH2N(1’)), 4.14 
and 4.28 (2H, s, CH2COO), 4.16 and 4.18 (2H, q, J 7.1, OCH2CH3), 4.42 and 4.80 (2H, 
s, CH2CON), 4.50 and 4.56 (2H, t, J 4.9, CH2N(1’)), 4.68 and 4.73 (2H, s, C(4’)CH2), 
5.17 and 5.23 (1H, br t, NH), 7.02 and 7.05 (1H, s, C(6)H), 7.73 and 7.94 (1H, s, 
C(5’)H), 9.06 and 9.20 (1H, br s, N(3)H); δC (100 MHz; CDCl3) (2 rotational isomers 
observed due to restricted rotation about the tertiary amide bond) 12.3 (C(5)-CH3), 15.2 
(OCH2CH3), 28.4 ((CH3)3), 40.1 (NHCH2), 42.6 and 43.4 (C(4’)CH2), 47.6 and 48.1 
(CH2COO), 47.8 and 48.9 (CH2CON), 50.2 and 50.4 (CH2N(1’)), 62.1 (OCH2CH3), 
69.3 (CH2CH2N(1’)), 69.9 (OCH2), 70.2 (OCH2), 70.4 (OCH2), 79.2 and 79.3 
(C(CH3)3), 110.8 and 110.8 (C(5)), 123.7 and 124.3  (C(5’)H), 140.8 and 140.9 (C(6)H), 
144.2 and 144.3 (C(4’)), 151.1 (C(4)O), 156.0 (CONH) 164.1 (C(2)O), 167.1 and 167.2 
(CH2CON), 168.6 and 168.9 (COO); m/z (ESI) 582 ([M+H]+, 100%), 482 (65); HRMS 
(ESI) (Found: [M+H]+, 582.2881. C25H40N7O9 requires m/z, 582.2882). Structure was 
determined and verified by NOE NMR experiments. 
 
Preparation of ethyl 2-[N4-(benzyloxycarbonyl)cytosin-1-ylacetyl]{[1-(8-tert-bu-
toxycarbonylamino-3,6-dioxaoctanyl)-1H-1,2,3-triazol-4-yl]methyl}amino acetate 
(97b) 
 
 
 
C32H44N8O10 
 
To the azide 83 (0.18 g, 0.68 mmol) in H2O/t-BuOH/DCM (15 mL, 1:1:1) was added 
the monomer 84b (0.29 g, 0.69 mmol), followed by CuSO4 ⋅ 5H2O (0.042 g, 25 mol %) 
and 1 M sodium ascorbate solution (0.340 mL, 50 mol %). The yellow solution was 
stirred for 48 h at room temperature. After this time the aqueous phase was separated 
and the organic phase was concentrated under reduced pressure. The crude residue was 
subjected to flash column chromatography (ethyl acetate-methanol 93:7) to yield the 
title compound (97b; 0.32 g, 0.46 mmol, 76 %) as an off-white foam: m.p. 70-73 °C; Rf 
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(ethyl acetate-methanol 93:7) = 0.26; υmax(film)/cm-1 3262m, 3143m, 2979m, 2931m, 
1745s, 1692s, 1668s, 1625s; δH (400 MHz; CDCl3) (2 rotational isomers observed due 
to restricted rotation about the tertiary amide bond) 1.22 and 1.27 (3H, t, J 7.1, CH3), 
1.42 (9H, s, (CH3)3), 3.22-3.31 (2H, m, NHCH2), 3.47-3.67 (6H, m, CH2OCH2CH2O), 
3.79-3.88 (2H, m, CH2CH2N(1’)), 4.09 (2H, br s, CH2COO), 4.13 and 4.18 (2H, q, J 
7.1, OCH2CH3), 4.39 and 4.88 (2H, s, CH2CON), 4.48 and 4.55 (2H, br t, J 4.9, 
CH2N(1’)), 4.67 and 4.76 (2H, s, C(4’)CH2), 5.19 (2H, s, OCH2Ar), 6.67 and 6.99 (1H, 
br t, NHCH2), 7.20-7.65 (7H, m, 5 × Ar-H, C(5)H and C(6)H), 7.71 and 8.12 (1H, s, 
C(5’)H); δC (100 MHz; CDCl3) (2 rotational isomers observed due to restricted rotation 
about the tertiary amide bond) 14.1 (CH3), 28.3 ((CH3)3), 40.3 (NHCH2), 42.8 and 43.8 
(C(4’)CH2), 47.5 (CH2COO), 49.1 (CH2CON), 49.7 and 50.3 (CH2N(1’)), 61.4 
(OCH2CH3), 67.9 (OCH2Ar), 69.9 (OCH2), 70.2 (OCH2), 70.4 (OCH2), 79.3 (C(CH3)3), 
95.2 (C(5)H), 123.1 (C(5’)H), 128.3 (Ar-CH), 128.4 (Ar-CH), 128.7 (Ar-CH), 134.4 
(Ar-C), 143.2 (C(4’)), 149.9 (C(6)H), 152.1 (NHCOO), 153.0 (C(2)O), 155.6 (CONH), 
163.2 (C(4)), 167.1 (CH2CON), 168.6 (COO); m/z (ESI) 701 ([M+H]+, 100%), 601 
(13); HRMS (ESI) (Found: [M+H]+, 701.3243. C32H45N8O10 requires m/z, 701.3253). 
 
Preparation of ethyl 2-[N6-(benzyloxycarbonyl)adenin-9-ylacetyl]{[1-(8-tert-bu-
toxycarbonylamino-3,6-dioxaoctanyl)-1H-1,2,3-triazol-4-yl]methyl}amino acetate 
(97c) 
 
 
 
C33H44N10O9 
 
To the azide 83 (0.24 g, 0.87 mmol) in H2O/t-BuOH/DCM (15 mL, 1:1:1) was added 
the monomer 84c (0.470 g, 1.05 mmol), followed by CuSO4 ⋅ 5H2O (0.054 g, 25 mol %) 
and 1 M sodium ascorbate solution (0.44 mL, 50 mol %). The yellow solution was 
stirred for 48 h at room temperature. After this time the aqueous phase was separated 
and the organic phase was concentrated under reduced pressure. The crude residue was 
subjected to flash column chromatography (ethyl acetate-methanol 9:1) to yield the title 
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compound (97c; 0.40 g, 0.55 mmol, 64%) as a white foam: m.p. 69-72 °C; Rf (ethyl ace-
tate-methanol 9:1) = 0.20; υmax(film)/cm-1 3362w, 3248w, 3134w, 2988m, 2936m, 
2884m, 1747s, 1706s, 1674s, 1612s; δH (400 MHz; CDCl3) (2 rotational isomers ob-
served due to restricted rotation about the tertiary amide bond) 1.19 and 1.22 (3H, t, J 
7.1, OCH2CH3), 1.41 (9H, s, (CH3)3), 3.24-3.32 (2H, m, NHCH2), 3.45 (2H, t, J 4.9, 
NHCH2CH2), 3.51-3.63 (4H, m, OCH2CH2O), 3.79 and 3.86  (2H, t, J 4.9, 
CH2CH2N(1’)), 4.13 and 4.24 (2H, q, J 7.1, OCH2CH3), 4.18 and 4.42 (2H, s, 
CH2COO), 4.50 and 4.60 (2H, t, J 4.9, CH2N(1’)), 4.71 and 4.84 (2H, s, CH2CON), 
5.01 and 5.42 (2H, s, C(4’)CH2), 5.10 and 5.22 (1H, m, NHCH2), 5.30 (2H, s, OCH2Ar), 
7.33-7.45 (5H, m, Ar-CH), 7.73 and 7.97 (1H, s, C(5’)H), 8.12 (1H, br s, C(8)H), 8.72 
and 8.76 (1H, s, C(2)H), 8.89 (1H, br s, C(6)-NH); δC (100 MHz; CDCl3) (2 rotational 
isomers observed due to restricted rotation about the tertiary amide bond)  14.1 and 14.2 
(OCH2CH3), 28.4 ((CH3)3), 40.3 (NHCH2), 42.8 and 43.8 (CH2CON), 43.8 and 44.2 
(C(4’)CH2), 47.8 and 49.2 (CH2COO), 50.2 and 50.5 (CH2N(1’)), 61.5 and 62.2 
(OCH2CH3), 67.7 (OCH2Ar), 69.1 and 69.2 (CH2CH2N(1’)), 70.1 (OCH2), 70.4 
(OCH2), 70.6 (OCH2), 79.5 (C(CH3)3), 121.4 (C(5)), 123.6 and 124.5 (C(5’)H), 128.5 
(Ar-CH), 128.6 (Ar-CH), 128.7 (Ar-CH), 135.5 (Ar-C), 141.8 and 142.3 (C(4’)), 144.1 
(C(8)H), 149.3 (C(4)), 151.1 (CH2CON), 151.4 (C(6)), 152.8 (C(2)H), 156.0 (CONH), 
166.3 (NHCOO), 168.6 and 168.7 (COO); m/z (ESI) 725 ([M+H]+, 100%), 649 (15); 
HRMS (ESI) (Found: [M+H]+, 725.3358. C33H45N10O9 requires m/z, 725.3365). 
 
Preparation of ethyl 2-{[1-(8-amino-3,6-dioxaoctanyl)-1H-1,2,3-triazol-4-yl] 
methyl}(thymin-1-ylacetyl)amino acetate trifluoroacetic acid (120a) 
 
 
 
C22H32F3N7O9 
 
97a (0.298 g, 0.510 mmol) was dissolved in dichloromethane (5 mL) and trifluoroacetic 
acid (5 mL) was added. After stirring for 1 h, the solvents were evaporated under re-
duced pressure to yield a sticky oil, which was used without further purification; δH 
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(400 MHz; D2O) (2 rotational isomers observed due to restricted rotation about the ter-
tiary amide bond) 1.20 (3H, t, J 7.1, OCH2CH3), 1.90 (3H, s, C(5)-CH3), 3.28-3.30 (2H, 
m, NHCH2), 3.50-3.53 (2H, m, NHCH2CH2), 3.56-3.61 (4H, m, OCH2CH2O), 3.78-3.85 
(2H, m, CH2CH2N(1’)), 4.14 and 4.28 (2H, s, CH2COO), 4.19 (2H, q, J 7.1, OCH2CH3), 
4.42 and 4.80 (2H, s, CH2CON), 4.51-4.53 (2H, m, J 4.9, CH2N(1’)), 4.68 and 4.73 
(2H, s, C(4’)CH2), 7.05 (1H, s, C(6)H), 7.73 and 7.94 (1H, s, C(5’)H). Signals corre-
sponding to NH were lost on deuteuration. 
 
Preparation of ethyl 2-[N4-(benzyloxycarbonyl)cytosin-1-ylacetyl]{[1-(8-amino-3,6-
dioxaoctanyl)-1H-1,2,3-triazol-4-yl]methyl}amino acetate trifluoroacetic acid 
(120b) 
 
 
 
C29H37F3N8O10 
 
97b (0.29 g, 0.51 mmol) was dissolved in dichloromethane (5 mL) and trifluoroacetic 
acid (5 mL) was added. After stirring for 1 h, the solvents were evaporated under re-
duced pressure to yield a glassy solid, which was used without further purification; δH 
(200 MHz; D2O) (2 rotational isomers observed due to restricted rotation about the ter-
tiary amide bond) 1.22 and 1.27 (3H, t, J 7.1, OCH2CH3), 3.24 (2H, br t, NHCH2), 3.47-
3.67 (6H, m, CH2OCH2CH2O), 3.79-3.88 (2H, m, CH2CH2N(1’)), 4.09 (2H, s, 
CH2COO), 4.13 and 4.18 (2H, q, J 7.1, OCH2CH3), 4.39 and 4.88 (2H, s, CH2CON), 
4.48 and 4.55 (2H, br t, CH2N(1’)), 4.67 and 4.76 (2H, s, C(4’)CH2), 5.19 (2H, s, 
OCH2Ar), 7.20-7.65 (7H, m, 5 × Ar-CH, C(5)H and C(6)H), 7.71 and 8.12 (s, 1H, 
C(5’)H). 
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Preparation of ethyl 2-[N6-(benzyloxycarbonyl)adenin-9-ylacetyl]{[1-(8-amino-3,6-
dioxaoctanyl)-1H-1,2,3-triazol-4-yl]methyl}amino acetate trifluoroacetic acid 
(120c) 
 
 
 
C30H37F3N10O9 
 
97c (0.37 g, 0.50 mmol) was dissolved in dichloromethane (5 mL) and trifluoroacetic 
acid (5 mL) was added. After stirring for 1 h, the solvents were evaporated under re-
duced pressure to yield a glassy solid, which was used without further purification; δH 
(200 MHz; D2O) (2 rotational isomers observed due to restricted rotation about the ter-
tiary amide bond) 1.22 (3H, t, J 7.1, CH3), 3.24-3.32 (2H, m, NHCH2), 3.46-3.63 (6H, 
m, CH2OCH2CH2O), 3.79 and 3.86 (2H, t, J 4.9, CH2CH2N(1’)), 4.25 (2H, q, J 7.1, 
OCH2CH3), 4.18 and 4.42 (2H, s, NCH2COO), 4.53-4.59 (2H, m, J 4.9, CH2N(1’)), 4.71 
and 4.84 (2H, s, CH2CON), 5.01 and 5.42 (2H, s, C(4’)CH2), 5.30 (2H, s, OCH2Ar), 
7.33-7.45 (5H, m, 5 × Ar-CH), 7.73 and 7.97 (1H, s, C(5’)H), 8.12 (1H, br s, C(8)H), 
8.72 and 8.76 (1H, s, C(2)H). Signals corresponding to NH were lost on deuteration.
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Preparation of ethyl 2-(thymin-1-ylacetyl){[1-(8-(pentacosa-10,12-diynamido)-3,6-
dioxaoctanyl)-1H-1,2,3-triazol-4-yl]methyl}amino acetate (95a) 
 
 
C45H71N7O8 
 
Method A 
120a (0.304 g, 0.510 mmol) was dissolved in dimethylformamide (6 mL) and triethyl-
amine (0.64 mL, 4.6 mmol) was added. To the stirring solution was added a freshly pre-
pared solution of 78 (0.217 g, 0.570 mmol) in dichloromethane (6 mL). The resulting 
solution was stirred overnight at room temperature. After this time the solvents were 
evaporated and the crude material obtained was subjected to flash column chromatogra-
phy (ethyl acetate-methanol 92:8) to yield the title compound (95a; 0.303 g, 0.362 
mmol; 71%) as a white solid. 
 
Method B 
To the azide 98 (0.10 g, 0.19 mmol) in H2O/t-BuOH/DCM (12 mL, 1:1:1) was added 
the propargyl monomer (84a; 0.052 g, 0.17 mmol), followed by CuSO4 ⋅ 5H2O 
(0.0055 g, 13 mol %) and 1 M sodium ascorbate solution (0.034 mL, 20 mol %). The 
solution was stirred for 48 h at room temperature. After this time the aqueous phase was 
separated and the organic phase was concentrated under reduced pressure. The crude 
residue was subjected to flash column chromatography (ethyl acetate-methanol 92:8) to 
give the title compound (95a; 0.084 g, 0.10 mmol, 59%) as a pale yellow foam: m.p. 
90-93 °C; Rf (ethyl acetate-methanol 92:8) = 0.28; υmax(film)/cm-1 3312m, 2926s, 
2856s, 1744m, 1711br s, 1675br s, 1539m; δH (400 MHz; CDCl3) (2 rotational isomers 
observed due to restricted rotation about the tertiary amide bond) 0.88 (3H, t, J 6.9, 
CH3), 1.24-1.29 (35H, m,  16 × CH2 and OCH2CH3), 1.89 and 1.91 (3H, d, JCH3-C(6)H 
1.2, C(5)-CH3), 2.15 (2H, t, J 7.6, CH2CONH), 2.21 (4H, t, J 7.1, 2 × (CH2C≡C)), 3.38-
3.42 (2H, m, NHCH2), 3.49-3.51 (2H, m, NHCH2CH2), 3.54-3.61 (4H, m, OCH2CH2O), 
3.83 and 3.84 (2H, t, J 4.8, CH2CH2N(1’)), 4.13 and 4.27 (2H, s, CH2COO), 4.15 and 
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4.21 (2H, q, J 7.1, OCH2CH3), 4.39 and 4.76 (2H, s, CH2CON), 4.49 and 4.54 (2H, t, J 
4.8, CH2N(1’)), 4.66 and 4.73 (2H, s, C(4’)CH2), 6.41 and 6.47 (1H, br t, NH), 7.01 and 
7.07 (1H, d, JC(6)H-CH3 1.2, C(6)H), 7.71 and 7.94 (1H, s, C(5’)H); δC (100 MHz; CDCl3) 
(2 rotational isomers observed due to restricted rotation about the tertiary amide bond) 
12.1 (C(5)-CH3), 14.1 (OCH2CH3 and CH3), 19.2 (CH2C≡C), 22.6 (CH2), 25.7 
(CH2CH2CONH), 28.2 (CH2), 28.3 (CH2), 28.8 (CH2), 28.9 (CH2), 29.0 (CH2), 29.1 
(CH2), 29.2 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2), 31.9 (CH2), 36.6 
(CH2CONH), 39.1 (NHCH2), 42.9 and 43.7 (C(4’)CH2), 47.7 and 49.0 (CH2COO), 47.9 
and 48.0 (CH2CON), 50.2 and 50.4 (CH2N(1’)), 61.5 and 62.1 (OCH2CH3), 65.2 and 
65.3 (C≡C-C≡C), 69.2 (CH2CH2N(1’)), 70.0 (OCH2), 70.1 (OCH2), 70.3 (OCH2), 77.7 
and 77.6 (C≡C-C≡C), 110.7 and 110.9 (C(5)), 123.7 and 124.2 (C(5’)H), 140.8 and 
141.0 (C(6)H), 142.4 and 142.8 (C(4’)), 151.0 (C(4)O), 164.2 (C(2)O), 167.1 and 167.4 
(CH2CON), 168.7 and 168.9 (COO), 173.6 (CONH); m/z (ESI) 838 ([M+H]+, 100%); 
HRMS (ESI) (Found: [M+H]+, 838.5443. C45H72N7O8 requires m/z, 838.5437). Three 
signals corresponding to CH2 from the lipid chain are missing due to the overlap in the 
aliphatic region of 13C NMR spectrum. 
 
Preparation of ethyl 2-(N4-(benzyloxycarbonyl)-cytosin-1-ylacetyl){[1-(8-(penta-
cosa-10,12-diynamido)-3,6-dioxaoctanyl)-1H-1,2,3-triazol-4-yl]methy} amino ace-
tate (95b) 
 
 
C52H76N8O9 
 
Method A 
120b (0.25 g, 0.35 mmol) was dissolved in dimethylformamide (5 mL) and triethyl-
amine (0.50 mL, 3.6 mmol) was added. To the stirring solution was added a freshly pre-
pared solution of pentacosa-10,12-diynoyl fluoride (78; 0.17 g, 0.44 mmol) in di-
chloromethane (5 mL). The resulting solution was stirred for 48 h at room temperature. 
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After this time the solvent was evaporated and the crude material obtained was sub-
jected to flash column chromatography (ethyl acetate-methanol 92:8) yielding the title 
compound (95b; 0.24 g, 0.25 mmol; 70%) as a white sticky foam. 
 
Method B 
To the azide 98 (0.24 g, 0.45 mmol) in H2O/t-BuOH/DCM (12 mL, 1:1:1) was added 
the monomer 84b (0.18 g, 0.42 mmol), followed by CuSO4 ⋅ 5H2O (0.011 g, 11 mol %) 
and 1 M sodium ascorbate solution (0.088 mL, 21 mol %). The solution was stirred for 
48 h at room temperature. After this time the solvent was evaporated and the crude resi-
due was subjected to flash column chromatography (ethyl acetate-methanol 95:5) to 
yield the title compound (95b; 0.12 g, 0.13 mmol, 31%) as a colourless sticky foam; Rf 
(ethyl acetate-methanol 95:5) = 0.18; υmax(film)/cm-1 3300w, 2926s, 2855s, 1746s, 
1668br s, 1628s, 1550m; δH (200 MHz; CDCl3) (2 rotational isomers observed due to 
restricted rotation about the tertiary amide bond) 0.88 (3H, t, J 6.9, CH3), 1.19-1.31 
(35H, m, 16 × CH2 and OCH2CH3), 2.12-2.25 (6H, m, CH2CONH and  2 × CH2C≡C), 
3.37-3.41 (2H, m, NHCH2), 3.47-3.54 (6H, m, CH2OCH2CH2O), 3.82 and 3.86 (2H, t, J 
4.8, CH2CH2N(1’)), 4.08 and 4.32 (2H, s, CH2COO), 4.16 and 4.20 (2H, q, J 7.1, 
OCH2CH3), 4.48 and 4.55 (2H, t, J 4.8, CH2N(1’)), 4.55 and 4.88 (2H, s, CH2CON), 
4.66 and 4.75 (2H, s, C(4’)CH2), 5.21 (2H, s, OCH2Ar), 6.27 and 6.32 (1H, br t, 
NHCH2), 7.25-7.28 (1H, m, C(5)H), 7.35-7.40 (5H, m, 5 × Ar-CH), 7.22-7.65 (1H, m, 
C(6)H), 7.22 and 8.18 (1H, s, C(5’)H); δC (100 MHz; CDCl3) (2 rotational isomers ob-
served due to restricted rotation about the tertiary amide bond) 14.1 (OCH2CH3 and 
CH3), 19.1 (CH2C≡C), 22.7 (CH2), 28.3 (CH2), 28.7 (CH2), 28.8 (CH2), 28.9 (CH2), 
29.1 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2), 29.7 (CH2), 31.9 (CH2), 
36.6 (CH2CONH), 39.2 (NHCH2), 43.1 and 43.9 (C(4’)CH2), 47.2 and 49.1 (CH2COO), 
49.5 and 49.6 (CH2CON), 50.2 and 50.4 (CH2N(1’)), 61.5 and 62.1 (OCH2CH3), 65.2 
and 65.3 (C≡C-C≡C), 68.3 (OCH2Ar), 69.2 (CH2CH2N(1’)), 69.3 (OCH2), 70.0 
(OCH2), 70.5 (OCH2), 77.5 and 77.6 (C≡C-C≡C), 95.1 (C(5)H), 124.2 and 124.3 
(C(5’)H), 128.3 (Ar-CH), 128.4 (Ar-CH), 128.7 (Ar-CH), 134.8 (Ar-C), 142.5 and 
142.8 (C(4’)), 149.6 (C(6)H), 152.1 (NHCO), 155.6 (C(2)O), 162.8 (C(4)), 166.7 and 
167.2 (CH2CON), 168.6 and 169.1 (COO), 173.4 and 173.6 (CONH); m/z (ESI) 957 
([M+H]+, 100%), 869 (3); HRMS (ESI) (Found: [M+H]+, 957.5797. C52H77N8O9 re-
quires m/z, 957.5808). Five signals corresponding to CH2 from the lipid chain are miss-
ing due to the overlap in the aliphatic region of 13C NMR spectrum. 
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Preparation of ethyl 2-[N6-(benzyloxycarbonyl)-adenine-9-ylacetyl]{[1-(8-
(pentacosa-10,12-diynamido)-3,6-dioxaoctanyl)-1H-1,2,3-triazol-4-yl]methy}amino 
acetate (95c) 
 
 
C53H76N10O8 
 
120c (0.37 g, 0.50 mmol) was dissolved in dimethylformamide (8 mL) and triethyl-
amine (0.80 mL, 5.7 mmol) was added. To the stirring solution was added a freshly pre-
pared solution of pentacosa-10,12-diynoyl fluoride (78; 0.21 g, 0.55 mmol) in di-
chloromethane (8 mL). The resulting solution was stirred for 48 h at room temperature. 
After this time the solvent was evaporated and the crude material obtained was sub-
jected to flash column chromatography (ethyl acetate-methanol 92:8) yielding the title 
compound (95c; 0.36 g, 0.37 mmol; 74%) as a white sticky solid; Rf (ethyl acetate-
methanol 92:8) = 0.31; υmax(film)/cm-1 3313m, 2928s, 2861s, 1745m, 1710br s, 1673br 
s, 1539m; δH (200 MHz; CDCl3) (2 rotational isomers observed due to restricted rota-
tion about the tertiary amide bond) 0.89 (3H, t, J 6.9, CH3), 1.26-1.57 (35H, m, 16 × 
CH2 and OCH2CH3), 2.11-2.19 (2H, m, CH2CONH), 2.22-2.28 (4H, m, 2 × CH2C≡C), 
3.38-3.40 (2H, m, NHCH2), 3.43-3.66 (6H, m, CH2OCH2CH2O), 3.86 and 3.93 (2H, t, J 
4.8, CH2CH2N(1’)), 4.19 and 4.26 (2H, q, J 7.1, OCH2CH3), 4.20 and 4.44 (2H, s, 
CH2COO), 4.52 and 4.61 (2H, t, J 4.8, CH2N(1’)), 4.71 and 4.87 (2H, s, CH2CON), 
5.05 and 5.43 (2H, s, C(4’)CH2), 5.33 (2H, s, OCH2Ar), 6.09 and 6.15 (1H, br t, 
NHCH2), 7.36-7.49 (5H, m, 5 × Ar-CH), 7.74 and 8.03 (1H, s, C(5’)H), 8.11 and 8.13 
(1H, s, C(8)H), 8.42 (1H, br s, C(6)-NH), 8.74 and 8.78 (1H, s, C(2)H); δC (400 MHz; 
CDCl3) (2 rotational isomers observed due to restricted rotation about the tertiary amide 
bond) 14.1 (OCH2CH3 and CH3), 19.2 (CH2C≡C), 22.7 (CH2), 28.3 (CH2), 28.4 (CH2), 
28.8 (CH2), 28.9 (CH2), 29.1 (CH2), 29.2 (CH2), 29.3 (CH2), 29.5 (CH2), 29.6 (CH2), 
29.7 (CH2), 31.9 (CH2), 36.6 (CH2CONH), 39.1 (NHCH2), 42.9 and 43.8 (CH2CON), 
43.9 and 44.2 (C(4’)CH2), 47.9 and 49.3 (CH2COO), 50.2 and 50.5 (CH2N(1’)), 61.6 
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and 62.3 (OCH2CH3), 65.2 and 65.8 (C≡C-C≡C), 67.8 (OCH2Ar), 69.2 and 69.3 
(CH2CH2N(1’)), 69.9 (OCH2), 70.0 (OCH2), 70.4 (OCH2), 77.2 and 77.5 (C≡C-C≡C), 
121.2 (C(5)), 123.8 and 124.5 (C(5’)H), 128.5 (Ar-CH), 128.6 (Ar-CH), 128.7 (Ar-CH), 
135.4 (Ar-C), 142.3 and 142.5 (C(4’)), 143.8 and 144.0 (C(8)H), 149.3 (C(4)), 150.8 
(NHCOO), 151.5 (C(6)), 152.8 (C(2)H), 166.4 (CH2CON), 168.6 and 168.7 (COO), 
173.3 (CONH); m/z (ESI) 981 ([M+H]+, 100%), 905 (12), 752 (10); HRMS (ESI) 
(Found: [M+H]+, 981.5919. C53H77N10O8 requires m/z, 981.5920). Five signals corre-
sponding to CH2 from the lipid chain are missing due to the overlap in the aliphatic re-
gion of 13C NMR spectrum. 
 
Preparation of 8-amino-3,6-dioxaoctan-1-azide hydrochloride (122) 
 
 
 
C6H15N4O2Cl 
 
Compound 83 (0.776 g, 2.83 mmol) was dissolved in ethyl acetate (15 mL) and 6 M 
hydrochloric acid (15 mL) was added. The mixture was stirred for 1 h and after this 
time the solvents were evaporated to yield the title compound (122; 0.589 g, 2.80 mmol; 
99%) as a sticky orange oil; υmax(film)/cm-1 3400m, 2927m, 2874m, 2112s (N3 str), 
1654w; δH (400 MHz; MeOH-d4) 3.12 (2H, br t, J 5.3, NHCH2), 3.38 (2H, t, J 5.3, 
CH2N3), 3.63-3.71 (6H, m, CH2OCH2CH2O), 3.75 (2H, t, J 5.3, CH2CH2N3); δC (50 
MHz; MeOH-d4) 41.0 (NHCH2), 52.1 (CH2N3), 68.2 (CH2CH2N3), 71.4 (OCH2), 71.7 
(OCH2), 71.8 (OCH2). Signal corresponding to NH2 protons were exchanged and were 
not seen. 
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Preparation of N-(8-azido-3,6-dioxaoctanyl)pentacosa-10,12-diynamide (98) 
 
 
 
C31H54N4O3 
 
To a solution of 122 (0.589 g, 2.80 mmol) in dimethylformamide (10 mL) was added 
triethylamine (1.95 mL, 13.9 mmol) followed by a solution of pentacosa-10,12-diynoyl 
fluoride (78; 1.15 g, 3.05 mmol) in dichloromethane (10 mL). The mixture was stirred 
for 20 h at room temperature. After this time the solvent was removed under reduced 
pressure and the residue was dissolved in dichloromethane (20 mL). This was then 
washed with 1 M sodium bicarbonate (2 × 10 mL), 1 M potassium hydrogen sulphate (2 
× 10 mL), water (10 mL) and brine (10 mL). The organic layer was dried with magne-
sium sulphate and the solvent removed in vacuo. The resulting crude solid was sub-
jected to flash column chromatography (ethyl acetate) to yield the title compound (98; 
1.30 g, 2.96 mmol, 80%) as a white-off blue solid: m.p. 70-72 °C; Rf (ethyl acetate) = 
0.34; υmax(film)/cm-1 3300s, 3084w, 2919s, 2848s, 2108s (N3 str), 1643s and 1557m; 
δH (400 MHz, CDCl3) 0.88 (3H, t, J 6.3, CH3CH2), 1.12-1.30 (32H, m, 16 × CH2), 2.15 
(2H, t, J 7.6, CH2CONH), 2.24 (4H, t, J 6.7, 2 × CH2C≡C), 3.38 (2H, t, J 5.0, 
CH2CH2N3), 3.44 (2H, br dt, NHCH2CH2O), 3.53 (2H, t, J 5.0, NHCH2CH2O), 3.60-
3.66 (4H, m, OCH2CH2O), 3.66 (2H, t, J 5.0, OCH2CH2N3), 5.55 (1H, br s, NH); 
δC (100 MHz, CDCl3) 14.1 (CH3), 19.1 (CH2C≡C), 22.6 (CH2), 28.2 (CH2), 28.3 (CH2), 
28.7 (CH2), 28.8 (CH2), 28.9 (CH2), 29.5 (CH2), 29.1 (CH2), 29.3 (CH2), 29.4 (CH2), 
29.5 (CH2), 29.6 (CH2), 29.6 (CH2), 31.9 (CH2), 36.6 (CH2CO), 39.0 (NHCH2), 50.6 
(CH2N3), 65.1 and 65.2 (C≡C-C≡C), 70.0 (NHCH2CH2O), 70.1 (OCH2CH2N3), 70.2 
(OCH2), 70.5 (OCH2), 77.4 and 77.5 (C≡C-C≡C), 173.1 (CO); m/z (CI) 531 ([M+H]+, 
20%), 88 (61), 86 (100), 72 (65), 58 (98); HRMS (ESI) (Found: [M+H]+, 531.4260. 
C31H55N4O3 requires m/z, 531.4269). Three signals corresponding to CH2 from the lipid 
chain are missing due to the overlap in the aliphatic region of 13C NMR spectrum. 
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Preparation of N-(8-azido-3,6-dioxaoctanyl)stearamide (99) 
 
 
 
C24H48N4O3 
 
To a solution of 122 (0.779 g, 3.70 mmol) in dimethylformamide (20 mL) was added 
triethylamine (2.60 mL; 18.5 mmol) followed by a solution of stearoyl fluoride (79; 
1.19 g, 4.15 mmol) in dichloromethane (20 mL). The mixture was stirred for 20 h at 
room temperature. After this time the solvent was removed under reduced pressure and 
the residue was dissolved in dichloromethane (40 mL). This was then washed with 1 M 
sodium bicarbonate (2 × 30 mL), 1 M potassium hydrogen sulphate (2 × 30 mL), water 
(30 mL) and brine (30 mL). The organic layer was dried over magnesium sulphate and 
the solvent removed under reduced pressure. The resulting yellow solid was subjected 
to flash column chromatography (ethyl acetate) to yield the title compound (99; 1.30 g, 
2.96 mmol, 80%) as a white solid: m.p. 65-66 °C; Rf (ethyl acetate) = 0.25; (Found C, 
65.43; H, 11.13; N, 12.58% C24H48N4O3 requires C, 65.41; H, 10.98; N, 12.71%); 
υmax(film)/cm-1 3307s, 3083w, 2918s, 2850s, 2107s (N3 str), 1641s and 1553m; δH (400 
MHz, CDCl3) 0.88 (3H, t, J 6.3, CH3), 1.26 (28H, s,  14 × CH2), 1.61 (2H, m, 
CH2CH2CO), 2.14 (2H, t, J 7.6, CH2CONH), 3.38 (2H, t, J 5.0, CH2CH2N3), 3.44 (2H, 
br dt, NHCH2CH2O), 3.54 (2H, t, J 5.0, NHCH2CH2O), 3.60-3.66 (4H, m, OCH2CH2O), 
3.67 (2H, t, J 5.0, OCH2CH2N3), 5.55 (1H, br s, NH); δC (100 MHz, CDCl3) 14.0 (CH3), 
22.6 (CH2), 25.7 (CH2CH2CO), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2), 29.6 
(CH2), 29.7 (CH2), 31.9 (CH2), 36.7 (CH2CO), 39.0 (NHCH2), 50.6 (CH2N3), 70.0 
(NHCH2CH2O), 70.1 (OCH2CH2N3), 70.2 (OCH2), 70.5 (OCH2), 173.2 (CO); m/z (CI) 
441 ([M+H]+, 3%), 415 (5), 86 (100), 72 (99); HRMS (ESI) (Found: [M+H]+, 441.3796. 
C24H49N4O3 requires m/z, 441.3799). Six signals corresponding to CH2 from the lipid 
chain are missing due to the overlap in the aliphatic region of 13C NMR spectrum. 
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Preparation of ethyl 2-(thymin-1-ylacetyl)((1-(8-stearamido-3,6-dioxaoctanyl)-1H-
1,2,3-triazol-4-yl)methyl)aminoacetate (96a) 
 
 
 
C38H65N7O8 
 
To the azide 99 (0.162 g, 0.340 mmol) in H2O/t-BuOH/DCM (15 mL, 1:1:1) was added 
the monomer 84a (0.106 mg, 0.370 mmol), followed by CuSO4 ⋅ 5H2O (0.023 g, 27 mol 
%) and 1 M sodium ascorbate solution (0.185 mL, 54 mol %). The yellow solution was 
stirred for 48 h at room temperature. After this time the aqueous phase was separated 
and the organic phase was concentrated. The crude residue was subjected to flash col-
umn chromatography (ethyl acetate-methanol 9:1) to give the title compound (96a; 
0.187 g, 0.250 mmol, 74%) as a yellow foam: m.p. 66-67 °C; Rf (ethyl acetate-methanol 
9:1) = 0.17; υmax(film)/cm-1 3309m, 3064m, 2924s, 2853s, 1744s, 1716br s, 1674br s, 
1545m; δH (400 MHz; CDCl3) (2 rotational isomers observed due to restricted rotation 
about the tertiary amide bond) 0.88 (3H, t, J 6.3, CH3), 1.26 (31H, s, 14 × CH2 and 
OCH2CH3), 1.53-1.58 (2H, m, CH2CH2CONH), 1.88 and 1.91 (3H, s, C(5)-CH3), 2.15 
(2H, t, J 7.6, CH2CONH), 3.38-3.40 (2H, m, NHCH2), 3.49-3.54 (2H, m, NHCH2CH2), 
3.57-3.60 (4H, m, OCH2CH2O), 3.79-3.86 (2H, m, CH2CH2N(1’)), 4.15 and 4.27 (2H, 
s, CH2COO), 4.16 and 4.21 (2H, q, J 7.1, OCH2CH3), 4.39 and 4.75 (2H, s, CH2CON), 
4.50 and 4.54 (2H, t, J 4.9, CH2N(1’)), 4.68 and 4.72 (2H, s, C(4’)CH2), 6.31 and 6.32 
(1H, br t, NH), 7.01 and 7.07 (1H, s, C(6)H), 7.71 and 7.94 (1H, s, C(5’)H), 8.98 and 
9.23 (1H, br s, N(3)H); δC (100 MHz; CDCl3) (2 rotational isomers observed due to re-
stricted rotation about the tertiary amide bond) 12.3 (C(5)-CH3), 14.1 (CH3CH2 and 
OCH2CH3), 22.7 (CH2), 25.8 (CH2CH2CONH), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 
29.6 (CH2), 29.7 (CH2), 31.9 (CH2), 36.6 (CH2CONH), 39.1 (NHCH2), 42.8 and 43.8 
(C(4’)CH2), 47.6 and 49.1 (CH2COO), 47.9 and 48.0 (CH2CON), 50.2 and 50.4 
(CH2N(1’)), 61.5 and 62.1 (OCH2CH3), 69.3 (CH2CH2N(1’)), 70.0 (OCH2), 70.1 
(OCH2), 70.3 (OCH2), 110.8 and 110.9 (C(5)), 123.8 and 124.2 (C(5’)H), 140.7 and 
141.0 (C(6)H), 142.4 and 142.8 (C(4’)), 151.1 (C(4)O), 164.1 (C(2)O), 167.1 and 167.3 
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(CH2CON), 168.6 and 168.9 (COO), 173.6 (CONH); m/z (CI) 748 ([M+H]+, 21%), 163 
(30), 146 (60), 77 (100); HRMS (ESI) (Found: [M+H]+, 748.4977. C38H66N7O8 requires 
m/z, 748.4967). Seven signals corresponding to CH2 from the lipid chain are missing 
due to the overlap in the aliphatic region of 13C NMR spectrum. 
 
Preparation of ethyl 2-[N4-(benzyloxycarbonyl)cytosin-1-ylacetyl]{[1-(8-
stearamido-3,6-dioxaoctanyl)-1H-1,2,3-triazol-4-yl]methyl}aminoacetate (96b) 
 
 
 
C45H70N8O9 
 
Method A 
To the azide 99 (0.24 g, 0.54 mmol) in H2O/t-BuOH/DCM (12 mL, 1:1:1) was added 
the monomer 84b (0.23 g, 0.53 mmol), followed by CuSO4 ⋅ 5H2O (0.035 g, 26 mol %) 
and 1 M sodium ascorbate solution (0.275 mL, 52 mol %). The solution was stirred for 
48 h at room temperature. After this time the aqueous phase was separated and the or-
ganic phase was concentrated. The crude residue was subjected to flash column chroma-
tography (ethyl acetate - methanol 93:7) to give the title compound (96b; 0.29 g, 0.33 
mmol, 62%) as a pale yellow foam. 
 
Method B 
107 (0.046 g, 0.15 mmol) was dissolved in dimethylformamide (4 mL) and HBTU 
(0.056 g, 0.14 mmol) followed by triethylamine (0.022 mL, 0.16 mmol) was added. The 
mixture was stirred for 15 min at room temperature and to this solution was added a so-
lution of 124 (0.11 g, 0.16 mmol) and triethylamine (0.147 mL, 1.06 mmol) in di-
methylformamide (4 mL). The mixture was stirred for 20 h at room temperature and 
after this time the solvent was evaporated and the crude residue subjected to flash col-
umn chromatography (ethyl acetate - methanol 95:5) to isolate the title compound (96b; 
0.069 g, 0.080 mmol; 53%) as pale yellow powder: m.p. 58-61 °C; Rf (ethyl acetate-
methanol 95:5) = 0.18; υmax(film)/cm-1 3298m, 2924s, 2854s, 1746s, 1667br s, 1628m, 
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1555m; δH (400 MHz; CDCl3) (2 rotational isomers observed due to restricted rotation 
about the tertiary amide bond) 0.88 (3H, t, J 6.3, CH3CH2), 1.22 (28H, s, 14 × CH2), 
1.27 (3H, t, J 7.1, OCH2CH3), 1.55-1.57 (2H, m, CH2CH2CONH), 2.12-2.16 (2H, m, 
CH2CONH), 3.38-3.40 (2H, m, NHCH2), 3.49-3.53 (2H, m, NHCH2CH2), 3.55-3.58 
(4H, m, OCH2CH2O), 3.82 and 3.86 (2H, t, J 4.8, CH2CH2N(1’)), 4.10 and 4.35 (2H, s, 
CH2COO), 4.15 and 4.21 (2H, q, J 7.1, OCH2CH3), 4.48 and 4.52 (2H, t, J 4.8, 
CH2N(1’)), 4.53 and 4.89 (2H, s, CH2CON), 4.66 and 4.78 (2H, s, C(4’)CH2), 5.21 (2H, 
s, OCH2Ar), 6.66-6.75 (1H, m, NHCH2), 7.22-7.24 (1H, m, C(5)H), 7.35-7.40 (5H, m, 5 
× Ar-CH), 7.48-7.52 (1H, m, C(6)H), 7.72 and 8.15 (1H, s, C(5’)H); δC (100 MHz; 
CDCl3) (2 rotational isomers observed due to restricted rotation about the tertiary amide 
bond) 14.0 (CH3 and OCH2CH3), 22.6 (CH2), 25.7 (CH2CH2CONH), 29.2 (CH2), 29.3 
(CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2), 29.7 (CH2), 31.8 (CH2), 36.6 (CH2CONH), 
39.1 (NHCH2), 42.8 and 43.9 (C(4’)CH2), 47.4 and 49.1 (CH2COO), 49.6 and 50.1 
(CH2CON), 49.8 and 50.3 (CH2N(1’)), 61.4 and 62.0 (OCH2CH3), 67.9 (OCH2Ar), 69.2 
(CH2CH2N(1’)), 70.0 (OCH2), 70.4 (OCH2), 70.5 (OCH2), 95.0 (C(5)H), 124.2 and 
124.3 (C(5’)H), 128.2 (Ar-CH), 128.3 (Ar-CH), 128.6 (Ar-CH), 134.9 (Ar-C), 142.3 
and 142.5 (C(4’)), 149.6 (C(6)H), 152.2 (NHCOO), 157.7 (C(2)O), 162.9 (C(4)), 166.7 
and 167.2  (CH2CON), 168.6 and 169.0 (COO), 173.4 and 173.5 (CONH); m/z (ESI) 
701 ([M+H]+, 100%), 601 (13); HRMS (ESI) (Found: [M+H]+, 867.5326. C45H71N8O9 
requires m/z, 867.5339). Six signals corresponding to CH2 from the lipid chain are miss-
ing due to the overlap in the aliphatic region of 13C NMR spectrum. 
 
Preparation of ethyl 2-[N6-(benzyloxycarbonyl)adenin-9-ylacetyl]{[1-(8-steara-
mido-3,6-dioxaoctanyl)-1H-1,2,3-triazol-4-yl]methyl}aminoacetate (96c) 
 
 
 
C46H70N10O8 
 
To the azide 99 (0.093 g, 0.21 mmol) in H2O/t-BuOH/DCM (6 mL, 1:1:1) was added 
the monomer 84c (0.091 g, 0.20 mmol), followed by CuSO4.5H2O (0.013 g, 26 mol %) 
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and 1 M sodium ascorbate (0.10 mL, 52 mol %). The solution was stirred for 48 h at 
room temperature. After this time the aqueous phase was separated and the organic 
phase was concentrated. The crude residue was subjected to flash column chromatogra-
phy (ethyl acetate - methanol 92:8) to give the title compound (96c; 0.10 g, 0.11 mmol, 
55%) as a white sticky foam; Rf (ethyl acetate-methanol 92:8) = 0.13; υmax(film)/cm-1 
3289w, 2916s, 2854s, 1742s, 1664s, 1618s; δH (400 MHz; CDCl3) (2 rotational isomers 
observed due to restricted rotation about the tertiary amide bond) 0.88 (3H, t, J 6.3, 
CH3CH2), 1.16-1.31 (31H, m, 14 × CH2 and OCH2CH3), 1.54-1.56 (2H, m, 
CH2CH2CONH), 2.08-2.12 (2H, m, CH2CONH), 3.30-3.35 (2H, m, NHCH2), 3.37-3.42 
(2H, m, NHCH2CH2), 3.45-3.58 (4H, m, OCH2CH2O), 3.79 and 3.86 (2H, t, J 4.8, 
CH2CH2N(1’)), 4.13 and 4.22 (2H, q, J 7.1, OCH2CH3), 4.14 and 4.38 (2H, s, 
CH2COO), 4.48 and 4.55 (2H, t, J 4.8, CH2N(1’)), 4.56 and 4.81 (2H, s, CH2CON), 
4.97 and 5.38 (2H, s, C(4’)CH2), 5.26 (2H, s, OCH2Ar), 6.05 and 6.11 (1H, br t, 
NHCH2), 7.31-7.43 (5H, m, 5 × Ar-CH), 7.58 and 7.97 (1H, s, C(5’)H), 8.03 and 8.06 
(1H, s, C(8)H), 8.66 (1H, br s, C(6)-NH), 8.68 and 8.72 (1H, s, C(2)H); δC (100 MHz; 
CDCl3) (2 rotational isomers observed due to restricted rotation about the tertiary amide 
bond) 14.1 (CH3 and OCH2CH3), 22.6 (CH2), 25.7 (CH2CH2CONH), 29.2 (CH2), 29.3 
(CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2), 29.7 (CH2), 31.9 (CH2), 36.6 (CH2CON), 
39.1 (NHCH2), 42.8 and 43.5 (CH2CON), 43.6 and 44.0 (C(4’)CH2), 47.8 and 49.2 
(CH2COO), 50.2 and 50.5  (CH2N(1’)), 61.5 and 62.2 (OCH2CH3), 67.7 (OCH2Ar), 
69.1 and 69.2 (CH2CH2N(1’)), 69.9 (OCH2), 70.4 (OCH2), 70.5 (OCH2), 121.4 (C(5)), 
123.8 and 124.3 (C(5’)H), 128.5 (Ar-CH), 128.6 (Ar-CH), 128.7 (Ar-CH), 135.4 (Ar-
C), 142.0 and 142.2 (C(4’)), 143.9 (C(8)H), 149.3 (C(4)), 151.1 (NHCOO), 151.4 
(C(6)), 152.8 (C(2)H), 166.3 and 166.4 (CONH), 168.6 and 168.7 (COO), 173.3 
(CONH); m/z (ESI) 891 ([M+H]+, 100%), 815 (12), 427 (10), 217 (8); HRMS (ESI) 
(Found: [M+H]+, 891.5447. C46H71N10O8 requires m/z, 891.5451). Six signals corre-
sponding to CH2 from the lipid chain are missing due to the overlap in the aliphatic re-
gion of 13C NMR spectrum. 
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Preparation of ethyl 2-{[1-(8-stearamido-3,6-dioxaoctanyl)-1H-1,2,3-triazol-4-
yl]methyl}tert-butoxycarbonylaminoacetate (123) 
 
 
 
C36H67N5O7 
 
To the azide 99 (0.10 g, 0.23 mmol) in H2O/t-BuOH/DCM (12 mL, 1:1:1) was added 
the monomer 111 (0.070 g, 0.29 mmol), followed by CuSO4 ⋅ 5H2O (0.0063 g, 11 mol 
%) and 1 M sodium ascorbate solution (0.048 mL, 21 mol %). The solution was stirred 
for 24 h at room temperature. After this time the aqueous phase was separated and the 
organic phase was concentrate under reduced pressure. The crude residue was subjected 
to flash column chromatography (ethyl acetate-light petroleum ether 9:1) to give the ti-
tle compound (123; 0.14 g, 0.21 mmol, 89 %) as a sticky solid; Rf (ethyl acetate-light 
petroleum 9:1) = 0.18; (Found C, 63.15; H, 9.78; N, 10.14% C36H67N5O7 requires C, 
63.40; H, 9.90; N, 10.27%); υmax(film)/cm-1 3304m, 2917s, 2850s, 1749m, 1699br s, 
1640s, 1556m; δH (400 MHz; CDCl3) (2 rotational isomers observed due to restricted 
rotation about the tertiary amide bond) 0.88 (3H, t, J 6.3, CH3), 1.26 (31H, s, 14 × CH2 
and OCH2CH3) 1.35 and 1.40 (9H, s, (CH3)3), 1.57 (2H, m, CH2CH2CONH), 2.15 (2H, 
m, CH2CONH), 3.36-3.39 (2H, m, NHCH2CH2O), 3.49-3.51 (2H, m, NHCH2CH2), 
3.51-3.58 (4H, m, OCH2CH2O), 3.80-3.83 (2H, m, CH2CH2N(1’)), 3.90 and 3.97 (2H, 
s, CH2COO), 4.13 (2H, q, J 7.2, OCH2CH3), 4.46-4.48 (2H, m, CH2N(1’)), 4.50 and 
4.52 (2H, s, C(4’)CH2), 6.01 and 6.28 (1H, br t, NH), 7.61 and 7.78 (1H, s, C(5’)H); δC 
(100 MHz; CDCl3) (2 rotational isomers observed due to restricted rotation about the 
tertiary amide bond) 14.1 (OCH2CH3), 14.1 (CH3CH2), 22.6 (CH2), 25.7 
(CH2CH2CONH), 28.1 ((CH3)3), 29.1 (CH2), 29.2 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 
(CH2), 29.6 (CH2), 31.8 (CH2), 36.6 (CH2CONH), 39.2 (NHCH2), 42.8 and 43.2 
(C(4’)CH2), 48.0 and 48.9 (CH2COO), 50.0 (CH2N(1’)), 60.9 (OCH2CH3), 69.9 
(OCH2), 70.1 (OCH2), 70.3 (OCH2), 80.5 (C(CH3)3), 123.1 and 123.5 (C(5’)H), 144.2 
and 144.6 (C(4’)), 155.2 (CON), 169.8 (COO), 173.2 (CONH); m/z (ESI) 682 ([M+H]+, 
100%), 654 (10), 582 (5); HRMS (ESI) (Found: [M+H]+, 682.5102. 
C36H68N5O7 requires m/z, 682.5113). Six signals corresponding to CH2 from the lipid 
chain are missing due to the overlap in the aliphatic region of 13C NMR spectrum. 
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Preparation of ethyl 2-{[1-(8-stearamido-3,6-dioxaoctanyl)-1H-1,2,3-triazol-4-
yl]methyl}aminoacetate trifluoroacetic acid (124) 
 
 
 
C33H60F3N5O7 
 
Compound 123 (0.138 g, 0.20 mmol) was dissolved with DCM (5 mL) and trifluoroace-
tic acid (5 mL) was added. The mixture was stirred for 1 h and after this time the sol-
vents were evaporated to yield the title compound (124; 0.132 g, 0.19 mmol, 95%) as 
colourless sticky solid, which was used without further purification; δH (400 MHz; 
CDCl3) (2 rotational isomers observed due to restricted rotation about the tertiary amide 
bond) 0.88 (3H, t, J 6.3, CH3), 1.16-1.37 (31H, m, 14 × CH2 and OCH2CH3), 1.49-1.60 
(2H, m, CH2CH2CONH), 2.15 (2H, m, CH2CONH), 3.36-3.40 (2H, m, NHCH2), 3.49-
3.52 (2H, m, NHCH2CH2), 3.51-3.58 (4H, m, OCH2CH2O), 3.79-3.83 (2H, m, 
CH2CH2N(1’)), 3.90 and 3.97 (2H, s, CH2COO), 4.13 (2H, q, J 7.2, OCH2CH3), 4.46-
4.48 (2H, m, CH2N(1’)), 4.50 and 4.52 (2H, s, C(4’)CH2), 6.01 and 6.28 (1H, br t, NH), 
7.61 and 7.78 (1H, s, C(5’)H); δC (100 MHz; CDCl3) (2 rotational isomers observed due 
to restricted rotation about the tertiary amide bond) 14.1 (OCH2CH3 and CH3), 22.6 
(CH2), 25.7 (CH2), 29.2 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2), 31.8 
(CH2), 36.6 (CH2), 39.2 (NHCH2), 42.8 and 43.2 (C(4’)CH2), 48.0 and 48.9 (CH2COO), 
50.0 (CH2N(1’)), 60.9 (OCH2CH3), 69.2 (OCH2), 69.3 (OCH2), 69.9 (OCH2), 70.1 
(OCH2), 123.1 and 123.5 (C(5’)H), 144.2 and 144.6 (C(4’)), 169.8 (COO), 173.2 
(CONH). Seven signals corresponding to CH2 from the lipid chain are missing due to 
the overlap in the aliphatic region of 13C NMR spectrum. 
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Preparation of ethyl 2-(thymin-1-ylacetyl){[1-(8-(pentacosa-10,12-diynamido)-3,6-
dioxaoctanyl)-1H-1,2,3-triazol-4-yl]methyl}aminoacetic acid (125a) 
 
 
C43H67N7O8 
 
95a (0.062 g, 0.074 mmol) was dissolved in tetrahydrofuran (5 mL) and 1 M lithium 
hydroxide solution (3 mL) was added. After stirring for 2 h, water (5 mL) was added 
and the aqueous layer separated and washed with dichloromethane (2 × 10 mL) before 
being acidified to pH 2 with 1 M hydrochloric acid solution. This acidic aqueous solu-
tion was then extracted with ethyl acetate (5 × 25 mL) and the combined organic phase 
was dried over magnesium sulphate anhydrous. After filtration, the solvent was evapo-
rated under reduced pressure giving a crude solid which was purified by flash column 
chromatography (dichloromethane-methanol-acetic acid 89:10:1). The title compound 
(125a; 0.051 g, 0.063 mmol; 82%) was obtained as a sticky white solid; Rf (dichloro-
methane-methanol-acetic acid 89:10:1) = 0.16; υmax(film)/cm-1 3328br s, 2927br s, 
2853s, 1767s, 1721s, 1679br s, 1545m; δH (400 MHz; DMSO-d6) (2 rotational isomers 
observed due to restricted rotation about the tertiary amide bond) 0.88 (3H, t, J 6.9, 
CH3), 1.24-1.29 (32H, br s,  16 × CH2), 1.71 (3H, s, C(5)-CH3), 2.01 (2H, t, J 7.6, 
CH2CONH), 2.22 (4H, t, J 7.1,  2 × CH2C≡C), 3.14-3.16 (2H, m, NHCH2), 3.30 (2H, m, 
NHCH2CH2), 3.43-3.51 (4H, m, OCH2CH2O), 3.73 (2H, m, CH2CH2N(1’)), 4.13 and 
4.27 (2H, s, CH2COO), 4.42-4.49 (4H, m, CH2CON and CH2N(1’)), 4.61 and 4.78 (2H, 
s, C(4’)CH2), 7.24 and 7.31 (1H, s, C(6)H), 7.91 and 8.12 (1H, s, C(5’)H); δC (100 
MHz; DMSO-d6) (2 rotational isomers observed due to restricted rotation about the ter-
tiary amide bond) 11.9 (C(5)-CH3), 13.9 (CH3), 18.2 (CH2C≡C), 22.7 (CH2), 25.3 
(CH2CH2CONH), 27.6 (CH2), 27.7 (CH2), 28.1 (CH2), 28.2 (CH2), 28.4 (CH2), 28.6 
(CH2), 28.7 (CH2), 28.8 (CH2), 28.9 (CH2), 29.0 (CH2), 31.3 (CH2), 35.6 (CH2CONH), 
38.7 (NHCH2), 42.1 (C(4’)CH2), 47.8 (CH2COO), 49.3 and 49.5 (CH2CON), 50.2 and 
50.4 (CH2N(1’)), 65.3 (C≡C-C≡C), 68.7 (CH2CH2N(1’)), 69.2 (OCH2), 69.4 (OCH2), 
69.5 (OCH2), 77.9 (C≡C-C≡C), 108.0 (C(5)), 123.8 (C(5’)H), 142.5 (C(6)H), 143.2 
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(C(4’)), 151.1 (C(4)O), 164.4 (C(2)O), 167.3 (CH2CON), 172.3 (CONH), 172.3 
(COOH); m/z (ESI) 810 ([M+H]+, 100%); HRMS (ESI) (Found: [M+H]+, 810.5113. 
C43H68N7O8 requires m/z, 810.5124). Four signals corresponding to CH2 from the lipid 
chain are missing due to the overlap in the aliphatic region of 13C NMR spectrum. 
 
Preparation of 2-(thymin-1-ylacetyl)((1-(8-stearamido-3,6-dioxaoctanyl)-1H-1,2,3-
triazol-4-yl)methyl)aminoacetic acid (126a) 
 
 
 
C36H61N7O8 
 
96a (0.119 g, 0.160 mmol) was dissolved in tetrahydrofuran (5 mL) and 1 M lithium 
hydroxide solution (3 mL) was added. After stirring for 2 h, water (5 mL) was added 
and the aqueous layer separated and washed with dichloromethane (2 × 10 mL) before 
being acidified to pH 2 with 1 M hydrochloric acid solution. This acidic aqueous solu-
tion was then extracted with ethyl acetate (5 × 25 mL) and the combined organic phase 
was dried over magnesium sulphate anhydrous. After filtration, the solvent was evapo-
rated under reduced pressure giving a crude solid which was purified by flash column 
chromatography (dichloromethane-methanol-acetic acid 89:10:1). The title compound 
(126a; 0.094 g, 0.13 mmol; 82%) was obtained as a white solid: m.p. 106-108 °C; Rf 
(dichloromethane-methanol-acetic acid 89:10:1) = 0.28; υmax(film)/cm-1 3217br m, 
2926s, 2854s, 1711s, 1669br s, 1555w; δH (400 MHz; CDCl3) (2 rotational isomers ob-
served due to restricted rotation about the tertiary amide bond) 0.88 (3H, t, J 6.3, CH3), 
1.12-1.33 (28H, m, 14 × CH2), 1.58 (2H, m, CH2CH2CONH), 1.88 and 1.91 (3H, s, 
C(5)-CH3), 2.15 (2H, t, J 7.6, CH2CONH), 3.38-3.40 (2H, m, NHCH2), 3.49-3.51 (2H, 
m, NHCH2CH2), 3.52-3.60 (4H, m, OCH2CH2O), 3.78-3.81 (2H, m, CH2CH2N(1’)), 
4.09 and 4.15 (2H, s, CH2COO), 4.48 and 4.52 (2H, br t, CH2N(1’)), 4.49 and 4.82 (2H, 
s, CH2CON), 4.69 and 4.71 (2H, s, C(4’)CH2), 6.45 (1H, br t, NH), 7.04 (1H, br s, 
C(6)H), 7.72 and 7.95 (1H, s, C(5’)H), 9.66 and 9.72 (1H, br s, N(3)H); δC (100 MHz; 
CDCl3) (2 rotational isomers observed due to restricted rotation about the tertiary amide 
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bond) 12.2 (C(5)-CH3), 14.1 (CH3), 22.7 (CH2), 25.7 (CH2CH2CONH), 29.1 (CH2), 
29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2), 29.7 (CH2), 31.9 (CH2), 36.6 
(CH2CONH), 39.1 (NHCH2), 42.6 and 43.6 (C(4’)CH2), 47.6 and 49.1 (CH2COO), 47.9 
and 48.0 (CH2CON), 50.1 and 50.2 (CH2N(1’)), 69.3 (CH2CH2N(1’)), 69.8 (OCH2), 
69.9 (OCH2), 70.3 (OCH2), 110.8 and 110.9 (C(5)), 124.5 and 124.6 (C(5’)H), 141.2 
(C(6)H), 142.2 and 142.4 (C(4’)), 151.2 (C(4)O), 164.5 (C(2)O), 167.1 and 167.3 
(CH2CON), 174.2 (CONH), 174.3 (COOH); m/z (ESI) 720 ([M+H]+, 100%); HRMS 
(ESI) (Found: [M+H]+, 720.4639. C36H62N7O8 requires m/z, 720.4654). Six signals cor-
responding to CH2 from the lipid chain are missing due to the overlap in the aliphatic 
region of 13C NMR spectrum. 
 
Attempted preparation of ethyl 2-(N4-(benzyloxycarbonyl)-cytosin-1-ylacetyl) {[1-
(8-(pentacosa-10,12-diynamido)-3,6-dioxaoctanyl)-1H-1,2,3-triazol-4-yl]methy} 
aminoacetic acid (125b) 
 
 
C50H72N8O9 
 
Compound 95b (0.25 g, 0.27 mmol) was dissolved in tetrahydrofuran (20 mL) and 1 M 
lithium hydroxide solution (10 mL) was added. The milky white solution was stirred at 
room temperature for 1 h. After this time water (40 mL) was added and the mixture was 
washed with dichloromethane (2 × 40 mL). The aqueous phase was then acidified to pH 
3 using 0.7 M citric acid solution and extracted with dichloromethane (9 × 80 mL). The 
combined organic phase was dried over anhydrous magnesium sulphate and filtrated. 
The crude residue was coevaporated with toluene (3 × 10 mL) and diethyl ether (3 × 
10 mL). The analysis of the sticky white solid obtained did not match the title com-
pound expected. 
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Attempted preparation of ethyl 2-[N4-(benzyloxycarbonyl)cytosin-1-ylacetyl]{[1-(8-
stearamido-3,6-dioxaoctanyl)-1H-1,2,3-triazol-4-yl]methyl}aminoacetic acid (126b) 
 
 
 
C43H66N8O9 
 
96b (0.093 g, 0.11 mmol) was dissolved in tetrahydrofuran (10 mL) and 1 M lithium 
hydroxide solution (5 mL) was added. The milky white solution was stirred at room 
temperature for 3 h. After this time water (20 mL) was added and the mixture was 
washed with dichloromethane (2 × 20 mL). The aqueous phase was then acidified to pH 
1 using 0.7 M citric acid solution and extracted with ethyl acetate (8 × 25 mL). The 
combined organic phase was dried over anhydrous magnesium sulphate and filtrated. 
After evaporation of the solvent, a white solid was obtained but further analysis failed 
confirming the structure of the product. 
 
Preparation of 2-[N6-(benzyloxycarbonyl)-adenine-9-ylacetyl]{[1-(8-(pentacosa-
10,12-diynamido)-3,6-dioxaoctanyl)-1H-1,2,3-triazol-4-yl]methyl}aminoacetic acid 
(125c) 
 
 
C51H72N10O8 
 
95c (0.13 g, 0.13 mmol) was dissolved in dioxane (1.2 mL) and 0.77 M sodium hydrox-
ide solution (0.42 mL) was added. After stirring for 30 min, water (2 mL) was added 
and the aqueous layer separated and washed with dichloromethane (3 × 5 mL) before 
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being acidified to pH 3 with 2 M citric acid solution. This acidic aqueous solution was 
then extracted with ethyl acetate (7 × 2 mL) and the combined organic phase was dried 
over magnesium sulphate anhydrous. After filtration, the solvent was evaporated under 
reduced pressure giving a crude solid which was purified by flash column chromatogra-
phy (dichloromethane-methanol-acetic acid 89:10:1). The title compound (125c; 0.11 g, 
0.12 mmol; 92%) was obtained as a sticky off-white solid; Rf (dichloromethane-
methanol-acetic acid 89:10:1) = 0.21; υmax(film)/cm-1 3329br s, 2927br s, 2853s, 1772s, 
1721s, 1679br s, 1545m; 1545m δH (200 MHz; CDCl3 + 1 drop MeOH-d4) (2 rotational 
isomers observed due to restricted rotation about the tertiary amide bond) 0.88 (3H, t, J 
6.9, CH3), 1.17-1.35 (26H, m, 13 × CH2), 1.40-1.48 (4H, m, 2 × CH2CH2C≡C), 1.50-
1.57 (2H, m, CH2CH2CONH), 2.05-2.12 (2H, m, CH2CONH), 2.15-2.20 (4H, m,  2 × 
CH2C≡C), 3.27-3.35 (2H, m, NHCH2), 3.39-3.58 (6H, m, CH2OCH2CH2O), 3.79 and 
3.83 (2H, t, J 4.8, CH2CH2N(1’)), 4.09 and 4.31 (2H, s, CH2COO), 4.43 and 4.52 (2H, t, 
J 4.8, CH2N(1’)), 4.63 and 4.76 (2H, s, CH2CON), 5.03 and 5.40 (2H, s, C(4’)CH2), 
5.23 (2H, s, OCH2Ar), 7.27-7.41 (5H, m, 5 × Ar-CH), 7.56 and 7.98 (1H, s, C(5’)H), 
8.05 and 8.08 (1H, s, C(8)H), 8.61 and 8.65 (1H, s, C(2)H); δC (400 MHz; CDCl3 + 1 
drop MeOH-d4) (2 rotational isomers observed due to restricted rotation about the terti-
ary amide bond) 13.1 (CH3), 19.2 (CH2C≡C), 22.6 (CH2), 28.3 (CH2CH2CO), 28.2 
(CH2CH2C≡C), 28.7 (CH2), 28.9 (CH2), 29.2 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 
(CH2), 29.6 (CH2), 29.8 (CH2), 31.8 (CH2), 36.3 (CH2CONH), 38.9 (NHCH2), 42.6 and 
43.5 (CH2CON), 43.6 and 44.1 (C(4’)CH2), 47.8 and 48.8 (CH2COO), 50.2 and 50.4 
(CH2N(1’)), 65.1 and 65.2 (C≡C-C≡C), 67.5 (OCH2Ar), 69.7 and 69.8 (CH2CH2N(1’)), 
69.9 (OCH2), 70.0 (OCH2), 70.4 (OCH2), 77.2 and 77.5 (C≡C-C≡C), 121.2 (C(5)), 
124.3 and 124.5 (C(5’)H), 128.5 (Ar-CH), 128.6 (Ar-CH), 128.7 (Ar-CH), 135.4 (Ar-
C), 142.1 and 142.3 (C(4’)), 143.8 and 144.0 (C(8)H), 149.5 (C(4)), 151.2 (NHCOO), 
151.5 (C(6)), 152.6 (C(2)H), 166.5 and 166.7 (CH2CON), 170.1 (CONH), 174.1 
(COOH); m/z (ESI) 953 ([M+H]+, 100%), 330 (7); HRMS (ESI) (Found: [M+H]+, 
953.5603. C51H73N10O8 requires m/z, 953.5607). Five signals corresponding to CH2 
from the lipid chain are missing due to the overlap in the aliphatic region of 13C NMR 
spectrum. 
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Preparation of 2-[N6-(benzyloxycarbonyl)adenin-9-ylacetyl]{[1-(8-stearamido-3,6-
dioxaoctanyl)-1H-1,2,3-triazol-4-yl]methyl}aminoacetic acid (126c) 
 
 
 
C44H66N10O8 
 
Compound 96c (0.10 g, 0.11 mmol) was dissolved in dioxane (1 mL) and 0.77 M so-
dium hydroxide solution (0.5 mL) was added. After stirring for 30 min, water (2 mL) 
was added and the aqueous layer separated and washed with dichloromethane (2 × 5 
mL) before being acidified to pH 3 with 2 M citric acid solution. This acidic aqueous 
solution was then extracted with ethyl acetate (7 × 5 mL) and the combined organic 
phase was dried over anhydrous magnesium sulphate. After filtration, the solvent was 
evaporated under reduced pressure giving a crude solid which was purified by flash col-
umn chromatography (dichloromethane-methanol-acetic acid 89:10:1). The title com-
pound (126c; 0.050 g, 0.058 mmol; 53%) was obtained as a white fluffy solid: Rf (di-
chloromethane-methanol-acetic acid 89:10:1) = 0.28; υmax(film)/cm-1 3217w, 2922s, 
2852s, 1745m, 1665m, 1613m; δH (400 MHz; CDCl3) (2 rotational isomers observed 
due to restricted rotation about the tertiary amide bond) 0.83 (3H, t, J 6.3, CH3), 1.15-
1.30 (28H, br s, 14 × CH2), 1.48-1.59 (2H, m, CH2CH2CONH), 2.09-2.17 (2H, m, 
CH2CONH), 3.25-3.32 (2H, m, NHCH2), 3.40-3.59 (6H, m, CH2OCH2CH2O), 3.81 and 
3.88 (2H, t, J 4.8, CH2CH2N(1’)), 4.10 and 4.23 (2H, s, CH2COO), 4.48 and 4.57 (2H, t, 
J 4.8, CH2N(1’)), 4.65 and 4.82 (2H, s, CH2CON), 5.13 and 5.50 (2H, s, C(4’)CH2), 
5.26 (2H, s, OCH2Ar), 7.22-7.43 (5H, m, 5 × Ar-CH), 7.79 and 8.11 (1H, s, C(5’)H), 
8.16 and 8.22 (1H, s, C(8)H), 8.57 and 8.60 (1H, s, C(2)H); δC (100 MHz; CDCl3) (2 
rotational isomers observed due to restricted rotation about the tertiary amide bond) 
14.3 (CH3), 22.9 (CH2), 26.1 (CH2CH2CON), 29.6 (CH2), 29.7 (CH2), 29.8 (CH2), 29.9 
(CH2), 30.0 (CH2), 30.1 (CH2), 32.2 (CH2), 36.7 (CH2CON), 39.4 (NHCH2), 43.1 and 
43.6 (CH2CON), 44.6 and 44.9 (C(4’)CH2), 48.0 and 48.9 (CH2COO), 50.5 and 
50.6  (CH2N(1’)), 67.9 (OCH2Ar), 69.3 and 69.4 (CH2CH2N(1’)), 69.9 (OCH2), 70.2 
(OCH2), 70.6 (OCH2), 121.1 (C(5)), 124.8 and 125.0 (C(5’)H), 128.5 (Ar-CH), 128.6 
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(Ar-CH), 128.7 (Ar-CH), 135.9 (Ar-C), 142.2 and 142.4 (C(4’)), 144.9 and 145.0 
(C(8)H), 149.7 (C(4)), 151.5 (NHCOOCH2), 152.0 (C(6)), 152.6 (C(2)H), 167.1 and 
167.3 (CH2CON), 171.5 (CONH), 175.8 (COOH); m/z (ESI) 863 ([M+H]+, 100%), 835 
(12), 382 (4), 330 (7), 278 (21); HRMS (ESI) (Found: [M+H]+, 863.5138. C46H71N10O8 
requires m/z, 863.5138). Six signals corresponding to CH2 from the lipid chain are miss-
ing due to the overlap in the aliphatic region of 13C NMR spectrum. 
 
Preparation of N-(thymin-1-ylacetyl)-N-(prop-2-ynyl)glycine (127) 
 
 
 
C12H13N3O5 
 
84a (0.243 g, 0.790 mmol) was dissolved in dioxane (2.4 mL), to this was added 0.77 M 
sodium hydroxide solution (2.57 mL). The mixture was stirred at room temperature for 
30 min. After this time, water (5.25 mL) was added and the solution was washed with 
dichloromethane (3 × 5 mL). The aqueous phase was then acidified to pH 3 using 2 M 
citric acid solution before being extracted with ethyl acetate (7 × 8 mL). The combined 
organic layers were washed with brine (8 mL), dried over anhydrous magnesium sul-
phate, filtered and evaporated to yield a crude residue that was subjected to flash col-
umn chromatography (dichloromethane-methanol-acetic acid 89:10:1). The title com-
pound (127; 1.25 g, 3.25 mmol; 89%) was obtained as a sticky white solid; Rf (di-
chloromethane-methanol-acetic acid 89:10:1) = 0.21; δH (200 MHz; CDCl3) (2 rota-
tional isomers observed due to restricted rotation about the tertiary amide bond) 1.26 
and 1.31 (2H, t, J 7.1, CH3), 1.34 (3H, s, C(5)CH3), 2.30 and 2.48 (1H, t, J 2.4, 
CHCCH2), 4.18 and 4.26 (2H, q, J 7.1, OCH2), 4.27-4.29 (4H, m, CH2NCH2), 4.50 and 
4.70 (2H, s, CH2CON), 7.01 (1H, s, C(6)H), 9.50 (1H, s, N(3)H); δC (50 MHz; CDCl3) 
(2 rotational isomers observed due to restricted rotation about the tertiary amide bond) 
12.2 (C(5)-CH3), 14.0 and 14.1 (CH3), 36.3 and 38.0 (HCCCH2), 47.7 (CH2COO), 48.0 
and 48.1 (CH2CON), 61.7 and 62.3 (OCH2), 73.8 and 74.6 (HCCCH2), 76.6 and 77.1 
(CH), 110.9 (C(5)), 141.1 (C(6)H), 151.3 (C(2)O), 164.5 (C(4)O), 167.1 (CH2CON), 
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168.7 and 168.9 (COO); m/z (ESI) 576 ([2M+NH4]+, 45%), 280 ([M+H]+, 100); HRMS 
(ESI) (Found: [M+H]+, 280.0931. C12H14N3O5 requires m/z, 280.0928). 
 
Preparation of N-{2-[(thymin-1-ylacetyl)-N-(prop-2-ynyl)amino]acetamido-ethyl}-
N-(thymin-1-ylacetyl) glycine ethyl ester (128) 
 
 
 
C25H31N7O9 
 
127 (0.034 g, 0.12 mmol) in dimethylformamide (10 mL) was added HATU (0.050 g, 
0.13 mmol) and DIPEA (0.025 mL, 0.14 mmol) and the solution was stirred for 15 min. 
After this time a solution of 82 (0.056 g, 0.13 mmol) in dimethylformamide (10 mL) 
was added dropwise, followed by DIPEA (0.100 mL, 0.58 mmol). The resulting mixture 
was stirred at room temperature for 20 h. After this time the solvents were removed in 
vacuo. The residue was dissolved in dichloromethane (10 mL) and the solution was 
washed successively with 1 M sodium bicarbonate (3 × 15 mL), 1 M potassium hydro-
gensulphate (2 × 15 mL), water (15 mL) and finally brine (20 mL). The organic layer 
was then dried over anhydrous magnesium sulphate and the solvent was evaporated un-
der reduced pressure to yield a crude residue which was purified by flash column chro-
matography (ethyl acetate-methanol 90:10) to yield the title compound (128; 0.022 g, 
0.04 mmol; 37%) as a white fluffy solid; Rf (ethyl acetate-methanol 90:10) = 0.15; δH 
(200 MHz; CDCl3) 0.88 (3H, br t, CH3), 1.85 (6H, s, C(5)-CH3 and C(5”)-CH3), 2.37-
2.42 (1H, m, HC≡C), 4.06-4.32 (12H, m, 6 × CH2), 4.43 (2H, s, CH2COO), 4.63 (2H, s, 
NCH2CONH), 6.96-7.00 (2H, s, C(6)H and C(6”)H), 9.25 (2H, br s, N(3)H); δC (50 
MHz; CDCl3) 11.8 (CH2CH3), 13.6 (C(5)-CH3 and C(5”)-CH3), 36.1 (HC≡CCH2), 37.1 
(NHCH2CH2), 46.8-48.1 (5 × CH2), 62.1 (OCH2CH3), 73.5 (HC≡CCH2), 76.6 
(HC≡CCH2), 110.5 (C(5) and C(5”)), 140.7 (C(6)H and C(6”)H), 151.1 (C(4)O), 
164.1 (C(2)O), 166.3 (CH2CON), 168.2 (COO), 168.6 (CONH); m/z (ESI) 591 
([M+NH4]+, 100), 573 ([M]+, 62), 377 (13), 355 (29); HRMS (ESI) (Found: [M+ NH4]+, 
591.2514. C25H35N8O9 requires m/z, 591.2522). 
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Preparation of N-{2-[(thymin-1-ylacetyl)-N-{[1-(8-stearamido-3,6-dioxaoctanyl)-
1H-1,2,3-triazol-4-yl]methyl}amino]acetamido ethyl}-N-(thymin-1-ylacetyl) glycine 
ethyl ester (129) 
 
 
C49H79N11O12 
 
To the azide 99 (0.014 g, 0.032 mmol) in H2O/t-BuOH/DCM (6 mL, 1:1:1) was added 
the dimer 128 (0.015 g, 0.026 mmol), followed by CuSO4.5H2O (0.002 g, 30 mol %) 
and 1 M sodium ascorbate (0.016 mL, 62 mol %). The solution was stirred for 24 h at 
room temperature. After this time the aqueous phase was separated and the organic 
phase was concentrated. The crude residue was subjected to flash column chromatogra-
phy (ethyl acetate - methanol 92:8) to give the title compound (129; 0.012 g, 
0.012 mmol, 46%) as a white sticky solid; Rf (ethyl acetate-methanol 90:10) = 0.15; m/z 
(ESI) 1038 [M+Na]+ (5%), 1015 ([M+H]+, 100), 987 (13), 463 (2), 441 (13), 391 (3), 
279 (2); HRMS (ESI) (Found: [M+H]+, 1014.5977. C49H80N11O12 requires m/z, 
1014.5982). 
 
Preparation of liposome solution 
 
The formation of liposomes was accomplished by first preparing solutions of 10,12-
pentacosadiynoic acid (5) of known concentration in chloroform. The same step was 
carried out for the chosen lipid model. Then, the appropriate amounts of 10,12-
pentacosadiynoic acid (5) and the chosen model were mixed in a test tube. Subse-
quently, the chloroform was evaporated using a gentle stream of nitrogen gas so that to 
obtain a thin (white) film on the glass. After addition of the appropriate amount of de-
ionised water to give a total lipid concentration of 1 mM, the sample was heated to 
about 80 °C and sonicated for 15 min using a probe type sonicator (Sonozap®). The 
formed liposomes solutions obtained are opaque-transparent. The solution was then 
cooled overnight to 4 °C in a fridge. After warming to room temperature, the solution 
was purged with nitrogen gas for 5 min. The polymerisation was finally achieved by 
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placing the sample under a UV lamp (254 nm) for a variable amount of time (up to 
30 min). The distance between the lamp and the sample was ca. 3 cm. The polymerized 
liposome solutions were stored for several months in glass vials at 4 °C in the fridge. 
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APPENDIX A§ 
 
 
Table 5:  Crystal data and structure refinement for compound 70 
 
Empirical formula  C18 H28 N4 O7 
Formula weight  412.44 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 15.901(3) Å α= 90°. 
 b = 6.8936(15) Å β= 100.450(12)°. 
 c = 19.098(5) Å γ = 90°. 
Volume 2058.7(8) Å3 
Z 4 
Density (calculated) 1.331 Mg/m3 
Absorption coefficient 0.103 mm-1 
F(000) 880 
Crystal size 0.60 x 0.24 x 0.08 mm3 
Theta range for data collection 1.54 to 23.32°. 
                                                 
§
 Data was collected by Dr Georgina Rosair on a Bruker X8 Apex2 CCD single crystal diffractometer at 
100K. 
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Index ranges -17<=h<=17, -7<=k<=7, -21<=l<=21 
Reflections collected 26151 
Independent reflections 2972 [R(int) = 0.0974] 
Completeness to theta = 23.32° 99.5 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.992 and 0.574 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2972 / 0 / 275 
Goodness-of-fit on F2 1.114 
Final R indices [I>2sigma(I)] R1 = 0.0487, wR2 = 0.1158 
R indices (all data) R1 = 0.1025, wR2 = 0.1596 
Largest diff. peak and hole 0.291 and -0.422 e.Å-3 
 
Table 6: Bond lengths [Å] and angles [°] for compound 70 
 
C(1)-O(2)  1.233(4) 
C(1)-N(1)  1.360(5) 
C(1)-C(3)  1.521(5) 
N(1)-C(13)  1.441(5) 
N(1)-C(19)  1.473(5) 
C(3)-N(4)  1.461(4) 
C(3)-H(3A)  0.9900 
C(3)-H(3B)  0.9900 
N(4)-C(11)  1.378(5) 
N(4)-C(5)  1.382(5) 
C(5)-C(6)  1.346(5) 
C(5)-H(5)  0.9500 
C(6)-C(8)  1.450(5) 
C(6)-C(7)  1.492(5) 
C(7)-H(7A)  0.9800 
C(7)-H(7B)  0.9800 
C(7)-H(7C)  0.9800 
C(8)-O(9)  1.236(4) 
C(8)-N(10)  1.383(5) 
N(10)-C(11)  1.373(5) 
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N(10)-H(10)  0.98(4) 
C(11)-O(12)  1.226(4) 
C(13)-C(14)  1.512(5) 
C(13)-H(13A)  0.9900 
C(13)-H(13B)  0.9900 
C(14)-O(15)  1.203(4) 
C(14)-O(16)  1.343(5) 
O(16)-C(17)  1.456(5) 
C(17)-C(18)  1.492(6) 
C(17)-H(17A)  0.9900 
C(17)-H(17B)  0.9900 
C(18)-H(18A)  0.9800 
C(18)-H(18B)  0.9800 
C(18)-H(18C)  0.9800 
C(19)-C(20)  1.517(5) 
C(19)-H(19A)  0.9900 
C(19)-H(19B)  0.9900 
C(20)-N(21)  1.454(5) 
C(20)-H(20A)  0.9900 
C(20)-H(20B)  0.9900 
N(21)-C(22)  1.354(5) 
N(21)-H(21)  0.79(4) 
C(22)-O(23)  1.218(5) 
C(22)-O(24)  1.350(5) 
O(24)-C(25)  1.481(5) 
C(25)-C(28)  1.514(6) 
C(25)-C(27)  1.519(6) 
C(25)-C(26)  1.520(6) 
C(26)-H(26A)  0.9800 
C(26)-H(26B)  0.9800 
C(26)-H(26C)  0.9800 
C(27)-H(27A)  0.9800 
C(27)-H(27B)  0.9800 
C(27)-H(27C)  0.9800 
C(28)-H(28A)  0.9800 
Appendix A 
212 
 
C(28)-H(28B)  0.9800 
C(28)-H(28C)  0.9800 
 
O(2)-C(1)-N(1) 121.4(3) 
O(2)-C(1)-C(3) 120.5(3) 
N(1)-C(1)-C(3) 118.1(3) 
C(1)-N(1)-C(13) 116.3(3) 
C(1)-N(1)-C(19) 125.2(3) 
C(13)-N(1)-C(19) 117.0(3) 
N(4)-C(3)-C(1) 110.1(3) 
N(4)-C(3)-H(3A) 109.6 
C(1)-C(3)-H(3A) 109.6 
N(4)-C(3)-H(3B) 109.6 
C(1)-C(3)-H(3B) 109.6 
H(3A)-C(3)-H(3B) 108.1 
C(11)-N(4)-C(5) 121.3(3) 
C(11)-N(4)-C(3) 117.8(3) 
C(5)-N(4)-C(3) 120.3(3) 
C(6)-C(5)-N(4) 123.8(3) 
C(6)-C(5)-H(5) 118.1 
N(4)-C(5)-H(5) 118.1 
C(5)-C(6)-C(8) 117.4(3) 
C(5)-C(6)-C(7) 123.4(3) 
C(8)-C(6)-C(7) 119.2(3) 
C(6)-C(7)-H(7A) 109.5 
C(6)-C(7)-H(7B) 109.5 
H(7A)-C(7)-H(7B) 109.5 
C(6)-C(7)-H(7C) 109.5 
H(7A)-C(7)-H(7C) 109.5 
H(7B)-C(7)-H(7C) 109.5 
O(9)-C(8)-N(10) 119.6(3) 
O(9)-C(8)-C(6) 124.7(3) 
N(10)-C(8)-C(6) 115.8(3) 
C(11)-N(10)-C(8) 126.9(3) 
C(11)-N(10)-H(10) 117(2) 
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C(8)-N(10)-H(10) 116(2) 
O(12)-C(11)-N(10) 122.7(3) 
O(12)-C(11)-N(4) 122.5(3) 
N(10)-C(11)-N(4) 114.7(3) 
N(1)-C(13)-C(14) 111.9(3) 
N(1)-C(13)-H(13A) 109.2 
C(14)-C(13)-H(13A) 109.2 
N(1)-C(13)-H(13B) 109.2 
C(14)-C(13)-H(13B) 109.2 
H(13A)-C(13)-H(13B) 107.9 
O(15)-C(14)-O(16) 124.3(4) 
O(15)-C(14)-C(13) 126.3(4) 
O(16)-C(14)-C(13) 109.3(3) 
C(14)-O(16)-C(17) 116.8(3) 
O(16)-C(17)-C(18) 106.4(3) 
O(16)-C(17)-H(17A) 110.5 
C(18)-C(17)-H(17A) 110.5 
O(16)-C(17)-H(17B) 110.5 
C(18)-C(17)-H(17B) 110.5 
H(17A)-C(17)-H(17B) 108.6 
C(17)-C(18)-H(18A) 109.5 
C(17)-C(18)-H(18B) 109.5 
H(18A)-C(18)-H(18B) 109.5 
C(17)-C(18)-H(18C) 109.5 
H(18A)-C(18)-H(18C) 109.5 
H(18B)-C(18)-H(18C) 109.5 
N(1)-C(19)-C(20) 114.7(3) 
N(1)-C(19)-H(19A) 108.6 
C(20)-C(19)-H(19A) 108.6 
N(1)-C(19)-H(19B) 108.6 
C(20)-C(19)-H(19B) 108.6 
H(19A)-C(19)-H(19B) 107.6 
N(21)-C(20)-C(19) 110.7(3) 
N(21)-C(20)-H(20A) 109.5 
C(19)-C(20)-H(20A) 109.5 
Appendix A 
214 
 
N(21)-C(20)-H(20B) 109.5 
C(19)-C(20)-H(20B) 109.5 
H(20A)-C(20)-H(20B) 108.1 
C(22)-N(21)-C(20) 124.7(3) 
C(22)-N(21)-H(21) 111(3) 
C(20)-N(21)-H(21) 115(3) 
O(23)-C(22)-O(24) 125.3(4) 
O(23)-C(22)-N(21) 123.7(4) 
O(24)-C(22)-N(21) 110.9(4) 
C(22)-O(24)-C(25) 119.9(3) 
O(24)-C(25)-C(28) 110.6(3) 
O(24)-C(25)-C(27) 109.9(3) 
C(28)-C(25)-C(27) 112.3(4) 
O(24)-C(25)-C(26) 102.0(3) 
C(28)-C(25)-C(26) 110.8(3) 
C(27)-C(25)-C(26) 110.8(4) 
C(25)-C(26)-H(26A) 109.5 
C(25)-C(26)-H(26B) 109.5 
H(26A)-C(26)-H(26B) 109.5 
C(25)-C(26)-H(26C) 109.5 
H(26A)-C(26)-H(26C) 109.5 
H(26B)-C(26)-H(26C) 109.5 
C(25)-C(27)-H(27A) 109.5 
C(25)-C(27)-H(27B) 109.5 
H(27A)-C(27)-H(27B) 109.5 
C(25)-C(27)-H(27C) 109.5 
H(27A)-C(27)-H(27C) 109.5 
H(27B)-C(27)-H(27C) 109.5 
C(25)-C(28)-H(28A) 109.5 
C(25)-C(28)-H(28B) 109.5 
H(28A)-C(28)-H(28B) 109.5 
C(25)-C(28)-H(28C) 109.5 
H(28A)-C(28)-H(28C) 109.5 
H(28B)-C(28)-H(28C) 109.5 
Symmetry transformations used to generate equivalent atoms:  
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Table 7: Torsion angles [°] for compound 70 
 
O(2)-C(1)-N(1)-C(13) -5.9(5) 
C(3)-C(1)-N(1)-C(13) 176.1(3) 
O(2)-C(1)-N(1)-C(19) -171.7(3) 
C(3)-C(1)-N(1)-C(19) 10.3(5) 
O(2)-C(1)-C(3)-N(4) -0.4(5) 
N(1)-C(1)-C(3)-N(4) 177.6(3) 
C(1)-C(3)-N(4)-C(11) 83.6(4) 
C(1)-C(3)-N(4)-C(5) -87.4(4) 
C(11)-N(4)-C(5)-C(6) 2.7(5) 
C(3)-N(4)-C(5)-C(6) 173.4(3) 
N(4)-C(5)-C(6)-C(8) -1.8(5) 
N(4)-C(5)-C(6)-C(7) 178.7(3) 
C(5)-C(6)-C(8)-O(9) -177.5(3) 
C(7)-C(6)-C(8)-O(9) 2.0(5) 
C(5)-C(6)-C(8)-N(10) 1.9(5) 
C(7)-C(6)-C(8)-N(10) -178.6(3) 
O(9)-C(8)-N(10)-C(11) 176.2(3) 
C(6)-C(8)-N(10)-C(11) -3.2(5) 
C(8)-N(10)-C(11)-O(12) -177.2(3) 
C(8)-N(10)-C(11)-N(4) 3.9(5) 
C(5)-N(4)-C(11)-O(12) 177.7(3) 
C(3)-N(4)-C(11)-O(12) 6.8(5) 
C(5)-N(4)-C(11)-N(10) -3.4(5) 
C(3)-N(4)-C(11)-N(10) -174.3(3) 
C(1)-N(1)-C(13)-C(14) -70.1(4) 
C(19)-N(1)-C(13)-C(14) 96.9(4) 
N(1)-C(13)-C(14)-O(15) -15.5(5) 
N(1)-C(13)-C(14)-O(16) 165.8(3) 
O(15)-C(14)-O(16)-C(17) -2.9(5) 
C(13)-C(14)-O(16)-C(17) 175.8(3) 
C(14)-O(16)-C(17)-C(18) 179.9(3) 
C(1)-N(1)-C(19)-C(20) -126.7(4) 
C(13)-N(1)-C(19)-C(20) 67.6(4) 
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N(1)-C(19)-C(20)-N(21) 62.3(4) 
C(19)-C(20)-N(21)-C(22) -176.4(4) 
C(20)-N(21)-C(22)-O(23) -165.8(4) 
C(20)-N(21)-C(22)-O(24) 15.8(6) 
O(23)-C(22)-O(24)-C(25) 1.5(6) 
N(21)-C(22)-O(24)-C(25) 179.8(3) 
C(22)-O(24)-C(25)-C(28) 60.3(4) 
C(22)-O(24)-C(25)-C(27) -64.3(4) 
C(22)-O(24)-C(25)-C(26) 178.2(3) 
Symmetry transformations used to generate equivalent atoms:  
  
 
Table 8: Hydrogen bonds for compound 70 [Å and °]. 
 
 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
 
 N(10)-H(10)...O(9)#1 0.98(4) 1.86(4) 2.838(4) 174(3) 
 N(21)-H(21)...O(12)#2 0.79(4) 2.35(4) 3.079(5) 153(4) 
 N(21)-H(21)...O(15)#3 0.79(4) 2.83(4) 3.349(4) 125(3) 
  
Symmetry transformations used to generate equivalent atoms:  
#1 -x+2,-y,-z+1    #2 -x+3/2,y+1/2,-z+1/2    #3 x,y+1,z     
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APPENDIX B** 
 
 
 
                                                 
**
 Data was collected by Dr Georgina Rosair on a Bruker X8 Apex2 CCD single crystal diffractometer at 
100K. 
Appendix B 
218 
 
Table 9 : Crystal data and structure refinement for compound 84a 
Empirical formula  C14 H17 N3 O5 
Formula weight  307.31 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 4.8969(15) Å α= 90° 
 b = 15.069(5) Å β= 96.444(13)° 
 c = 20.118(5) Å γ = 90° 
Volume 1475.2(8) Å3 
Z 4 
Density (calculated) 1.384 Mg/m3 
Absorption coefficient 0.107 mm-1 
F(000) 648 
Crystal size 0.44 x 0.20 x 0.12 mm3 
Theta range for data collection 1.69 to 33.12°. 
 
Index ranges -6<=h<=6, 0<=k<=21, 0<=l<=28 
Reflections collected 31957 
Independent reflections 6683 [R(int) = 0.0763] 
Completeness to theta = 25.00° 89.5 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9873 and 0.6355 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6683 / 19 / 206 
Goodness-of-fit on F2 0.996 
Final R indices [I>2sigma(I)] R1 = 0.0922, wR2 = 0.2518 
R indices (all data) R1 = 0.1223, wR2 = 0.2700 
Largest diff. peak and hole 0.395 and -0.518 e.Å-3 
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Table 10 : Bond lengths [Å] and angles [°] for compound 84a 
N(1)-C(2)  1.373(6) 
N(1)-C(6)  1.394(6) 
N(1)-C(8)  1.447(6) 
C(2)-O(2)  1.222(5) 
C(2)-N(3)  1.382(5) 
N(3)-C(4)  1.377(6) 
N(3)-H(3N)  0.899(19) 
C(4)-O(4)  1.237(5) 
C(4)-C(5)  1.454(7) 
C(5)-C(6)  1.339(6) 
C(5)-C(7)  1.508(6) 
C(6)-H(6)  0.9500 
C(7)-H(7A)  0.9800 
C(7)-H(7B)  0.9800 
C(7)-H(7C)  0.9800 
C(8)-C(9)  1.518(7) 
C(8)-H(8A)  0.9900 
C(8)-H(8B)  0.9900 
C(9)-O(9)  1.230(6) 
C(9)-N(10)  1.368(6) 
N(10)-C(14)  1.455(6) 
N(10)-C(11)  1.460(6) 
C(11)-C(12)  1.475(7) 
C(11)-H(11A)  0.9900 
C(11)-H(11B)  0.9900 
C(12)-C(13)  1.191(7) 
C(13)-H(13)  0.9500 
C(14)-C(15)  1.517(7) 
C(14)-H(14A)  0.9900 
C(14)-H(14B)  0.9900 
C(15)-O(15)  1.201(5) 
C(15)-O(16)  1.321(5) 
O(16)-C(17)  1.490(6) 
C(17)-C(18)  1.472(7) 
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C(17)-H(17A)  0.9900 
C(17)-H(17B)  0.9900 
C(18)-H(18A)  0.9800 
C(18)-H(18B)  0.9800 
C(18)-H(18C)  0.9800 
 
C(2)-N(1)-C(6) 121.2(4) 
C(2)-N(1)-C(8) 117.8(4) 
C(6)-N(1)-C(8) 120.8(4) 
O(2)-C(2)-N(1) 122.5(4) 
O(2)-C(2)-N(3) 122.5(4) 
N(1)-C(2)-N(3) 115.0(4) 
C(4)-N(3)-C(2) 127.0(4) 
C(4)-N(3)-H(3N) 115(3) 
C(2)-N(3)-H(3N) 118(3) 
O(4)-C(4)-N(3) 120.8(4) 
O(4)-C(4)-C(5) 123.9(4) 
N(3)-C(4)-C(5) 115.3(4) 
C(6)-C(5)-C(4) 118.4(4) 
C(6)-C(5)-C(7) 123.0(4) 
C(4)-C(5)-C(7) 118.5(4) 
C(5)-C(6)-N(1) 123.1(4) 
C(5)-C(6)-H(6) 118.5 
N(1)-C(6)-H(6) 118.5 
C(5)-C(7)-H(7A) 109.5 
C(5)-C(7)-H(7B) 109.5 
H(7A)-C(7)-H(7B) 109.5 
C(5)-C(7)-H(7C) 109.5 
H(7A)-C(7)-H(7C) 109.5 
H(7B)-C(7)-H(7C) 109.5 
N(1)-C(8)-C(9) 110.1(4) 
N(1)-C(8)-H(8A) 109.6 
C(9)-C(8)-H(8A) 109.6 
N(1)-C(8)-H(8B) 109.6 
C(9)-C(8)-H(8B) 109.6 
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H(8A)-C(8)-H(8B) 108.1 
O(9)-C(9)-N(10) 122.6(4) 
O(9)-C(9)-C(8) 121.4(4) 
N(10)-C(9)-C(8) 116.0(4) 
C(9)-N(10)-C(14) 119.1(4) 
C(9)-N(10)-C(11) 122.6(4) 
C(14)-N(10)-C(11) 118.3(4) 
N(10)-C(11)-C(12) 111.8(4) 
N(10)-C(11)-H(11A) 109.3 
C(12)-C(11)-H(11A) 109.3 
N(10)-C(11)-H(11B) 109.3 
C(12)-C(11)-H(11B) 109.3 
H(11A)-C(11)-H(11B) 107.9 
C(13)-C(12)-C(11) 175.1(5) 
C(12)-C(13)-H(13) 180.0 
N(10)-C(14)-C(15) 114.6(4) 
N(10)-C(14)-H(14A) 108.6 
C(15)-C(14)-H(14A) 108.6 
N(10)-C(14)-H(14B) 108.6 
C(15)-C(14)-H(14B) 108.6 
H(14A)-C(14)-H(14B) 107.6 
O(15)-C(15)-O(16) 125.3(4) 
O(15)-C(15)-C(14) 122.9(4) 
O(16)-C(15)-C(14) 111.7(4) 
C(15)-O(16)-C(17) 116.3(3) 
C(18)-C(17)-O(16) 106.8(4) 
C(18)-C(17)-H(17A) 110.4 
O(16)-C(17)-H(17A) 110.4 
C(18)-C(17)-H(17B) 110.4 
O(16)-C(17)-H(17B) 110.4 
H(17A)-C(17)-H(17B) 108.6 
C(17)-C(18)-H(18A) 109.5 
C(17)-C(18)-H(18B) 109.5 
H(18A)-C(18)-H(18B) 109.5 
C(17)-C(18)-H(18C) 109.5 
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H(18A)-C(18)-H(18C) 109.5 
H(18B)-C(18)-H(18C) 109.5 
 
Table 11: Torsion angles [°] for compound 96a 
C(6)-N(1)-C(2)-O(2) -174.9(4) 
C(8)-N(1)-C(2)-O(2) -0.9(6) 
C(6)-N(1)-C(2)-N(3) 3.7(6) 
C(8)-N(1)-C(2)-N(3) 177.7(4) 
O(2)-C(2)-N(3)-C(4) 176.2(4) 
N(1)-C(2)-N(3)-C(4) -2.4(6) 
C(2)-N(3)-C(4)-O(4) 178.7(4) 
C(2)-N(3)-C(4)-C(5) -0.3(7) 
O(4)-C(4)-C(5)-C(6) -177.2(5) 
N(3)-C(4)-C(5)-C(6) 1.8(6) 
O(4)-C(4)-C(5)-C(7) 2.7(7) 
N(3)-C(4)-C(5)-C(7) -178.3(4) 
C(4)-C(5)-C(6)-N(1) -0.5(7) 
C(7)-C(5)-C(6)-N(1) 179.6(4) 
C(2)-N(1)-C(6)-C(5) -2.4(7) 
C(8)-N(1)-C(6)-C(5) -176.2(4) 
C(2)-N(1)-C(8)-C(9) -79.0(5) 
C(6)-N(1)-C(8)-C(9) 95.0(5) 
N(1)-C(8)-C(9)-O(9) -9.2(6) 
N(1)-C(8)-C(9)-N(10) 173.0(4) 
O(9)-C(9)-N(10)-C(14) -3.2(6) 
C(8)-C(9)-N(10)-C(14) 174.6(4) 
O(9)-C(9)-N(10)-C(11) 174.9(4) 
C(8)-C(9)-N(10)-C(11) -7.2(6) 
C(9)-N(10)-C(11)-C(12) -75.3(5) 
C(14)-N(10)-C(11)-C(12) 102.8(4) 
N(10)-C(11)-C(12)-C(13) 42(7) 
C(9)-N(10)-C(14)-C(15) -93.3(5) 
C(11)-N(10)-C(14)-C(15) 88.5(5) 
N(10)-C(14)-C(15)-O(15) -164.9(4) 
N(10)-C(14)-C(15)-O(16) 17.7(6) 
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O(15)-C(15)-O(16)-C(17) -2.5(7) 
C(14)-C(15)-O(16)-C(17) 174.9(4) 
C(15)-O(16)-C(17)-C(18) -167.5(4) 
 
Table 12: Hydrogen bonds for compound 84a [Å and °]. 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
 
 N(3)-H(3N)...O(4)#1 0.899(19) 1.90(2) 2.804(5) 179(5) 
 
 
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1,-y+2,-z+2      
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